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1COLORECTAL CANCER
Ö®Ã®Ê½Ê¦ù
Colorectal cancer is a major health problem. Colorectal cancer mainly occurs in 
developed countries.1 /ŶƚŚĞEĞƚŚĞƌůĂŶĚƐ ŝƚ ŝƐƚŚĞƐĞĐŽŶĚŵŽƐƚĐŽŵŵŽŶĐĂŶĐĞƌĂŵŽŶŐ
ŵĂůĞƐ;ƌĞƉƌĞƐĞŶƟŶŐϭϲйŽĨĂůůĐĂŶĐĞƌƐͿ͕ĂŌĞƌƉƌŽƐƚĂƚĞĐĂŶĐĞƌ;ϮϬйͿ͕ĂŶĚ ŝƚ ŝƐ ƚŚĞƚŚŝƌĚ
ŵŽƐƚ ĨƌĞƋƵĞŶƚĐĂŶĐĞƌĂŵŽŶŐĨĞŵĂůĞƐ ;ϭϯйͿ͕ĂŌĞƌďƌĞĂƐƚĐĂŶĐĞƌ ;ϮϴйͿĂŶĚƐŬŝŶĐĂŶĐĞƌ
;ĞǆĐůƵĚŝŶŐ ďĂƐĂů ĐĞůů ĐĂƌĐŝŶŽŵĂ͖ ϭϱйͿ͘2 /Ŷ ϮϬϭϱ͕ ƚŚĞ ĂŐĞͲƐƚĂŶĚĂƌĚŝǌĞĚ ŝŶĐŝĚĞŶĐĞ ƌĂƚĞ
;tŽƌůĚ^ƚĂŶĚĂƌĚŝǌĞĚWŽƉƵůĂƟŽŶ;t^ZͿͿǁĂƐϰϰ͘ϯƉĞƌϭϬϬ͕ϬϬϬƉĞƌƐŽŶͲǇĞĂƌƐ͘dŚĞĂďƐŽůƵƚĞ
ŶƵŵďĞƌŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐŚĂƐŵŽƌĞƚŚĂŶĚŽƵďůĞĚŝŶƚŚĞ
ůĂƐƚ Ϯϱ ǇĞĂƌƐ͖ ĨƌŽŵ ϳ͕ϭϬϬ ŝŶ ϭϵϵϬ ƚŽ ϭϱ͕ϴϬϬ ŝŶ ϮϬϭϱ͘2 The majority of the colorectal 
ĐĂŶĐĞƌƐ;ĂƉƉƌŽǆŝŵĂƚĞůǇϲϬйͿŝƐůŽĐĂƚĞĚŝŶƚŚĞĐŽůŽŶ͘ƐĂƌĞƐƵůƚŽĨƚŚĞŝŶƚƌŽĚƵĐƟŽŶŽĨƚŚĞ
ƵƚĐŚĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƐĐƌĞĞŶŝŶŐƉƌŽŐƌĂŵĂŶĚĂŐŝŶŐŽĨƚŚĞƉŽƉƵůĂƟŽŶ͕ƚŚĞŝŶĐŝĚĞŶĐĞŽĨ
colorectal cancer is increasing in the Netherlands.3, 4 
Z®Ý»¥ãÊÙÝ







hypertension, cardiac and vascular diseases, diabetes mellitus and previous malignancy 
;&ŝŐƵƌĞϭͿ͘
ĚĚŝƟŽŶĂůůǇ͕  ƐĞǀĞƌĂů ůŝĨĞƐƚǇůĞͲ Žƌ ĞŶǀŝƌŽŶŵĞŶƚĂů ĨĂĐƚŽƌƐ͕ ŝŶĐůƵĚŝŶŐ ŽďĞƐŝƚǇ͕  ƉŚǇƐŝĐĂů
ĂĐƟǀŝƚǇ͕ ŚŝŐŚĐŽŶƐƵŵƉƟŽŶŽĨƌĞĚĂŶĚƉƌŽĐĞƐƐĞĚŵĞĂƚ͕ĂůĐŽŚŽůŝŶƚĂŬĞ͕ƐŵŽŬŝŶŐ͕ŚŽƌŵŽŶĞ
ƌĞƉůĂĐĞŵĞŶƚ ƚŚĞƌĂƉǇ ĂŶĚ ŶŽŶͲƐƚĞƌŽŝĚĂů ĂŶƟͲŝŶŇĂŵŵĂƚŽƌǇ ĚƌƵŐƐ ŝŶŇƵĞŶĐĞ ƚŚĞ ƌŝƐŬ ŽĨ
developing colorectal cancer.6-8KƚŚĞƌŚŝŐŚͲƌŝƐŬŐƌŽƵƉƐŝŶĐůƵĚĞƉĂƟĞŶƚƐǁŝƚŚŝŶŇĂŵŵĂƚŽƌǇ
ďŽǁĞůĚŝƐĞĂƐĞ ůŝŬĞƵůĐĞƌĂƟǀĞ ĐŽůŝƟƐ ĂŶĚƌŽŚŶ Ɛ͛ ĚŝƐĞĂƐĞ͘9 Furthermore, individuals can 
ďĞĂƚŝŶĐƌĞĂƐĞĚƌŝƐŬĚƵĞƚŽƚŚĞŝƌŐĞŶĞƟĐĐŽŶƐƟƚƵƟŽŶ͘ƉƉƌŽǆŝŵĂƚĞůǇϱйŽĨĂůůĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌƐ ĂƌĞ ŐĞŶĞƟĐĂůůǇ ĚĞƚĞƌŵŝŶĞĚ͘ dŚĞ ŵĂŝŶ ŚĞƌĞĚŝƚĂƌǇ ĨŽƌŵƐ ĂƌĞ >ǇŶĐŚ ƐǇŶĚƌŽŵĞ
;ŚĞƌĞĚŝƚĂƌǇ ŶŽŶͲƉŽůǇƉŽƐŝƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌͿ͕ ĨĂŵŝůŝĂů ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ;ŶŽŶͲƉŽůǇƉŽƐŝƐͿ
ĂŶĚĂĚĞŶŽŵĂƚŽƵƐƉŽůǇƉŽƐŝƐ;Dz,ĂƐƐŽĐŝĂƚĞĚƉŽůǇƉŽƐŝƐͿ͘10





















FIGURE 1 WƌŽƉŽƌƟŽŶ ŽĨ ĐŽŵŽƌďŝĚŝƟĞƐ ƉƌĞƐĞŶƚ Ăƚ ĚŝĂŐŶŽƐŝƐ ĂŵŽŶŐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ 
 diagnosed in the Netherlands between 1994-2014, by age group.
 Source: Netherlands Cancer Registry (southeast part)
^ã¦ÝÊ¥ã«®ÝÝ
dŚĞ ƚƵŵŽƵƌͲŶŽĚĞͲŵĞƚĂƐƚĂƐŝƐ ;dEDͿ ƐƚĂŐŝŶŐ ƐǇƐƚĞŵ ŝƐŵŽƐƚ ĐŽŵŵŽŶůǇ ƵƐĞĚ ƚŽ ĐůĂƐƐŝĨǇ
invasiveness of the disease.11dŚĞƐǇƐƚĞŵĐŽŶƐŝƐƚƐŽĨĨŽƵƌƐƚĂŐĞƐ͖ƐƚĂŐĞ/ƚŽ/s͘ /ŶƐƚĂŐĞ/
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͕ ƚŚĞƚƵŵŽƵƌŚĂƐŐƌŽǁŶƚŚƌŽƵŐŚƐĞǀĞƌĂůůĂǇĞƌƐŽĨƚŚĞůĂƌŐĞďŽǁĞů͕ĞǆĐĞƉƚ
ŝƚƐŵƵƐĐƵůĂƌǁĂůů͘^ƚĂŐĞ//ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƐŚĂǀĞŐƌŽǁŶƚŚƌŽƵŐŚƚŚĞǁĂůů͕ďƵƚŚĂǀĞŶŽƚ






in the Netherlands. The most recent guidelines for colorectal cancer, revised in 2014, 
ĐŽŶƚĂŝŶƌĞĐŽŵŵĞŶĚĂƟŽŶƐĨŽƌĚŝĂŐŶŽƐŝƐ͕ƚƌĞĂƚŵĞŶƚĂŶĚĨŽůůŽǁͲƵƉ͘10
&ŽƌĐŽůŽŶĐĂŶĐĞƌƉĂƟĞŶƚƐ͕ƚŚĞƉƌŝŵĂƌǇƚƌĞĂƚŵĞŶƚŝƐƐƵƌŐŝĐĂůƌĞŵŽǀĂůŽĨƉĂƌƚŽĨƚŚĞĐŽůŽŶ
in which the tumour is located, and of regional lymph nodes. The two ends of the colon 
ĂƌĞ ƌĞĐŽŶŶĞĐƚĞĚ͕ Žƌ ƐŽŵĞƟŵĞƐ Ă ƚĞŵƉŽƌĂƌǇ ĐŽůŽƐƚŽŵǇ ŵĂǇ ďĞ ĐŽŶƐƚƌƵĐƚĞĚ͘ ^ŝŶĐĞ
ƚŚĞ ŝŶƚƌŽĚƵĐƟŽŶŽĨ ůĂƉĂƌŽƐĐŽƉŝĐ ƐƵƌŐĞƌǇ ŝŶ ϭϵϵϭ14, this minimally invasive approach is 
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1
ŵŽƌĞ ŽŌĞŶ ƉĞƌĨŽƌŵĞĚ ŝŶ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĐŽŵƉĂƌĞĚ ƚŽ ƚŚĞ ĐŽŶǀĞŶƟŽŶĂů
ŽƉĞŶ ĂďĚŽŵŝŶĂů ƌĞƐĞĐƟŽŶ͘15 >ĂƉĂƌŽƐĐŽƉŝĐ ƐƵƌŐĞƌǇ ĂƉƉĞĂƌƐ ƚŽ ďĞ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ
ůĞƐƐ ƉŽƐƚŽƉĞƌĂƟǀĞ ƉĂŝŶ͕ ďĞƩĞƌ ƉƵůŵŽŶĂƌǇ ĨƵŶĐƟŽŶ͕ ƌĞĚƵĐĞĚ ŽĐĐƵƌƌĞŶĐĞ ŽĨ ŝůĞƵƐ ĂŶĚ
shorter hospital stay compared with open surgery, without compromising oncological 
outcome.16-19 ĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ĐĂŶ ďĞ ƵƐĞĚǁŝƚŚ ƚŚĞ ŝŶƚĞŶƟŽŶ ƚŽ ĞƌĂĚŝĐĂƚĞ ĂŶǇ








ǁŝƚŚ dϭ ƚƵŵŽƵƌƐ͘ Ŷ ĂďĚŽŵŝŶŽƉĞƌŝŶĞĂů ƌĞƐĞĐƟŽŶ ;ŝŶĐůƵĚŝŶŐ Ă ƉĞƌŵĂŶĞŶƚ ĐŽůŽƐƚŽŵǇͿ






ŝŶ ƚŚĞŵŝĚϭϵϵϬ Ɛ͛ ƌĞƐƵůƚĞĚ ŝŶĂĚĞĐƌĞĂƐĞĚ ůŽĐĂů ƌĞĐƵƌƌĞŶĐĞƌĂƚĞ͘25 The Dutch Colorectal 
ĂŶĐĞƌ'ƌŽƵƉ;'ͿŝŶǀĞƐƟŐĂƚĞĚƚŚĞĞīĞĐƚƐŽĨƉƌĞŽƉĞƌĂƟǀĞƌĂĚŝŽƚŚĞƌĂƉǇŝŶĐŽŵďŝŶĂƟŽŶ
ǁŝƚŚ ƐƚĂŶĚĂƌĚŝǌĞĚdD͘dŚŝƐĂŶĚƐĞǀĞƌĂůŽƚŚĞƌ ƐƚƵĚŝĞƐ ƐŚŽǁĞĚ ƚŚĞƐƵƌǀŝǀĂůďĞŶĞĮƚƐŽĨ
ƉƌĞŽƉĞƌĂƟǀĞ ƌĂĚŝŽƚŚĞƌĂƉǇ͘26-28 ^ŝŶĐĞϮϬϬϭ͕ƉƌĞŽƉĞƌĂƟǀĞ ƌĂĚŝŽƚŚĞƌĂƉǇďĞĐĂŵĞƐƚĂŶĚĂƌĚ
ƉƌĂĐƟĐĞ ĨŽƌ Ăůů ƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ǁŝƚŚ ĐůŝŶŝĐĂů dϮͲdϰ ƚƵŵŽƵƌƐ͘ ĚĚŝƟŽŶĂůůǇ͕  ƐŝŶĐĞ
2004, based on results of previous studies29, 30͕ƉƌĞŽƉĞƌĂƟǀĞĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇďĞĐĂŵĞ
the standard treatment for locally advanced rectal cancer. Nowadays, neoadjuvant 
ƌĂĚŝŽƚŚĞƌĂƉǇ ŝƐ ŝŶĚŝĐĂƚĞĚ ĨŽƌ ƉĂƟĞŶƚƐǁŝƚŚ ĐůŝŶŝĐĂů dϭͲdϮ ƚƵŵŽƵƌƐǁŝƚŚ ƉŽƐŝƟǀĞ ůǇŵƉŚ
ŶŽĚĞƐ ĂŶĚ ĨŽƌ ƉĂƟĞŶƚƐ ǁŝƚŚ ĐůŝŶŝĐĂů dϯ ƚƵŵŽƵƌƐ ǁŝƚŚ хϱ ŵŝůůŝŵĞƚĞƌ ;ŵŵͿ ĞǆƚƌĂŵƵƌĂů
ŝŶǀĂƐŝŽŶ͘EĞŽĂĚũƵǀĂŶƚĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇŝƐƌĞĐŽŵŵĞŶĚĞĚĨŽƌƉĂƟĞŶƚƐǁŝƚŚĐůŝŶŝĐĂůdϰ
ƚƵŵŽƵƌƐ͕dϯƚƵŵŽƵƌƐŝŶǁŚŝĐŚƚŚĞĚŝƐƚĂŶĐĞƚŽƚŚĞŵĞƐŽƌĞĐƚĂůĨĂƐĐŝĂŝƐчϭŵŵĂŶĚƚƵŵŽƵƌƐ
with clinical N2.10 Neoadjuvant chemoradiotherapy can result in complete disappearance 
ŽĨƚƵŵŽƵƌĂŶĚŝŶǀŽůǀĞĚŶŽĚĞƐ͘ƉƉƌŽǆŝŵĂƚĞůǇϭϱйƚŽϮϬйŽĨƚŚĞƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ
ǁŚŽ ƵŶĚĞƌŐŽ ŶĞŽĂĚũƵǀĂŶƚ ĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇ ĞǆƉĞƌŝĞŶĐĞ Ă ƉĂƚŚŽůŽŐŝĐĂů ĐŵƉůĞƚĞ
ƌĞƐƉŽŶƐĞŝŶǁŚŝĐŚŶŽƌĞƐŝĚƵĂůƚƵŵŽƵƌŝƐƌĞƉŽƌƚĞĚĂƚŚŝƐƚŽůŽŐǇĂŌĞƌĂƐƚĂŶĚĂƌĚƌĞƐĞĐƟŽŶ͘31 
Habr-Gama et al.32ŝŶƚƌŽĚƵĐĞĚĂƐŽͲĐĂůůĞĚ͞ǁĂŝƚͲĂŶĚͲƐĞĞƉŽůŝĐǇ͟ŝŶϮϬϬϰ͕ŝŶǁŚŝĐŚƉĂƟĞŶƚƐ
ǁŝƚŚ ůŽǁ ƌĞĐƚĂů ĐĂŶĐĞƌ ǁŚŽ ĂĐŚŝĞǀĞĚ Ă ĐůŝŶŝĐĂů ĐŽŵƉůĞƚĞ ƌĞƐƉŽŶƐĞ ĂŌĞƌ ŶĞŽĂĚũƵǀĂŶƚ
chemoradiotherapy were closely followed and did not undergo surgery. Although the 












ĂŶĚŽǆĂůŝƉůĂƟŶŽƌŝƌŝŶŽƚĞĐĂŶŚĂǀĞďĞĐŽŵĞĂǀĂŝůĂďůĞ͘/ŶƚŚĞĞĂƌůǇϮϭst century a new class 
of agents, usually referred to as targeted therapy, was introduced including bevacizumab, 
ĐĞƚƵǆŝŵĂďĂŶĚƉĂŶŝƚƵŵƵŵĂď͕ǁŚŝĐŚŚĂǀĞŝŵƉƌŽǀĞĚƚŚĞƉƌŽŐŶŽƐŝƐŽĨƉĂƟĞŶƚƐǁŝƚŚƐƚĂŐĞ
/sƌĞŵĂƌŬĂďůǇ37, 38͕ĚĞĮŶŝŶŐƚŚĞďĂĐŬďŽŶĞŽĨĐƵƌƌĞŶƚƐǇƐƚĞŵŝĐƚŚĞƌĂƉǇ͘39-43 According to the 
ƵƚĐŚŶĂƟŽŶĂůƚƌĞĂƚŵĞŶƚŐƵŝĚĞůŝŶĞƐ͕ƉĂƟĞŶƚƐǁŝƚŚŶŽŶͲƌĞƐĞĐƚĂďůĞŵĞƚĂƐƚĂƟĐĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌ ƐŚŽƵůĚďĞ ƚƌĞĂƚĞĚǁŝƚŚĮƌƐƚͲůŝŶĞŵŽŶŽͲŽƌ ĐŽŵďŝŶĂƟŽŶĐŚĞŵŽƚŚĞƌĂƉǇǁŝƚŚ ƚŚĞ
ĂĚĚŝƟŽŶŽĨďĞǀĂĐŝǌƵŵĂďĂƐƚĂƌŐĞƚĞĚƚŚĞƌĂƉǇ͘10ƉƉƌŽǆŝŵĂƚĞůǇϭϬйŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ
ƉĂƟĞŶƚƐŝƐĚŝĂŐŶŽƐĞĚǁŝƚŚƉĞƌŝƚŽŶĞĂůŵĞƚĂƐƚĂƐĞƐ͘13, 44, 45 Recently, the understanding that 
peritoneal carcinomatosis results from loco-regional rather than systemic spread, resulted 
ŝŶƚŚĞĚĞǀĞůŽƉŵĞŶƚŽĨůŽĐŽͲƌĞŐŝŽŶĂůƚƌĞĂƚŵĞŶƚŵŽĚĂůŝƟĞƐĐŽŵďŝŶŝŶŐĐǇƚŽƌĞĚƵĐƟǀĞƐƵƌŐĞƌǇ
;Z^Ϳ ĂŶĚ ŚǇƉĞƌƚŚĞƌŵŝĐ ŝŶƚƌĂƉĞƌŝƚŽŶĞĂů ĐŚĞŵŽƚŚĞƌĂƉǇ ;,/WͿ͘46 /Ŷ ƚŚĞ EĞƚŚĞƌůĂŶĚƐ͕
Z^Ͳ,/WǁĂƐŝŶƚƌŽĚƵĐĞĚϮϬǇĞĂƌƐĂŐŽ͘dŚĞŶƵŵďĞƌŽĨŚŽƐƉŝƚĂůƐŽīĞƌŝŶŐZ^Ͳ,/WŚĂƐ
increased gradually, all using a uniform technique.47, 48
DÊÙã½®ãùÄÝçÙò®ò½
EŝŶĞƉĞƌĐĞŶƚŽĨĂůůĐĂŶĐĞƌƉĂƟĞŶƚƐĚŝĞĨƌŽŵĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͕ ŵĂŬŝŶŐŝƚƚŚĞĨŽƵƌƚŚŵŽƐƚ
common cause of death from cancer worldwide.1/ŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͕ϱ͕ϭϭϳƉĂƟĞŶƚƐĚŝĞĚ








ĐŽŶƚƌŝďƵƚĞĚ ƚŽ ďĞƩĞƌ ƉĞƌŝŽƉĞƌĂƟǀĞ ĐĂƌĞ ĂŶĚ Ă ĚĞĐƌĞĂƐĞ ŽĨ ŵŽƌďŝĚŝƚǇ ďǇ ŵŝŶŝŵĂůůǇ
invasive surgery.52, 53 &ƵƌƚŚĞƌŵŽƌĞ͕ ŽǀĞƌ ƟŵĞ ƚŚĞ ĂĚŵŝŶŝƐƚƌĂƟŽŶ ŽĨ ;;ŶĞŽͿĂĚũƵǀĂŶƚͿ






























FIGURE 2 dƌĞŶĚŝŶƉŽƐƚŽƉĞƌĂƟǀĞϯϬͲĚĂǇŵŽƌƚĂůŝƚǇŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐĚŝĂŐŶŽƐĞĚŝŶƚŚĞ 
 Netherlands between 2005-2014, by year of diagnosis.



























FIGURE 3  dƌĞŶĚŝŶϭͲ͕ϯͲ͕ĂŶĚϱͲǇĞĂƌƌĞůĂƟǀĞƐƵƌǀŝǀĂůŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐĚŝĂŐŶŽƐĞĚŝŶƚŚĞ 
 Netherlands between 1989-2014, by period of diagnosis.
 Source: Netherlands Cancer Registry















care and outcome. 
^ƵƌǀŝǀĂů ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŝƐ ŝŶŇƵĞŶĐĞĚ ďǇ ǀĂƌŝŽƵƐ ĚĞƚĞƌŵŝŶĂŶƚƐ͘ dƵŵŽƵƌͲƌĞůĂƚĞĚ
ĨĂĐƚŽƌƐ ŝŶĐůƵĚŝŶŐ ƚƵŵŽƵƌ ƐƚĂŐĞ ĂŶĚ ĚŝīĞƌĞŶƟĂƟŽŶ ŐƌĂĚĞ ůĂƌŐĞůǇ ŝŶŇƵĞŶĐĞ ƐƵƌǀŝǀĂů͘
WĂƟĞŶƚĐŚĂƌĂĐƚĞƌŝƐƟĐƐůŝŬĞĂŐĞĂƚĚŝĂŐŶŽƐŝƐĂŶĚĐŽŵŽƌďŝĚŝƚǇŽŌĞŶŝŶŇƵĞŶĐĞƚŚĞĐŚŽŝĐĞŽĨ
oncological treatment, which results in altered survival rates. Furthermore, demographic 
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1WÙã/͗Ê½ÊÙã½ÄÙÝçÙò®ò½͗ÄÊòÙ½½Ö®ãçÙChapter 2 ŐŝǀĞƐ ĂŶ ŽǀĞƌǀŝĞǁ ŽĨ ƚƌĞŶĚƐ ŝŶ ƐƵƌǀŝǀĂů ĂŵŽŶŐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ
diagnosed between 1989-2014 in the Netherlands. Chapter 3 compares survival rates 
ĂŵŽŶŐŶŽŶͲŵĞƚĂƐƚĂƐƟĐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐďĞƚǁĞĞŶĚŝīĞƌĞŶƚĂŐĞŐƌŽƵƉƐ͘
WÙã//͗ãÙÃ®ÄÄãÝÊ¥ÝçÙò®ò½
Chapter 4 ƌĞǀĞĂůƐ ǁŚĞƚŚĞƌ ƐĞĐŽŶĚ ĐŽůŽƌĞĐƚĂů ƚƵŵŽƵƌƐ ŚĂǀĞ ĂŶ ĞīĞĐƚ ŽŶ ŽŶĐŽůŽŐŝĐĂů
ƚƌĞĂƚŵĞŶƚ͕ƐŚŽƌƚͲĂŶĚůŽŶŐͲƚĞƌŵƉĂƟĞŶƚŽƵƚĐŽŵĞƐ͘Chapter 5 analyzes whether hospital 
ǀŽůƵŵĞĨŽƌĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ ŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚƐƵƌŐŝĐĂůĐĂƌĞĐŚĂƌĂĐƚĞƌŝƐƟĐƐĂŶĚŽǀĞƌĂůů
ƐƵƌǀŝǀĂů͘ /Ŷchapter 6ƉƌĞĚŝĐƟŽŶŵŽĚĞůƐ ĨŽƌƉŽƐƚŽƉĞƌĂƟǀĞϵϬͲĚĂǇŵŽƌƚĂůŝƚǇĂŶĚŽǀĞƌĂůů
ƐƵƌǀŝǀĂůĨŽƌĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐĂƌĞĚĞǀĞůŽƉĞĚĂŶĚǀĂůŝĚĂƚĞĚ͘Chapter 7ŝŶǀĞƐƟŐĂƚĞƐ
ǁŚŝĐŚ ĚĞŵŽŐƌĂƉŚŝĐ ĂŶĚ ĐůŝŶŝĐĂů ǀĂƌŝĂďůĞƐ ĂƌĞ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ƚŚĞ ƟŵŝŶŐ ŽĨ ĂĚũƵǀĂŶƚ
ĐŚĞŵŽƚŚĞƌĂƉǇĂŶĚŚŽǁƚŚŝƐƟŵŝŶŐŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚŽǀĞƌĂůůƐƵƌǀŝǀĂů͘




dŚĞ ƐƚƵĚŝĞƐ ŝŶ ƚŚŝƐ ƚŚĞƐŝƐ ĂƌĞ ďĂƐĞĚ ŽŶ ĚĂƚĂ ĨƌŽŵ ƚŚĞ ŶĂƟŽŶǁŝĚĞEĞƚŚĞƌůĂŶĚƐ ĂŶĐĞƌ
ZĞŐŝƐƚƌǇ;EZͿ͕ŵĂŶĂŐĞĚďǇƚŚĞEĞƚŚĞƌůĂŶĚƐŽŵƉƌĞŚĞŶƐŝǀĞĂŶĐĞƌKƌŐĂŶŝƐĂƟŽŶ;/<E>Ϳ͘
dŚĞEZǁĂƐĞƐƚĂďůŝƐŚĞĚŝŶϭϵϴϵĂŶĚŝƐĂƉŽƉƵůĂƟŽŶͲďĂƐĞĚƌĞŐŝƐƚƌǇďĂƐĞĚŽŶŶŽƟĮĐĂƟŽŶ
of all newly diagnosed malignancies in the Netherlands by the automated pathological 
ĂƌĐŚŝǀĞ;W>'ͿĂŶĚƚŚĞEĂƟŽŶĂůZĞŐŝƐƚƌǇŽĨ,ŽƐƉŝƚĂůŝƐĐŚĂƌŐĞŝĂŐŶŽƐŝƐ ;>DZͿ͘^ŝŶĐĞ
ϭϵϵϯ͕ ƚŚĞ ƐŽƵƚŚĞĂƐƚ ƉĂƌƚ ŽĨ ƚŚĞEĞƚŚĞƌůĂŶĚƐ ƌĞŐŝƐƚĞƌƐ ĐŽŵŽƌďŝĚ ĐŽŶĚŝƟŽŶƐ ƉƌĞƐĞŶƚ Ăƚ
ƟŵĞŽĨĐĂŶĐĞƌĚŝĂŐŶŽƐŝƐ͘62, 63dŚĞEZŝƐƵƐĞĚĨŽƌƐƵƉƉŽƌƟŶŐĞƉŝĚĞŵŝŽůŽŐŝĐĂůĂŶĚĐůŝŶŝĐĂů
ƌĞƐĞĂƌĐŚ͕ĚĞǀĞůŽƉŝŶŐĂŶĚĞǀĂůƵĂƟŶŐŐƵŝĚĞůŝŶĞƐ͕ĞǀĂůƵĂƟŶŐƐĐƌĞĞŶŝŶŐƉƌŽŐƌĂŵƐ͕ƉůĂŶŶŝŶŐ







sŝƚĂů ƐƚĂƚƵƐŽĨ Ăůů ƉĂƟĞŶƚƐ ŝƐ ŽďƚĂŝŶĞĚĂĐƟǀĞůǇŽŶĂ ƌĞŐƵůĂƌďĂƐŝƐ ďǇ ůŝŶŬŝŶŐ ƚŚĞ ĐĂŶĐĞƌ
ƌĞŐŝƐƚƌǇĚĂƚĂďĂƐĞƚŽƚŚĞDƵŶŝĐŝƉĂůWĞƌƐŽŶĂůZĞĐŽƌĚƐĂƚĂďĂƐĞ;'Ϳ͘
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impact of dietary and lifestyle risk factors 
ŽŶƌŝƐŬŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͗ĂƋƵĂŶƟƚĂƟǀĞ
overview of the epidemiological evidence. 
/Ŷƚ:ĂŶĐĞƌ͘ ϮϬϬϵ͖ϭϮϱ;ϭͿ͗ϭϳϭͲϴϬ͘
ϳ͘ &ůŽƐƐŵĂŶŶ͕ZŽƚŚǁĞůůWD͕ƌŝƟƐŚŽĐƚŽƌƐ
ƐƉŝƌŝŶ d͕  ƚŚĞ h<d/d͘  īĞĐƚ ŽĨ ĂƐƉŝƌŝŶ
ŽŶ ůŽŶŐͲƚĞƌŵ ƌŝƐŬ ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͗
consistent evidence from randomised 
ĂŶĚ ŽďƐĞƌǀĂƟŽŶĂů ƐƚƵĚŝĞƐ͘ >ĂŶĐĞƚ͘
ϮϬϬϳ͖ϯϲϵ;ϵϱϳϯͿ͗ϭϲϬϯͲϭϯ͘
ϴ͘ ZĞŶŶĞƌƚ'͕ZĞŶŶĞƌƚ,^͕WŝŶĐŚĞǀD͕>ĂǀŝĞK͕
'ƌƵďĞƌ ^͘ hƐĞ ŽĨ ŚŽƌŵŽŶĞ ƌĞƉůĂĐĞŵĞŶƚ
therapy and the risk of colorectal cancer. J 
ůŝŶKŶĐŽů͘ϮϬϬϵ͖Ϯϳ;ϮϳͿ͗ϰϱϰϮͲϳ͘
ϵ͘ ĂƵŵŐĂƌƚ͕^ĂŶĚďŽƌŶt:͘ /ŶŇĂŵŵĂƚŽƌǇ
ďŽǁĞů ĚŝƐĞĂƐĞ͗ ĐůŝŶŝĐĂů ĂƐƉĞĐƚƐ ĂŶĚ
ĞƐƚĂďůŝƐŚĞĚĂŶĚĞǀŽůǀŝŶŐƚŚĞƌĂƉŝĞƐ͘>ĂŶĐĞƚ͘
ϮϬϬϳ͖ϯϲϵ;ϵϱϳϯͿ͗ϭϲϰϭͲϱϳ͘
10. Netherlands Comprehensive Cancer 
KƌŐĂŶŝƐĂƟŽŶ͘ EĂƟŽŶĂů ǀŝĚĞŶĐĞ ĂƐĞĚ
Guideline for Colon and Rectal Cancer 2014 
΀ϯͲϴͲϮϬϭϳ΁͘ ǀĂŝůĂďůĞ ĨƌŽŵ͗ ŚƩƉ͗ͬͬǁǁǁ͘
ŽŶĐŽůŝŶĞ͘ŶůͬĐŽůŽŶĐĂƌĐŝŶŽŽŵ͘
ϭϭ͘ tŝƩĞŬŝŶĚ  '&͕  ,ƵƩĞƌ Z͕ <ůŝŵƉĮŶŐĞƌ D͕
^ŽďŝŶ>͘dEDƚůĂƐ͘ĞƌůŝŶ͗^ƉƌŝŶŐĞƌͲsĞƌůĂŐ͖
2004.
ϭϮ͘ >ĞŵŵĞŶƐ s͕ ǀĂŶ ^ƚĞĞŶďĞƌŐĞŶ >͕ :ĂŶƐƐĞŶͲ
,ĞŝũŶĞŶD͕DĂƌƟũŶ,͕ZƵƩĞŶ,͕ŽĞďĞƌŐŚ
JW. Trends in colorectal cancer in the south 
ŽĨ ƚŚĞ EĞƚŚĞƌůĂŶĚƐ ϭϵϳϱͲϮϬϬϳ͗ ƌĞĐƚĂů
cancer survival levels with colon cancer 
ƐƵƌǀŝǀĂů͘ĐƚĂKŶĐŽů͘ϮϬϭϬ͖ϰϵ;ϲͿ͗ϳϴϰͲϵϲ͘
ϭϯ͘ >ĞŵŵĞŶƐs͕<ůĂǀĞƌz>͕sĞƌǁĂĂůs:͕ZƵƩĞŶ
,:͕ ŽĞďĞƌŐŚ :t͕ ĚĞ ,ŝŶŐŚ /,͘ WƌĞĚŝĐƚŽƌƐ
and survival of synchronous peritoneal 
ĐĂƌĐŝŶŽŵĂƚŽƐŝƐ ŽĨ ĐŽůŽƌĞĐƚĂů ŽƌŝŐŝŶ͗ Ă
ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚǇ͘ /Ŷƚ : ĂŶĐĞƌ͘ 
ϮϬϭϭ͖ϭϮϴ;ϭϭͿ͗ϮϳϭϳͲϮϱ͘
14. Jacobs M, Verdeja JC, Goldstein HS. 
DŝŶŝŵĂůůǇ ŝŶǀĂƐŝǀĞ ĐŽůŽŶ ƌĞƐĞĐƟŽŶ
;ůĂƉĂƌŽƐĐŽƉŝĐ ĐŽůĞĐƚŽŵǇͿ͘ ^ƵƌŐ >ĂƉĂƌŽƐĐ
ŶĚŽƐĐ͘ϭϵϵϭ͖ϭ;ϯͿ͗ϭϰϰͲϱϬ͘
ϭϱ͘ ,ĂŵĂŬĞƌ D͕ ^ĐŚŝƉŚŽƌƐƚ ,͕ sĞƌǁĞŝũ
ED͕ WƌŽŶŬ ͘ /ŵƉƌŽǀĞĚ ƐƵƌǀŝǀĂů ĨŽƌ ŽůĚĞƌ
ƉĂƟĞŶƚƐƵŶĚĞƌŐŽŝŶŐ ƐƵƌŐĞƌǇ ĨŽƌ ĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌ ďĞƚǁĞĞŶ ϮϬϬϴ ĂŶĚ ϮϬϭϭ͘ /Ŷƚ :
ŽůŽƌĞĐƚĂůŝƐ͘ϮϬϭϰ͖Ϯϵ;ϭϬͿ͗ϭϮϯϭͲϲ͘
16. Schwenk W, Haase O, Neudecker J, Muller 
:D͘ ^ŚŽƌƚ ƚĞƌŵ ďĞŶĞĮƚƐ ĨŽƌ ůĂƉĂƌŽƐĐŽƉŝĐ
ĐŽůŽƌĞĐƚĂů ƌĞƐĞĐƟŽŶ͘ ŽĐŚƌĂŶĞ ĂƚĂďĂƐĞ
^ǇƐƚZĞǀ͘ ϮϬϬϱ;ϯͿ͗ϬϬϯϭϰϱ͘
ϭϳ͘ KŚƚĂŶŝ,͕dĂŵĂŵŽƌŝz͕ ƌŝŵŽƚŽz͕ EŝƐŚŝŐƵĐŚŝ
z͕  DĂĞĚĂ <͕ ,ŝƌĂŬĂǁĂ <͘  ŵĞƚĂͲĂŶĂůǇƐŝƐ
of the short- and long-term results of 
randomized controlled trials that compared 
laparoscopy-assisted and open colectomy 
ĨŽƌĐŽůŽŶĐĂŶĐĞƌ͘ :ĂŶĐĞƌ͘ ϮϬϭϮ͖ϯ͗ϰϵͲϱϳ͘
ϭϴ͘ dƌĂƐƚƵůůŝ ^͕ ŝƌŽĐĐŚŝ Z͕ >ŝƐƚŽƌƟ ͕ ĂǀĂůŝĞƌĞ
͕ ǀĞŶŝĂ E͕ 'ƵůůĂ E͕ Ğƚ Ăů͘ >ĂƉĂƌŽƐĐŽƉŝĐ
ǀƐ ŽƉĞŶ ƌĞƐĞĐƟŽŶ ĨŽƌ ƌĞĐƚĂů ĐĂŶĐĞƌ͗ Ă
meta-analysis of randomized clinical trials. 
ŽůŽƌĞĐƚĂůŝƐ͘ϮϬϭϮ͖ϭϰ;ϲͿ͗ĞϮϳϳͲϵϲ͘
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1ϭϵ͘ <ƵŚƌǇ ͕ ^ĐŚǁĞŶŬ t͕ 'ĂƵƉƐĞƚ Z͕ ZŽŵŝůĚ
h͕ ŽŶũĞƌ :͘ >ŽŶŐͲƚĞƌŵ ŽƵƚĐŽŵĞ ŽĨ
laparoscopic surgery for colorectal 
ĐĂŶĐĞƌ͗ Ă ĐŽĐŚƌĂŶĞ ƐǇƐƚĞŵĂƟĐ ƌĞǀŝĞǁ ŽĨ
randomised controlled trials. Cancer Treat 
ZĞǀ͘ ϮϬϬϴ͖ϯϰ;ϲͿ͗ϰϵϴͲϱϬϰ͘
ϮϬ͘ ^ĂƌŐĞŶƚ͕^ŽďƌĞƌŽ͕'ƌŽƚŚĞǇ͕K͛ŽŶŶĞůů
D:͕ ƵǇƐĞD͕ŶĚƌĞ d͕  Ğƚ Ăů͘ ǀŝĚĞŶĐĞ ĨŽƌ
ĐƵƌĞďǇĂĚũƵǀĂŶƚ ƚŚĞƌĂƉǇ ŝŶ ĐŽůŽŶ ĐĂŶĐĞƌ͗
ŽďƐĞƌǀĂƟŽŶƐ ďĂƐĞĚ ŽŶ ŝŶĚŝǀŝĚƵĂů ƉĂƟĞŶƚ
ĚĂƚĂĨƌŽŵϮϬ͕ϴϵϴƉĂƟĞŶƚƐŽŶϭϴƌĂŶĚŽŵŝǌĞĚ
ƚƌŝĂůƐ͘:ůŝŶKŶĐŽů͘ϮϬϬϵ͖Ϯϳ;ϲͿ͗ϴϳϮͲϳ͘
Ϯϭ͘ ŶĚƌĞ d͕  ŽůŝŶ W͕  >ŽƵǀĞƚ ͕ 'ĂŵĞůŝŶ ͕
ŽƵĐŚĞ K͕ ĐŚŝůůĞ ͕ Ğƚ Ăů͘ ^ĞŵŝŵŽŶƚŚůǇ
ǀĞƌƐƵƐŵŽŶƚŚůǇƌĞŐŝŵĞŶŽĨŇƵŽƌŽƵƌĂĐŝůĂŶĚ




22. Bleeker WA, Mulder NH, Hermans J, 
KƩĞƌ Z͕ WůƵŬŬĞƌ :d͘  dŚĞ ĂĚĚŝƟŽŶ ŽĨ ůŽǁͲ





23. Haller DG, Catalano PJ, Macdonald JS, 
K͛ZŽƵƌŬĞD͕&ƌŽŶƟĞƌĂD^͕:ĂĐŬƐŽŶs͕Ğƚ
Ăů͘WŚĂƐĞ///ƐƚƵĚǇŽĨŇƵŽƌŽƵƌĂĐŝů͕ůĞƵĐŽǀŽƌŝŶ͕
ĂŶĚ ůĞǀĂŵŝƐŽůĞ ŝŶŚŝŐŚͲƌŝƐŬ ƐƚĂŐĞ // ĂŶĚ ///
ĐŽůŽŶ ĐĂŶĐĞƌ͗ ĮŶĂů ƌĞƉŽƌƚ ŽĨ /ŶƚĞƌŐƌŽƵƉ
ϬϬϴϵ͘:ůŝŶKŶĐŽů͘ϮϬϬϱ͖Ϯϯ;ϯϰͿ͗ϴϲϳϭͲϴ͘
24. Moertel CG, Fleming TR, Macdonald JS, 
,ĂůůĞƌ '͕ >ĂƵƌŝĞ :͕ dĂŶŐĞŶ D͕ Ğƚ Ăů͘




Ϯϱ͘ ŶŬĞƌt͕dŚĂůĞƌ,d͕ ƌĂŶŽƌD>͕WŽůǇĂŬd͘ 
dŽƚĂůŵĞƐŽƌĞĐƚĂů ĞǆĐŝƐŝŽŶ ŝŶ ƚŚĞ ŽƉĞƌĂƟǀĞ
treatment of carcinoma of the rectum. J 
ŵŽůů^ƵƌŐ͘ϭϵϵϱ͖ϭϴϭ;ϰͿ͗ϯϯϱͲϰϲ͘
26. Camma C, Giunta M, Fiorica F, Pagliaro 
>͕ ƌĂǆŝ ͕ ŽƩŽŶĞ D͘ WƌĞŽƉĞƌĂƟǀĞ
ƌĂĚŝŽƚŚĞƌĂƉǇ ĨŽƌ ƌĞƐĞĐƚĂďůĞ ƌĞĐƚĂů ĐĂŶĐĞƌ͗
ŵĞƚĂͲĂŶĂůǇƐŝƐ͘ :D͘ϮϬϬϬ͖Ϯϴϰ;ϴͿ͗ϭϬϬϴͲ
15.
Ϯϳ͘ <ĂƉŝƚĞŝũŶ ͕ DĂƌŝũŶĞŶ ͕ EĂŐƚĞŐĂĂů /͕
WƵƩĞƌ ,͕ ^ƚĞƵƉ t,͕ tŝŐŐĞƌƐ d͕  Ğƚ Ăů͘
WƌĞŽƉĞƌĂƟǀĞ ƌĂĚŝŽƚŚĞƌĂƉǇ ĐŽŵďŝŶĞĚ
ǁŝƚŚ ƚŽƚĂů ŵĞƐŽƌĞĐƚĂů ĞǆĐŝƐŝŽŶ ĨŽƌ
ƌĞƐĞĐƚĂďůĞ ƌĞĐƚĂů ĐĂŶĐĞƌ͘  E ŶŐů : DĞĚ͘
ϮϬϬϭ͖ϯϰϱ;ϵͿ͗ϲϯϴͲϰϲ͘
28. Swedish Rectal Cancer T, Cedermark 
B, Dahlberg M, Glimelius B, Pahlman 
>͕ ZƵƚƋǀŝƐƚ >͕ Ğƚ Ăů͘ /ŵƉƌŽǀĞĚ ƐƵƌǀŝǀĂů
ǁŝƚŚ ƉƌĞŽƉĞƌĂƟǀĞ ƌĂĚŝŽƚŚĞƌĂƉǇ ŝŶ
ƌĞƐĞĐƚĂďůĞ ƌĞĐƚĂů ĐĂŶĐĞƌ͘  E ŶŐů : DĞĚ͘
ϭϵϵϳ͖ϯϯϲ;ϭϰͿ͗ϵϴϬͲϳ͘
Ϯϵ͘ ŽƐƐĞƚ :&͕  ŽůůĞƩĞ >͕ ĂůĂŝƐ '͕ DŝŶĞƵƌ
>͕ DĂŝŶŐŽŶ W͕  ZĂĚŽƐĞǀŝĐͲ:ĞůŝĐ >͕ Ğƚ
Ăů͘ ŚĞŵŽƚŚĞƌĂƉǇ ǁŝƚŚ ƉƌĞŽƉĞƌĂƟǀĞ
ƌĂĚŝŽƚŚĞƌĂƉǇŝŶƌĞĐƚĂůĐĂŶĐĞƌ͘ EŶŐů:DĞĚ͘
ϮϬϬϲ͖ϯϱϱ;ϭϭͿ͗ϭϭϭϰͲϮϯ͘
30. Gerard JP, Conroy T, Bonnetain F, Bouche 
O, Chapet O, Closon-Dejardin MT, et al. 
WƌĞŽƉĞƌĂƟǀĞƌĂĚŝŽƚŚĞƌĂƉǇǁŝƚŚŽƌǁŝƚŚŽƵƚ
ĐŽŶĐƵƌƌĞŶƚ ŇƵŽƌŽƵƌĂĐŝů ĂŶĚ ůĞƵĐŽǀŽƌŝŶ ŝŶ
dϯͲϰƌĞĐƚĂůĐĂŶĐĞƌƐ͗ƌĞƐƵůƚƐŽĨ&&ϵϮϬϯ͘:
ůŝŶKŶĐŽů͘ϮϬϬϲ͖Ϯϰ;ϮϴͿ͗ϰϲϮϬͲϱ͘
ϯϭ͘ DĂĂƐD͕ EĞůĞŵĂŶƐ W:͕ sĂůĞŶƟŶŝ s͕ ĂƐ W͕ 
ZŽĚĞů͕<ƵŽ>:͕ĞƚĂů͘>ŽŶŐͲƚĞƌŵŽƵƚĐŽŵĞ
ŝŶ ƉĂƟĞŶƚƐ ǁŝƚŚ Ă ƉĂƚŚŽůŽŐŝĐĂů ĐŽŵƉůĞƚĞ
ƌĞƐƉŽŶƐĞ ĂŌĞƌ ĐŚĞŵŽƌĂĚŝĂƟŽŶ ĨŽƌ ƌĞĐƚĂů
ĐĂŶĐĞƌ͗ Ă ƉŽŽůĞĚ ĂŶĂůǇƐŝƐ ŽĨ ŝŶĚŝǀŝĚƵĂů
ƉĂƟĞŶƚĚĂƚĂ͘>ĂŶĐĞƚKŶĐŽů͘ϮϬϭϬ͖ϭϭ;ϵͿ͗ϴϯϱͲ
44.
32. Habr-Gama A, Perez RO, Nadalin W, 
^ĂďďĂŐĂ:͕ZŝďĞŝƌŽh͕:ƌ͘ ͕^ŝůǀĂĞ^ŽƵƐĂ,͕
:ƌ͘ ͕ Ğƚ Ăů͘ KƉĞƌĂƟǀĞ ǀĞƌƐƵƐ ŶŽŶŽƉĞƌĂƟǀĞ
treatment for stage 0 distal rectal cancer 
ĨŽůůŽǁŝŶŐ ĐŚĞŵŽƌĂĚŝĂƟŽŶ ƚŚĞƌĂƉǇ͗ ůŽŶŐͲ
ƚĞƌŵƌĞƐƵůƚƐ͘ŶŶ^ƵƌŐ͘ϮϬϬϰ͖ϮϰϬ;ϰͿ͗ϳϭϭͲϳ͖
discussion 7-8.
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ϯϯ͘ DĞƵůĞŶďĞůĚ ,:͕ ǀĂŶ ^ƚĞĞŶďĞƌŐĞŶ >E͕
:ĂŶƐƐĞŶͲ,ĞŝũŶĞŶ D>͕ >ĞŵŵĞŶƐ s͕
ƌĞĞŵĞƌƐ ':͘ ^ŝŐŶŝĮĐĂŶƚ ŝŵƉƌŽǀĞŵĞŶƚ
ŝŶ ƐƵƌǀŝǀĂů ŽĨ ƉĂƟĞŶƚƐ ƉƌĞƐĞŶƟŶŐ ǁŝƚŚ
ŵĞƚĂƐƚĂƟĐ ĐŽůŽŶ ĐĂŶĐĞƌ ŝŶ ƚŚĞ ƐŽƵƚŚ ŽĨ




Trendsin incidence, treatment and survival 
ŽĨƉĂƟĞŶƚƐǁŝƚŚƐƚĂŐĞ/sĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͗
Ă ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐĞƌŝĞƐ͘ ŽůŽƌĞĐƚĂů ŝƐ͘
ϮϬϭϮ͖ϭϰ;ϭͿ͗ϱϲͲϲϭ͘
35. Galandiuk S, Wieand HS, Moertel CG, 
Cha SS, Fitzgibbons RJ, Jr., Pemberton 
:,͕ Ğƚ Ăů͘ WĂƩĞƌŶƐ ŽĨ ƌĞĐƵƌƌĞŶĐĞ ĂŌĞƌ
ĐƵƌĂƟǀĞ ƌĞƐĞĐƟŽŶ ŽĨ ĐĂƌĐŝŶŽŵĂ ŽĨ ƚŚĞ
colon and rectum. Surg Gynecol Obstet. 
ϭϵϵϮ͖ϭϳϰ;ϭͿ͗ϮϳͲϯϮ͘
ϯϲ͘ DĐƌĚůĞ ͘  ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͗
ĞīĞĐƟǀĞŶĞƐƐ ŽĨ ĨŽůůŽǁ ƵƉ͘ D:͘
ϮϬϬϬ͖ϯϮϭ;ϳϮϳϮͿ͗ϭϯϯϮͲϱ͘
ϯϳ͘ ,Ƶƌǁŝƚǌ ,͕ &ĞŚƌĞŶďĂĐŚĞƌ >͕ EŽǀŽƚŶǇ t͕
Cartwright T, Hainsworth J, Heim W, et al. 
ĞǀĂĐŝǌƵŵĂď ƉůƵƐ ŝƌŝŶŽƚĞĐĂŶ͕ ŇƵŽƌŽƵƌĂĐŝů͕
ĂŶĚ ůĞƵĐŽǀŽƌŝŶ ĨŽƌ ŵĞƚĂƐƚĂƟĐ ĐŽůŽƌĞĐƚĂů





ĂƐ ĮƌƐƚͲůŝŶĞ ƚƌĞĂƚŵĞŶƚ ĨŽƌ ŵĞƚĂƐƚĂƟĐ
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͗ ƵƉĚĂƚĞĚ ĂŶĂůǇƐŝƐ ŽĨ
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Results from the Dutch Cancer Registry
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The incidence of both colon and rectal cancer has risen. The use of adjuvant chemotherapy 
ĨŽƌƐƚĂŐĞ///ĐŽůŽŶĐĂŶĐĞƌŝŶĐƌĞĂƐĞĚ͕ĂƐǁĞůůĂƐƚŚĞƵƐĞŽĨŶĞŽĂĚũƵǀĂŶƚ;ĐŚĞŵŽͿƌĂĚŝŽƚŚĞƌĂƉǇ
ĨŽƌƌĞĐƚĂůĐĂŶĐĞƌ;ϭϰйƚŽϲϬйĂŶĚϮйƚŽϲϲйƌĞƐƉĞĐƟǀĞůǇͿ͘dŚĞĂĚŵŝŶŝƐƚƌĂƟŽŶŽĨƐǇƐƚĞŵŝĐ






ďĞ ĂƩƌŝďƵƚĞĚ ƚŽ ƚŚĞŽŶŐŽŝŶŐ ĂĚǀĂŶĐĞŵĞŶƚƐ ŝŶ ƚƌĞĂƚŵĞŶƚ͕ ďƵƚ ĂůƐŽ ƚŽ ŝŵƉƌŽǀĞŵĞŶƚ ŝŶ
ŽƚŚĞƌĨĂĐƚŽƌƐŝŶƚŚĞĐĂƌĞŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͕ƉĂƌƟĐƵůĂƌůǇŝŶŵŽƌĞƌĞĐĞŶƚǇĞĂƌƐ͘
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INTRODUCTION
Colorectal cancer is one of the most common cancer types in developed countries, with 
ŵŽƌĞƚŚĂŶϭϱ͕ϬϬϬƉĂƟĞŶƚƐĚŝĂŐŶŽƐĞĚ ŝŶ ƚŚĞEĞƚŚĞƌůĂŶĚƐ ŝŶϮϬϭϲ͘1, 2 The epidemiology 
ĂŶĚƚƌĞĂƚŵĞŶƚŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌŚĂǀĞƐĞĞŶŵĂũŽƌĐŚĂŶŐĞƐŽǀĞƌƚŚĞǇĞĂƌƐ͕ĂŶĚĂƌĞƐƟůů
ĐŚĂŶŐŝŶŐƚŽĚĂǇ͘dŚĞŝŶĐŝĚĞŶĐĞŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌŝŶƚŚĞƵƚĐŚƉŽƉƵůĂƟŽŶŚĂƐŝŶĐƌĞĂƐĞĚ
ŽǀĞƌ ƟŵĞ ĂŶĚ ĂůƚŚŽƵŐŚ ŵŽƌƚĂůŝƚǇ ƌĂƚĞƐ ŚĂǀĞ ĚĞĐƌĞĂƐĞĚ͕ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŝƐ ƐƟůů ƚŚĞ
ƐĞĐŽŶĚůĞĂĚŝŶŐĐĂƵƐĞŽĨĐĂŶĐĞƌͲƌĞůĂƚĞĚĚĞĂƚŚ͕ĂĐĐŽƵŶƟŶŐĨŽƌŽǀĞƌϰ͕ϵϬϬĚĞĂƚŚƐŝŶϮϬϭϰ͘1 
dŽ ĨƵƌƚŚĞƌ ĚĞĐƌĞĂƐĞ ŵŽƌƚĂůŝƚǇ ƌĂƚĞƐ͕ ƚŚĞ ƵƚĐŚ ŐŽǀĞƌŶŵĞŶƚ ŝŶƚƌŽĚƵĐĞĚ Ă ŶĂƟŽŶǁŝĚĞ




ƐƵĐĐĞƐƐĨƵůŵƵůƟŵŽĚĂůŝƚǇŵĂŶĂŐĞŵĞŶƚŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƌĞƋƵŝƌĞƐ ĂŵƵůƟĚŝƐĐŝƉůŝŶĂƌǇ
ĂƉƉƌŽĂĐŚ͕ ĚƵĞ ƚŽ ƚŚĞ ƌĂƉŝĚůǇ ŝŶĐƌĞĂƐŝŶŐ ĚŝĂŐŶŽƐƟĐ ĂŶĚ ƚŚĞƌĂƉĞƵƟĐ ŽƉƟŽŶƐ ŝŶ ƚŚĞƐĞ
ĚŝīĞƌĞŶƚĂƐƉĞĐƚƐŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌĐĂƌĞ͘dƐĐĂŶŶŝŶŐŚĂƐďĞĐŽŵĞƐƚĂŶĚĂƌĚĨŽƌƐƚĂŐŝŶŐ









12&ŽƌŵĞƚĂƐƚĂƟĐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͕  ƚŚĞƵƐĞŽĨĐŽŵďŝŶĂƟŽŶĐŚĞŵŽƚŚĞƌĂƉǇ͕ ǀĂƌŝŽƵƐŶĞǁ
ƐǇƐƚĞŵŝĐ ĂŶĚ ƌĞŐŝŽŶĂů ŵƵůƟŵŽĚĂůŝƚǇ ƚƌĞĂƚŵĞŶƚ͕ ŵĞƚĂƐƚĂƐĞĐƚŽŵŝĞƐ ĂŶĚ ŽƚŚĞƌ ůŽĐĂů
treatments are increasingly being performed.13-16 
ZĞŐĂƌĚŝŶŐƚŚĞĐŽŶƟŶƵŽƵƐĐŚĂŶŐĞƐŝŶƚŚĞĚŝĂŐŶŽƐƟĐƉƌŽĐĞƐƐĂŶĚƚƌĞĂƚŵĞŶƚŽĨĐŽůŽƌĞĐƚĂů




colorectal cancer between 1989 and 2014 in the Netherlands, which are considered to be 
ŝŶĚŝĐĂƟǀĞĨŽƌŽƚŚĞƌĮƌƐƚǁŽƌůĚĐŽƵŶƚƌŝĞƐ͘
26 | C H A P T E R  2
METHODS
ãÊ½½ã®ÊÄ
EĂƟŽŶǁŝĚĞ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ĚĂƚĂ ŽŶ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĨƌŽŵ ϭϵϴϵ ŽŶǁĂƌĚƐ
ǁĞƌĞŽďƚĂŝŶĞĚĨƌŽŵƚŚĞEĞƚŚĞƌůĂŶĚƐĂŶĐĞƌZĞŐŝƐƚƌǇ;EZͿ͘^ŝŶĐĞϭϵϴϵ͕ƚŚĞEZƌĞŐŝƐƚĞƌƐ
ĂůůŶĞǁůǇĚŝĂŐŶŽƐĞĚŵĂůŝŐŶĂŶĐŝĞƐŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͘dŚĞEZƌĞĐĞŝǀĞƐƚŚĞŶŽƟĮĐĂƟŽŶ
mainly from the pathology departments of hospitals, all taking part in the automated 
ƉĂƚŚŽůŽŐǇ ĂƌĐŚŝǀĞ ;W>'Ϳ͕ ĂŶĚ ƚŚĞEĂƟŽŶĂů ZĞŐŝƐƚƌǇ ŽĨ ,ŽƐƉŝƚĂů ŝƐĐŚĂƌŐĞ ŝĂŐŶŽƐĞƐ
;>DZͿ͘&ŽůůŽǁŝŶŐƚŚĞŶŽƟĮĐĂƟŽŶ͕ƚƌĂŝŶĞĚƌĞŐŝƐƚƌĂƌƐŐĂƚŚĞƌƉĂƟĞŶƚ͕ƚƵŵŽƵƌĂŶĚƚƌĞĂƚŵĞŶƚ
ĐŚĂƌĂĐƚĞƌŝƐƟĐƐĚŝƌĞĐƚůǇĨƌŽŵƚŚĞŵĞĚŝĐĂůƌĞĐŽƌĚƐ͘
ŶĂƚŽŵŝĐĂů ƐƵďƐŝƚĞ ŽĨ ƚŚĞ ƚƵŵŽƵƌ ŝƐ ĐŽĚĞĚ ĂĐĐŽƌĚŝŶŐ ƚŽ /ŶƚĞƌŶĂƟŽŶĂů ůĂƐƐŝĮĐĂƟŽŶ ŽĨ
ŝƐĞĂƐĞƐ ĨŽƌKŶĐŽůŽŐǇ ;/ͲKͿ͘17 dŚĞ dED ;ƚƵŵŽƵƌͲŶŽĚĞͲŵĞƚĂƐƚĂƐŝƐͿ ĐůĂƐƐŝĮĐĂƟŽŶǁĂƐ
ƵƐĞĚĨŽƌƐƚĂŐĞŶŽƟĮĐĂƟŽŶŽĨƚŚĞƉƌŝŵĂƌǇƚƵŵŽƵƌ͕ ĂĐĐŽƌĚŝŶŐƚŽƚŚĞĞĚŝƟŽŶǀĂůŝĚĂƚƟŵĞ
of cancer diagnosis.18 WĂƚŚŽůŽŐŝĐĂů dED ƚŽŽŬƉƌĞĐĞĚĞŶĐĞŽǀĞƌ ĐůŝŶŝĐĂů ƐƚĂŐĞĞǆĐĞƉƚ ĨŽƌ
ƵŶŬŶŽǁŶƉĂƚŚŽůŽŐŝĐĂůƐƚĂŐĞ͘/ŶĐĂƐĞŽĨĂƉŽƐŝƟǀĞĐD͕ƐƚĂŐĞǁĂƐĂůǁĂǇƐƌĞŐŝƐƚĞƌĞĚĂƐƐƚĂŐĞ
/s͘
All cases of primary colorectal cancer diagnosed in the period 1989-2014 were selected 
ĨŽƌƚŚŝƐƐƚƵĚǇ͘dŚĞƐƚƵĚǇƉĞƌŝŽĚǁĂƐĚŝǀŝĚĞĚŝŶƚŽĮǀĞƟŵĞƉĞƌŝŽĚƐŽĨĮǀĞǇĞĂƌƐĞĂĐŚ;ϭϵϴϵͲ










were applied.17 Annual incidence and mortality were described per 100,000 person-years 
ĂŶĚ ƐƚĂŶĚĂƌĚŝǌĞĚ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ƵƌŽƉĞĂŶ ^ƚĂŶĚĂƌĚ WŽƉƵůĂƟŽŶ ;^ZͿ͘ /Ŷ ĂĚĚŝƟŽŶ͕
ĂŶĂůǇƐĞƐŽĨƚƌĞŶĚƐŝŶŝŶĐŝĚĞŶĐĞĂŶĚŵŽƌƚĂůŝƚǇŽǀĞƌĚŝīĞƌĞŶƚƟŵĞƉĞƌŝŽĚƐǁĞƌĞĂĐŚŝĞǀĞĚ
by performing the average annual percentage of change analysis.  
&ŽƌƚŚĞĂŶĂůǇƐĞƐŽŶƚƌĞĂƚŵĞŶƚĂŶĚƐƵƌǀŝǀĂů͕ƉĂƟĞŶƚƐǁŝƚŚĞŝƚŚĞƌ͚ ŶŽŚŝƐƚŽůŽŐŝĐĂůůǇĐŽŶĮƌŵĞĚ
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͛Žƌ ͚ƵŶŬŶŽǁŶdEDƐƚĂŐĞ͛ǁĞƌĞĞǆĐůƵĚĞĚ͘ &ŽƌŵĞƚĂĐŚƌŽŶŽƵƐƉƌŝŵĂƌǇ
ƚƵŵŽƵƌƐ͕ ƚŚĞ ĮƌƐƚ ĚŝĂŐŶŽƐĞĚ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ǁĂƐ ŝŶĐůƵĚĞĚ͘ /Ŷ ĐĂƐĞ ŽĨ ƐǇŶĐŚƌŽŶŽƵƐ
ŵƵůƟƉůĞĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͕ ƚŚĞƚƵŵŽƵƌǁŝƚŚƚŚĞŵŽƐƚĂĚǀĂŶĐĞĚdEDƐƚĂŐĞǁĂƐƵƐĞĚĨŽƌ
ƚŚĞƐĞĂŶĂůǇƐĞƐ͘dƌĞĂƚŵĞŶƚĐŚĂƌĂĐƚĞƌŝƐƟĐƐǁĞƌĞƌĞƉŽƌƚĞĚĂƐƉĞƌĐĞŶƚĂŐĞƐƉĞƌĂŐĞŐƌŽƵƉĂŶĚ





















dŚĞƉƌŽƉŽƌƟŽŶĂůƐƚĂŐĞĚŝƐƚƌŝďƵƟŽŶ ŝŶdĂďůĞϭƐŚŽǁĞĚĂĚĞĐƌĞĂƐĞ ŝŶƐƚĂŐĞ //ŽǀĞƌƟŵĞ͕
ǁŚĞƌĞĂƐƚŚĞƉƌŽƉŽƌƟŽŶŽĨƐƚĂŐĞ/sŝŶĐƌĞĂƐĞĚ͘DŽƌĞŽǀĞƌ͕ ĂƌĞĐĞŶƚƚƌĞŶĚŝƐƚŚĞŝŶĐƌĞĂƐŝŶŐ




years. Figure 1a illustrates that age standardized incidence has increased predominantly 
ĨŽƌ ŵĂůĞ ĐŽůŽŶ ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ͘ dŚĞŵŽƌƚĂůŝƚǇ ŽĨ ďŽƚŚ ŵĂůĞ ĂŶĚ ĨĞŵĂůĞ ĐŽůŽŶ ĐĂŶĐĞƌ
ƉĂƟĞŶƚƐ ĚĞĐƌĞĂƐĞĚ ƐŝŐŶŝĮĐĂŶƚůǇ ŽǀĞƌƟŵĞ͘ dŚĞ ŝŶĐŝĚĞŶĐĞŽĨ ƌĞĐƚĂů ĐĂŶĐĞƌ ŝƐ ƉƌĞƐĞŶƚĞĚ
in Figure 1b, showing a stable incidence among females, whereas the incidence among 
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TABLE 1 dƵŵŽƵƌ ƐŝƚĞ ĚŝƐƚƌŝďƵƟŽŶ ŽĨ Ăůů ƉĂƟĞŶƚƐ ĚŝĂŐŶŽƐĞĚ ǁŝƚŚ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͕  ĂŶĚ ĂŐĞ͕ 
 ŐĞŶĚĞƌ͕ ŵŽƌƉŚŽůŽŐǇĂŶĚdEDƐƚĂŐĞĚŝƐƚƌŝďƵƟŽŶŽĨĂůůƉĂƟĞŶƚƐĚŝĂŐŶŽƐĞĚǁŝƚŚĐŽůŽŶŽƌ 
 rectal cancer in the Netherlands between 1989 and 2014, by period of diagnosis 
 ;ŶсϮϲϳ͕ϳϲϱͿ͘
Period of diagnosis
1989-1994 1995-1999 2000-2004 2005-2009 2010-2014
n ;йͿ n ;йͿ n ;йͿ n ;йͿ n ;йͿ
COLORECTAL CANCER
   Colon 30,136 ;ϲϲͿ 28,417 ;ϲϱͿ 32,486 ;ϲϱͿ 40,140 ;ϲϳͿ 47,674 ;ϲϵͿ
   Rectum 15,812 ;ϯϰͿ 14,973 ;ϯϱͿ 17,114 ;ϯϱͿ 19,741 ;ϯϯͿ 21,272 ;ϯϭͿ
COLON CANCER
Age at diagnosis
   <50 years 1,885 ;ϲͿ 1,583 ;ϲͿ 1,714 ;ϱͿ 1,826 ;ϱͿ 2,047 ;ϰͿ
   50-59 years 3,418 ;ϭϭͿ 3,432 ;ϭϮͿ 4,195 ;ϭϯͿ 4,878 ;ϭϮͿ 5,008 ;ϭϭͿ
   60-69 years 7,668 ;ϮϱͿ 6,989 ;ϮϱͿ 7,793 ;ϮϰͿ 10,025 ;ϮϱͿ 13,135 ;ϮϴͿ
   70-79 years 10,330 ;ϯϰͿ 9,935 ;ϯϱͿ 11,381 ;ϯϱͿ 13,467 ;ϯϰͿ 16,254 ;ϯϰͿ
шϴϬǇĞĂƌƐ 6,835 ;ϮϯͿ 6,478 ;ϮϯͿ 7,403 ;ϮϯͿ 9,944 ;ϮϱͿ 11,230 ;ϮϰͿ
Gender
   Male 13,916 ;ϰϲͿ 13,720 ;ϰϴͿ 15,938 ;ϰϵͿ 20,369 ;ϱϭͿ 25,054 ;ϱϯͿ
   Female 16,220 ;ϱϰͿ 14,697 ;ϱϮͿ 16,548 ;ϱϭͿ 19,771 ;ϰϵͿ 22,620 ;ϰϳͿ
Morphology
   Adenocarcinoma 22,994 ;ϳϲͿ 22,195 ;ϳϴͿ 25,945 ;ϴϬͿ 32,455 ;ϴϭͿ 40,015 ;ϴϰͿ
   Mucinous adenocarcinoma 5,739 ;ϭϵͿ 4,908 ;ϭϳͿ 5,141 ;ϭϲͿ 5,736 ;ϭϰͿ 5,305 ;ϭϭͿ
   Signet ring cell carcinoma 287 ;ϭͿ 314 ;ϭͿ 375 ;ϭͿ 571 ;ϭͿ 650 ;ϭͿ
   Other 1,116 ;ϰͿ 1,000 ;ϰͿ 1,025 ;ϯͿ 1,378 ;ϯͿ 1,704 ;ϰͿ
TNM-stage
   Stage 0 1 ;ϬͿ 0 ;ϬͿ 4 ;ϬͿ 7 ;ϬͿ 41 ;ϬͿ
^ƚĂŐĞ/ 4,673 ;ϭϲͿ 4,291 ;ϭϱͿ 4,768 ;ϭϱͿ 6,279 ;ϭϲͿ 8,729 ;ϭϴͿ
^ƚĂŐĞ// 11,267 ;ϯϳͿ 10,209 ;ϯϲͿ 11,311 ;ϯϱͿ 12,579 ;ϯϭͿ 13,850 ;ϮϵͿ
^ƚĂŐĞ/// 6,637 ;ϮϮͿ 6,778 ;ϮϰͿ 7,895 ;ϮϰͿ 10,001 ;ϮϱͿ 11,972 ;ϮϱͿ
^ƚĂŐĞ/s 5,833 ;ϭϵͿ 5,433 ;ϭϵͿ 6,691 ;ϮϭͿ 8,861 ;ϮϮͿ 11,211 ;ϮϰͿ
^ƚĂŐĞy 1,725 ;ϲͿ 1,706 ;ϲͿ 1,817 ;ϲͿ 2,413 ;ϲͿ 1,871 ;ϰͿ
RECTAL CANCER
Age at diagnosis
   <50 years 1,173 ;ϳͿ 1,030 ;ϳͿ 1,125 ;ϳͿ 1,274 ;ϲͿ 1,315 ;ϲͿ
   50-59 years 2,278 ;ϭϰͿ 2,425 ;ϭϲͿ 3,085 ;ϭϴͿ 3,430 ;ϭϳͿ 3,319 ;ϭϲͿ
   60-69 years 4,403 ;ϮϴͿ 4,101 ;ϮϳͿ 4,838 ;ϮϴͿ 5,787 ;ϮϵͿ 6,740 ;ϯϮͿ
   70-79 years 4,974 ;ϯϭͿ 4,718 ;ϯϮͿ 5,135 ;ϯϬͿ 5,906 ;ϯϬͿ 6,391 ;ϯϬͿ
шϴϬǇĞĂƌƐ 2,984 ;ϭϵͿ 2,699 ;ϭϴͿ 2,931 ;ϭϳͿ 3,344 ;ϭϳͿ 3,507 ;ϭϲͿ
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TABLE 1 dƵŵŽƵƌ ƐŝƚĞ ĚŝƐƚƌŝďƵƟŽŶ ŽĨ Ăůů ƉĂƟĞŶƚƐ ĚŝĂŐŶŽƐĞĚ ǁŝƚŚ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͕  ĂŶĚ ĂŐĞ͕ 
 ŐĞŶĚĞƌ͕ ŵŽƌƉŚŽůŽŐǇĂŶĚdEDƐƚĂŐĞĚŝƐƚƌŝďƵƟŽŶŽĨĂůůƉĂƟĞŶƚƐĚŝĂŐŶŽƐĞĚǁŝƚŚĐŽůŽŶŽƌ 
 rectal cancer in the Netherlands between 1989 and 2014, by period of diagnosis 
 ;ŶсϮϲϳ͕ϳϲϱͿ͘;ŽŶƟŶƵĞĚͿ
Period of diagnosis
1989-1994 1995-1999 2000-2004 2005-2009 2010-2014
n ;йͿ n ;йͿ n ;йͿ n ;йͿ n ;йͿ
Gender
   Male 8,763 ;ϱϱͿ 8,555 ;ϱϳͿ 9,970 ;ϱϴͿ 11,674 ;ϱϵͿ 13,116 ;ϲϮͿ
   Female 7,049 ;ϰϱͿ 6,418 ;ϰϯͿ 7,144 ;ϰϮͿ 8,067 ;ϰϭͿ 8,156 ;ϯϴͿ
Morphology
   Adenocarcinoma 13,768 ;ϴϳͿ 13,189 ;ϴϴͿ 15,115 ;ϴϴͿ 17,701 ;ϵϬͿ 19,578 ;ϵϮͿ
   Mucinous adenocarcinoma 1,630 ;ϭϬͿ 1,431 ;ϭϬͿ 1,550 ;ϵͿ 1,516 ;ϴͿ 1,188 ;ϲͿ
   Signet ring cell carcinoma 287 ;ϭͿ 314 ;ϭͿ 375 ;ϭͿ 571 ;ϭͿ 650 ;ϭͿ
   Other 330 ;ϮͿ 258 ;ϮͿ 348 ;ϮͿ 370 ;ϮͿ 374 ;ϮͿ
TNM-stage
   Stage 0 1 ;ϬͿ 3 ;ϬͿ 26 ;ϬͿ 435 ;ϮͿ 1,017 ;ϱͿ
^ƚĂŐĞ/ 4,175 ;ϮϲͿ 3,845 ;ϮϲͿ 4,402 ;ϮϲͿ 5,097 ;ϮϲͿ 6,076 ;ϮϵͿ
^ƚĂŐĞ// 4,344 ;ϮϳͿ 3,837 ;ϮϲͿ 4,309 ;ϮϱͿ 4,427 ;ϮϮͿ 4,106 ;ϭϵͿ
^ƚĂŐĞ/// 3,573 ;ϮϯͿ 3,614 ;ϮϰͿ 4,278 ;ϮϱͿ 4,945 ;ϮϱͿ 5,214 ;ϮϱͿ
^ƚĂŐĞ/s 2,436 ;ϭϱͿ 2,427 ;ϭϲͿ 3,078 ;ϭϴͿ 3,901 ;ϮϬͿ 4,236 ;ϮϬͿ
^ƚĂŐĞy 1,283 ;ϴͿ 1,247 ;ϴͿ 1,021 ;ϲͿ 936 ;ϱͿ 623 ;ϯͿ
dÙãÃÄã
/Ŷ dĂďůĞ Ϯ͕ ƚƌĞŶĚƐ ŝŶ ƚƌĞĂƚŵĞŶƚ ĨŽƌ ĐŽůŽŶ ĂŶĚ ƌĞĐƚĂů ĐĂŶĐĞƌ ĂƌĞ ƉƌĞƐĞŶƚĞĚ͘ ůŵŽƐƚ Ăůů
ƉĂƟĞŶƚƐĚŝĂŐŶŽƐĞĚǁŝƚŚƐƚĂŐĞ/Ͳ///ĐŽůŽŶĐĂŶĐĞƌƵŶĚĞƌǁĞŶƚƌĞƐĞĐƟŽŶ;ƚŚŝƐŝŶĐůƵĚĞƐůŽĐĂů
ĞǆĐŝƐŝŽŶƐƵĐŚĂƐƉŽůǇƉĞĐƚŽŵǇͿ͘ĚŵŝŶŝƐƚƌĂƟŽŶŽĨĂĚũƵǀĂŶƚƐǇƐƚĞŵŝĐƚŚĞƌĂƉǇŝŶĐƌĞĂƐĞĚŝŶ
ƉĂƟĞŶƚƐǁŝƚŚƐƚĂŐĞ /// ĐŽůŽŶĐĂŶĐĞƌ͘ WĂƟĞŶƚƐĚŝĂŐŶŽƐĞĚǁŝƚŚƐƚĂŐĞ /sĐŽůŽŶĐĂŶĐĞƌ ůĞƐƐ
ĨƌĞƋƵĞŶƚůǇ ƵŶĚĞƌǁĞŶƚ ƌĞƐĞĐƟŽŶŽĨ ƚŚĞ ƉƌŝŵĂƌǇ ƚƵŵŽƵƌǁŝƚŚŽƵƚ ƐǇƐƚĞŵŝĐ ƚŚĞƌĂƉǇ͘ dŚĞ
ĐŽŵďŝŶĂƟŽŶŽĨƐǇƐƚĞŵŝĐƚŚĞƌĂƉǇĂŶĚƌĞƐĞĐƟŽŶ͕ƚŚĞƵƐĞŽĨŽŶůǇƐǇƐƚĞŵŝĐƚŚĞƌĂƉǇ͕ ĂŶĚƚŚĞ
use of metastasectomy increased.
The primary tumour in non-metastasized rectal cancer was almost always resected, similar 
ƚŽĐŽůŽŶĐĂŶĐĞƌ͘ dŚĞƵƐĞŽĨĂĚũƵǀĂŶƚƌĂĚŝŽƚŚĞƌĂƉǇŝŶƉĂƟĞŶƚƐǁŝƚŚƌĞĐƚĂůĐĂŶĐĞƌĚĞĐƌĞĂƐĞĚ
ƐŝŐŶŝĮĐĂŶƚůǇ͕  ǁŚĞƌĞĂƐ ƚŚĞ ƵƐĞ ŽĨ ŶĞŽĂĚũƵǀĂŶƚ ƌĂĚŝŽƚŚĞƌĂƉǇ ĂŶĚ ĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇ









































































Incidence, males Incidence, females




































































Incidence, males Incidence, females
Mortality, males Mortality, females
Annual percentage of change
/ŶĐŝĚĞŶĐĞ;ϵϱй/Ϳ DŽƌƚĂůŝƚǇ;ϵϱй/Ϳ
COLON CANCER
Male 1.54  ;ϭ͘ϯϳͲϭ͘ϳϭͿ -0.73 ;ͲϬ͘ϵϳͲͲϬ͘ϰϵͿ
Female 1.06 ;Ϭ͘ϴϱͲϭ͘ϮϲͿ -1.02 ;Ͳϭ͘ϮϮͲͲϬ͘ϴϮͿ
RECTAL CANCER
Male 0.75 ;Ϭ͘ϱϰͲϬ͘ϵϱͿ -0.59 ;ͲϬ͘ϴϯͲͲϬ͘ϯϰͿ
Female 0.37 ;Ϭ͘ϬϵͲϬ͘ϲϱͿ -0.58 ;ͲϬ͘ϵϰͲͲϬ͘ϮϯͿ
FIGURE 1 /ŶĐŝĚĞŶĐĞ ĂŶĚ ŵŽƌƚĂůŝƚǇ ƌĂƚĞƐ ƉĞƌ ϭϬϬ͕ϬϬϬ ƉĞƌƐŽŶͲǇĞĂƌƐ͕ ĨŽƌ ĐŽůŽŶ ĐĂŶĐĞƌ ;ĂͿ ĂŶĚ 
 ƌĞĐƚĂůĐĂŶĐĞƌ;ďͿ͕ĂŐĞͲƐƚĂŶĚĂƌĚŝƐĞĚƚŽƚŚĞ^Z͕ĂĐĐŽƌĚŝŶŐƚŽŐĞŶĚĞƌ;ŶсϮϲϬ͕ϳϳϰͿ͘















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ĐĂŶĐĞƌ͘  ;ĞͿZĞůĂƟǀĞƐƵƌǀŝǀĂůĂŵŽŶŐƉĂƟĞŶƚƐǁŝƚŚƉŽƐƚŽƉĞƌĂƟǀĞƐƚĂŐĞ / ƌĞĐƚĂůĐĂŶĐĞƌ ;ŝŶĐůƵĚŝŶŐƉŽƐƚŽƉĞƌĂƟǀĞ
ƐƚĂŐĞϬͿ͘;ĨͿZĞůĂƟǀĞƐƵƌǀŝǀĂůĂŵŽŶŐƉĂƟĞŶƚƐǁŝƚŚƉŽƐƚŽƉĞƌĂƟǀĞƐƚĂŐĞ//ƌĞĐƚĂůĐĂŶĐĞƌ͘ ;ŐͿZĞůĂƟǀĞƐƵƌǀŝǀĂůĂŵŽŶŐ
ƉĂƟĞŶƚƐ ǁŝƚŚ ƉŽƐƚŽƉĞƌĂƟǀĞ ƐƚĂŐĞ /// ƌĞĐƚĂů ĐĂŶĐĞƌ͘  ;ŚͿ ZĞůĂƟǀĞ ƐƵƌǀŝǀĂů ĂŵŽŶŐ ƉĂƟĞŶƚƐ ǁŝƚŚ ƉŽƐƚŽƉĞƌĂƟǀĞ
ƐƚĂŐĞ/sƌĞĐƚĂůĐĂŶĐĞƌ͘ ;ŝͿZĞůĂƟǀĞƐƵƌǀŝǀĂůĂŵŽŶŐƉĂƟĞŶƚƐǁŝƚŚĐŽůŽŶĐĂŶĐĞƌ͕ ĂůůƉŽƐƚŽƉĞƌĂƟǀĞƐƚĂŐĞƐĂŶĚĂŐĞƐ͘ 
;ũͿZĞůĂƟǀĞƐƵƌǀŝǀĂůĂŵŽŶŐƉĂƟĞŶƚƐǁŝƚŚƌĞĐƚĂůĐĂŶĐĞƌ͕ ĂůůƉŽƐƚŽƉĞƌĂƟǀĞƐƚĂŐĞƐĂŶĚĂŐĞƐ͘
^çÙò®ò½
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DISCUSSION
dŚĞ ĐƵƌƌĞŶƚ ůĂƌŐĞ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚǇ ƉƌŽǀŝĚĞƐ ĂŶ ŽǀĞƌǀŝĞǁ ŽĨ ƚŚĞ ƌĞŵĂƌŬĂďůĞ








ǁŝƚŚ ƚƌĞŶĚƐ ŝŶŽƚŚĞƌƵƌŽƉĞĂŶĐŽƵŶƚƌŝĞƐ͘20 dŚĞ ŝŵƉůĞŵĞŶƚĂƟŽŶŽĨĂŶĂƟŽŶǁŝĚĞďŽǁĞů
ƐĐƌĞĞŶŝŶŐƉƌŽŐƌĂŵŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐĞǆƉůĂŝŶƐƚŚĞƐƚĞĞƉŝŶĐƌĞĂƐĞŝŶƚŚĞŝŶĐŝĚĞŶĐĞŽĨďŽƚŚ
ĐŽůŽŶĂŶĚ ƌĞĐƚĂů ĐĂŶĐĞƌ ŝŶϮϬϭϰ͕ǁŚŝĐŚ ŝƐĞǆƉĞĐƚĞĚ ƚŽĐŽŶƟŶƵĞ ĨŽƌ ƐĞǀĞƌĂů ǇĞĂƌƐ͕ĂŌĞƌ
which it is likely to decrease.21, 22 The annual colorectal cancer mortality in the Netherlands 
ŚĂƐĚĞĐƌĞĂƐĞĚŵŽĚĞƐƚůǇŽǀĞƌ ƚŚĞǇĞĂƌƐ͘ /ƚ ŝƐ ƚŽďĞĞǆƉĞĐƚĞĚ ƚŚĂƚ͕ƵůƟŵĂƚĞůǇ͕ ŵŽƌƚĂůŝƚǇ
rates will further decrease because of the screening program, by earlier diagnosis and 
ƚŚĞƌĞďǇŵŽƌĞĐƵƌĂƟǀĞƚƌĞĂƚŵĞŶƚŽƉƟŽŶƐ͘23 
The increasing incidence and decreasing annual colorectal cancer mortality points towards 
ĂŶ ŝŵƉƌŽǀĞŵĞŶƚ ŝŶ ƐƵƌǀŝǀĂů ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ͕ ǁŚŝĐŚ ŚĂƐ ďĞĞŶ ĂƩƌŝďƵƚĞĚ
previously to advancements in treatment.24 Results from the present study show that 
ĨŽƌŵĂůŽŶĐŽůŽŐŝĐĂů ƌĞƐĞĐƟŽŶ ŝƐƐƟůů ƚŚĞĐŽƌŶĞƌƐƚŽŶĞ ŝŶƚŚĞƚƌĞĂƚŵĞŶƚŽĨŶŽŶͲŵĞƚĂƐƚĂƟĐ
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͕ ĂůƚŚŽƵŐŚƚŚĞŝŶƚƌŽĚƵĐƟŽŶŽĨƐĐƌĞĞŶŝŶŐƉƌŽŐƌĂŵƐǁŝůůŝŶĐƌĞĂƐĞƚŚĞƵƐĞ
ŽĨůĞƐƐŝŶǀĂƐŝǀĞƉƌŽĐĞĚƵƌĞƐƐƵĐŚĂƐƉŽůǇƉĞĐƚŽŵŝĞƐĂŶĚůŽĐĂůĞǆĐŝƐŝŽŶƐ͘
^ŝŶĐĞ ƚŚĞ ϭϵϵϬ Ɛ͕͛ ƚŚĞ ƵƐĞ ŽĨ ĂĚũƵǀĂŶƚ ƐǇƐƚĞŵŝĐ ƚŚĞƌĂƉǇ ŝƐ ƌĞĐŽŵŵĞŶĚĞĚ ĨŽƌ ƐƚĂŐĞ ///
ĐŽůŽŶ ĐĂŶĐĞƌ͕  ĂŶĚ ƚŚĞ ĂĚŵŝŶŝƐƚƌĂƟŽŶ ŚĂƐ ĐŽŶƟŶƵĞĚ ƚŽ ŝŶĐƌĞĂƐĞ ĚƵƌŝŶŐ ŵŽƌĞ ƌĞĐĞŶƚ




chemotherapy in 2008-2012.12 Compared with colon cancer, rectal cancer treatment 
ĐŚĂŶŐĞĚ ƐŝŐŶŝĮĐĂŶƚůǇ ŽǀĞƌ ƌĞĐĞŶƚ ĚĞĐĂĚĞƐ͘ ^ŝŶĐĞ ϮϬϬϭ͕ ƚŚĞ ƚŽƚĂů ŵĞƐŽƌĞĐƚĂů ĞǆĐŝƐŝŽŶ
;dDͿƚĞĐŚŶŝƋƵĞďĞĐĂŵĞƚŚĞƐƚĂŶĚĂƌĚĨŽƌƌĞĐƚĂůĐĂŶĐĞƌƐƵƌŐĞƌǇŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐĂŶĚ
contributed to improved survival.7, 30 ^ŝŵƵůƚĂŶĞŽƵƐůǇ͕  ƉƌĞŽƉĞƌĂƟǀĞ ƌĂĚŝŽƚŚĞƌĂƉǇ ĂŶĚ
ĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇǁĞƌĞŝŵƉůĞŵĞŶƚĞĚŝŶƚŚĞƚƌĞĂƚŵĞŶƚĨŽƌƐƚĂŐĞ//ͬ///ƌĞĐƚĂůĐĂŶĐĞƌŝŶƚŚĞ
Netherlands, as demonstrated by the trends in this study.7dŚĞĂĚĚŝƟŽŶŽĨŶĞŽĂĚũƵǀĂŶƚ
;ĐŚĞŵŽͿƌĂĚŝŽƚŚĞƌĂƉǇ ŚĂƐ ŶŽƚ ĚĞŵŽŶƐƚƌĂƚĞĚ ĂŶ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ďĞŶĞĮƚ ĨŽƌ ƚŚĞ ǁŚŽůĞ
ŐƌŽƵƉ ŽĨ ƉĂƟĞŶƚƐ ŝŶ ƌĂŶĚŽŵŝǌĞĚ ƚƌŝĂůƐ͕ ĂůƚŚŽƵŐŚ Ă ŵŽƌĞ ƚĂŝůŽƌĞĚ ĂƉƉůŝĐĂƟŽŶ ĨŽƌ ŚŝŐŚ
risk groups might impact survival based on subgroup analysis.31-35 Whether neoadjuvant 
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ĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇ ƐŚŽƵůĚ ďĞ ĐŽŵďŝŶĞĚ ǁŝƚŚ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ŝŶ ƐƚĂŐĞ //ͬ///
rectal cancer is a subject of controversy due to inconclusive evidence. The current Dutch 
ŐƵŝĚĞůŝŶĞƐĚŝƐĐŽƵƌĂŐĞƚŚĞƵƐĞŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇďĂƐĞĚŽŶŶĞŐĂƟǀĞƐƚƵĚŝĞƐ͕ďƵƚ
ŵŽƐƚŐƵŝĚĞůŝŶĞƐŝŶƚŚĞh^ĂŶĚŵĂŶǇŽƚŚĞƌĐŽƵŶƚƌŝĞƐĚŽƌĞĐŽŵŵĞŶĚŝƚƐƵƐĞ͘36-38 
dŚĞ ĮŶĚŝŶŐƐ ĨŽƌ ŵĞƚĂƐƚĂƐŝǌĞĚ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƐŚŽǁ Ă ĐŽŶƟŶƵĂƟŽŶ ŽĨ ƚŚĞ ƚƌĞŶĚƐ ŝŶ
ƚƌĞĂƚŵĞŶƚĚĞƐĐƌŝďĞĚƉƌĞǀŝŽƵƐůǇŝŶƚŚĞƵƚĐŚƉŽƉƵůĂƟŽŶ͕ǁŝƚŚĂƐŚŝŌĨƌŽŵƌĞƐĞĐƟŽŶŽĨƚŚĞ
ƉƌŝŵĂƌǇƚƵŵŽƵƌĂůŽŶĞƚŽĞŝƚŚĞƌĐŚĞŵŽƚŚĞƌĂƉǇĂůŽŶĞŽƌŝŶĐŽŵďŝŶĂƟŽŶǁŝƚŚƐƵƌŐĞƌǇŽĨƚŚĞ
primary tumour, and an increase of the use of metastasectomy.14, 15, 24, 39, 40 However, there is 
ƐƟůůƌŽŽŵĨŽƌŝŵƉƌŽǀĞŵĞŶƚƐŝŶĐĞƚŚĞƉƌŽƉŽƌƟŽŶŽĨƉĂƟĞŶƚƐƵŶĚĞƌŐŽŝŶŐĂŵĞƚĂƐƚĂƐĞĐƚŽŵǇ
ĨŽƌ ůŝǀĞƌŽŶůǇĚŝƐĞĂƐĞƐŚŽǁƐ ůĂƌŐĞ ŝŶƐƟƚƵƟŽŶĂůǀĂƌŝĂƟŽŶ ĂŶĚ ŝƐĚĞƐĐƌŝďĞĚƚŽďĞĂƌŽƵŶĚ
ϮϬйŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͕ǁŚŝĐŚŝƐĐŽŵƉĂƌĂďůĞƚŽĚĂƚĂĨƌŽŵ'ƌĞĂƚͲƌŝƚĂŝŶĂŶĚ&ƌĂŶĐĞ͘14, 41, 42 
Despite the advancements in the treatment of colorectal cancer, the increase in 5-year 
survival in the more recent periods seems remarkable as there have been no major 
ďƌĞĂŬƚŚƌŽƵŐŚƐ ŝŶ ƚƌĞĂƚŵĞŶƚ ĂŶĚ ŵŽƐƚ ŽĨ ƚŚĞ ƚƌĞŶĚƐ ŝŶ ƚƌĞĂƚŵĞŶƚ ŚĂǀĞ ůĞǀĞůĞĚ Žī͕
ĞǆĐĞƉƚ ĨŽƌ ƚŚĞ ƵƐĞ ŽĨŵĞƚĂƐƚĂƐĞĐƚŽŵǇ͘ ĞƐŝĚĞƐ ĚĞǀĞůŽƉŝŶŐ ƚƌĞĂƚŵĞŶƚ ƐƚƌĂƚĞŐŝĞƐ͕ ŽƚŚĞƌ
mechanisms might play a role. Firstly, it is striking that the most obvious gain in survival 
ďĞƚǁĞĞŶƚŚĞĚŝīĞƌĞŶƚƟŵĞƉĞƌŝŽĚƐŝŶƚŚŝƐƐƚƵĚǇǁĂƐŵĂĚĞŝŶƚŚĞĮƌƐƚǇĞĂƌĂŌĞƌĚŝĂŐŶŽƐŝƐ͘
dŚŝƐ ƐƵŐŐĞƐƚƐ Ă ƐƵďƐƚĂŶƟĂů ŝŵƉƌŽǀĞŵĞŶƚ ŝŶ ƚŚĞ ŵĂŶĂŐĞŵĞŶƚ ŽĨ ĨĂĐƚŽƌƐ ĂƐƐŽĐŝĂƚĞĚ
with short term mortality such as emergency surgery, advanced age, comorbidity, and 
ƉŽƐƚŽƉĞƌĂƟǀĞ ĐŽŵƉůŝĐĂƟŽŶƐ͕ ĂŶĚ ďǇŵĞĂŶƐ ŽĨ ďĞƩĞƌ ƉƌĞͲ ĂŶĚ ƉŽƐƚŽƉĞƌĂƟǀĞ ĐĂƌĞ ĂŶĚ




ĨƵƌƚŚĞƌ ŝŵƉƌŽǀĞƐ ƚŚĞ ƐƚĂŐĞ ƐƉĞĐŝĮĐ ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů ŝŶ ƐƚĂŐĞ /s͘ 15 Thirdly, neoadjuvant 
ĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇ ŝŶ ƌĞĐƚĂů ĐĂŶĐĞƌ ŵŝŐŚƚ ŚĂǀĞ ƐŚŝŌĞĚ ƐƚĂŐĞ ƐƉĞĐŝĮĐ ŽƵƚĐŽŵĞ͕ ƐŝŶĐĞ
ƉŽƐƚŽƉĞƌĂƟǀĞƐƚĂŐĞŚĂƐďĞĞŶƵƐĞĚŝŶƚŚŝƐƐƚƵĚǇ͘WĂƟĞŶƚƐǁŚŽƌĞƐƉŽŶĚǁĞůůƚŽŶĞŽĂĚũƵǀĂŶƚ
ƚƌĞĂƚŵĞŶƚ ŚĂǀĞ ďĞĞŶ ĚŽǁŶƐƚĂŐĞĚ͕ ƚŚĞƌĞďǇ ĚĞƚĞƌŝŽƌĂƟŶŐ ƐƵƌǀŝǀĂů ƌĂƚĞƐ ŝŶ ƚŚĞ ŚŝŐŚĞƌ
ƐƚĂŐĞƐ͘,ŽǁĞǀĞƌ͕ ƚŚĞƐĞĚŽǁŶƐƚĂŐĞĚƉĂƟĞŶƚƐƐƚĂƌƚĞĚŽƵƚĂƐĐůŝŶŝĐĂůůǇŚŝŐŚĞƌƐƚĂŐĞƐ͕ǁŝƚŚ
worse prognosis, thereby possibly also decreasing survival rates for the lower stages. 
dŚĞƐƚĂŐŶĂƟŽŶŝŶƐƵƌǀŝǀĂůŝŵƉƌŽǀĞŵĞŶƚŽĨƐƚĂŐĞ///ƌĞĐƚĂůĐĂŶĐĞƌŝŶϮϬϭϬͲϮϬϭϰŵŝŐŚƚďĞ
ĞǆƉůĂŝŶĞĚďǇƚŚŝƐƉŚĞŶŽŵĞŶŽŶ͘>ĂƐƚůǇ͕  ƚŚĞ ŝŵƉƌŽǀĞŵĞŶƚ ŝŶƐƵƌǀŝǀĂů ŝŶƚŚĞŵŽƌĞƌĞĐĞŶƚ
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ŶŽƚŚĞƌ ŝŶƚĞƌĞƐƟŶŐĮŶĚŝŶŐ ŝƐ ƚŚĂƚŽǀĞƌƟŵĞ͕ ƌĞĐƚĂůĐĂŶĐĞƌƐƵƌǀŝǀĂůŚĂƐĐĂƵŐŚƚƵƉǁŝƚŚ
ĐŽůŽŶĐĂŶĐĞƌ ƐƵƌǀŝǀĂůĂŶĚĞǀĞŶƐƵƌƉĂƐƐĞĚ ƚŚĞ ůĂƩĞƌ ŝŶ ƚŚĞŵŽƌĞ ƌĞĐĞŶƚƉĞƌŝŽĚƐŽĨŽƵƌ
study. This has previously been described, and our results show a progression of this 
trend.24, 48 A smaller cohort study from Germany describes an equally good outcome 
ĨŽƌƐƚĂŐĞ//ͬ///ĐŽůŽŶĂŶĚƌĞĐƚĂůĐĂŶĐĞƌ͘ 49dŚĞƌĞĂƌĞƐĞǀĞƌĂůƉŽƐƐŝďůĞĞǆƉůĂŶĂƟŽŶƐ͘&ŝƌƐƚůǇ͕ 




ĚĞĐĂĚĞƐĂŌĞƌƚŚĞŝŶƚƌŽĚƵĐƟŽŶŽĨdD͘50 Comorbidity is more frequent among colon cancer 
ƉĂƟĞŶƚƐ͕ĂŶĚƉŽƐƚŽƉĞƌĂƟǀĞĐŽŵƉůŝĐĂƟŽŶƐŝŶĐŽůŽŶĐĂŶĐĞƌƉĂƟĞŶƚƐŚĂǀĞĂŚŝŐŚĞƌŝŵƉĂĐƚ
ŽŶŵŽƌƚĂůŝƚǇ ƚŚĂŶ ŝŶ ƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͘43, 51 This is especially important considering 
ƚŚĂƚĐŽůŽŶĐĂŶĐĞƌ ŝƐŵŽƌĞŽŌĞŶƚƌĞĂƚĞĚ ŝŶĂŶĞŵĞƌŐĞŶĐǇƐĞƫŶŐ͘52 >ĂƐƚůǇ͕  ƌĞĐƚĂůĐĂŶĐĞƌ
ƉĂƟĞŶƚƐŚĂǀĞĂƚĞŶĚĞŶĐǇƚŽďĞĚŝĂŐŶŽƐĞĚĂƚĂŶĞĂƌůŝĞƌƐƚĂŐĞ͕ƉĞƌŚĂƉƐĚƵĞƚŽĐŽŵƉůĂŝŶƚƐ
of rectal bleeding which is more commonly seen with distal tumours.53, 54 
,ŝŐŚƋƵĂůŝƚǇ͕ ůŽŶŐͲƚĞƌŵŶĂƟŽŶǁŝĚĞƉŽƉƵůĂƟŽŶͲďĂƐĞĚĚĂƚĂǁĂƐƵƐĞĚĨŽƌƚŚŝƐƐƚƵĚǇ͕ ŵĂŬŝŶŐ
ŝƚƉŽƐƐŝďůĞƚŽĚĞƐĐƌŝďĞƚƌĞŶĚƐŝŶƌĞĐĞŶƚǇĞĂƌƐŝŶƚŚĞĐŽŶƚĞǆƚŽĨůŽŶŐͲƚĞƌŵƚƌĞŶĚƐ͘,ŽǁĞǀĞƌ͕ 
ƚŚĞƌĞ ĂƌĞ ĂůƐŽ ƐŽŵĞ ůŝŵŝƚĂƟŽŶƐ ƚŽ ƚŚŝƐ ƐƚƵĚǇ͘ ŽŵŽƌďŝĚŝƚǇ͕  ƐŽĐŝŽĞĐŽŶŽŵŝĐ ƐƚĂƚƵƐ ĂŶĚ
ĞƚŚŶŝĐŝƚǇǁĞƌĞŵŝƐƐŝŶŐ͕ǁŚŝĐŚŵŝŐŚƚŚĂǀĞŝŶŇƵĞŶĐĞĚƐƵƌǀŝǀĂůŝŶĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͘
ůƐŽ͕ǁĞĚĞĐŝĚĞĚƚŽƵƐĞƉŽƐƚŽƉĞƌĂƟǀĞƐƚĂŐĞ ĨŽƌŽƵƌĂŶĂůǇƐĞƐ͕ĞŶĐŽƵŶƚĞƌŝŶŐĂĚŝůĞŵŵĂ




discrepancy between clinical and pathological stage.55, 56
/ŶĐŽŶĐůƵƐŝŽŶ͕ƚŚŝƐƐƚƵĚǇƐŚŽǁĞĚĂŶŝŶĐƌĞĂƐĞŝŶŝŶĐŝĚĞŶĐĞĂŶĚĂŶŽŶŐŽŝŶŐŝŵƉƌŽǀĞŵĞŶƚ
ŝŶƐƵƌǀŝǀĂů͘dŚŝƐŝŵƉƌŽǀĞŵĞŶƚŝŶƐƵƌǀŝǀĂůŝƐĂĐŽŶƟŶƵƵŵ͕ǁŚŝĐŚŝƐƉĂƌƚůǇĚƵĞƚŽĞǀŽůǀŝŶŐ




T R E N D S  I N  S U R V I VA L  A M O N G  C O L O R E C TA L  C A N C E R  PAT I E N T S | 39
2
REFERENCES








ϯ͘ dŽĞƐͲŽƵƚĞŶĚŝũŬ ͕ ǀĂŶ >ĞĞƌĚĂŵ D͕
ĞŬŬĞƌ͕ǀĂŶ,ĞĞƐ&͕ WĞŶŶŝŶŐ͕EĂŐƚĞŐĂĂů
/͕ Ğƚ Ăů͘ ZĞĂůͲdŝŵĞ DŽŶŝƚŽƌŝŶŐ ŽĨ ZĞƐƵůƚƐ
ƵƌŝŶŐ&ŝƌƐƚzĞĂƌŽĨƵƚĐŚŽůŽƌĞĐƚĂůĂŶĐĞƌ
^ĐƌĞĞŶŝŶŐ WƌŽŐƌĂŵ ĂŶĚ KƉƟŵŝǌĂƟŽŶ ďǇ
ůƚĞƌŝŶŐ&ĞĐĂů/ŵŵƵŶŽĐŚĞŵŝĐĂůdĞƐƚƵƚͲŽī
>ĞǀĞůƐ͘'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇ͘ϮϬϭϲ͘
ϰ͘ ŽŬŬĞƌŝŶŬ 'D͕ ƵŝũƐ &͕  ĚĞ ZƵŝũƚĞƌ t͕
Rosman C, Sietses C, Strobel R, et al. 
/ŵƉƌŽǀĞĚ ƋƵĂůŝƚǇ ŽĨ ĐĂƌĞ ĨŽƌ ƉĂƟĞŶƚƐ
ƵŶĚĞƌŐŽŝŶŐ ĂŶ ĂďĚŽŵŝŶŽƉĞƌŝŶĞĂů ĞǆĐŝƐŝŽŶ
ĨŽƌ ƌĞĐƚĂů ĐĂŶĐĞƌ͘  Ƶƌ : ^ƵƌŐ KŶĐŽů͘
ϮϬϭϱ͖ϰϭ;ϮͿ͗ϮϬϭͲϳ͘
ϱ͘ ^ŚĂƌŵĂ W͕  'ƵƉƚĂ E͕ <ƵŝƉĞƌƐ :͕ ZĞƉŝĐŝ
A, Wallace M. Advanced imaging in 




KƉĞŶ ^ƵƌŐĞƌǇ ĨŽƌ ZĞĐƚĂů ĂŶĐĞƌ͘  E ŶŐů :
DĞĚ͘ϮϬϭϱ͖ϯϳϯ;ϮͿ͗ϭϵϰ͘
ϳ͘ <ĂƉŝƚĞŝũŶ ͕ DĂƌŝũŶĞŶ ͕ EĂŐƚĞŐĂĂů /͕
WƵƩĞƌ ,͕ ^ƚĞƵƉ t,͕ tŝŐŐĞƌƐ d͕  Ğƚ Ăů͘
WƌĞŽƉĞƌĂƟǀĞ ƌĂĚŝŽƚŚĞƌĂƉǇ ĐŽŵďŝŶĞĚ
ǁŝƚŚ ƚŽƚĂů ŵĞƐŽƌĞĐƚĂů ĞǆĐŝƐŝŽŶ ĨŽƌ
ƌĞƐĞĐƚĂďůĞ ƌĞĐƚĂů ĐĂŶĐĞƌ͘  E ŶŐů : DĞĚ͘
ϮϬϬϭ͖ϯϰϱ;ϵͿ͗ϲϯϴͲϰϲ͘
8. Buunen M, Veldkamp R, Hop WC, Kuhry 
͕ :ĞĞŬĞů :͕ ,ĂŐůŝŶĚ ͕ Ğƚ Ăů͘ ^ƵƌǀŝǀĂů ĂŌĞƌ
laparoscopic surgery versus open surgery 
ĨŽƌ ĐŽůŽŶ ĐĂŶĐĞƌ͗ ůŽŶŐͲƚĞƌŵ ŽƵƚĐŽŵĞ ŽĨ
Ă ƌĂŶĚŽŵŝƐĞĚ ĐůŝŶŝĐĂů ƚƌŝĂů͘ >ĂŶĐĞƚ KŶĐŽů͘
ϮϬϬϵ͖ϭϬ;ϭͿ͗ϰϰͲϱϮ͘
9. Jobsen J, Aarts, MJ, Siesling, S, Klaase, J, 
>ŽƵǁŵĂŶ͕ t:͕ WŽŽƌƚŵĂŶƐ͕ WD͕ >ǇďĞĞƌƚ͕
D>͕<ŽŶŝŶŐ͕͕ ^ƚƌƵŝŬŵĂŶƐ͕,͕ŽĞďĞƌŐŚ͕
:t͘hƐĞŽĨƉƌŝŵĂƌǇƌĂĚŝŽƚŚĞƌĂƉǇĨŽƌƌĞĐƚĂů
cancer in the Netherlands between 1997 
ĂŶĚ ϮϬϬϴ͗ Ă ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚǇ͘ ůŝŶ
KŶĐŽů;ZŽůůZĂĚŝŽůͿ͘ϮϬϭϮ͖Ϯϰ;ϭͿ͗ĞϭͲϴ͘
10. Smith JJ, Garcia-Aguilar J. Advances 
and challenges in treatment of locally 
advanced rectal cancer. J Clin Oncol. 
ϮϬϭϱ͖ϯϯ;ϭϲͿ͗ϭϳϵϳͲϴϬϴ͘
11. Andre T, Boni C, Navarro M, Tabernero J, 
,ŝĐŬŝƐŚd͕ dŽƉŚĂŵ͕ĞƚĂů͘/ŵƉƌŽǀĞĚŽǀĞƌĂůů





Wilt JH, Pruijt JF. Adjuvant chemotherapy is 
not associated with improved survival for 
ĂůůŚŝŐŚͲƌŝƐŬĨĂĐƚŽƌƐŝŶƐƚĂŐĞ//ĐŽůŽŶĐĂŶĐĞƌ͘ 
/Ŷƚ:ĂŶĐĞƌ͘ ϮϬϭϲ͖ϭϯϵ;ϭͿ͗ϭϴϳͲϵϯ͘
ϭϯ͘ ǀĂŶ ĚĞƌ WŽŽů ͕ ĂŵŚƵŝƐ͕ Z͕ /:ǌĞƌŵĂŶƐ͕
:E͕ĚĞtŝůƚ͕:,͕ŐŐĞƌŵŽŶƚ͕D͕<ƌĂŶƐĞ͕Z͕
Verhoef, C. Trends in incidence, treatment 
ĂŶĚ ƐƵƌǀŝǀĂů ŽĨ ƉĂƟĞŶƚƐ ǁŝƚŚ ƐƚĂŐĞ /s
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͗ Ă ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ
ƐĞƌŝĞƐ͘ŽůŽƌĞĐƚĂůŝƐ͘ϮϬϭϮ͖ϭϰ;ϭͿ͗ϱϲͲϲϭ͘
ϭϰ͘ ĚĞ ZŝĚĚĞƌ :͕ >ĞŵŵĞŶƐ s͕ KǀĞƌďĞĞŬ
>/͕ EĂŐƚĞŐĂĂů /͕ ĚĞ tŝůƚ :,͕ ƵƚĐŚ >ŝǀĞƌ
^ƵƌŐĞƌǇ '͘ >ŝǀĞƌ ZĞƐĞĐƟŽŶ ĨŽƌ DĞƚĂƐƚĂƟĐ
ŝƐĞĂƐĞ͖  WŽƉƵůĂƟŽŶͲĂƐĞĚ ŶĂůǇƐŝƐ ŽĨ
dƌĞŶĚƐ͘ŝŐ^ƵƌŐ͘ϮϬϭϲ͖ϯϯ;ϮͿ͗ϭϬϰͲϭϯ͘
ϭϱ͘ ǀĂŶ ĚĞƌ 'ĞĞƐƚ >' >Ͳ:͕ <ŽŽƉŵĂŶ D͕
sĞƌŚŽĞĨ ͕ ůĨĞƌŝŶŬ D͕ ĚĞ tŝůƚ :,͘
EĂƟŽŶǁŝĚĞƚƌĞŶĚƐŝŶŝŶĐŝĚĞŶĐĞ͕ƚƌĞĂƚŵĞŶƚ
ĂŶĚ ƐƵƌǀŝǀĂů ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ
ǁŝƚŚ ƐǇŶĐŚƌŽŶŽƵƐ ŵĞƚĂƐƚĂƐĞƐ͘ ͘ ůŝŶ ǆƉ
DĞƚĂƐƚĂƐŝƐ͘ϮϬϭϱ͖ϯϮ;ϱͿ͗ϰϱϳͲϲϱ͘
40 | C H A P T E R  2
ϭϲ͘ ^ŝŵŬĞŶƐ >,͕ ǀĂŶ dŝŶƚĞƌĞŶ ,͕ DĂǇ ͕
ƚĞŶ dŝũĞ :͕ ƌĞĞŵĞƌƐ ':͕ >ŽŽƐǀĞůĚ K:͕
et al. Maintenance treatment with 
capecitabine and bevacizumab in 
ŵĞƚĂƐƚĂƟĐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ;/ZKϯͿ͗ Ă
phase 3 randomised controlled trial of the 
ƵƚĐŚ ŽůŽƌĞĐƚĂů ĂŶĐĞƌ 'ƌŽƵƉ͘ >ĂŶĐĞƚ͘
ϮϬϭϱ͖ϯϴϱ;ϵϵϴϬͿ͗ϭϴϰϯͲϱϮ͘
17. Fritz A, Percy C, Jack A, Shanmugaratnam 
<͕ ^ŽďŝŶ >͕ WĂƌŬŝŶD͕Ğƚ Ăů͘ /ŶƚĞƌŶĂƟŽŶĂů
ůĂƐƐŝĮĐĂƟŽŶ ŽĨ ŝƐĞĂƐĞƐ ĨŽƌ KŶĐŽůŽŐǇ
;/ͲKͿ͘ 'ĞŶĞǀĂ͗ tŽƌůĚ ,ĞĂůƚŚ
KƌŐĂŶŝǌĂƟŽŶ͖ϮϬϬϬ͘
ϭϴ͘ tŝƩĞŬŝŶĚ '&͕  ,ƵƩĞƌ Z͕ <ůŝŵƉĮŶŐĞƌ D͕
>͘ ^͘ dED ĂƚůĂƐ͘ ĞƌůŝŶ͗ ^ƉƌŝŶŐĞƌͲsĞƌƐůĂŐ͖
2004.
ϭϵ͘ WĞƌŵĞ DW͕  ^ƚĂƌĞ :͕ ƐƚĞǀĞ :͘ KŶ
ĞƐƟŵĂƟŽŶ ŝŶ ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů͘ ŝŽŵĞƚƌŝĐƐ͘
ϮϬϭϮ͖ϲϴ;ϭͿ͗ϭϭϯͲϮϬ͘
ϮϬ͘ hZ' ĚĂƚĂďĂƐĞ ϮϬϭϲ͘ ǀĂŝůĂďůĞ ĨƌŽŵ͗
ŚƩƉ͗ͬͬĞĐŽ͘ŝĂƌĐ͘ĨƌͬĞƵƌĞŐ͘
Ϯϭ͘ DĂŶĚĞů :^͕ ŚƵƌĐŚ dZ͕ ŽŶĚ :,͕ ĚĞƌĞƌ &͕ 
'ĞŝƐƐĞƌ D^͕ DŽŶŐŝŶ ^:͕ Ğƚ Ăů͘ dŚĞ ĞīĞĐƚ
of fecal occult-blood screening on the 
ŝŶĐŝĚĞŶĐĞ ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͘  E ŶŐů :
DĞĚ͘ϮϬϬϬ͖ϯϰϯ;ϮϮͿ͗ϭϲϬϯͲϳ͘
ϮϮ͘ ĂƵďĞƌ '͘ dŚĞ ŝŵƉĂĐƚ ŽĨ ƐĐƌĞĞŶŝŶŐ ŽŶ




CS, Fraser CG, Carey FA, Steele RJ, et 
Ăů͘ /ŵƉĂĐƚ ŽĨ ƚŚĞ h< ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ
screening pilot studies on incidence, stage 
ĚŝƐƚƌŝďƵƟŽŶ ĂŶĚ ŵŽƌƚĂůŝƚǇ ƚƌĞŶĚƐ͘ ĂŶĐĞƌ
ƉŝĚĞŵŝŽů͘ϮϬϭϮ͖ϯϲ;ϰͿ͗ĞϮϯϮͲϰϮ͘
Ϯϰ͘ >ĞŵŵĞŶƐ s͕ ǀĂŶ ^ƚĞĞŶďĞƌŐĞŶ͕ >͕ :ĂŶƐƐĞŶͲ
,ĞŝũŶĞŶ͕D͕DĂƌƟũŶ͕,͕ZƵƩĞŶ͕,͕ŽĞďĞƌŐŚ
JW. Trends in colorectal cancer in the south 
ŽĨ ƚŚĞ EĞƚŚĞƌůĂŶĚƐ ϭϵϳϱͲϮϬϬϳ͗ ZĞĐƚĂů
cancer survival levels with colon cancer 
ƐƵƌǀŝǀĂů͘ĐƚĂKŶĐŽů͘ϮϬϭϬ͖ϰϵ;ϲͿ͗ϳϴϰͲϵϲ͘
25. Moertel CG, Fleming TR, Macdonald JS, 
,ĂůůĞƌ '͕ >ĂƵƌŝĞ :͕ 'ŽŽĚŵĂŶ W:͕ Ğƚ Ăů͘
>ĞǀĂŵŝƐŽůĞ ĂŶĚ ŇƵŽƌŽƵƌĂĐŝů ĨŽƌ ĂĚũƵǀĂŶƚ
therapy of resected colon carcinoma. N 
ŶŐů:DĞĚ͘ϭϵϵϬ͖ϯϮϮ;ϲͿ͗ϯϱϮͲϴ͘
Ϯϲ͘ K͛ŽŶŶĞůů D:͕ DĂŝůůŝĂƌĚ :͕ <ĂŚŶ D:͕
Macdonald JS, Haller DG, Mayer RJ, et al. 
ŽŶƚƌŽůůĞĚ ƚƌŝĂů ŽĨ ŇƵŽƌŽƵƌĂĐŝů ĂŶĚ ůŽǁͲ
dose leucovorin given for 6 months as 
ƉŽƐƚŽƉĞƌĂƟǀĞ ĂĚũƵǀĂŶƚ ƚŚĞƌĂƉǇ ĨŽƌ ĐŽůŽŶ
ĐĂŶĐĞƌ͘ :ůŝŶKŶĐŽů͘ϭϵϵϳ͖ϭϱ;ϭͿ͗ϮϰϲͲϱϬ͘
27. Benson AB, 3rd, Venook AP, Bekaii-Saab T, 
ŚĂŶ ͕ ŚĞŶ z:͕ ŽŽƉĞƌ ,^͕ Ğƚ Ăů͘ ŽůŽŶ




Consensus Guidelines for management 
ŽĨƉĂƟĞŶƚƐǁŝƚŚĐŽůŽŶĂŶĚƌĞĐƚĂůĐĂŶĐĞƌ͘ Ă
personalized approach to clinical decision 
ŵĂŬŝŶŐ͘ŶŶKŶĐŽů͘ϮϬϭϮ͖Ϯϯ;ϭϬͿ͗ϮϰϳϵͲϱϭϲ͘
Ϯϵ͘ ƵƚĐŚŶĂƟŽŶĂůĐůŝŶŝĐĂůŐƵŝĚĞůŝŶĞƐĐŽůŽƌĞĐƚĂů
ĐĂƌĐŝŶŽŵĂ ϮϬϭϳ͘ ǀĂŝůĂďůĞ ĨƌŽŵ͗ ŚƩƉ͗ͬͬ
ǁǁǁ͘ŽŶĐŽůŝŶĞ͘ŶůͬĐŽůŽƌĞĐƚĂĂůĐĂƌĐŝŶŽŽŵ͘
ϯϬ͘ ĚĞŶƵůŬD͕<ƌŝũŶĞŶW͕ DĂƌŝũŶĞŶ͕ZƵƩĞŶ
,:͕ ǀĂŶ ĚĞ WŽůůͲ&ƌĂŶƐĞ >s͕ WƵƩĞƌ ,͕ Ğƚ Ăů͘
/ŵƉƌŽǀĞĚŽǀĞƌĂůůƐƵƌǀŝǀĂůĨŽƌƉĂƟĞŶƚƐǁŝƚŚ
ƌĞĐƚĂůĐĂŶĐĞƌƐŝŶĐĞϭϵϵϬ͗ƚŚĞĞīĞĐƚƐŽĨdD
ƐƵƌŐĞƌǇ ĂŶĚ ƉƌĞͲŽƉĞƌĂƟǀĞ ƌĂĚŝŽƚŚĞƌĂƉǇ͘
Ƶƌ:ĂŶĐĞƌ͘ ϮϬϬϴ͖ϰϰ;ϭϮͿ͗ϭϳϭϬͲϲ͘
ϯϭ͘ ǀĂŶ 'ŝũŶ t͕ DĂƌŝũŶĞŶ ͕ EĂŐƚĞŐĂĂů /͕
<ƌĂŶĞŶďĂƌŐD͕WƵƩĞƌ,͕tŝŐŐĞƌƐd͕ ĞƚĂů͘
WƌĞŽƉĞƌĂƟǀĞ ƌĂĚŝŽƚŚĞƌĂƉǇ ĐŽŵďŝŶĞĚ ǁŝƚŚ
ƚŽƚĂů ŵĞƐŽƌĞĐƚĂů ĞǆĐŝƐŝŽŶ ĨŽƌ ƌĞƐĞĐƚĂďůĞ
ƌĞĐƚĂů ĐĂŶĐĞƌ͗ ϭϮͲǇĞĂƌ ĨŽůůŽǁͲƵƉ ŽĨ ƚŚĞ
ŵƵůƟĐĞŶƚƌĞ͕ ƌĂŶĚŽŵŝƐĞĚ ĐŽŶƚƌŽůůĞĚ dD
ƚƌŝĂů͘>ĂŶĐĞƚKŶĐŽů͘ϮϬϭϭ͖ϭϮ;ϲͿ͗ϱϳϱͲϴϮ͘
ϯϮ͘ ^ĞďĂŐͲDŽŶƚĞĮŽƌĞ ͕ ^ƚĞƉŚĞŶƐ Z:͕ ^ƚĞĞůĞ
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ϯϯ͘ ŽƐƐĞƚ :&͕  ŽůůĞƩĞ >͕ ĂůĂŝƐ '͕ DŝŶĞƵƌ
>͕ DĂŝŶŐŽŶ W͕  ZĂĚŽƐĞǀŝĐͲ:ĞůŝĐ >͕ Ğƚ
Ăů͘ ŚĞŵŽƚŚĞƌĂƉǇ ǁŝƚŚ ƉƌĞŽƉĞƌĂƟǀĞ
ƌĂĚŝŽƚŚĞƌĂƉǇŝŶƌĞĐƚĂůĐĂŶĐĞƌ͘ EŶŐů:DĞĚ͘
ϮϬϬϲ͖ϯϱϱ;ϭϭͿ͗ϭϭϭϰͲϮϯ͘
34. Sauer R, Becker H, Hohenberger W, Rodel C, 
tŝƩĞŬŝŶĚ͕&ŝĞƚŬĂƵZ͕ĞƚĂů͘WƌĞŽƉĞƌĂƟǀĞ
ǀĞƌƐƵƐ ƉŽƐƚŽƉĞƌĂƟǀĞ ĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇ
ĨŽƌ ƌĞĐƚĂů ĐĂŶĐĞƌ͘  E ŶŐů : DĞĚ͘
ϮϬϬϰ͖ϯϱϭ;ϭϳͿ͗ϭϳϯϭͲϰϬ͘
35. Gerard JP, Conroy T, Bonnetain F, Bouche 
O, Chapet O, Closon-Dejardin MT, et al. 
WƌĞŽƉĞƌĂƟǀĞƌĂĚŝŽƚŚĞƌĂƉǇǁŝƚŚŽƌǁŝƚŚŽƵƚ
ĐŽŶĐƵƌƌĞŶƚ ŇƵŽƌŽƵƌĂĐŝů ĂŶĚ ůĞƵĐŽǀŽƌŝŶ ŝŶ
dϯͲϰƌĞĐƚĂůĐĂŶĐĞƌƐ͗ƌĞƐƵůƚƐŽĨ&&ϵϮϬϯ͘:
ůŝŶKŶĐŽů͘ϮϬϬϲ͖Ϯϰ;ϮϴͿ͗ϰϲϮϬͲϱ͘
36. Hong TS, Ryan DP. Adjuvant Chemotherapy 
ĨŽƌ>ŽĐĂůůǇĚǀĂŶĐĞĚZĞĐƚĂůĂŶĐĞƌ͗ /Ɛ /ƚĂ
'ŝǀĞŶ͍:ůŝŶKŶĐŽů͘ϮϬϭϱ͖ϯϯ;ϭϳͿ͗ϭϴϳϴͲϴϬ͘
ϯϳ͘ ŽƐƐĞƚ :&͕  ĂůĂŝƐ '͕DŝŶĞƵƌ >͕DĂŝŶŐŽŶ W͕ 
Stojanovic-Rundic S, Bensadoun RJ, et al. 
Fluorouracil-based adjuvant chemotherapy 
ĂŌĞƌ ƉƌĞŽƉĞƌĂƟǀĞ ĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇ
ŝŶ ƌĞĐƚĂů ĐĂŶĐĞƌ͗ ůŽŶŐͲƚĞƌŵ ƌĞƐƵůƚƐ ŽĨ ƚŚĞ
KZd ϮϮϵϮϭ ƌĂŶĚŽŵŝƐĞĚ ƐƚƵĚǇ͘ >ĂŶĐĞƚ
KŶĐŽů͘ϮϬϭϰ͖ϭϱ;ϮͿ͗ϭϴϰͲϵϬ͘
38. Bujko K, Glynne-Jones R, Bujko M. 
ŽĞƐ ĂĚũƵǀĂŶƚ ŇƵŽƌŽƉǇƌŝŵŝĚŝŶĞͲďĂƐĞĚ
ĐŚĞŵŽƚŚĞƌĂƉǇ ƉƌŽǀŝĚĞ Ă ďĞŶĞĮƚ ĨŽƌ
ƉĂƟĞŶƚƐ ǁŝƚŚ ƌĞƐĞĐƚĞĚ ƌĞĐƚĂů ĐĂŶĐĞƌ
who have already received neoadjuvant 
ƌĂĚŝŽĐŚĞŵŽƚŚĞƌĂƉǇ͍  ƐǇƐƚĞŵĂƟĐ
review of randomised trials. Ann Oncol. 
ϮϬϭϬ͖Ϯϭ;ϵͿ͗ϭϳϰϯͲϱϬ͘
ϯϵ͘ ůĨĞƌŝŶŬ D͕ ĚĞ :ŽŶŐ <W͕  <ůĂĂƐĞ :D͕
^ŝĞŵĞƌŝŶŬ :͕ ĚĞ tŝůƚ :,͘ DĞƚĂĐŚƌŽŶŽƵƐ
ŵĞƚĂƐƚĂƐĞƐ ĨƌŽŵ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͗
Ă ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚǇ ŝŶ EŽƌƚŚͲ




Trends in incidence, treatment and survival 
ŽĨƉĂƟĞŶƚƐǁŝƚŚƐƚĂŐĞ/sĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͗
Ă ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐĞƌŝĞƐ͘ ŽůŽƌĞĐƚĂů ŝƐ͘
ϮϬϭϮ͖ϭϰ;ϭͿ͗ϱϲͲϲϭ͘
ϰϭ͘ ƚ >ĂŵͲŽĞƌ :͕ ů ůŝ ͕ sĞƌŚŽĞǀĞŶ Z,͕
ZŽƵŵĞŶ ZD͕ >ĞŵŵĞŶƐ s͕ ZŝũŬĞŶ D͕ Ğƚ
Ăů͘>ĂƌŐĞǀĂƌŝĂƟŽŶŝŶƚŚĞƵƟůŝǌĂƟŽŶŽĨůŝǀĞƌ
ƌĞƐĞĐƟŽŶƐ ŝŶ ƐƚĂŐĞ /s ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ
ƉĂƟĞŶƚƐ ǁŝƚŚ ŵĞƚĂƐƚĂƐĞƐ ĐŽŶĮŶĞĚ ƚŽ ƚŚĞ
ůŝǀĞƌ͘ Ƶƌ:^ƵƌŐKŶĐŽů͘ϮϬϭϱ͖ϰϭ;ϵͿ͗ϭϮϭϳͲϮϱ͘
ϰϮ͘ DŽƌƌŝƐ :͕ &ŽƌŵĂŶ ͕ dŚŽŵĂƐ :͕ YƵŝƌŬĞ
W͕  dĂǇůŽƌ &͕  &ĂŝƌůĞǇ >͕ Ğƚ Ăů͘ ^ƵƌŐŝĐĂů
management and outcomes of colorectal 
cancer liver metastases. Br J Surg. 
ϮϬϭϬ͖ϵϳ;ϳͿ͗ϭϭϭϬͲϴ͘




ƌĂƚĞƐ ŝŶ ŐĂƐƚƌŽŝŶƚĞƐƟŶĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ͘
ŶŶ^ƵƌŐKŶĐŽů͘ϮϬϭϯ͖ϮϬ;ϮͿ͗ϯϳϭͲϴϬ͘
ϰϰ͘ 'ŽŽŝŬĞƌ'͕ĞŬŬĞƌ:t͕ĂƐƟĂĂŶŶĞƚ͕ǀĂŶ
ĚĞƌ 'ĞĞƐƚ >'͕ DĞƌŬƵƐ :t͕ ǀĂŶ ĚĞ sĞůĚĞ
:͕ Ğƚ Ăů͘ ZŝƐŬ ĨĂĐƚŽƌƐ ĨŽƌ ĞǆĐĞƐƐŵŽƌƚĂůŝƚǇ
ŝŶ ƚŚĞ ĮƌƐƚ ǇĞĂƌ ĂŌĞƌ ĐƵƌĂƟǀĞ ƐƵƌŐĞƌǇ
for colorectal cancer. Ann Surg Oncol. 
ϮϬϭϮ͖ϭϵ;ϴͿ͗ϮϰϮϴͲϯϰ͘
ϰϱ͘ ǀĂŶŽŽƌŶ^͕^ƚĞŐĞŵĂŶ/͕^ƚƌŽŽďĂŶƚƐ<͕
Mundt MW, de Wijkerslooth TR, Fockens P, 
ĞƚĂů͘&ĞĐĂůŝŵŵƵŶŽĐŚĞŵŝĐĂůƚĞƐƟŶŐƌĞƐƵůƚƐ
ĂŶĚ ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ ŽĨ ĐŽůŽŶŝĐ ůĞƐŝŽŶƐ͘
ŶĚŽƐĐŽƉǇ͘ϮϬϭϱ͖ϰϳ;ϭϭͿ͗ϭϬϭϭͲϳ͘
ϰϲ͘ ƌĞƩŚĂƵĞƌ D͕ <ĂŵŝŶƐŬŝ D&͕  >ŽďĞƌŐ D͕
ĂƵďĞƌ '͕ ZĞŐƵůĂ :͕ <ƵŝƉĞƌƐ :͕ Ğƚ Ăů͘
WŽƉƵůĂƟŽŶͲĂƐĞĚ ŽůŽŶŽƐĐŽƉǇ ^ĐƌĞĞŶŝŶŐ
ĨŽƌŽůŽƌĞĐƚĂůĂŶĐĞƌ͗ZĂŶĚŽŵŝǌĞĚůŝŶŝĐĂů
dƌŝĂů͘ :D /ŶƚĞƌŶDĞĚ͘ ϮϬϭϲ͖ϭϳϲ;ϳͿ͗ϴϵϰͲ
902.
47. de Haan MC, Thomeer M, Stoker J, Dekker 
͕ <ƵŝƉĞƌƐ :͕ ǀĂŶ ĂůůĞŐŽŽŝũĞŶ D͘ hŶŝƚ
ĐŽƐƚƐ ŝŶ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ĐŽůŽƌĞĐƚĂů
cancer screening using CT colonography 
performed in university hospitals in The 
EĞƚŚĞƌůĂŶĚƐ͘ Ƶƌ ZĂĚŝŽů͘ ϮϬϭϯ͖Ϯϯ;ϰͿ͗ϴϵϳͲ
907.
ϰϴ͘ ǀĂŶ 'ŝũŶ t͕ <ƌŝũŶĞŶ W͕  >ĞŵŵĞŶƐ s͕ ĚĞŶ
ƵůŬD͕WƵƩĞƌ,͕ǀĂŶĚĞsĞůĚĞ:͘YƵĂůŝƚǇ
assurance in rectal cancer treatment in 
ƚŚĞEĞƚŚĞƌůĂŶĚƐ͗ Ă ĐĂƚĐŚ ƵƉ ĐŽŵƉĂƌĞĚ ƚŽ
ĐŽůŽŶ ĐĂŶĐĞƌ ƚƌĞĂƚŵĞŶƚ͘ Ƶƌ : ^ƵƌŐKŶĐŽů͘
ϮϬϭϬ͖ϯϲ;ϰͿ͗ϯϰϬͲϰ͘
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ϰϵ͘ &ŝƐĐŚĞƌ :͕ ,ĞůůŵŝĐŚ '͕ :ĂĐŬŝƐĐŚ d͕  WƵīĞƌ
͕ ŝŵŵĞƌ :͕ ůĞǇů ͕ Ğƚ Ăů͘ KƵƚĐŽŵĞ ĨŽƌ
ƐƚĂŐĞ // ĂŶĚ /// ƌĞĐƚĂů ĂŶĚ ĐŽůŽŶ ĐĂŶĐĞƌ
ĞƋƵĂůůǇŐŽŽĚĂŌĞƌƚƌĞĂƚŵĞŶƚŝŵƉƌŽǀĞŵĞŶƚ
ŽǀĞƌ ƚŚƌĞĞ ĚĞĐĂĚĞƐ͘ /Ŷƚ : ŽůŽƌĞĐƚĂů ŝƐ͘
ϮϬϭϱ͖ϯϬ;ϲͿ͗ϳϵϳͲϴϬϲ͘
50. Hohenberger W, Weber K, Matzel K, 
Papadopoulos T, Merkel S. Standardized 
ƐƵƌŐĞƌǇ ĨŽƌ ĐŽůŽŶŝĐ ĐĂŶĐĞƌ͗ ĐŽŵƉůĞƚĞ
ŵĞƐŽĐŽůŝĐ ĞǆĐŝƐŝŽŶ ĂŶĚ ĐĞŶƚƌĂů ůŝŐĂƟŽŶͲͲ
technical notes and outcome. Colorectal 
ŝƐ͘ϮϬϬϵ͖ϭϭ;ϰͿ͗ϯϱϰͲϲϰ͖ĚŝƐĐƵƐƐŝŽŶϲϰͲϱ͘
ϱϭ͘ ǀĂŶ ĚĞƌ ^ŝũƉ DW͕  ĂƐƟĂĂŶŶĞƚ ͕ DĞƐŬĞƌ
t͕ǀĂŶĚĞƌ'ĞĞƐƚ>'͕ƌĞƵŐŽŵ:͕^ƚĞƵƉ
t,͕ĞƚĂů͘ŝīĞƌĞŶĐĞƐďĞƚǁĞĞŶĐŽůŽŶĂŶĚ
ƌĞĐƚĂů ĐĂŶĐĞƌ ŝŶ ĐŽŵƉůŝĐĂƟŽŶƐ͕ ƐŚŽƌƚͲƚĞƌŵ
ƐƵƌǀŝǀĂů ĂŶĚ ƌĞĐƵƌƌĞŶĐĞƐ͘ /Ŷƚ : ŽůŽƌĞĐƚĂů
ŝƐ͘ϮϬϭϲ͖ϯϭ;ϭϬͿ͗ϭϲϴϯͲϵϭ͘






ϱϯ͘ ĂůĚĂƌĞůůĂ ͕ ƌŽĐĞƫ ͕ DĞƐƐĞƌŝŶŝ >͕
WĂĐŝ ͘ dƌĞŶĚƐ ŝŶ ĐŽůŽƌĞĐƚĂů ŝŶĐŝĚĞŶĐĞ ďǇ
ĂŶĂƚŽŵŝĐ ƐƵďƐŝƚĞ ĨƌŽŵ ϭϵϴϱ ƚŽ ϮϬϬϱ͗ Ă
ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚǇ͘ /Ŷƚ : ŽůŽƌĞĐƚĂů
ŝƐ͘ϮϬϭϯ͖Ϯϴ;ϱͿ͗ϲϯϳͲϰϭ͘
54. Stapley S, Peters TJ, Sharp D, Hamilton W. 
dŚĞŵŽƌƚĂůŝƚǇŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌŝŶƌĞůĂƟŽŶ
ƚŽ ƚŚĞ ŝŶŝƟĂů ƐǇŵƉƚŽŵ Ăƚ ƉƌĞƐĞŶƚĂƟŽŶ
ƚŽ ƉƌŝŵĂƌǇ ĐĂƌĞ ĂŶĚ ƚŽ ƚŚĞ ĚƵƌĂƟŽŶ ŽĨ
ƐǇŵƉƚŽŵƐ͗ Ă ĐŽŚŽƌƚ ƐƚƵĚǇ ƵƐŝŶŐ ŵĞĚŝĐĂů
ƌĞĐŽƌĚƐ͘ƌ:ĂŶĐĞƌ͘ ϮϬϬϲ͖ϵϱ;ϭϬͿ͗ϭϯϮϭͲϱ͘
ϱϱ͘ ůͲ^ƵŬŚŶŝ ͕DŝůŽƚ >͕ &ƌƵŝƚŵĂŶD͕ ĞǇĞŶĞ
:͕sŝĐƚŽƌ:͕^ĐŚŵŽĐŬĞƌ^͕ĞƚĂů͘ŝĂŐŶŽƐƟĐ
ĂĐĐƵƌĂĐǇ ŽĨ DZ/ ĨŽƌ ĂƐƐĞƐƐŵĞŶƚ ŽĨ
T category, lymph node metastases, 




ϱϲ͘ EĞƌĂĚ ͕ >ĂŚĂǇĞ D:͕ DĂĂƐ D͕ EĞůĞŵĂŶƐ
W͕  ĂŬĞƌƐ &͕ ĞĞƚƐ '>͕ Ğƚ Ăů͘ ŝĂŐŶŽƐƟĐ
ĐĐƵƌĂĐǇ ŽĨ d ĨŽƌ >ŽĐĂů ^ƚĂŐŝŶŐ ŽĨ
ŽůŽŶ ĂŶĐĞƌ͗  ^ǇƐƚĞŵĂƟĐ ZĞǀŝĞǁ ĂŶĚ


















WƌŝŵĂƌǇ ƐƚĂŐĞ /Ͳ/// ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌƉĂƟĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚ ƌĞƐĞĐƟŽŶďĞƚǁĞĞŶϮϬϬϴͲ
ϮϬϭϯ ǁĞƌĞ ƐĞůĞĐƚĞĚ ĨƌŽŵ ƚŚĞ EĞƚŚĞƌůĂŶĚƐ ĂŶĐĞƌ ZĞŐŝƐƚƌǇ͘ WĂƟĞŶƚƐ ǁĞƌĞ ŐƌŽƵƉĞĚ ďǇ
ĂŐĞ͗фϲϱ͕ϲϱͲϳϰ͕ϳϱͲϴϰĂŶĚшϴϱǇĞĂƌƐ͘KǀĞƌĂůůƐƵƌǀŝǀĂů͕ƌĞůĂƟǀĞƐƵƌǀŝǀĂůĂŶĚĐŽŶĚŝƟŽŶĂů
ƌĞůĂƟǀĞƐƵƌǀŝǀĂů;ĐŽŶĚŝƟŽŶŽĨƐƵƌǀŝǀŝŶŐϭǇĞĂƌͿ͕ǁĞƌĞĐĂůĐƵůĂƚĞĚďǇĂŐĞŐƌŽƵƉƐĂŶĚƚƵŵŽƵƌ
ůŽĐĂůŝǌĂƟŽŶ͘ &ƵƌƚŚĞƌŵŽƌĞ͕ ƌĞůĂƟǀĞ ĞǆĐĞƐƐ ƌŝƐŬƐ ŽĨ ĚĞĂƚŚ͕ ϯϬͲĚĂǇ͕  ϭͲǇĞĂƌ ŵŽƌƚĂůŝƚǇ ĂŶĚ
ϭͲǇĞĂƌĞǆĐĞƐƐŵŽƌƚĂůŝƚǇǁĞƌĞĐĂůĐƵůĂƚĞĚ͘
Results
ϱϮ͕Ϯϵϲ ƉĂƟĞŶƚƐ ǁĞƌĞ ŝŶĐůƵĚĞĚ͘ ŝīĞƌĞŶĐĞƐ ŝŶ ϱͲǇĞĂƌ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ǁĞƌĞ ŽďƐĞƌǀĞĚ
ďĞƚǁĞĞŶĂŐĞŐƌŽƵƉƐ ;ĐŽůŽŶĐĂŶĐĞƌ͗ϴϮй͕ϳϯй͕ϱϲйĂŶĚϯϱй͖ ƌĞĐƚĂů ĐĂŶĐĞƌ͗ϴϮй͕ϳϰй͕
ϱϲйĂŶĚϯϴй͖pфϬ͘ϬϬϬϭͿ͘ŐĞͲƌĞůĂƚĞĚĚŝīĞƌĞŶĐĞƐǁĞƌĞůĞƐƐƉƌŽŵŝŶĞŶƚŝŶƌĞůĂƟǀĞƐƵƌǀŝǀĂů
ĂŶĚĚŝƐĂƉƉĞĂƌĞĚŝŶĐŽŶĚŝƟŽŶĂůƌĞůĂƟǀĞƐƵƌǀŝǀĂů͘dŚŝƌƚǇͲĚĂǇŵŽƌƚĂůŝƚǇƌĂƚĞƐĚĞĐƌĞĂƐĞĚŽǀĞƌ
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INTRODUCTION
EŽǁĂĚĂǇƐŵŽƌĞ ƚŚĂŶ ϱϬйŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŝƐ ďĞŝŶŐ ĚŝĂŐŶŽƐĞĚ ŝŶ ƉĂƟĞŶƚƐ ŽǀĞƌ ϳϬ
years of age.1 The incidence of colorectal cancer among elderly people in the Dutch 
ƉŽƉƵůĂƟŽŶǁŝůůŝŶĐƌĞĂƐĞĚƵĞƚŽĂŐĞŝŶŐŽĨƚŚĞƉŽƉƵůĂƟŽŶĂŶĚƚŚĞŝŶƚƌŽĚƵĐƟŽŶŽĨƚŚĞƵƚĐŚ





ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚǇ ;ƉĞƌŝŽĚ ϭϵϵϭͲϮϬϬϱͿ ƐŚŽǁĞĚ ĂŶ ŽǀĞƌĂůů ŵŽƌƚĂůŝƚǇ ŽĨ ϮϬͲϮϯй
ŝŶĞůĚĞƌůǇƉĂƟĞŶƚƐ ;ĂŐĞĚшϳϱ ǇĞĂƌƐͿǁŝƚŚŝŶ ƚŚĞĮƌƐƚƉŽƐƚŽƉĞƌĂƟǀĞ ǇĞĂƌ ĂŌĞƌ ĐŽůŽƌĞĐƚĂů




ƵƌŝŶŐ ƚŚĞ ůĂƐƚ ĚĞĐĂĚĞ ƐĞǀĞƌĂů ĚĞǀĞůŽƉŵĞŶƚƐ ŝŶ ƉĞƌŝͲŽƉĞƌĂƟǀĞ ĐĂƌĞ ŚĂǀĞ ďĞĞŶŵĂĚĞ͗
ƐƵƌŐŝĐĂůƚĞĐŚŶŝƋƵĞƐŚĂǀĞĐŚĂŶŐĞĚ͕ŝ͘Ğ͘ƚŚĞŝŶƚƌŽĚƵĐƟŽŶŽĨŵŝŶŝŵĂůůǇŝŶǀĂƐŝǀĞĞŶĚŽƐĐŽƉŝĐ
surgery.4-6ůƐŽƌĞĨĞƌƌĂůŽĨƉĂƟĞŶƚƐƚŽŚŝŐŚͲǀŽůƵŵĞĐĞŶƚĞƌƐĂŶĚĚŝīĞƌĞŶƟĂƟŽŶŽĨƐƵƌŐŝĐĂů












ƌĞŐŝƐƚƌǇ ďĂƐĞĚ ŽŶ ŶŽƟĮĐĂƟŽŶ ŽĨ Ăůů ŶĞǁůǇ ĚŝĂŐŶŽƐĞĚŵĂůŝŐŶĂŶĐŝĞƐ ŝŶ ƚŚĞEĞƚŚĞƌůĂŶĚƐ
ďǇ ƚŚĞ ĂƵƚŽŵĂƚĞĚ ƉĂƚŚŽůŽŐŝĐĂů ĂƌĐŚŝǀĞ ;W>'Ϳ ĂŶĚ ƚŚĞ EĂƟŽŶĂů ZĞŐŝƐƚƌǇ ŽĨ ,ŽƐƉŝƚĂů
ŝƐĐŚĂƌŐĞŝĂŐŶŽƐŝƐ;>DZͿ͘
/ŶĨŽƌŵĂƟŽŶŽŶƉĂƟĞŶƚĂŶĚƚƵŵŽƵƌĐŚĂƌĂĐƚĞƌŝƐƟĐƐ͕ĚŝĂŐŶŽƐŝƐĂŶĚƚƌĞĂƚŵĞŶƚŝƐƌŽƵƟŶĞůǇ
ĞǆƚƌĂĐƚĞĚ ĨƌŽŵ ƚŚĞ ŵĞĚŝĐĂů ƌĞĐŽƌĚƐ͘ dŚĞ ƋƵĂůŝƚǇ ŽĨ ƚŚĞ ĚĂƚĂ ŝƐ ŚŝŐŚ ĚƵĞ ƚŽ ƚŚŽƌŽƵŐŚ
ƚƌĂŝŶŝŶŐŽĨ ƚŚĞ ƌĞŐŝƐƚƌĂƟŽŶ ƚĞĂŵĂŶĚ ĐŽŵƉƵƚĞƌŝǌĞĚ ĐŽŶƐŝƐƚĞŶĐǇ ĐŚĞĐŬƐĂƚ ƌĞŐŝŽŶĂů ĂŶĚ
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ŶĂƟŽŶĂůůĞǀĞů͘ŶĂƚŽŵŝĐĂůƐŝƚĞŽĨƚŚĞƚƵŵŽƵƌŝƐƌĞŐŝƐƚĞƌĞĚĂĐĐŽƌĚŝŶŐƚŽƚŚĞ/ŶƚĞƌŶĂƟŽŶĂů





newly diagnosed with cancer in the south-eastern part of the Netherlands, an area 
ǁŝƚŚϮ͘ϰŵŝůůŝŽŶŝŶŚĂďŝƚĂŶƚƐ;~ϭϱйŽĨƚŚĞƵƚĐŚƉŽƉƵůĂƟŽŶͿĂŶĚŶŽƵŶŝǀĞƌƐŝƚǇŚŽƐƉŝƚĂůƐ͘















ĐĂŶĐĞƌǁĂƐ ĐůĂƐƐŝĮĞĚ ĂƐ ƐƵƌŐĞƌǇ͕  ƐƵƌŐĞƌǇǁŝƚŚ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ Žƌ ŽƚŚĞƌ͘  ZĞĐƚĂů










from all causes of death. 
3T R E N D S  I N  S U R V I VA L  A M O N G  C O L O R E C TA L  C A N C E R  PAT I E N T S | 47
ZĞůĂƟǀĞƐƵƌǀŝǀĂůǁĂƐĐĂůĐƵůĂƚĞĚĨŽƌƚŚĞĚŝīĞƌĞŶƚĂŐĞŐƌŽƵƉƐĂƐƚŚĞƌĂƟŽŽĨƚŚĞƐƵƌǀŝǀĂů
ŽďƐĞƌǀĞĚ ĂŵŽŶŐ ƚŚĞ ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĂŶĚ ƚŚĞ ƐƵƌǀŝǀĂů ƚŚĂƚǁŽƵůĚ ŚĂǀĞďĞĞŶĞǆƉĞĐƚĞĚ
ďĂƐĞĚŽŶƚŚĞĐŽƌƌĞƐƉŽŶĚŝŶŐ;ĂŐĞ͕ŐĞŶĚĞƌĂŶĚǇĞĂƌͿŐĞŶĞƌĂůƉŽƉƵůĂƟŽŶ͘13ZĞůĂƟǀĞƐƵƌǀŝǀĂů
ŝƐƚŚĞƉƌĞĨĞƌƌĞĚǁĂǇƚŽĚĞƐĐƌŝďĞƚŚĞƉƌŽŐŶŽƐŝƐŽĨĞůĚĞƌůǇĐĂŶĐĞƌƉĂƟĞŶƚƐ͕ĂƐŝƚƚĂŬĞƐŝŶƚŽ




ŝīĞƌĞŶĐĞƐ ŝŶƉĂƟĞŶƚĂŶĚ ƚƵŵŽƵƌĐŚĂƌĂĐƚĞƌŝƐƟĐƐĂĐƌŽƐƐ ƚŚĞĚŝīĞƌĞŶƚĂŐĞŐƌŽƵƉƐǁĞƌĞ
ĞǀĂůƵĂƚĞĚƵƐŝŶŐʖ2 ƚĞƐƚƐĂŌĞƌƐƚƌĂƟĮĐĂƟŽŶďǇƚƵŵŽƵƌůŽĐĂůŝǌĂƟŽŶ͘
KǀĞƌĂůů ƐƵƌǀŝǀĂů ǁĂƐ ĐĂůĐƵůĂƚĞĚ ƵƐŝŶŐ ƚŚĞ <ĂƉůĂŶͲDĞŝĞƌŵĞƚŚŽĚ͘ &ƵƌƚŚĞƌŵŽƌĞ͕ ƌĞůĂƟǀĞ
ƐƵƌǀŝǀĂůĂŶĚĐŽŶĚŝƟŽŶĂůƌĞůĂƟǀĞƐƵƌǀŝǀĂůǁĞƌĞĐĂůĐƵůĂƚĞĚƵƐŝŶŐƚŚĞWŽŚĂƌWĞƌŵĞŵĞƚŚŽĚ͘14
























TABLE 1 WĂƟĞŶƚ ĂŶĚ ƚƵŵŽƵƌ ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ ŽĨ ƉĂƟĞŶƚƐǁŚŽ ƵŶĚĞƌǁĞŶƚ ƐƵƌŐŝĐĂů ƌĞƐĞĐƟŽŶ ĨŽƌ 
 ƐƚĂŐĞ /Ͳ///ĐŽůŽŶŽƌ ƌĞĐƚĂůĐĂŶĐĞƌĚŝĂŐŶŽƐĞĚ ŝŶ ƚŚĞƉĞƌŝŽĚϮϬϬϴͲϮϬϭϯĂĐĐŽƌĚŝŶŐƚŽĂŐĞ 
 ;ŶсϱϮ͕ϮϵϲͿ͘
<65 years 65-74 years 75-84 years шϴϱǇĞĂƌƐ
n ;йͿ n ;йͿ n ;йͿ n ;йͿ p value
COLON CANCER
Total 9,847 ;ϮϳͿ 11,607 ;ϯϮͿ 11,775 ;ϯϮͿ 3,235 ;ϵͿ
Gender <0.0001
   Male 5,263 ;ϱϯͿ 6,393 ;ϱϱͿ 5,813 ;ϰϵͿ 1,265 ;ϯϵͿ
   Female 4,584 ;ϰϳͿ 5,214 ;ϰϱͿ 5,962 ;ϱϭͿ 1,970 ;ϲϭͿ
Period of diagnosis <0.0001
   2008-2009 3,293 ;ϯϯͿ 3,555 ;ϯϭͿ 3,770 ;ϯϮͿ 1,088 ;ϯϯͿ
   2010-2011 3,311 ;ϯϰͿ 3,853 ;ϯϯͿ 3,993 ;ϯϰͿ 1,122 ;ϯϱͿ
   2012-2013 3,243 ;ϯϯͿ 4,199 ;ϯϲͿ 4,012 ;ϯϰͿ 1,025 ;ϯϮͿ
Stage <0.0001
^ƚĂŐĞ/ 1,887 ;ϭϵͿ 2,599 ;ϮϮͿ 2,482 ;ϮϭͿ 533 ;ϭϲͿ
^ƚĂŐĞ// 3,831 ;ϯϵͿ 4,758 ;ϰϭͿ 5,399 ;ϰϲͿ 1,610 ;ϱϬͿ
^ƚĂŐĞ/// 4,129 ;ϰϮͿ 4,250 ;ϯϳͿ 3,894 ;ϯϯͿ 1,092 ;ϯϰͿ
Treatment <0.0001
   Surgery only 5,369 ;ϱϱͿ 7,836 ;ϲϳͿ 10,396 ;ϴϴͿ 3,213 ;ϵϵͿ
   Surgery + adjuvant CT 4,366 ;ϰϰͿ 3,665 ;ϯϮͿ 1,313 ;ϭϭͿ 15 ;ϭͿ
   Other‡ 112 ;ϭͿ 106 ;ϭͿ 66 ;ϭͿ 7 ;ϭͿ
ŵĞƌŐĞŶĐǇƌĞƐĞĐƟŽŶΎ <0.0001
ŵĞƌŐĞŶƚ 849 ;ϵͿ 783 ;ϳͿ 794 ;ϳͿ 347 ;ϭϭͿ
ůĞĐƟǀĞ 8,830 ;ϵϭͿ 10,660 ;ϵϯͿ 10,842 ;ϵϯͿ 2,836 ;ϴϵͿ
^ƵƌŐŝĐĂůƉƌŽĐĞĚƵƌĞΎΎ <0.0001
KƉĞŶƌĞƐĞĐƟŽŶ 6,063 ;ϲϮͿ 7,351 ;ϲϰͿ 8,160 ;ϳϬͿ 2,455 ;ϳϲͿ
>ĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƟŽŶ 3,687 ;ϯϴͿ 4,166 ;ϯϲͿ 3,534 ;ϯϬͿ 757 ;ϮϰͿ
EƵŵďĞƌŽĨĐŽŵŽƌďŝĚŝƟĞƐΎΎΎ <0.0001
   0 690 ;ϰϵͿ 416 ;ϮϰͿ 261 ;ϭϱͿ 51 ;ϭϯͿ
   1 393 ;ϮϴͿ 487 ;ϮϴͿ 390 ;ϯϵϬͿ 97 ;ϮϰͿ
шϮ 331 ;ϮϯͿ 812 ;ϰϴͿ 1,044 ;ϲϮͿ 253 ;ϲϯͿ
RECTAL CANCER
Total 6,209 ;ϯϵͿ 5,385 ;ϯϰͿ 3,612 ;ϮϯͿ 626 ;ϰͿ
Gender <0.0001
   Male 3,851 ;ϲϮͿ 3,537 ;ϲϲͿ 2,109 ;ϱϴͿ 298 ;ϰϳͿ
   Female 2,385 ;ϯϴͿ 1,848 ;ϯϰͿ 1,503 ;ϰϮͿ 328 ;ϱϯͿ
Period of diagnosis <0.0001
   2008-2009 2,099 ;ϯϯͿ 1,700 ;ϯϭͿ 1,204 ;ϯϯͿ 232 ;ϯϳͿ
   2010-2011 2,106 ;ϯϰͿ 1,822 ;ϯϰͿ 1,186 ;ϯϯͿ 227 ;ϯϲͿ
   2012-2013 2,004 ;ϯϯͿ 1,863 ;ϯϱͿ 1,222 ;ϯϰͿ 167 ;ϮϳͿ
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TABLE 1 WĂƟĞŶƚ ĂŶĚ ƚƵŵŽƵƌ ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ ŽĨ ƉĂƟĞŶƚƐǁŚŽ ƵŶĚĞƌǁĞŶƚ ƐƵƌŐŝĐĂů ƌĞƐĞĐƟŽŶ ĨŽƌ 
 ƐƚĂŐĞ /Ͳ/// ĐŽůŽŶŽƌ ƌĞĐƚĂůĐĂŶĐĞƌĚŝĂŐŶŽƐĞĚ ŝŶ ƚŚĞƉĞƌŝŽĚϮϬϬϴͲϮϬϭϯĂĐĐŽƌĚŝŶŐ ƚŽĂŐĞ 
 ;ŶсϱϮ͕ϮϵϲͿ͘;ŽŶƟŶƵĞĚͿ
<65 years 65-74 years 75-84 years шϴϱǇĞĂƌƐ
n ;йͿ n ;йͿ n ;йͿ n ;йͿ p value
Stage <0.0001
^ƚĂŐĞ/ 1,015 ;ϭϲͿ 1,046 ;ϭϵͿ 735 ;ϮϬͿ 131 ;ϮϭͿ
^ƚĂŐĞ// 1,417 ;ϮϯͿ 1,397 ;ϮϲͿ 1,157 ;ϯϮͿ 225 ;ϯϲͿ
^ƚĂŐĞ/// 3,777 ;ϲϭͿ 2,942 ;ϱϱͿ 1,720 ;ϰϴͿ 270 ;ϰϯͿ
Treatment <0.0001
   Surgery only 590 ;ϭϬͿ 759 ;ϭϰͿ 888 ;ϮϱͿ 293 ;ϰϳͿ
   Surgery + neoadjuvant RT 2,593 ;ϰϮͿ 2,518 ;ϰϳͿ 2,026 ;ϱϲͿ 314 ;ϱϬͿ
   Surgery + neoadjuvant CTRT 2,725 ;ϰϯͿ 1,892 ;ϯϱͿ 630 ;ϭϳͿ 19 ;ϯͿ
   Other‡ 301 ;ϱͿ 216 ;ϰͿ 68 ;ϮͿ 0 ;ϬͿ
^ƵƌŐŝĐĂůƉƌŽĐĞĚƵƌĞΎΎ <0.0001
KƉĞŶƌĞƐĞĐƟŽŶ 3,632 ;ϱϵͿ 3,327 ;ϲϮͿ 2,305 ;ϲϰͿ 438 ;ϳϬͿ
>ĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƟŽŶ 2,490 ;ϰϭͿ 1,987 ;ϯϴͿ 1,276 ;ϯϲͿ 184 ;ϯϬͿ
EƵŵďĞƌŽĨĐŽŵŽƌďŝĚŝƟĞƐΎΎΎ <0.0001
   0 486 ;ϱϳͿ 256 ;ϯϮͿ 100 ;ϭϵͿ 7 ;ϭϭͿ
   1 231 ;ϮϳͿ 268 ;ϯϯͿ 153 ;ϮϴͿ 17 ;ϮϰͿ
шϮ 147 ;ϭϲͿ 273 ;ϯϱͿ 287 ;ϱϯͿ 45 ;ϲϱͿ








ŐƌŽƵƉƐŚĂĚ ƐůŝŐŚƚůǇŚŝŐŚĞƌƉƌŽƉŽƌƟŽŶƐĞŵĞƌŐĞŶĐǇ ƌĞƐĞĐƟŽŶƐ ;pфϬ͘ϬϬϬϭͿ͘ &ƵƌƚŚĞƌŵŽƌĞ͕
ĨŽƌďŽƚŚĐŽůŽŶĂŶĚƌĞĐƚĂůĐĂŶĐĞƌ͕ ƐƚĂŐĞĚŝīĞƌĞĚƐŝŐŶŝĮĐĂŶƚůǇ͕ ĞƐƉĞĐŝĂůůǇĂŶŝŶĐƌĞĂƐĞŝŶƐƚĂŐĞ
//ĂŶĚĂĚĞĐƌĞĂƐĞŝŶƐƚĂŐĞ///ƉĂƟĞŶƚƐĂƉƉĞĂƌĞĚǁŝƚŚŝŶĐƌĞĂƐŝŶŐĂŐĞ͘&ƵƌƚŚĞƌŵŽƌĞ͕ĂŚŝŐŚĞƌ

























ǁĞƌĞ ŽďƐĞƌǀĞĚ͕ ĐŽŵƉĂƌĞĚ ƚŽ ƚŚĞ ŽǀĞƌĂůů ƐƚƵĚǇ ƉŽƉƵůĂƟŽŶ͘ &ƵƌƚŚĞƌŵŽƌĞ͕ ĂŐĞͲƌĞůĂƚĞĚ
























































































































FIGURE 2 ZĞůĂƟǀĞƐƵƌǀŝǀĂůĂĐĐŽƌĚŝŶŐƚŽĂŐĞŽĨƉĂƟĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĨŽƌƐƚĂŐĞ 
 /Ͳ///ĐŽůŽŶ;ĂͿŽƌƌĞĐƚĂů;ďͿĐĂŶĐĞƌ;ŶсϱϮ͕ϮϵϲͿ͘





































































FIGURE 3 ŽŶĚŝƟŽŶĂůƐƵƌǀŝǀĂůĂĐĐŽƌĚŝŶŐƚŽĂŐĞŽĨƉĂƟĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĨŽƌ 
 ƐƚĂŐĞ/Ͳ///ĐŽůŽŶ;ĂͿŽƌƌĞĐƚĂůĐĂŶĐĞƌ;ďͿ;Ŷсϰϳ͕ϮϵϯͿ͘
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TABLE 2 ZĞůĂƟǀĞ ĞǆĐĞƐƐ ƌŝƐŬƐ ŽĨ ĚĞĂƚŚ ;ZZͿ ĨŽƌ ƌĞůĂƟǀĞ ĂŶĚ ĐŽŶĚŝƟŽŶĂů ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů ŽĨ 
 ƉĂƟĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĨŽƌƐƚĂŐĞ/Ͳ///ĐŽůŽŶŽƌƌĞĐƚĂůĐĂŶĐĞƌĚŝĂŐŶŽƐĞĚ 
 ŝŶƚŚĞƉĞƌŝŽĚϮϬϬϴͲϮϬϭϯĂĐĐŽƌĚŝŶŐƚŽĂŐĞ;ŶсϱϮ͕ϮϵϲͿ͘
 RS ϵϱй/ CRS ϵϱй/
COLON CANCER
<65 years reference reference
65-74 years 1.2 1.13-1.32 1.1 1.00-1.21
75-84 years 1.7 1.56-1.83 1.1 0.95-1.20
шϴϱǇĞĂƌƐ 2.1 1.80-2.38 1.1 0.98-1.76
RECTAL CANCER
<65 years reference reference
65-74 years 1.2 1.03-1.29 1.0 0.96-1.25
75-84 years 1.7 1.50-1.94 1.1 0.99-1.79




TABLE 3 ZĞůĂƟǀĞ ĞǆĐĞƐƐ ƌŝƐŬƐ ŽĨ ĚĞĂƚŚ ;ZZͿ ĨŽƌ ƌĞůĂƟǀĞ ĂŶĚ ĐŽŶĚŝƟŽŶĂů ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů ŽĨ 
 ƉĂƟĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĨŽƌƐƚĂŐĞ/Ͳ///ĐŽůŽŶŽƌƌĞĐƚĂůĐĂŶĐĞƌĚŝĂŐŶŽƐĞĚ 
 in the period 2008-2013, in the south-eastern part of the Netherlands, according to age 
 ;Ŷсϳ͕ϰϵϱͿ͘
 RS ϵϱй/ CRS ϵϱй/
COLON CANCER
<65 years reference reference
65-74 years 1.1 0.86-1.33 1.0 0.77-1.30
75-84 years 1.1 0.88-1.41 0.9 0.69-1.28
шϴϱǇĞĂƌƐ 1.2 0.84-1.67 0.6 0.29-1.22
RECTAL CANCER
<65 years reference reference
65-74 years 1.2 0.89-1.66 1.0 0.65-1.38
75-84 years 2.1 1.54-2.95 1.8 0.97-2.64




Ɛ Ă ƐƵďĂŶĂůǇƐŝƐ͕ ĂŶĂůǇƐĞƐ ǁĞƌĞ ƌĞƉĞĂƚĞĚ ŝŶĐůƵĚŝŶŐ ƉĂƟĞŶƚƐ ŽĨ ƚŚĞ ŝŶĚŚŽǀĞŶ ĂƌĞĂ
ŝŶĐůƵĚŝŶŐŝŶĨŽƌŵĂƟŽŶŽŶƚŚĞƉƌĞƐĞŶĐĞŽĨĐŽŵŽƌďŝĚĚŝƐĞĂƐĞƐ;Ŷсϳ͕ϰϵϱͿ͘ƐƐŚŽǁŶŝŶdĂďůĞ
ϯ͕ ĂŐĞͲƌĞůĂƚĞĚ ĚŝīĞƌĞŶĐĞƐ ŝŶ ZZ ĨŽƌ ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů ĂŶĚ ĐŽŶĚŝƟŽŶĂů ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů
ĚŝƐĂƉƉĞĂƌĞĚĂŌĞƌĂĚũƵƐƚŵĞŶƚĨŽƌƚŚĞŶƵŵďĞƌŽĨĐŽŵŽƌďŝĚŝƟĞƐĂŵŽŶŐƉĂƟĞŶƚƐǁŝƚŚĐŽůŽŶ
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ƚƌŝƉůĞĚ ĐŽŵƉĂƌĞĚ ƚŽ ƉŽƐƚŽƉĞƌĂƟǀĞ ϯϬͲĚĂǇŵŽƌƚĂůŝƚǇ ƌĂƚĞƐ ;ĐŽůŽŶ ĐĂŶĐĞƌ͗ ϭϬ͘ϳй ǀĞƌƐƵƐ
ϰ͘Ϯй͖ ƌĞĐƚĂů ĐĂŶĐĞƌ͗ϳ͘ϭйǀĞƌƐƵƐϮ͘ϯйͿ͘ &ŽƌďŽƚŚ ĐŽůŽŶĂŶĚ ƌĞĐƚĂů ĐĂŶĐĞƌƉĂƟĞŶƚƐ͕ ĂŐĞ
ĂŶĚƚƵŵŽƵƌƐƚĂŐĞǁĞƌĞƐŝŐŶŝĮĐĂŶƚĨĂĐƚŽƌƐĨŽƌƉŽƐƚŽƉĞƌĂƟǀĞϯϬͲĚĂǇĂŶĚϭͲǇĞĂƌŵŽƌƚĂůŝƚǇ
;pфϬ͘ϬϬϬϭĨŽƌĂůůǀĂƌŝĂďůĞƐͿ;dĂďůĞϰͿ͘ĚĚŝƟŽŶĂůůǇ͕ ŝŶĐƌĞĂƐĞĚϯϬͲĚĂǇĂŶĚϭͲǇĞĂƌŵŽƌƚĂůŝƚǇ
ǁĞƌĞŽďƐĞƌǀĞĚǁŚĞŶ ĐŽůŽŶ ĐĂŶĐĞƌƉĂƟĞŶƚƐƵŶĚĞƌǁĞŶƚ ĂŶĞŵĞƌŐĞŶĐǇ ƌĞƐĞĐƟŽŶ͕ǁŚĞŶ
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐƵŶĚĞƌǁĞŶƚŽƉĞŶƌĞƐĞĐƟŽŶŽƌǁŚĞŶĐŽŵŽƌďŝĚŝƟĞƐǁĞƌĞƉƌĞƐĞŶƚ
ĂƚƟŵĞŽĨĚŝĂŐŶŽƐŝƐ;pфϬ͘ϬϬϬϭĨŽƌĂůůǀĂƌŝĂďůĞƐͿ͘&ƵƌƚŚĞƌŵŽƌĞ͕ϯϬͲĚĂǇĂŶĚϭͲǇĞĂƌŵŽƌƚĂůŝƚǇ









ŵŽƌƚĂůŝƚǇ͘ ^ƵďĂŶĂůǇƐŝƐ ƐŚŽǁĞĚ ƚŚĂƚ ƉĂƟĞŶƚƐ ǁŝƚŚ ƚǁŽ Žƌ ŵŽƌĞ ĐŽŶĐŽŵŝƚĂŶƚ ĚŝƐĞĂƐĞƐ
ƉƌĞƐĞŶƚĂƚĚŝĂŐŶŽƐŝƐŚĂĚŚŝŐŚĞƐƚĞǆĐĞƐƐŵŽƌƚĂůŝƚǇ͘








TABLE 4 KǀĞƌĂůůϯϬͲĚĂǇŵŽƌƚĂůŝƚǇ͕ ϭͲǇĞĂƌŵŽƌƚĂůŝƚǇĂŶĚĞǆĐĞƐƐŵŽƌƚĂůŝƚǇ ƌĂƚĞƐŽĨƉĂƟĞŶƚƐǁŚŽ 
 ƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĨŽƌƐƚĂŐĞ/Ͳ///ĐŽůŽŶŽƌƌĞĐƚĂůĐĂŶĐĞƌĚŝĂŐŶŽƐĞĚŝŶƚŚĞƉĞƌŝŽĚ 
 ϮϬϬϴͲϮϬϭϯĂĐĐŽƌĚŝŶŐƚŽĂŐĞ;ŶсϱϮ͕ϮϵϲͿ͘
  WŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇ;йͿ Excess ŵŽƌƚĂůŝƚǇ;йͿ
 n <30 days p value 1st year p value 1st year
COLON CANCER
Overall 36,464 4.2 10.7
Gender 0.054 0.084
   Male 18,734 4.4 10.9 7.7
   Female 17,730 3.9 10.3 7.7
Age <0.0001 <0.0001
   <65 years 9,847 1.0 4.1 3.6
   65-74 years 11,607 2.2 7.2 5.7
   75-84 years 11,775 6.0 14.8 10.5
шϴϱǇĞĂƌƐ 3,235 13.8 27.3 17.3
Stage <0.0001 <0.0001
^ƚĂŐĞ/ 7,501 3.3 6.7 3.8
^ƚĂŐĞ// 15,598 4.3 9.5 6.3
^ƚĂŐĞ/// 13,365 4.4 14.1 11.5
ŵĞƌŐĞŶĐǇƌĞƐĞĐƟŽŶΏ <0.0001 <0.0001
ŵĞƌŐĞŶƚ 2,773 11.9 23.2 20.7
ůĞĐƟǀĞ 33,168 3.5 9.6 6.5
Surgical approach <0.0001 <0.0001
KƉĞŶƌĞƐĞĐƟŽŶ 24,029 5.4 13.3 10.2
>ĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƟŽŶ 12,144 1.8 5.5 2.8
EƵŵďĞƌŽĨĐŽŵŽƌďŝĚŝƟĞƐ <0.0001 <0.0001
0 1,418 1.8 4.9 3.0
1 1,367 2.8 7.0 4.3
шϮ 2,440 5.7 14.8 11.3
RECTAL CANCER
Overall 15,832 2.3 7.1
Gender <0.0001 <0.0001
   Male 9,795 2.8 7.8 5.5
   Female 6,037 1.7 5.8 3.9
Age <0.0001 <0.0001
   <65 years 6,209 0.6 2.7 2.2
   65-74 years 5,385 1.8 6.0 4.4
   75-84 years 3,612 4.7 13.2 8.9
шϴϱǇĞĂƌƐ 626 10.1 23.1 12.9
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TABLE 4 KǀĞƌĂůůϯϬͲĚĂǇŵŽƌƚĂůŝƚǇ͕ ϭͲǇĞĂƌŵŽƌƚĂůŝƚǇĂŶĚĞǆĐĞƐƐŵŽƌƚĂůŝƚǇ ƌĂƚĞƐŽĨƉĂƟĞŶƚƐǁŚŽ 
 ƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĨŽƌƐƚĂŐĞ/Ͳ///ĐŽůŽŶŽƌƌĞĐƚĂůĐĂŶĐĞƌĚŝĂŐŶŽƐĞĚŝŶƚŚĞƉĞƌŝŽĚ 
 ϮϬϬϴͲϮϬϭϯĂĐĐŽƌĚŝŶŐƚŽĂŐĞ;ŶсϱϮ͕ϮϵϲͿ͘;ŽŶƟŶƵĞĚͿ
  WŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇ;йͿ Excess ŵŽƌƚĂůŝƚǇ;йͿ
 n <30 days p value 1st year p value 1st year
Stage <0.0001 <0.0001
^ƚĂŐĞ/ 2,927 2.4 5.3 2.9
^ƚĂŐĞ// 4,196 2.8 8.0 5.5
^ƚĂŐĞ/// 8,709 2.1 7.4 5.4
Surgical approach <0.0001 <0.0001
KƉĞŶƌĞƐĞĐƟŽŶ 9,702 3.0 8.4 6.1
>ĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƟŽŶ 5,937 1.4 5.0 2.9
EƵŵďĞƌŽĨĐŽŵŽƌďŝĚŝƟĞƐ <0.0001 <0.0001
0 849 0.7 4.1 2.7
1 669 1.7 5.6 3.6








ǁŝƚŚ ŶŽŶͲŵĞƚĂƐƚĂƟĐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ďĞƚǁĞĞŶ ĚŝīĞƌĞŶƚ ĂŐĞ ŐƌŽƵƉƐ͘ /ƚ ĐŽŶƐŝĚĞƌƐ
ŽǀĞƌĂůůͲ͕ ƌĞůĂƟǀĞͲ ĂŶĚ ĐŽŶĚŝƟŽŶĂů ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů͘tĞ ĨŽƵŶĚ ƚŚĂƚ ƚŚĞ ƐƵďƐƚĂŶƟĂů ĂŐĞͲ




ǁĞƌĞ ĚŽƵďůĞĚ ƚŽ ƚƌŝƉůĞĚ ĐŽŵƉĂƌĞĚ ƚŽ ƉŽƐƚŽƉĞƌĂƟǀĞ ϯϬͲĚĂǇŵŽƌƚĂůŝƚǇ ;ϰ͘Ϯй ĨŽƌ ĐŽůŽŶ





/Ŷ Ă ƉƌĞǀŝŽƵƐ ƵƚĐŚ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚǇ ďǇ ĞŬŬĞƌ Ğƚ Ăů͕͘ ƉŽƐƚŽƉĞƌĂƟǀĞ ϭͲǇĞĂƌ






ĐĂŶĐĞƌ͗ ϳ͘ϳй ǀĞƌƐƵƐ ϳ͘ϱй͕ ĂŶĚ ƌĞĐƚĂů ĐĂŶĐĞƌ͗ ϱ͘ϱй ǀĞƌƐƵƐ ϯ͘ϳйͿ͘3 hŶĨŽƌƚƵŶĂƚĞůǇ͕  ĚĂƚĂ
ŽŶĞŵĞƌŐĞŶĐǇƌĞƐĞĐƟŽŶǁĞƌĞŶŽƚĂǀĂŝůĂďůĞŝŶƚŚĞƐƚƵĚǇŽĨĞŬŬĞƌĞƚĂů͘tĞĐĂŶŶŽƚƌƵůĞ
ŽƵƚƚŚĂƚĞŵĞƌŐĞŶĐǇƉƌŽĐĞĚƵƌĞƐŶŽƚŽŶůǇŚĂǀĞĂĚŝƌĞĐƚĞīĞĐƚŽŶŵŽƌƚĂůŝƚǇďƵƚĂůƐŽŚĂǀĞ




ŽŶ ƉŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇ ĐŽŵƉĂƌŝŶŐ ŽƉĞŶ ǀĞƌƐƵƐ ůĂƉĂƌŽƐĐŽƉŝĐ ƚĞĐŚŶŝƋƵĞƐ ƐŚŽǁĞĚ Ă














ĂƉƌŽůŽŶŐĞĚƉŽƐƚŽƉĞƌĂƟǀĞŚŽƐƉŝƚĂůƐƚĂǇ͘23-27 Furthermore, a study by Morris et al. showed 
ƚŚĂƚ ŝŶĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐĚŝĂŐŶŽƐĞĚ ŝŶŶŐůĂŶĚ͕^ǁĞĚĞŶŽƌEŽƌǁĂǇ͕ ƚŚĞĞǆĐĞƐƐ
ŵŽƌƚĂůŝƚǇǁĂƐŵŽƐƚĞǀŝĚĞŶƚǁŝƚŚŝŶ ƚŚĞĮƌƐƚϯŵŽƚŚƐĂŌĞƌĚŝĂŐŶŽƐŝƐ ĂŶĚ ĨŽƌ ƚŚĞŽůĚĞƐƚ
ƉĂƟĞŶƚƐ͘28
ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ŝƐ ĚĞĮŶĞĚ ĂƐ ƚŚĞ ƉƌŽďĂďŝůŝƚǇ ŽĨ ƐƵƌǀŝǀŝŶŐ ĨƌŽŵ Ăůů ĐĂƵƐĞƐ ŽĨ ĚĞĂƚŚ ĂŶĚ
ƚŚĞƌĞĨŽƌĞŵĂǇŽǀĞƌĞƐƟŵĂƚĞƚŚĞŝŵƉĂĐƚŽĨĐĂŶĐĞƌŽŶƐƵƌǀŝǀĂů͘dŚĞƌĞĨŽƌĞ͕ƌĞůĂƟǀĞƐƵƌǀŝǀĂů





resilient in this age group by colorectal cancer surgery and its recovery process. 




probable cause for early mortality, one can conclude that colorectal cancer itself is not 












by combining surgery and radiotherapy in rectal cancer may be underlying. A previous 
ƵƚĐŚƉŽƉƵůĂƟŽŶͲďĂƐĞĚƐƚƵĚǇƐƵƉƉŽƌƚƐƚŚĞůĂƩĞƌĞǆƉůĂŶĂƟŽŶ͘32 
dŚĞƌĞƐƵůƚƐŽĨƚŚŝƐƐƚƵĚǇƐŚŽƵůĚďĞŝŶƚĞƌƉƌĞƚĞĚǁŝƚŚĐŽŶƐŝĚĞƌĂƟŽŶŽĨĐĞƌƚĂŝŶůŝŵŝƚĂƟŽŶƐ͘
WƌĞǀŝŽƵƐ ƐƚƵĚŝĞƐ ŝĚĞŶƟĮĞĚƉŽƐƚŽƉĞƌĂƟǀĞĐŽŵƉůŝĐĂƟŽŶƐĂƐ ƌŝƐŬ ĨĂĐƚŽƌƐ ĨŽƌĚĞĂƚŚĚƵƌŝŶŐ




ĂƐ ĐůŝŶŝĐŝĂŶƐ ĂƐƐƵŵĞ Ă ůĞƐƐĞƌ ƌŝƐŬ ĨŽƌ ĐŽŵƉůŝĐĂƟŽŶƐǁŝƚŚ ƚŚŝƐ ƉƌŽĐĞĚƵƌĞ͘ &ƵƌƚŚĞƌŵŽƌĞ͕










ƌĞƐĞĐƟŽŶ ĂŶĚ ƚŚĞ ƉƌĞƐĞŶĐĞ ŽĨ ĐŽŵŽƌďŝĚŝƟĞƐ ŶŽƚ ŽŶůǇ ŚĂĚ Ă ƉƌŽŵŝŶĞŶƚ ŝŵƉĂĐƚ ŽŶ




were 85 years or older. To the best of our knowledge, our study included one of the largest 
ĐŽŚŽƌƚƐŽĨƉĂƟĞŶƚƐĂŐĞĚϴϱǇĞĂƌƐĂŶĚŽůĚĞƌĚĞƐĐƌŝďĞĚŝŶůŝƚĞƌĂƚƵƌĞ͘
ZĞƐƵůƚƐŽĨƚŚŝƐƐƚƵĚǇƐŚŽǁĞĚƚŚĂƚŵŽƌƚĂůŝƚǇ͕ ĞƐƉĞĐŝĂůůǇǁŝƚŚŝŶƚŚĞĮƌƐƚǇĞĂƌĂŌĞƌƐƵƌŐĞƌǇ





Although our study cannot determine which factors determined this improvement, it 
ƵŶĚĞƌůŝŶĞƐƐƵƌǀŝǀĂůŝŶĞůĚĞƌůǇĂŌĞƌŵĂũŽƌƐƵƌŐĞƌǇŝƐŵŽĚŝĮĂďůĞ͘
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cancer. This study evaluated treatment patterns and patient outcomes in synchronous 
colorectal cancer compared with solitary colorectal cancer patients.
Patients and methods
All patients diagnosed with primary colorectal cancer between 2008 and 2013, who 
ƵŶĚĞƌǁĞŶƚĞůĞĐƚŝǀĞƐƵƌŐĞƌǇ͕ǁĞƌĞƐĞůĞĐƚĞĚĨƌŽŵƚŚĞEĞƚŚĞƌůĂŶĚƐĂŶĐĞƌZĞŐŝƐƚƌǇ͘hƐŝŶŐ
multivariable regressions, the effects of synchronous colorectal cancer were assessed 
ĨŽƌďŽƚŚƐŚŽƌƚͲƚĞƌŵŽƵƚĐŽŵĞƐ;ƉƌŽůŽŶŐĞĚƉŽƐƚŽƉĞƌĂƚŝǀĞŚŽƐƉŝƚĂůĂĚŵŝƐƐŝŽŶ͕ĂŶĂƐƚŽŵŝĐ








ǁĂƐ ĐŽŶĚƵĐƚĞĚ ;ŶсϵϯϰͿ͘ ^ǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌƐ ǁŝƚŚ Ăƚ ůĞĂƐƚ ŽŶĞ ƐƚĂŐĞ //Ͳ///






dŚĞ ŝŶĐŝĚĞŶĐĞ ŽĨ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌƐ ŝŶ ƚŚĞ ƵƚĐŚ ƉŽƉƵůĂƚŝŽŶ ŝƐ ϱй͘
Synchronous colorectal cancers were associated with decreased survival compared with 
solitary colorectal cancer. The results emphasize the importance identifying synchronous 
tumours, preferably before surgery to provide optimal treatment.
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INTRODUCTION
/Ŷ ƚŚĞǁĞƐƚĞƌŶǁŽƌůĚ͕ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŝƐ ƚŚĞ ƚŚŝƌĚ ĂŶĚ ƐĞĐŽŶĚŵŽƐƚ ĐŽŵŵŽŶĐĂŶĐĞƌ
among men and women, and it is the second and third most common cause of cancer 
death.1 Patients with primary colorectal cancer can have more than one lesion at the time 
of initial presentation.2 Previous studies report a frequency of synchronous colorectal 
ĐĂŶĐĞƌƐ ǀĂƌǇŝŶŐ ĨƌŽŵϭ ƚŽϴй͘2-7 WĂƌƚŽĨ ƚŚŝƐ ǀĂƌŝĂƚŝŽŶ ĐĂŶďĞĞǆƉůĂŝŶĞĚďǇĚŝĨĨĞƌĞŶĐĞƐ
in definitions, selection criteria, patient populations and time periods studied. Risk 
factors for developing synchronous colorectal cancers are largely unknown, although 
familial polyposis and ulcerative colitis with dysplasia have been suggested to influence 
synchronous colorectal cancer development.8, 9
&Žƌ ƐƚĂŐĞ /Ͳ/// ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƚŝĞŶƚƐ͕ ƐƵƌŐĞƌǇ ŽĨ ƚŚĞ ƉƌŝŵĂƌǇ ƚƌĞĂƚŵĞŶƚ ŝƐ ƚŚĞ
ĐŽƌŶĞƌƐƚŽŶĞŽĨĐƵƌĂƚŝǀĞƚƌĞĂƚŵĞŶƚ͘EĞŽĂĚũƵǀĂŶƚ;ĐŚĞŵŽͿƌĂĚŝŽƚŚĞƌĂƉǇŝƐƌĞĐŽŵŵĞŶĚĞĚ
ŝŶƵƚĐŚĂŶĚŵĞƌŝĐĂŶƚƌĞĂƚŵĞŶƚŐƵŝĚĞůŝŶĞƐ ĨŽƌƉĂƚŝĞŶƚƐǁŝƚŚƐƚĂŐĞ //Ͳ/// ƌĞĐƚĂůĐĂŶĐĞƌ͕
ǁŚĞƌĞĂƐ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ŝƐ ƌĞĐŽŵŵĞŶĚĞĚ ĨŽƌ ƉĂƚŝĞŶƚƐ ǁŝƚŚ ƐƚĂŐĞ /// ĐŽůŽŶ
cancer.10, 11
A preoperative diagnosis of synchronous colorectal cancers may modify the type of 
surgical procedure and influence clinical decision making on the use of additional 
ƚƌĞĂƚŵĞŶƚƐ͘DŽƌĞŽǀĞƌ͕ƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƐŵŽƌĞŽĨƚĞŶŵĂǇƌĞƋƵŝƌĞĞǆƚĞŶĚĞĚ
surgery and, if overlooked, may be diagnosed as early metachronous cancers, possibly at 
a more advanced stage. 
ŽŶĨůŝĐƚŝŶŐĞǀŝĚĞŶĐĞĞǆŝƐƚƐĂďŽƵƚǁŚĞƚŚĞƌƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƐŚĂǀĞƚŚĞƐĂŵĞ
prognosis in survival as solitary colorectal cancer patients.2, 6, 12, 13 Many clinical series 
were based on single centre numbers and the analysis of less than 50 patients.4, 5, 14 The 
objectives of this study were to investigate, in depth, the various clinicopathological 
features of synchronous colorectal cancer patients compared with solitary colorectal 
cancer patients, and its association with treatment patterns, short-term postoperative 





ŽŶ ƉĂƚŝĞŶƚ ĂŶĚ ƚƵŵŽƵƌ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ͕ ĚŝĂŐŶŽƐŝƐ ĂŶĚ ƚƌĞĂƚŵĞŶƚ ŝƐ ƌŽƵƚŝŶĞůǇ ĞǆƚƌĂĐƚĞĚ
from the medical records. The quality of the data is high due to thorough training of the 




for stage notification of the primary tumour, according to the edition valid at time of 
cancer diagnosis.16 &ƵƌƚŚĞƌŵŽƌĞ͕ ĚĞƚĂŝůĞĚ ŝŶĨŽƌŵĂƚŝŽŶ ǁĂƐ ĂǀĂŝůĂďůĞ ŽŶ͗ ĞŵĞƌŐĞŶĐǇ
ƌĞƐĞĐƚŝŽŶ;фϮϰŚĂĨƚĞƌƉƌĞƐĞŶƚĂƚŝŽŶͿĂŶĚĂŶĂƐƚŽŵŽƚŝĐůĞĂŬĂŐĞĂƐĂƐƵƌŐŝĐĂůĐŽŵƉůŝĐĂƚŝŽŶ͘
Anastomotic leakage was recorded as such if a surgical intervention or readmission was 
necessary within 2 months after primary anastomosis. Data on prolonged postoperative 
ŚŽƐƉŝƚĂů ĂĚŵŝƐƐŝŽŶ ;хϭϰ ĚĂǇƐ͖ ǇĞƐͬŶŽͿ ǁĞƌĞ ĂǀĂŝůĂďůĞ ĨŽƌ ƉĂƚŝĞŶƚƐ ĚŝĂŐŶŽƐĞĚ ŝŶ ϮϬϭϮͲ
ϮϬϭϯ͘WƌŽůŽŶŐĞĚƉŽƐƚŽƉĞƌĂƚŝǀĞŚŽƐƉŝƚĂůĂĚŵŝƐƐŝŽŶĂĨƚĞƌƐƵƌŐĞƌǇƐĞƌǀĞĚĂƐĂƉƌŽǆǇĨŽƌĂ
complicated postoperative period. 
¥®Ä®ã®ÊÄÊ¥ÝùÄ«ÙÊÄÊçÝÊ½ÊÙã½ÄÙ
A slightly modified version of the Warren and Gates criteria were used to define multiple 
colorectal cancer.17 Synchronous colorectal cancer was defined as two or more invasive 
ƚƵŵŽƵƌƐƚŚĂƚĂƌĞĚŝĂŐŶŽƐĞĚƐŝŵƵůƚĂŶĞŽƵƐůǇŽƌǁŝƚŚŝŶƐŝǆŵŽŶƚŚƐ͘DƵůƚŝƉůĞŝŶĚĞƉĞŶĚĞŶƚ
tumours in the same segment of the colon and rectum are regarded as different 
malignancies and are counted as two or more primary cancers. For every synchronous 
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƚŝĞŶƚ͕ ƚŚĞ ŵŽƐƚ ĞǆƚĞŶƐŝǀĞ ƚƵŵŽƵƌ ĂĐĐŽƌĚŝŶŐ ƚŽ dED ƐƚĂŐĞ ǁĂƐ
ĚĞƐŝŐŶĂƚĞĚ ĂƐ ƚŚĞ ŝŶĚĞǆ ƚƵŵŽƵƌ ŝŶ ƚŚĞ ĂŶĂůǇƐĞƐ͘tŚĞŶ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ
ƉĂƚŝĞŶƚƐǁĞƌĞĚŝĂŐŶŽƐĞĚǁŝƚŚĂƚ ůĞĂƐƚŽŶĞŽĨƚŚĞ ůĞƐŝŽŶƐĂƐƐƚĂŐĞ /s͕Ăůů ƚƵŵŽƵƌƐǁĞƌĞ
ĐůĂƐƐŝĨŝĞĚĂƐƐƚĂŐĞ/s͘
^ãçùÖÊÖç½ã®ÊÄ








stage was based on the pathological TNM classification. Tumour localization was 
ĐĂƚĞŐŽƌŝǌĞĚ ŝŶƚŽĂŶĂƚŽŵŝĐĂůƐƵďƐŝƚĞƐ͗ĐŽůŽŶĂƐĐĞŶĚĞŶƐ;ϭϴ͘ϬͲϭϴ͘ϮͿ͖ĐŽůŽŶƚƌĂŶƐǀĞƌƐƵŵ






























FIGURE 1  Overview of patients included in the study.
^ãã®Ýã®½Ä½ùÝÝ
ŝĨĨĞƌĞŶĐĞƐ ŝŶ ƉĂƚŝĞŶƚ ĂŶĚ ƚƵŵŽƵƌ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ ǁĞƌĞ ĞǀĂůƵĂƚĞĚ ƵƐŝŶŐ ʖϸ͘  ƉƌŝŽƌŝ
outcomes of interest were type of surgical procedure, prolonged postoperative hospital 
admission, anastomic leakage, postoperative 30-day mortality, and administration of 
neoadjuvant or adjuvant treatment and were analyzed between synchronous and solitary 
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƚŝĞŶƚƐƵƐŝŶŐƵŶŝǀĂƌŝĂďůĞ;ʖϸƚĞƐƚƐͿĂŶĚŵƵůƚŝǀĂƌŝĂďůĞĂŶĂůǇƐĞƐ;ůŽŐŝƐƚŝĐ
ƌĞŐƌĞƐƐŝŽŶŵŽĚĞůƐͿ͘
Survival was defined as the time from the date of resection to death or last follow-up date 
for patients who were still alive. Relative survival was defined as the ratio of the survival 
ŽďƐĞƌǀĞĚĂŵŽŶŐ ƚŚĞ ĐĂŶĐĞƌƉĂƚŝĞŶƚƐ ĂŶĚ ƚŚĞ ƐƵƌǀŝǀĂů ƚŚĂƚǁŽƵůĚŚĂǀĞďĞĞŶĞǆƉĞĐƚĞĚ
ďĂƐĞĚŽŶƚŚĞĐŽƌƌĞƐƉŽŶĚŝŶŐ;ĂŐĞ͕ŐĞŶĚĞƌ͕ĂŶĚǇĞĂƌͿŐĞŶĞƌĂůƉŽƉƵůĂƚŝŽŶ͘ZĞůĂƚŝǀĞƐƵƌǀŝǀĂů
was calculated using the Pohar Perme method.18ZĞůĂƚŝǀĞĞǆĐĞƐƐƌŝƐŬƐŽĨĚĞĂƚŚ;ZZͿǁĞƌĞ
estimated using a multivariable generalized linear model with a Poisson distribution, 
ďĂƐĞĚŽŶĐŽůůĂƉƐĞĚƌĞůĂƚŝǀĞƐƵƌǀŝǀĂůĚĂƚĂ͕ƵƐŝŶŐĞǆĂĐƚƐƵƌǀŝǀĂů ƚŝŵĞƐ͕ĂĚũƵƐƚŝŶŐ ĨŽƌĂŐĞ͕








From 2008 to 2013, 41,060 patients were diagnosed with primary colorectal cancer 
ĂŶĚƵŶĚĞƌǁĞŶƚĞůĞĐƚŝǀĞƐƵƌŐĞƌǇ͘KĨƚŚĞƐĞ͕ϭ͕ϵϲϵ;ϰ͘ϴйͿƉĂƚŝĞŶƚƐŵĞƚƚŚĞĚĞĨŝŶŝƚŝŽŶĨŽƌ
synchronous colorectal cancer. Patient and tumour characteristics are presented in Table 
ϭ͘^ǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƚŝĞŶƚƐǁĞƌĞƐůŝŐŚƚůǇŽůĚĞƌ;ŵĞĂŶĂŐĞϳϭцϭϬ͘ϲǇĞĂƌƐ
ǀĞƌƐƵƐϲϵцϭϭ͘ϰ ǇĞĂƌƐͿ͕ŵŽƌĞŽĨƚĞŶŵĂůĞ͕ ĂŶĚĚŝĂŐŶŽƐĞĚǁŝƚŚŵŽƌĞĂĚǀĂŶĐĞĚ ƚƵŵŽƵƌ
ƐƚĂŐĞ;ƐƚĂŐĞ///Ͳ/sͿĐŽŵƉĂƌĞĚǁŝƚŚƐŽůŝƚĂƌǇĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƚŝĞŶƚƐ;ĂůůƉфϬ͘ϬϬϬϭͿ͘




2 sCRC >2 sCRC
n ;йͿ n ;йͿ n ;йͿ p value
Total 39,091 1,865 104
Gender фϬ͘ϬϬϬϭΎ
   Male 20,945 ;ϱϰͿ 1,132 ;ϲϭͿ 65 ;ϲϯͿ
   Female 18,146 ;ϰϲͿ 733 ;ϯϵͿ 39 ;ϯϳͿ
Age фϬ͘ϬϬϬϭΎ
   <65 years 13,284 ;ϯϰͿ 430 ;ϮϯͿ 26 ;ϮϱͿ
   65-74 years 12,576 ;ϯϮͿ 632 ;ϯϰͿ 33 ;ϯϮͿ
   75-84 years 10,599 ;ϮϳͿ 656 ;ϯϱͿ 38 ;ϯϲͿ
шϴϱǇĞĂƌƐ 2,632 ;ϳͿ 147 ;ϴͿ 7 ;ϳͿ
^ƚĂŐĞ;ŝŶĚĞǆƚƵŵŽƵƌŝŶƐZͿ фϬ͘ϬϬϬϭΎ
/ 6,659 ;ϭϳͿ 263 ;ϭϰͿ 18 ;ϭϳͿ
// 12,689 ;ϯϯͿ 593 ;ϯϮͿ 33 ;ϯϮͿ
/// 14,629 ;ϯϳͿ 752 ;ϰϬͿ 37 ;ϯϲͿ
/s 5,114 ;ϭϯͿ 257 ;ϭϰͿ 16 ;ϭϱͿ
>ŽĐĂƟŽŶŽĨƚƵŵŽƵƌ;ŝŶĚĞǆƚƵŵŽƵƌŝŶƐZͿ фϬ͘ϬϬϬϭΎ
   Colon ascendens 10,333 ;ϮϲͿ 499 ;ϮϳͿ 35 ;ϯϯͿ
   Colon transversum 4,642 ;ϭϮͿ 291 ;ϭϱͿ 23 ;ϮϮͿ
   Colon descendens 11,151 ;ϮϵͿ 571 ;ϯϭͿ 27 ;ϮϴͿ
EK^ͬŽƚŚĞƌ 452 ;ϭͿ 93 ;ϱͿ 0 ;ϬͿ
   Rectum 12,313 ;ϯϮͿ 411 ;ϮϮͿ 19 ;ϭϳͿ
Ύp<0.05 between solitary and synchronous CRC
sCRC synchronous colorectal cancer
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Wã®ÄãÝó®ã«ãóÊÝùÄ«ÙÊÄÊçÝÊ½ÊÙã½ÄÙÝ
KĨ ƚŚĞ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƚŝĞŶƚƐ͕ ƚŚĞ ŵĂũŽƌŝƚǇ ;Ŷсϭ͕ϴϲϱ͕ ϵϱйͿ ŚĂĚ ƚǁŽ
tumours. Table 2 gives an overview of the anatomical and stage distribution of the first 
and second tumour of patients with two synchronous colorectal cancers. 












Colon descendens-Colon descendens 353 ;ϭϵͿ
Colon ascendens-Colon ascendens 253 ;ϭϯͿ
Rectum-Colon descendens 236 ;ϭϯͿ
Rectum-Rectum 193 ;ϭϬͿ
Colon descendens-Colon ascendens 171 ;ϵͿ
Colon transversum-Colon ascendens 136 ;ϳͿ
Colon descendens-Colon transversum 129 ;ϳͿ
Colon transversum-Colon transversum 123 ;ϳͿ
Rectum-Colon ascendens 108 ;ϲͿ




the colon or rectum
Most of the synchronous colorectal cancer patients were diagnosed with at least one 
ƐƚĂŐĞ ///ͬ/s ƚƵŵŽƵƌ ;Ŷсϭ͕ϬϬϵ͕ ϱϰйͿ͘ KĨ ƚŚĞƐĞ ƉĂƚŝĞŶƚƐ͕ ϰϱϭ ;ϰϯй͕ Ϯϰй ŽĨ ƚŽƚĂůͿ ǁĞƌĞ
ĚŝĂŐŶŽƐĞĚǁŝƚŚƚǁŽƐƚĂŐĞ///ƚƵŵŽƵƌƐĂŶĚϮϰϭ;Ϯϯй͕ϭϯйŽĨƚŽƚĂůͿǁĞƌĞĚŝĂŐŶŽƐĞĚǁŝƚŚ
ƚǁŽƐƚĂŐĞ/sƚƵŵŽƵƌƐ͘
Half of the synchronous tumours were located in similar segments of the large bowel 
;ŶсϵϮϮ͕ϱϬйͿ͘/Ŷϭ͕ϮϮϮ;ϲϲйͿƉĂƚŝĞŶƚƐ͕ďŽƚŚƚƵŵŽƵƌƐǁĞƌĞůŽĐĂůŝǌĞĚŝŶƚŚĞĐŽůŽŶ͕ŽĨǁŚŝĐŚ
ϳϮϵ;ϲϬй͖ϯϵйŽĨƚŽƚĂůͿǁĞƌĞŝŶŽŶĞĐŽůŽŶƐĞŐŵĞŶƚ͘/Ŷϭϵϯ;ϭϬйͿƉĂƚŝĞŶƚƐ͕ďŽƚŚƚƵŵŽƵƌƐ
were situated in the rectum.
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Figure 2 shows the type of surgical procedures for the different anatomical sites in 






TABLE 3 ƌƵĚĞƉĞƌĐĞŶƚĂŐĞƐĂŶĚĂĚũƵƐƚĞĚŽĚĚƐ ƌĂƚŝŽƐ७ ĨŽƌ ƚƌĞĂƚŵĞŶƚǀĂƌŝĂďůĞƐĂŶĚƐŚŽƌƚͲƚĞƌŵ 
 postoperative outcomes among patients with solitary or synchronous colorectal cancer 
 ;Ŷсϰϭ͕ϬϲϬͿ͘
    DƵůƟǀĂƌŝĂďůĞĂŶĂůǇƐŝƐ
Variable Total n ƌƵĚĞ;йͿ p value KZ७ ϵϱй/
a. EĞŽĂĚũƵǀĂŶƚ;ĐŚĞŵŽͿƌĂĚŝĂƟŽŶ1
Solitary CRC 9,286 85.9 фϬ͘ϬϬϬϭΎ reference
Synchronous CRC 327 78.0 0.6 0.48-0.84
b. ^ƵƌŐŝĐĂůĂƉƉƌŽĂĐŚ;ůĂƉĂƌŽƐĐŽƉŝĐǀĞƌƐƵƐŽƉĞŶƌĞƐĞĐƟŽŶͿ2
Solitary CRC 33,678 45.4 фϬ͘ϬϬϬϭΎ reference
Synchronous CRC 1,644 34.9 0.9 0.83-1.06
c. ^ƵƌŐŝĐĂůĂƉƉƌŽĂĐŚ;ůĂƉĂƌŽƐĐŽƉŝĐĐŽŶǀĞƌƚĞĚƚŽŽƉĞŶƌĞƐĞĐƟŽŶǀĞƌƐƵƐůĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƟŽŶͿ3
Solitary CRC 15,282 16.7 фϬ͘ϬϬϬϭΎ reference
Synchronous CRC 574 22.7 1.0 0.81-1.31
d. WƌŽůŽŶŐĞĚƉŽƐƚŽƉĞƌĂƟǀĞŚŽƐƉŝƚĂůƐƚĂǇ;хϭϰĚĂǇƐͿ4
Solitary CRC 11,858 16.7 фϬ͘ϬϬϬϭΎ reference
Synchronous CRC 679 23.0 1.2 0.92-1.45
e. ŶĂƐƚŽŵŽƟĐůĞĂŬĂŐĞ5
Solitary CRC 31,001 4.9 0.48 reference
Synchronous CRC 2,397 5.3 0.9 0.74-1.13
f. WŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇ6
Solitary CRC 34,531 4.7 0.42 reference
Synchronous CRC 1,142 5.3 0.7 0.54-1.01
g. Adjuvant chemotherapy 7
Solitary CRC 8,260 63.1 фϬ͘ϬϬϬϭΎ reference
Synchronous CRC 564 48.6  0.7 0.54-0.87
KZKĚĚƐZĂƚŝŽ͖/ŽŶĨŝĚĞŶĐĞ/ŶƚĞƌǀĂů͖ƐZƐǇŶĐŚƌŽŶŽƵƐZ





ƌĞƐĞĐƚŝŽŶ Žƌ ůĂƉĂƌŽƐĐŽƉŝĐ ĐŽŶǀĞƌƚĞĚ ƚŽ ŽƉĞŶ ƌĞƐĞĐƚŝŽŶ ;Ŷсϭϱ͕ϴϱϲͿ͖ 4/ŶĐůƵĚĞĚ ƉĂƚŝĞŶƚƐ ĚŝĂŐŶŽƐĞĚ ŝŶ ϮϬϭϮͲ
ϮϬϭϯ;ŶсϭϮ͕ϱϯϳͿ͖5/ŶĐůƵĚĞĚƉĂƚŝĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƚŝŽŶǁŝƚŚƉƌŝŵĂƌǇĂŶĂƐƚŽŵŽƐŝƐ;Ŷсϯϯ͕ϯϵϴͿ͖
6/ŶĐůƵĚĞĚƉĂƚŝĞŶƚƐǁŝƚŚƐƚĂŐĞ /Ͳ///ZǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂů ƌĞƐĞĐƚŝŽŶ ;Ŷсϯϱ͕ϲϳϯͿ͖ 7/ŶĐůƵĚĞĚƉĂƚŝĞŶƚƐǁŝƚŚ
ƐƚĂŐĞ///ĐŽůŽŶĐĂŶĐĞƌ;Ŷсϴ͕ϴϮϰͿ͘


































































































































































































































































































prolonged postoperative hospital stay, presence of anastomotic leakage, postoperative 
mortality and administration of neoadjuvant or adjuvant treatment among solitary and 
synchronous colorectal cancer. 
^ǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƚŝĞŶƚƐǁŝƚŚĂƚůĞĂƐƚŽŶĞƐƚĂŐĞ//Ͳ///ƌĞĐƚĂůƚƵŵŽƵƌ;ŝŶĚĞǆ
ƚƵŵŽƵƌͿ ǁĞƌĞ ůĞƐƐ ůŝŬĞůǇ ƚŽ ƌĞĐĞŝǀĞ ŶĞŽĂĚũƵǀĂŶƚ ƚƌĞĂƚŵĞŶƚ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƐŽůŝƚĂƌǇ






tumour was located in the rectum and the other tumour was located in a colon segment. 
KĨƚŚĞƐĞƉĂƚŝĞŶƚƐ͕ƚŚĞŵĂũŽƌŝƚǇ;Ŷсϱϲ͕ϲϭйͿǁĂƐƚƌĞĂƚĞĚǁŝƚŚŶĞŽĂĚũƵǀĂŶƚƌĂĚŝŽƚŚĞƌĂƉǇ͕
ǁŚĞƌĞĂƐϰϭƉĂƚŝĞŶƚƐ;ϯϵйͿƌĞĐĞŝǀĞĚŶĞŽĂĚũƵǀĂŶƚĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇ͘dŚĞĂĚŵŝŶŝƐƚƌĂƚŝŽŶ








ĨƚĞƌ ĐĂƐĞͲŵŝǆ ĂĚũƵƐƚŵĞŶƚ͕ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌƐ ǁĞƌĞ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ĂŶ
ŝŶĐƌĞĂƐĞĚZZŽĨĚĞĂƚŚ;ĂĚũƵƐƚĞĚZZƐǇŶĐŚƌŽŶŽƵƐǀĞƌƐƵƐƐŽůŝƚĂƌǇĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌϭ͘ϭ
;ϭ͘ϬϭͲϭ͘ϮϯͿͿ͘ /Ŷ ĂĚĚŝƚŝŽŶ͕ ĂĨƚĞƌ ƐƚƌĂƚŝĨŝĐĂƚŝŽŶďǇ ƚƵŵŽƵƌ ƐƚĂŐĞ͕ ƚŚĞ ĂƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶ






patient outcomes and 5-year relative survival in synchronous and solitary colorectal 
cancer patients. We found a decreased use of neoadjuvant and adjuvant treatment in 
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synchronous colorectal cancer patients. Furthermore, synchronous colorectal cancers 
were independently associated with a decrease in survival. 
Definitions of synchronous colorectal cancer tend to differ in the literature. The 
ƉƌĞǀĂůĞŶĐĞ ŽĨ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƌĂŶŐĞĚ ĨƌŽŵ ĂƉƉƌŽǆŝŵĂƚĞůǇ ϭй ƚŽ ϴй͘2-
7 ^ǇŶĐŚƌŽŶŽƵƐ ĂŶĚ ŵĞƚĂĐŚƌŽŶŽƵƐ ĐĂŶĐĞƌƐ ŽĨƚĞŶ ǁĞƌĞ ŵŝǆĞĚ ƚŽŐĞƚŚĞƌ ŝŶ ƉƌĞǀŝŽƵƐ
studies.4, 8, 19-23 Synchronous colorectal cancer is generally defined as two or more distinct 
colorectal tumours diagnosed within 6 months after initial diagnosis.2, 5, 6, 8, 22-25 /ŶŽƚŚĞƌ
studies, colorectal cancers diagnosed within a year of the initial diagnosis were classified 
as synchronous, and in others, those diagnosed simultaneously at time of surgery.6, 7, 
26, 27 We considered patients with two or more invasive colorectal cancers, diagnosed 
simultaneously or within 6 months, as synchronous colorectal cancer. 
/Ŷ ƚŚĞ ƉƌĞƐĞŶƚ ƐƚƵĚǇ͕ ϲϭй ŽĨ ƚŚĞ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƚŝĞŶƚƐ ǁĞƌĞ ŵĂůĞ͕
ĐŽŵƉĂƌĞĚǁŝƚŚϱϰйŽĨƚŚĞƐŽůŝƚĂƌǇĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƚŝĞŶƚƐ͘ DŽƐƚŽƚŚĞƌƐƚƵĚŝĞƐĂůƐŽ
reported that synchronous colorectal cancer were more frequent in men than women.2, 
5-7 However, some studies showed no association between gender and the presence of 
synchronous colorectal cancers.23, 26/ƚŝƐƵŶĐůĞĂƌǁŚĞƚŚĞƌƚŚĞŵĂůĞƉƌĞĚŽŵŝŶĂŶĐĞƌĞĨůĞĐƚƐ
ĂŶŝŶĐƌĞĂƐĞĚƌŝƐŬĨĂĐƚŽƌƚŽĚĞǀĞůŽƉƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌŽƌĂŐƌĞĂƚĞƌĞǆƉŽƐƵƌĞ
of men to environmental risk factors associated with synchronous colorectal cancer. 
Furthermore, we found that synchronous colorectal cancer patients were older and 
diagnosed with more advanced tumour stage compared with solitary colorectal cancer. 
These findings are comparable with other studies.5-7, 26
/ŶϱϬйŽĨ ƚŚĞƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƚŝĞŶƚƐ͕ ƚƵŵŽƵƌƐǁĞƌĞ ůŽĐĂƚĞĚ ŝŶƐŝŵŝůĂƌ
ƐĞŐŵĞŶƚƐŽĨƚŚĞůĂƌŐĞďŽǁĞů͘ /ŶůŝŶĞǁŝƚŚƉƌĞǀŝŽƵƐƵƚĐŚƐƚƵĚŝĞƐŽĨsĂŶ>ĞĞƌƐƵŵĞƚĂů͘
and Mulder et al., we found that synchronous colorectal cancer patients were more likely 
ƚŽƵŶĚĞƌŐŽĞǆƚĞŶĚĞĚƐƵƌŐĞƌǇ͘6, 7 We found that patients with synchronous tumours that 
ǁĞƌĞůŽĐĂƚĞĚŝŶĚŝĨĨĞƌĞŶƚƐĞŐŵĞŶƚƐŽĨƚŚĞůĂƌŐĞďŽǁĞů͕ŵŽƐƚůǇƌĞƋƵŝƌĞĚ;ƐƵďͿƚŽƚĂů;ƉƌŽƚŽͿ
ĐŽůĞĐƚŽŵǇŽƌĞǆƚĞŶĚĞĚƐƵƌŐĞƌǇ͘KŶĞĐŽƵůĚĞǆƉĞĐƚƚŚĂƚǁŚĞŶƚƵŵŽƵƌƐǁĞƌĞůŽĐĂƚĞĚŝŶƚŚĞ
same or adjacent segment, the choice for surgery will be simple, either a hemicolectomy 
ŽƌĂŶĞǆƚĞŶĚĞĚŚĞŵŝĐŽůĞĐƚŽŵǇǁŝƚŚƚŚĞĂĚũĂĐĞŶƚƐĞŐŵĞŶƚ͘,ŽǁĞǀĞƌ͕ŝĨ͕ĨŽƌŝŶƐƚĂŶĐĞ͕ŽŶĞ
tumour is located in the right colon while the other tumour is simultaneously located 
ŝŶƚŚĞƌĞĐƚƵŵ͕ĞŝƚŚĞƌĂ;ƐƵďͿƚŽƚĂů;ƉƌŽƚŽͿĐŽůĞĐƚŽŵǇĐĂŶďĞƉĞƌĨŽƌŵĞĚ͕ŽƌƚǁŽƐĞƉĂƌĂƚĞ
resections with two anastomoses can be performed. The latter can result in a higher 
risk of anastomotic leakage. We found no associations between having synchronous 
colorectal cancer and the presence of anastomotic leakage. 





situated in a colon segment, more often received neoadjuvant radiotherapy compared 
to synchronous colorectal cancer patients in which both tumours were located in the 
ƌĞĐƚƵŵ ;ϲϭйǀĞƌƐƵƐϱϮйͿ͘ /ƚ ŝƐ ƉŽƐƐŝďůĞ ƚŚĂƚƉĂƚŝĞŶƚƐǁŝƚŚĂ ƐƚĂŐĞ /// ƌĞĐƚĂů ƚƵŵŽƵƌĂƐ
ŝŶĚĞǆƚƵŵŽƵƌĂŶĚĂƚƵŵŽƵƌůŽĐĂƚĞĚŝŶƚŚĞĐŽůŽŶǁĞƌĞůĞƐƐŽĨƚĞŶƚƌĞĂƚĞĚǁŝƚŚŶĞŽĂĚũƵǀĂŶƚ
chemoradiotherapy to avoid the postponement of surgery and treatment of the colon 
tumour. 
^ǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƚŝĞŶƚƐǁŝƚŚ Ăƚ ůĞĂƐƚ ŽŶĞ ƐƚĂŐĞ /// ĐŽůŽŶ ƚƵŵŽƵƌǁĞƌĞ
associated with a lower probability of receiving adjuvant chemotherapy compared with 
ƐŽůŝƚĂƌǇĐŽůŽŶƚƵŵŽƵƌƐ͘tĞĚŽŶŽƚŚĂǀĞĂŶŽďǀŝŽƵƐĞǆƉůĂŶĂƚŝŽŶĨŽƌƚŚŝƐĨŝŶĚŝŶŐ͕ĂŶĚŶŽ
ĚĂƚĂĂƌĞĂǀĂŝůĂďůĞĨƌŽŵƉƌĞǀŝŽƵƐƐƚƵĚŝĞƐ͘KŶĞŵŝŐŚƚĞǆƉĞĐƚƚŚĂƚƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂů
cancer patients may be highly susceptible to adjuvant therapy. The proportion of 
solitary colorectal cancer patients who were treated with adjuvant chemotherapy was 
ϲϯйĐŽŵƉĂƌĞĚǁŝƚŚϰϵй ŝŶ ƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌƉĂƚŝĞŶƚƐ͘dŚĞ ƌĞůĂƚŝǀĞůǇ ůŽǁ
utilization of adjuvant chemotherapy overall in the Netherlands could be carried over 
ĂŶĚďĞĂŵƉůŝĨŝĞĚŝŶƉĂƚŝĞŶƚƐǁŝƚŚƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͘ǆƉůĂŶĂƚŝŽŶƐĐŽƵůĚďĞ
that synchronous colorectal cancer patients were in worse general health or had more 
ƐƵƌŐŝĐĂůĐŽŵƉůŝĐĂƚŝŽŶƐŽĨƚŚĞĞǆƚĞŶĚĞĚƐƵƌŐĞƌǇ͕ĂůƚŚŽƵŐŚĂƉƌŽůŽŶŐĞĚŚŽƐƉŝƚĂůƐƚĂǇǁĂƐ
not observed. 
Five-year survival for synchronous colorectal cancer patients was worse than for solitary 
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƚŝĞŶƚƐ ;ϳϲй ǀĞƌƐƵƐ ϲϵйͿ͘ ŽŶĨůŝĐƚŝŶŐ ƌĞƐƵůƚƐ ŚĂǀĞ ďĞĞŶ ƌĞƉŽƌƚĞĚ
regarding long-term prognosis of synchronous colorectal cancer patients. The majority 
of the studies showed no difference in survival rates between synchronous and solitary 
colorectal cancer.2, 6, 12, 13, 28, 29 Some studies reported worse survival for synchronous 
colorectal cancer. 26, 30, 31ƉƌĞǀŝŽƵƐƵƚĐŚƐƚƵĚǇŽĨ>ŝƵĞƚĂů͘ƐŚŽǁĞĚƚŚĂƚŽǀĞƌĂůůƐƵƌǀŝǀĂůŽĨ
patients with one colon cancer was significantly better than those with two, irrespective 
of lag-time between the two colon cancers.32 Poor prognosis of synchronous colorectal 
cancer is thought to be caused by the relatively frequent distant metastasis that occur in 
synchronous colorectal cancer patients.26 
dŚĞŵĂŝŶ ƐƚƌĞŶŐƚŚ ŽĨ ƚŚŝƐ ƐƚƵĚǇ ŝƐ ƚŚĞ ƵƐĞ ŽĨ Ă ůĂƌŐĞ ĚĂƚĂƐĞƚ ŝŶĐůƵĚŝŶŐ ĂƉƉƌŽǆŝŵĂƚĞůǇ
2000 synchronous colorectal cancer patients. We believe that this is the largest cohort 
published on this subject. Moreover, the objectives of this study were to investigate, in 
depth, the effects of synchronous colorectal cancer on choice of treatment and short- and 
ůŽŶŐͲƚĞƌŵƉĂƚŝĞŶƚƐ͛ŽƵƚĐŽŵĞƐ͘ůŝŶŝĐĂůŝŵƉůŝĐĂƚŝŽŶƐŝŶƚĞƌŵƐŽĨƚƌĞĂƚŵĞŶƚĂŶĚƉƌŽŐŶŽƐŝƐ
of synchronous colorectal cancer patients were seldom analyzed in large cohorts.4, 5, 8, 23, 24 
Some limitations of this study should be acknowledged. The main limitation is the lack 
ŽĨĚĂƚĂŽŶ ƚŚĞƉƌĞƐĞŶĐĞŽĨ ŝŶŚĞƌŝƚĞĚƐǇŶĚƌŽŵĞƐ ;>ǇŶĐŚ͕&W͕,EWͿ͘dŚĞƐĞ ŝŶŚĞƌŝƚĞĚ
syndromes are known to be predisposing conditions for synchronous colorectal cancer.5 
ůƚŚŽƵŐŚ ƚŚĞ EZ ĐŽůůĞĐƚƐ Ă ŚƵŐĞ ǀĂƌŝĞƚǇ ŽĨ ƉŽƚĞŶƚŝĂů ĐĂƐĞͲŵŝǆ ĨĂĐƚŽƌƐ͕ ǁĞ ĐĂŶŶŽƚ
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ĞǆĐůƵĚĞ ƚŚĂƚŽƚŚĞƌ ĨĂĐƚŽƌƐ͕ ƐƵĐŚĂƐ ĨƵŶĐƚŝŽŶĂů ƐƚĂƚƵƐ͕ƉĂƚŝĞŶƚƉƌĞĨĞƌĞŶĐĞƐ͕ ĂŶĚ ƐƉĞĐŝĨŝĐ
postoperative complications other than anastomotic leakage, may have influenced our 
results as well.
/ŶĨŽƌŵĂƚŝŽŶ ŽŶ ĚŝĨĨĞƌĞŶĐĞƐ ŝŶ ƉĂƚŝĞŶƚ ĂŶĚ ƚƌĞĂƚŵĞŶƚ ŽƵƚĐŽŵĞƐ ďĞƚǁĞĞŶ ƐŽůŝƚĂƌǇ ĂŶĚ
synchronous colorectal cancer on a national level is relevant, because a preoperative 
ĚŝĂŐŶŽƐŝƐŽĨƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƐŵĂǇŵŽĚŝĨǇŽƌĞǆƚĞŶĚƚŚĞƚǇƉĞŽĨƐƵƌŐŝĐĂů
ƉƌŽĐĞĚƵƌĞĂŶĚŝŶĨůƵĞŶĐĞĐůŝŶŝĐĂůĚĞĐŝƐŝŽŶŵĂŬŝŶŐŽĨƚŚĞƵƐĞŽĨĂĚĚŝƚŝŽŶĂůƚƌĞĂƚŵĞŶƚƐ͘/ƚŝƐ
important to identify the presence of synchronous tumours, preferably before surgery, 
to provide an optimal treatment. Preoperative total colonoscopy should be performed, if 
possible, in all patients with colorectal cancer to detect synchronous tumours. Moreover, 




with colorectal cancer. Synchronous colorectal cancer patients were associated with 
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SUPPLEMENTARY FIGURE 1 &ŝǀĞͲǇĞĂƌƌĞůĂƚŝǀĞƐƵƌǀŝǀĂůĨŽƌƉĂƚŝĞŶƚƐǁŝƚŚƐŽůŝƚĂƌǇ;Ŷсϯϵ͕ϬϵϭͿ;ĂͿŽƌ 
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High-volume hospitals have been associated with improved patient outcomes for tumours 
ǁŝƚŚĂƌĞůĂƚŝǀĞůǇůŽǁŝŶĐŝĚĞŶĐĞƚŚĂƚƌĞƋƵŝƌĞĐŽŵƉůĞǆƐƵƌŐĞƌŝĞƐ͕ƐƵĐŚĂƐŽĞƐŽƉŚĂŐĞĂůĂŶĚ
pancreatic cancer. The volume-outcome association for colorectal cancer is under debate. 
Objective
This study investigates whether hospital volume for colorectal cancer is associated with 
surgical care characteristics and 5-year overall survival.
Design
This is a population-based study.
Settings




All patients with primary non-metastatic colorectal cancer who underwent resection 
between 2005-2012 were included.
Main outcome measures
Differences in surgical approach, anastomotic leakage and postoperative 30-day mortality 
ďĞƚǁĞĞŶ ŚŽƐƉŝƚĂů ǀŽůƵŵĞƐ ǁĞƌĞ ĂŶĂůǇǌĞĚ ƵƐŝŶŐ ʖ2 tests and multivariable logistic 
ƌĞŐƌĞƐƐŝŽŶĂŶĂůǇƐĞƐ͘ŽǆƉƌŽƉŽƌƚŝŽŶĂůŚĂǌĂƌĚŵŽĚĞůƐǁĞƌĞƵƐĞĚƚŽŝŶǀĞƐƚŝŐĂƚĞƚŚĞĞĨĨĞĐƚ
of hospital volume on overall survival.
Results
dŚŝƐ ƐƚƵĚǇ ŝŶĐůƵĚĞĚ ϲϭ͕ϯϵϰ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƚŝĞŶƚƐ͘ /Ŷ ϮϬϭϮ͕ ϯϭ ŽĨ ƚŚĞ ϵϭ ŚŽƐƉŝƚĂůƐ
ƉĞƌĨŽƌŵĞĚůĞƐƐƚŚĂŶϱϬĐŽůŽŶĐĂŶĐĞƌƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌĂŶĚϮϭŽĨƚŚĞϵϬŚŽƐƉŝƚĂůƐƉĞƌĨŽƌŵĞĚ
ůĞƐƐƚŚĂŶϮϬƌĞĐƚĂůĐĂŶĐĞƌƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌ͘EŽĚŝĨĨĞƌĞŶĐĞƐŝŶĂŶĂƐƚŽŵŽƚŝĐůĞĂŬĂŐĞďĞƚǁĞĞŶ
hospital volumes were observed. Only small differences between hospital volumes were 
ƌĞǀĞĂůĞĚĨŽƌĐŽŶǀĞƌƐŝŽŶŽĨůĂƉĂƌŽƐĐŽƉŝĐƚŽŽƉĞŶƌĞƐĞĐƚŝŽŶ;KZфϱϬǀĞƌƐƵƐшϭϬϬƌĞƐĞĐƚŝŽŶƐͬ
year ϭ͘Ϯϱ ;ϵϱй/ϭ͘ϬϲͲϭ͘ϰϲͿ ĂŶĚƉŽƐƚŽƉĞƌĂƚŝǀĞϯϬͲĚĂǇŵŽƌƚĂůŝƚǇ ;ĐŽůŽŶ͗KZфϱϬǀĞƌƐƵƐ
шϭϬϬƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌϭ͘ϭϳ;ϭ͘ϬϮͲϭ͘ϯϱͿ͖ƌĞĐƚƵŵ͗KZфϮϬǀĞƌƐƵƐшϰϬƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌϭ͘ϰϮ
;ϭ͘ϬϵͲϭ͘ϴϰͿͿ͘EŽĚŝĨĨĞƌĞŶĐĞƐŝŶŽǀĞƌĂůůƐƵƌǀŝǀĂůǁĞƌĞĨŽƵŶĚďĞƚǁĞĞŶŚŽƐƉŝƚĂůǀŽůƵŵĞƐ͘
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Limitations
Although we adjusted for several patient and tumour characteristics, data on surgeon 
volume, data regarding local recurrences, specific postoperative complications other 
than anastomotic leakage and on comorbidity were not available. 
Conclusion
/Ŷ ƚŚĞ EĞƚŚĞƌůĂŶĚƐ͕ ŶŽ ĚŝĨĨĞƌĞŶĐĞƐ ŝŶ ϱͲǇĞĂƌ ƐƵƌǀŝǀĂů ǁĞƌĞ ƌĞǀĞĂůĞĚ ďĞƚǁĞĞŶ ŚŽƐƉŝƚĂů




care and the need for reliable parameters thereof. Differences in hospital volume and 
ŝƚƐƌĞůĂƚŝŽŶǁŝƚŚƉĂƚŝĞŶƚŽƵƚĐŽŵĞƐŚĂǀĞďĞĞŶƐƚƵĚŝĞĚĞǆƚĞŶƐŝǀĞůǇŝŶƚŚĞŽŶŐŽŝŶŐĚĞďĂƚĞ
of centralization of surgical care.1-3ƐƉĞĐŝĂůůǇŝŶƚƵŵŽƵƌƐǁŝƚŚĂƌĞůĂƚŝǀĞůǇůŽǁŝŶĐŝĚĞŶĐĞ
ƚŚĂƚƌĞƋƵŝƌĞĐŽŵƉůĞǆƐƵƌŐĞƌŝĞƐ͕ƐƵĐŚĂƐŽĞƐŽƉŚĂŐĞĂůĂŶĚƉĂŶĐƌĞĂƚŝĐĐĂŶĐĞƌ͕ƉĂƚŝĞŶƚƐŚĂǀĞ
better short- and long-term outcomes when operated in high-volume hospitals.4-9 
/ŶϮϬϭϭƚŚĞƵƚĐŚ^ ŽĐŝĞƚǇĨŽƌ^ ƵƌŐĞƌǇĞƐƚĂďůŝƐŚĞĚĂŵŝŶŝŵƵŵǀŽůƵŵĞŶŽƌŵŽĨϱϬĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌƉĞƌŚŽƐƉŝƚĂů͘ĚĚŝƚŝŽŶĂůůǇ͕ĨŽƌƌĞĐƚĂůĐĂŶĐĞƌĂŵŝŶŝŵƵŵǀŽůƵŵĞ
ŶŽƌŵŽĨϮϬƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌƉĞƌŚŽƐƉŝƚĂůŝƐƌĞƋƵŝƌĞĚ͘10 For colorectal cancer patients, the 
volume-outcome association is under debate. 
A Cochrane review from 2012 showed that 5-year overall survival was higher for colorectal 
cancer patients treated in high-volume hospitals. For rectal cancer patients only, 5-year 
overall survival but not postoperative mortality was higher in high-volume hospitals. 
The quality of the evidence was regarded low in this review, and evidence was based on 
studies with a large heterogeneity in volume definitions.11 
^ŝŶĐĞ ŝƚ ŝƐ ƐƚŝůůŶŽƚĐůĞĂƌ ƚŽǁŚĂƚĞǆƚĞŶƚŚŽƐƉŝƚĂůǀŽůƵŵĞĚŝĨĨĞƌĞŶĐĞƐďĞƚǁĞĞŶŚŽƐƉŝƚĂůƐ
lead to differences in short- and long-term patient outcomes, we aimed to investigate 
whether hospital volume determines surgical care characteristics, postoperative 30-day 
mortality and long-term survival in colorectal cancer patients in the Netherlands. 
Based on previous literature, we hypothesize that high-volume hospitals are not 






ŵĂŶĂŐĞĚ ďǇ ƚŚĞEĞƚŚĞƌůĂŶĚƐ ŽŵƉƌĞŚĞŶƐŝǀĞ ĂŶĐĞƌKƌŐĂŶŝƐĂƚŝŽŶ ;/<E>Ϳ͘ /ŶĨŽƌŵĂƚŝŽŶ
ŽŶ ƉĂƚŝĞŶƚ ĂŶĚ ƚƵŵŽƵƌ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ͕ ĚŝĂŐŶŽƐŝƐ ĂŶĚ ƚƌĞĂƚŵĞŶƚ ŝƐ ƌŽƵƚŝŶĞůǇ ĞǆƚƌĂĐƚĞĚ
from the medical records. The quality of the data is high due to thorough training of the 
registration team and computerized consistency checks at regional and national level. 
ŶĂƚŽŵŝĐĂůƐŝƚĞŽĨƚŚĞƚƵŵŽƵƌŝƐƌĞŐŝƐƚĞƌĞĚĂĐĐŽƌĚŝŶŐƚŽƚŚĞ/ŶƚĞƌŶĂƚŝŽŶĂůůĂƐƐŝĨŝĐĂƚŝŽŶŽĨ
ŝƐĞĂƐĞʹKŶĐŽůŽŐǇ;/ͲKͿ͘12dŚĞdED;ƚƵŵŽƵƌͲŶŽĚĞͲŵĞƚĂƐƚĂƐŝƐͿĐůĂƐƐŝĨŝĐĂƚŝŽŶŝƐƵƐĞĚĨŽƌ
stage notification of the primary tumour, according to the edition valid at time of cancer 
diagnosis.13 
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^ãçùÖÊÖç½ã®ÊÄ
ůů ƉĂƚŝĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚ ƐƵƌŐŝĐĂů ƌĞƐĞĐƚŝŽŶ ĨŽƌ ƉƌŝŵĂƌǇ ƐƚĂŐĞ /Ͳ/// ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ
;ϭϴͲϮϬͿďĞƚǁĞĞŶϮϬϬϱͲϮϬϭϮǁĞƌĞŝŶĐůƵĚĞĚ͘ĂƚĂĨŽƌƚŚĞĞǀĂůƵĂƚŝŽŶŽĨƐƵƌŐŝĐĂůĐĂƌĞ;Ğ͘Ő͘
ƐƵƌŐŝĐĂůĂƉƉƌŽĂĐŚ͕ĞŵĞƌŐĞŶĐǇƌĞƐĞĐƚŝŽŶĂŶĚĂŶĂƐƚŽŵŽƚŝĐůĞĂŬĂŐĞͿǁĞƌĞĂǀĂŝůĂďůĞŝŶƚŚĞ
NCR since 2008, therefore we limited our selection for these analyses to patients who 
underwent surgical resection in 2009-2012. Patients who underwent surgical resection 
ǁŝƚŚŽƵƚƉƌŝŵĂƌǇĂŶĂƐƚŽŵŽƐŝƐǁĞƌĞĞǆĐůƵĚĞĚ ĨƌŽŵ ƚŚĞĂŶĂůǇƐĞƐ ƌĞŐĂƌĚŝŶŐĂŶĂƐƚŽŵŽƚŝĐ
ůĞĂŬĂŐĞ;ŶсϮ͕ϵϴϭͿ͘
Disease stage was based on the pathological TNM classification. Patients were stratified by 
ƚƵŵŽƵƌůŽĐĂůŝǌĂƚŝŽŶ͗ĐŽůŽŶ;ϭϴͿĂŶĚƌĞĐƚƵŵ;ƌĞĐƚŽƐŝŐŵŽŝĚĂŶĚƌĞĐƚƵŵ͕ϭϵͲϮϬͿ͘dƵŵŽƵƌ






mortality. Anastomotic leakage was only recorded as such if a surgical intervention or 




ĨƚĞƌ ƐƚƌĂƚŝĨŝĐĂƚŝŽŶďǇ ƚƵŵŽƵƌ ůŽĐĂůŝǌĂƚŝŽŶ͕ ƚŚĞŶƵŵďĞƌŽĨ ƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌƉĞƌŚŽƐƉŝƚĂů
over the period 2005-2012 were calculated. Hospitals were divided per year into separate 
categories for colon and rectal cancer, based on their annual hospital volume. Hospital 
ǀŽůƵŵĞĨŽƌĐŽůŽŶĐĂŶĐĞƌǁĂƐĚŝǀŝĚĞĚ ŝŶƚŽ ĨŽƵƌĐĂƚĞŐŽƌŝĞƐ͗фϱϬ͖ϱϬͲϳϰ͖ϳϱͲϵϵĂŶĚшϭϬϬ
ƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌ͘ ,ŽƐƉŝƚĂů ǀŽůƵŵĞ ĨŽƌ ƌĞĐƚĂů ĐĂŶĐĞƌ ǁĂƐ ĚŝǀŝĚĞĚ ŝŶƚŽ ƚŚƌĞĞ ĐĂƚĞŐŽƌŝĞƐ͗
фϮϬ͖ϮϬͲϯϵĂŶĚшϰϬƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌ͘dŚĞůŽǁĞƐƚĐĂƚĞŐŽƌǇĨŽƌĐŽůŽŶĐĂŶĐĞƌǁĂƐďĂƐĞĚŽŶ
the Dutch minimum volume norm for colorectal cancer, since there were no minimum 
requirements available for colon cancer separately. The lowest category for rectal cancer 
was based on the Dutch minimum volume norm for rectal cancer. The higher categories 
for both colon and rectal cancer were chosen to create equal distribution of patients 
between hospital volume categories.
All hospitals in the Netherlands were included. Hospitals that merged in the period 2005-
2012 were counted as separate until the date of the merge and as one after the merge or 
the subsequent year if this was during the year.
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Differences in patient and tumour characteristics, observed proportions of anastomotic 
leakage and postoperative 30-day mortality between hospital volumes were calculated 
ƵƐŝŶŐʖ2 tests after stratification by tumour localization. Additionally, for patients with a 
tumour located in the colon, differences in surgical approach between hospital volumes 
were analyzed using the same methods. Multivariable logistic regression models 
ǁĞƌĞ ƵƐĞĚ ƚŽ ĚĞƚĞƌŵŝŶĞ ĂĚũƵƐƚĞĚ ŽĚĚƐ ƌĂƚŝŽƐ ;KZͿ ĨŽƌ ƐƵƌŐŝĐĂů ĂƉƉƌŽĂĐŚ͕ ƉƌĞƐĞŶĐĞ ŽĨ
anastomotic leakage and postoperative 30-day mortality adjusting for gender, age, T 
ƐƚĂŐĞ͕EƐƚĂŐĞ͕ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶŐƌĂĚĞ͕ ƚƵŵŽƵƌ ůŽĐĂƚŝŽŶĂŶĚŶĞŽĂĚũƵǀĂŶƚ ƚƌĞĂƚŵĞŶƚ ;ƚŚĞ
ůĂƚƚĞƌĨŽƌƌĞĐƚĂůĐĂŶĐĞƌŽŶůǇͿ͘
Crude 1-, 3- and 5-year overall survival was calculated using the Kaplan-Meier method 
and differences in overall survival outcomes were assessed with the log-rank test. Overall 
ƐƵƌǀŝǀĂůǁĂƐĂůƐŽĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐŽǆƉƌŽƉŽƌƚŝŽŶĂůŚĂǌĂƌĚŵŽĚĞůƐ͘WĂƚŝĞŶƚƐǁŚŽƐƵƌǀŝǀĞĚ
the first 30 days after the date of resection were included in the survival analyses. Follow-
up time was defined as the time between 30 days after resection and either date of death 
or last follow-up date for patients who were still alive. Patient and tumour characteristics 
influencing survival were included as covariates in the model to discriminate independent 
risk factors for death. 
PǀĂůƵĞƐďĞůŽǁϬ͘ϬϱǁĞƌĞĐŽŶƐŝĚĞƌĞĚƐƚĂƚŝƐƚŝĐĂůůǇƐŝŐŶŝĨŝĐĂŶƚ͘^ ^ͬ^dd® statistical software 
;^^ƐǇƐƚĞŵϵ͘ϰ͕^^/ŶƐƚŝƚƵƚĞ͕ĂƌǇ͕EͿǁĂƐƵƐĞĚĨŽƌĂůůĂŶĂůǇƐĞƐ͘
Results
Over the period 2005-2012, 61,496 patients underwent surgical resection for primary 
ŶŽŶͲŵĞƚĂƐƚĂƚŝĐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͗ϰϭ͕ϬϭϱĐŽůŽŶĐĂŶĐĞƌƉĂƚŝĞŶƚƐĂŶĚϮϬ͕ϰϴϭƌĞĐƚĂůĐĂŶĐĞƌ
patients. Table 1 presents the number of hospitals per hospital volume per year, showing 
a decreasing trend in low-volume hospitals. Figure 1 shows the annual average hospital 
volume, per hospital, in the period 2005-2012, combined with  the annual minimum and 
ŵĂǆŝŵƵŵ;ƌĂŶŐĞͿŚŽƐƉŝƚĂůǀŽůƵŵĞ͕ƉĞƌŚŽƐƉŝƚĂů͕ĨŽƌĐŽůŽŶ;ĂͿĂŶĚƌĞĐƚĂů;ďͿĐĂŶĐĞƌ͘
































































































































































































































































































































































































































Range annual minimum - maximum hospital volume in period 2005-2012
































Range annual minimum - maximum hospital volume in period 2005-2012
Annual average hospital volume in period 2005-2012
FIGURE 1  The annual average hospital volume, per hospital, in the period 2005–2012, combined 
 ǁŝƚŚ ƚŚĞ ĂŶŶƵĂů ŵŝŶŝŵƵŵ ĂŶĚŵĂǆŝŵƵŵ ;ƌĂŶŐĞͿ ŚŽƐƉŝƚĂů ǀŽůƵŵĞ͕ ƉĞƌ ŚŽƐƉŝƚĂů͕ ĨŽƌ
 ĐŽůŽŶĐĂŶĐĞƌ;ĂͿĂŶĚƌĞĐƚĂůĐĂŶĐĞƌ;ďͿ;Ŷсϲϭ͕ϰϵϲͿ͘
Table 2 shows the distribution of patient and tumour characteristics of the patients 
who underwent surgical resection for colorectal cancer by hospital volume and tumour 
localization. Statistically significant differences were found between hospital volumes for 
colon as well as rectal cancer with regard to age, period of resection, T stage, N stage and 
differentiation grade.
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TABLE 2  Patient and tumour characteristics of patients who underwent surgical resection for 
 ĐŽůŽŶŽƌƌĞĐƚĂůĐĂŶĐĞƌ;Ŷсϲϭ͕ϰϵϲͿ͘
Hospital volume/year
<50/yr 50-74/yr 75-99/yr шϭϬϬͬǇƌ p value
n ;йͿ n ;йͿ n ;йͿ n ;йͿ
COLON CANCER
Total 8,279 ;ϮϬͿ 11,645 ;ϮϵͿ 8,663 ;ϮϭͿ 12,428 ;ϯϬͿ
Gender 0.59
   Male 4,269 ;ϱϭͿ 5,908 ;ϱϭͿ 4,403 ;ϱϭͿ 6,296 ;ϱϭͿ
   Female 4,010 ;ϰϵͿ 5,737 ;ϰϵͿ 4,260 ;ϰϵͿ 6,132 ;ϰϵͿ
Age Ϭ͘ϬϬϭΎ
   < 60 years 1,425 ;ϭϳͿ 1,937 ;ϭϳͿ 1,399 ;ϭϲͿ 1,895 ;ϭϱͿ
   60-69 years 2,213 ;ϮϳͿ 3,076 ;ϮϲͿ 2,215 ;ϮϲͿ 3,283 ;ϮϲͿ
   70-79 years 2,750 ;ϯϯͿ 4,029 ;ϯϱͿ 2,975 ;ϯϰͿ 4,416 ;ϯϲͿ
шϴϬǇĞĂƌƐ 1,891 ;ϮϯͿ 2,603 ;ϮϮͿ 2,074 ;ϮϰͿ 2,834 ;ϮϯͿ
WĞƌŝŽĚŽĨƌĞƐĞĐƟŽŶ фϬ͘ϬϬϬϭΎ
   2005-2006 2,674 ;ϯϯͿ 2,723 ;ϮϯͿ 1,934 ;ϮϯͿ 1,248 ;ϭϬͿ
   2007-2008 2,204 ;ϮϲͿ 3,171 ;ϮϳͿ 1,993 ;ϮϯͿ 2,133 ;ϭϳͿ
   2009-2010 1,942 ;ϮϯͿ 2,835 ;ϮϱͿ 2,340 ;ϮϲͿ 3,656 ;ϯϬͿ
   2011-2012 1,459 ;ϭϴͿ 2,916 ;ϮϱͿ 2,396 ;ϮϴͿ 5,391 ;ϰϯͿ
T stage Ϭ͘ϬϭϬΎ
   T1 598 ;ϳͿ 873 ;ϴͿ 601 ;ϳͿ 903 ;ϳͿ
   T2 1,329 ;ϭϲͿ 1,864 ;ϭϲͿ 1,377 ;ϭϲͿ 1,907 ;ϭϱͿ
   T3 5,192 ;ϲϯͿ 7,257 ;ϲϮͿ 5,604 ;ϲϱͿ 7,629 ;ϲϰͿ
   T4 1,160 ;ϭϰͿ 1,651 ;ϭϲͿ 1,081 ;ϭϮͿ 1,689 ;ϭϰͿ
N stage Ϭ͘ϬϭϴΎ
   N0 5,206 ;ϲϯͿ 7,471 ;ϲϰͿ 5,681 ;ϲϱͿ 7,896 ;ϲϰͿ
   N1 2,012 ;ϮϰͿ 2,789 ;ϮϰͿ 2,018 ;ϮϯͿ 3,093 ;ϮϱͿ
   N2 1,061 ;ϭϯͿ 1,385 ;ϭϮͿ 1,027 ;ϭϮͿ 1,439 ;ϭϭͿ
ŝīĞƌĞŶƟĂƟŽŶŐƌĂĚĞ фϬ͘ϬϬϬϭΎ
tĞůůͬŵŽĚĞƌĂƚĞĚ 6,218 ;ϳϱͿ 8,699 ;ϳϱͿ 6,574 ;ϳϲͿ 9,310 ;ϳϱͿ
WŽŽƌͬƵŶĚŝīĞƌĞŶƟĂƚĞĚ 1,235 ;ϭϱͿ 1,932 ;ϭϲͿ 1,376 ;ϭϲͿ 1,902 ;ϭϱͿ
hŶŬŶŽǁŶ 826 ;ϭϬͿ 1,014 ;ϵͿ 713 ;ϴͿ 1,216 ;ϭϬͿ
dƵŵŽƵƌůŽĐĂƟŽŶ 0.79
   Colon ascendens 3,187 ;ϯϴͿ 4,401 ;ϯϴͿ 3,284 ;ϯϴͿ 4,819 ;ϯϵͿ
   Colon transversum 1,513 ;ϭϴͿ 2,162 ;ϭϴͿ 1,599 ;ϭϴͿ 2,200 ;ϭϳͿ
   Colon descendens 3,446 ;ϰϮͿ 4,878 ;ϰϮͿ 3,633 ;ϰϮͿ 5,197 ;ϰϮͿ
ŽůŽŶEK^ͬŽƚŚĞƌ 133 ;ϮͿ 204 ;ϮͿ 147 ;ϮͿ 212 ;ϮͿ
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TABLE 2  Patient and tumour characteristics of patients who underwent surgical resection for 
 ĐŽůŽŶŽƌƌĞĐƚĂůĐĂŶĐĞƌ;Ŷсϲϭ͕ϰϵϲͿ͘(Continued)
Hospital volume/year
<20/yr 20-39/yr шϰϬͬǇƌ p value
n ;йͿ n ;йͿ n ;йͿ
RECTAL CANCER
Total 2,545 ;ϭϯͿ 8,830 ;ϰϯͿ 9,106 ;ϰϰͿ
Gender 0.73
   Male 1,525 ;ϲϬͿ 5,366 ;ϲϭͿ 5,503 ;ϲϬͿ
   Female 1,020 ;ϰϬͿ 3,464 ;ϯϵͿ 3,603 ;ϰϬͿ
Age Ϭ͘ϬϮϳΎ
   < 60 years 627 ;ϮϰͿ 2,148 ;ϭϰͿ 2,174 ;ϮϰͿ
   60-69 years 781 ;ϯϭͿ 2,764 ;ϯϮͿ 2,991 ;ϯϮͿ
   70-79 years 757 ;ϯϬͿ 2,734 ;ϯϭͿ 2,788 ;ϯϭͿ
шϴϬǇĞĂƌƐ 380 ;ϭϱͿ 1,184 ;ϭϯͿ 1,153 ;ϭϯͿ
WĞƌŝŽĚŽĨƌĞƐĞĐƟŽŶ фϬ͘ϬϬϬϭΎ
   2005-2006 782 ;ϯϭͿ 2,072 ;ϮϯͿ 1,772 ;ϮϬͿ
   2007-2008 626 ;ϮϱͿ 2,245 ;ϮϱͿ 2,176 ;ϮϰͿ
   2009-2010 611 ;ϮϰͿ 2,295 ;ϮϳͿ 2,252 ;ϮϰͿ
   2011-2012 526 ;ϮϬͿ 2,218 ;ϮϱͿ 2,906 ;ϯϮͿ
T stage Ϭ͘ϬϬϬϭΎ
   T1 241 ;ϵͿ 886 ;ϭϬͿ 1,067 ;ϭϮͿ
   T2 872 ;ϯϰͿ 2,939 ;ϯϰͿ 2,935 ;ϯϮͿ
   T3 1,332 ;ϱϮͿ 4,553 ;ϱϭͿ 4,623 ;ϱϭͿ
   T4 100 ;ϰͿ 452 ;ϱͿ 481 ;ϱͿ
N stage Ϭ͘ϬϰϱΎ
   N0 1,649 ;ϲϱͿ 5,896 ;ϲϳͿ 6,184 ;ϲϴͿ
   N1 603 ;ϮϰͿ 1,955 ;ϮϮͿ 1,972 ;ϮϮͿ
   N2 293 ;ϭϭͿ 979 ;ϭϭͿ 950 ;ϭϬͿ
dƵŵŽƵƌůŽĐĂƟŽŶ фϬ͘ϬϬϬϭΎ
   Rectosigmoid 405 ;ϭϲͿ 1,270 ;ϭϰͿ 1,101 ;ϭϮͿ
   Rectum 2,140 ;ϴϰͿ 7,560 ;ϴϲͿ 8,005 ;ϴϴͿ
Ύp<0.05 between hospital volume categories
^çÙ¦®½ÖÖÙÊ«®ÄÊ½ÊÄÄÙÖã®ÄãÝ
Table 3a presents observed proportions and adjusted odds ratios of laparoscopic resection 
by hospital volume. The distribution of surgical approach differed between hospital 
ǀŽůƵŵĞƐ;pфϬ͘ϬϬϬϭͿ͘DŽƌĞŽǀĞƌ͕ĂŵŽŶŐƉĂƚŝĞŶƚƐŝŶŝƚŝĂůůǇƚƌĞĂƚĞĚůĂƉĂƌŽƐĐŽƉŝĐĂůůǇ͕ĂŚŝŐŚĞƌ
proportion of patients underwent conversion from laparoscopic to open resection in low-
ǀŽůƵŵĞŚŽƐƉŝƚĂůƐĐŽŵƉĂƌĞĚƚŽŚŝŐŚͲǀŽůƵŵĞŚŽƐƉŝƚĂůƐ;pсϬ͘ϬϭϭͿ;dĂďůĞϯďͿ͘
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TABLE 3 ƌƵĚĞ ƉĞƌĐĞŶƚĂŐĞƐ ĂŶĚ ĂĚũƵƐƚĞĚ ŽĚĚƐ ƌĂƚŝŽƐϸ ĨŽƌ ůĂƉĂƌŽƐĐŽƉŝĐ ƌĞƐĞĐƚŝŽŶ ;ĂͿ ĂŶĚ
ĐŽŶǀĞƌƐŝŽŶ ĨƌŽŵ ůĂƉĂƌŽƐĐŽƉŝĐ ƚŽ ŽƉĞŶ ƌĞƐĞĐƚŝŽŶ ;ďͿ ĂŵŽŶŐ ĐŽůŽŶ ĐĂŶĐĞƌ ƉĂƚŝĞŶƚƐ͖
ĂŶĂƐƚŽŵŽƚŝĐůĞĂŬĂŐĞ;ĐͿĂŶĚƉŽƐƚŽƉĞƌĂƚŝǀĞϯϬͲĚĂǇŵŽƌƚĂůŝƚǇ;ĚͿĂŵŽŶŐĐŽůŽŶĂŶĚƌĞĐƚĂů
cancer patients.
   DƵůƟǀĂƌŝĂďůĞĂŶĂůǇƐŝƐ
 ƌƵĚĞ;йͿ p value OR² ϵϱй/
a. >ĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƟŽŶa
K>KEEZ фϬ͘ϬϬϭΎ
фϱϬͬǇƌ 42.2 1.04 0.96-1.13
ϱϬͲϳϰͬǇƌ 43.4 1.10 1.03-1.18




фϱϬͬǇƌ 20.2 1.25 1.06-1.46
ϱϬͲϳϰͬǇƌ 19.4 1.20 1.05-1.37




фϱϬͬǇƌ 8.2 0.95 0.81-1.10
ϱϬͲϳϰͬǇƌ 8.4 0.99 0.88-1.13
ϳϱͲϵϵͬǇƌ 8.4 0.97 0.85-1.11
шϭϬϬͬǇƌ 8.6 reference
Zd>EZ 0.97
фϮϬͬǇƌ 13.2 1.03 0.79-1.34




фϱϬͬǇƌ 4.4 1.17 1.02-1.35
ϱϬͲϳϰͬǇƌ 4.7 1.24 1.09-1.41
ϳϱͲϵϵͬǇƌ 4.3 1.10 0.96-1.27
шϭϬϬͬǇƌ 3.9 reference
Zd>EZ Ϭ͘ϬϬϳΎ
фϮϬͬǇƌ 3.4 1.42 1.09-1.84
ϮϬͲϯϵͬǇƌ 2.6 1.12 0.92-1.36
шϰϬͬǇƌ 2.3  reference  
KZKĚĚƐƌĂƚŝŽ͕/ŽŶĨŝĚĞŶĐĞŝŶƚĞƌǀĂů









Table 3c presents observed proportions and adjusted odds ratios of anastomotic leakage 
by hospital volume and tumour localization. For both colon and rectal cancer patients no 
ĚŝĨĨĞƌĞŶĐĞƐǁĞƌĞĨŽƵŶĚďĞƚǁĞĞŶŚŽƐƉŝƚĂůǀŽůƵŵĞƐ;ĐŽůŽŶpсϬ͘ϴϭ͖ƌĞĐƚƵŵpсϬ͘ϵϳͿ͘
WÊÝãÊÖÙã®òÃÊÙã½®ãù
Table 3d presents observed proportions and adjusted odds ratios for postoperative 30-
day mortality by hospital volume and tumour localization. For both colon and rectal 
ĐĂŶĐĞƌ͕ ƉŽƐƚŽƉĞƌĂƚŝǀĞŵŽƌƚĂůŝƚǇ ǁĂƐŵĂƌŐŝŶĂůůǇ ŚŝŐŚĞƌ ŝŶ ůŽǁͲǀŽůƵŵĞ ŚŽƐƉŝƚĂůƐ ;ĐŽůŽŶ
pсϬ͘ϬϮϵ͖ƌĞĐƚƵŵ pсϬ͘ϬϬϳͿ͘
^çÙò®ò½




Table 4 shows adjusted hazard ratios for death by hospital volume. The risk of death was 





TABLE 4 ŽǆƌĞŐƌĞƐƐŝŽŶĂŶĂůǇƐŝƐĨŽƌƚŚĞƌĞůĂƚŝŽŶŽĨƚŚĞŶƵŵďĞƌŽĨƉĂƚŝĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂů 
 resection for colon or rectal cancer per hospital per year and the risk of death of colon 
 ĂŶĚƌĞĐƚĂůĐĂŶĐĞƌƉĂƚŝĞŶƚƐŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͕ϮϬϬϱͲϮϬϭϮ;Ŷсϱϴ͕ϮϭϴͿ͘
Adjusted












² Adjusted for gender, age, year of surgical resection, T stage, N stage, differentiation grade and tumour location.




























































^ç¦ÙÊçÖ Ä½ùÝÝ ø½ç®Ä¦ Öã®ÄãÝó«Ê çÄÙóÄã ÃÙ¦Äù
ÙÝã®ÊÄ
ƐĂƐĞŶƐŝƚŝǀŝƚǇĂŶĂůǇƐŝƐ͕ĂůůĂŶĂůǇƐĞƐǁĞƌĞƌĞƉĞĂƚĞĚĨŽƌƚŚĞƉĞƌŝŽĚϮϬϬϵͲϮϬϭϮĞǆĐůƵĚŝŶŐ
patients who underwent emergency resection. Similar results were found for surgical 






patient outcomes. We found no differences in overall survival between hospitals that 
did and did not meet the Dutch minimum volume norms for colorectal cancer. However, 
marginal differences were found between hospital volumes in surgical approach and 
postoperative 30-day mortality.
Our data were based on all consecutive non-metastatic colorectal cancer patients, who 
ƵŶĚĞƌǁĞŶƚƌĞƐĞĐƚŝŽŶŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐďĞƚǁĞĞŶϮϬϬϱͲϮϬϭϮ͘ŽŶĨůŝĐƚŝŶŐĞǀŝĚĞŶĐĞĞǆŝƐƚƐ
as to whether hospital volume is associated with differences in postoperative mortality 
and overall survival in colorectal cancer. The variation in results between studies may be 
caused by the hospital volume categories that are differently defined in the literature. 
dŚĞĐƵƚͲŽĨĨĨŽƌ͞ůŽǁͲǀŽůƵŵĞ͟ƌĂŶŐĞĚĨƌŽŵчϮϱƚŽчϵϬĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƌĞƐĞĐƚŝŽŶƐ͕ĂŶĚ
the number of colorectal cancer resections considered as “high-volume” ranged from 
шϮϱƚŽшϭϭϬ͘11 Furthermore, the low-volume thresholds used in this study would place 
ƵƚĐŚŚŽƐƉŝƚĂůƐ ŝŶŚŝŐŚͲǀŽůƵŵĞĐĂƚĞŐŽƌŝĞƐ ŝŶŵŽƐƚ ƐƚƵĚŝĞƐŽƌŝŐŝŶĂƚŝŶŐ ĨƌŽŵ ƚŚĞhŶŝƚĞĚ
^ƚĂƚĞƐ ;h^Ϳ͘1, 14, 15 Other studies categorized hospitals based on the colorectal cancer 
hospital volume16, 17, whereas we intentionally separated colon and rectal cancers due to 
differences in surgical procedures. A subgroup analysis in a meta-analysis of the Cochrane 
collaboration, where studies were grouped according to continent of origin, showed that 
ƐƚƵĚŝĞƐŽƌŝŐŝŶĂƚŝŶŐĨƌŽŵŽƚŚĞƌĐŽƵŶƚƌŝĞƐƚŚĂŶƚŚĞh^ŚĂĚŶŽƐŝŐŶŝĨŝĐĂŶƚŚŽƐƉŝƚĂůǀŽůƵŵĞ
ĞĨĨĞĐƚŽŶϱͲǇĞĂƌƐƵƌǀŝǀĂů͕ǁŚĞƌĞĂƐh^ĚĂƚĂƐƵŐŐĞƐƚĞĚĂƉŽƚĞŶƚŝĂůďĞŶĞĨŝƚĨŽƌŚŝŐŚͲǀŽůƵŵĞ
hospitals.11^ŝŵŝůĂƌ ƚŽ ƚŚĞƌĞƐƵůƚƐ ĨŽƵŶĚ ŝŶŶŽŶͲh^ƐƚƵĚŝĞƐ͕ǁĞĚĞŵŽŶƐƚƌĂƚĞĚŶŽďĞƚƚĞƌ
survival in high-volume hospitals. Moreover, patient selection varied between studies, 
some only included patients older than 65 years with colorectal cancer.18, 19 Furthermore, 
ǁĞĞǆĐůƵĚĞĚƉĂƚŝĞŶƚƐǁŝƚŚŵĞƚĂƐƚĂƚŝĐĚŝƐĞĂƐĞǁŚŝůĞŽƚŚĞƌƐŚĂǀĞŝŶĐůƵĚĞĚƚŚĞƐĞ͘19-23 
For colon cancer patients who were initially treated laparoscopically, we found a slightly 
ŚŝŐŚĞƌ ƉƌŽƉŽƌƚŝŽŶ ŽĨ ƉĂƚŝĞŶƚƐ ;ϰйͿ ĐŽŶǀĞƌƚĞĚ ĨƌŽŵ ůĂƉĂƌŽƐĐŽƉŝĐ ƚŽ ŽƉĞŶ ƌĞƐĞĐƚŝŽŶ ŝŶ
ŚŽƐƉŝƚĂůƐ ǁŝƚŚ фϱϬ ƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌ ĐŽŵƉĂƌĞĚ ƚŽ ŚŽƐƉŝƚĂůƐ ǁŝƚŚ шϭϬϬ ƌĞƐĞĐƚŝŽŶƐͬǇĞĂƌ͘
sĂŶ ƌŶŝŶŐ Ğƚ Ăů͘ ƐŚŽǁĞĚ Ă ƐŝŵŝůĂƌ ƚƌĞŶĚ ŝŶ Ă ƉŽƉƵůĂƚŝŽŶͲďĂƐĞĚ ƐƚƵĚǇ ŝŶ ƚŚĞ ƐŽƵƚŚĞƌŶ
part of the Netherlands.24>ĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƚŝŽŶŝƐƉƌŽǀĞŶƚŽďĞƐĂĨĞ͕ǁŝƚŚĐŽŵƉĂƌĂďůĞ
disease-free and overall survival compared to open resection.25, 26 However, conversion 
to open resection is associated with increased morbidity, longer length of hospital stay 
and shorter disease-free survival.27-29 The technique of laparoscopic resection is still in 
progress, hence it is likely that variance in proportions of laparoscopic resection between 
hospitals will decrease. 
/ŶƚĞƌĞƐƚŝŶŐůǇ͕ŵĂƌŐŝŶĂůĚŝĨĨĞƌĞŶĐĞƐŝŶƉŽƐƚŽƉĞƌĂƚŝǀĞŵŽƌƚĂůŝƚǇƌĂƚĞƐǁĞƌĞƉƌĞƐĞŶƚďĞƚǁĞĞŶ
hospital volumes for patients with colon or rectal cancer. For rectal cancer patients, this 




these results are compared with our results, it seems that the postoperative mortality 
rates have not been changed over time. More studies found an association between 
postoperative mortality and hospital volumes.1, 14, 21-23, 31, 32ƉŽƐƐŝďůĞĞǆƉůĂŶĂƚŝŽŶĐŽƵůĚďĞ
that a higher standard of care is provided in high-volume hospitals by more specialised and 
ĞǆƉĞƌŝĞŶĐĞĚƐƵƌŐĞŽŶƐĂŶĚďǇ ƚĞĐŚŶŝĐĂůůǇŵŽƌĞĂĚǀĂŶĐĞĚĞƋƵŝƉŵĞŶƚ͘ŶŽƚŚĞƌƉŽƐƐŝďůĞ
ĞǆƉůĂŶĂƚŝŽŶ ĐŽƵůĚ ďĞ ƚŚĂƚ ůŽǁͲǀŽůƵŵĞ ŚŽƐƉŝƚĂůƐ ǁŝƚŚ ŚŝŐŚĞƌ ƉŽƐƚŽƉĞƌĂƚŝǀĞ ŵŽƌƚĂůŝƚǇ
rates are less skilled to recognize and manage serious complications once they occur, a 
ƉŚĞŶŽŵĞŶŽŶŬŶŽǁŶĂƐĨĂŝůƵƌĞƚŽƌĞƐĐƵĞ;&dZͿ͘33 Nevertheless, Henneman et al. recently 
showed that annual average hospital volume was not significantly associated with FTR in 
the Netherlands.34 We found no associations between hospital volumes and the presence 
ŽĨĂŶĂƐƚŽŵŽƚŝĐůĞĂŬĂŐĞ͕ĞǀĞŶƚŚŽƵŐŚůŽǁĞƌƌĂƚĞƐŽĨƉŽƐƚŽƉĞƌĂƚŝǀĞĐŽŵƉůŝĐĂƚŝŽŶƐŝŶŚŝŐŚͬ
ǀŽůƵŵĞŚŽƐƉŝƚĂůƐǁĞƌĞĞǆƉĞĐƚĞĚ͘ĂƚĂŽŶŽƚŚĞƌƐƉĞĐŝĨŝĐƉŽƐƚŽƉĞƌĂƚŝǀĞĐŽŵƉůŝĐĂƚŝŽŶƐǁĞƌĞ
not available. Finally, elderly patients and patients with comorbidities were reported to 
be associated with higher risk of postoperative mortality, but this was not associated with 
hospital volume.24   
The main strengths of this study are the use of a large dataset including more than 
60,000 colorectal cancer patients and the inclusion of all hospitals in the Netherlands. 
Furthermore, the lowest volume categories in our study were based on the Dutch 
minimum volume norms. We calculated the annual hospital volume according to tumour 
location, instead of calculating an average over the included years. 
Due to the increasing incidence of colorectal cancer35, hospital volumes became 
substantially higher through the years. Moreover, during the study period some hospitals 
ŚĂǀĞŵĞƌŐĞĚ͕ ƚŚĞƌĞďǇ ŝŶĐƌĞĂƐŝŶŐ ƚŚĞŝƌ ĂŶŶƵĂů ŚŽƐƉŝƚĂů ǀŽůƵŵĞ͘ /Ŷ ĂŶƚŝĐŝƉĂƚŝŽŶ ŽĨ ƚŚĞ
mergers, hospitals might collaborate and make agreements about referral of patients 
ǁŚŽŶĞĞĚĐŽŵƉůĞǆƐƵƌŐĞƌŝĞƐ͘dŚŝƐĐŽƵůĚŚĂǀĞůĞĚƚŽĂŚŝŐŚĞƌŶƵŵďĞƌŽĨĐŽŵƉůĞǆƉĂƚŝĞŶƚƐ
treated in certain hospitals, which may have led to a worse outcome in these hospitals. 
ůƚŚŽƵŐŚƚŚĞŶƵŵďĞƌŽĨƌĞĨĞƌƌĞĚƉĂƚŝĞŶƚƐŵĂǇďĞƐŵĂůůĂŶĚŽŶĞŵŝŐŚƚĞǆƉĞĐƚƚŽƐĞĞĂ
minor effect,  we have adjusted for several patient and tumour characteristics in our 
analyses. 
However, some shortcomings of our study should be noted. We could not adjust for 
ŚŽƐƉŝƚĂůǀŽůƵŵĞŽĨůŽĐĂůƌĞĐƵƌƌĞŶĐĞƐ;ŵĂŝŶůǇĨŽƌƌĞĐƚĂůĐĂŶĐĞƌͿ͕ǁŚŝĐŚĂƌĞŵŽƐƚůǇƚƌĞĂƚĞĚ
in a limited number of hospitals, thereby underestimating the volume of these hospitals. 
Moreover, a recent Dutch study by Homan et al., suggested a trend towards higher 
ŝŶǀŽůǀĞĚĐŝƌĐƵŵĨĞƌĞŶƚŝĂůƌĞƐĞĐƚŝŽŶŵĂƌŐŝŶŝŶƌĞĐƚĂůĐĂŶĐĞƌƉĂƚŝĞŶƚƐŽĨϭϯйŝŶůŽǁͲǀŽůƵŵĞ
ŚŽƐƉŝƚĂůƐ ;фϮϬͬǇƌͿ ǀĞƌƐƵƐ ϲй ŝŶ ŚŝŐŚͲǀŽůƵŵĞ ŚŽƐƉŝƚĂůƐ ;хϰϬͬǇƌͿ ŝŶ Ă ƐŵĂůů ĂƌĞĂ ŽĨ ƚŚĞ
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Netherlands.36 However, data on completeness of the surgical resection, as well as, data 
regarding local recurrence were not routinely available in the nationwide cancer registry. 
&ƵƌƚŚĞƌŵŽƌĞ͕ǁĞĐĂŶŶŽƚĞǆĐůƵĚĞ ƚŚĂƚŽƚŚĞƌ ĨĂĐƚŽƌƐ͕ ƐƵĐŚĂƐǀĂƌŝĂƚŝŽŶ ŝŶ ĐŽŵŽƌďŝĚŝƚŝĞƐ
between patients treated in different hospitals, may have influenced our results as well. 
Moreover, we studied the number of resections on hospital level and not on surgeon 
level. Several studies showed that postoperative mortality was lower for surgeons with a 
higher caseload of colon cancer patients, regardless of the hospital volume of the hospital 
in which the surgeons practiced.15, 22, 31, 37-39 This suggests that an association between 
hospital volumes and postoperative mortality could be mediated by surgeon volume. 
hŶĨŽƌƚƵŶĂƚĞůǇ͕ĚĂƚĂŽŶƐƵƌŐĞŽŶǀŽůƵŵĞǁĞƌĞŶŽƚĂǀĂŝůĂďůĞ͘
Due to the large dataset, one might dispute whether the statistically significant differences 
ƚŚĂƚǁĞƌĞ ƉƌĞƐĞŶƚ ďĞƚǁĞĞŶ ŚŽƐƉŝƚĂů ǀŽůƵŵĞƐ ĂƌĞ ĐůŝŶŝĐĂůůǇ ƌĞůĞǀĂŶƚ͘ &Žƌ ĞǆĂŵƉůĞ͕ ƚŚĞ
difference in postoperative mortality between lowest and highest volume hospitals 
ǁĂƐ ĂƉƉƌŽǆŝŵĂƚĞůǇ ϭй͘ &ƵƚƵƌĞ ƐƚƵĚŝĞƐ ƐŚŽƵůĚ ĨŽĐƵƐ ŽŶ ƚŚĞ ŝĚĞŶƚŝĨŝĐĂƚŝŽŶ ŽĨ ƉƌŽĐĞƐƐĞƐ
associated with good outcomes and factors causing variation between individual 
hospitals. However, identification of these processes and their effect on quality of care 
remains challenging. 
/ŶĐŽŶĐůƵƐŝŽŶ͕ŶŽĚŝĨĨĞƌĞŶĐĞƐ ŝŶϱͲǇĞĂƌŽǀĞƌĂůůƐƵƌǀŝǀĂůǁĞƌĞƌĞǀĞĂůĞĚďĞƚǁĞĞŶŚŽƐƉŝƚĂů
volumes for non-metastatic colorectal cancer patients. However, marginal differences 
in surgical approach and postoperative 30-day mortality were present between hospital 
ǀŽůƵŵĞƐ͘ǆƉůŽƌŝŶŐĨĂĐƚŽƌƐĐĂƵƐŝŶŐǀĂƌŝĂƚŝŽŶďĞƚǁĞĞŶŚŽƐƉŝƚĂůƐǁŝůůƉƌŽǀŝĚĞŵŽƌĞŝŶƐŝŐŚƚ
in the quality of care debate on whether undergoing a resection in a low-volume hospital 
is a risk factor for unfavourable patient outcomes.
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ĂƐ ƚŚĞ ďĂƐŝƐ ĨŽƌ ĚĞǀĞůŽƉŵĞŶƚ ŽĨ ƚŚĞ ƉƌĞĚŝĐƟŽŶŵŽĚĞů͘ ŝƐĐƌŝŵŝŶĂƟŽŶ ĂŶĚ ĐĂůŝďƌĂƟŽŶ




ϵϬͲĚĂǇŵŽƌƚĂůŝƚǇ ĂŶĚŽǀĞƌĂůů ƐƵƌǀŝǀĂů ŝŶĐůƵĚĞĚŐĞŶĚĞƌ ĂŶĚĂŐĞŽĨ ƚŚĞƉĂƟĞŶƚ͕ ƐƚĂŐĞŽĨ
ƚŚĞƉƌŝŵĂƌǇƚƵŵŽƵƌ͕ ƵƌŐĞŶĐǇŽĨƌĞƐĞĐƟŽŶ;ĐŽůŽŶĐĂŶĐĞƌͿ͕ƐƵƌŐŝĐĂůĂƉƉƌŽĂĐŚ;ůĂƉĂƌŽƐĐŽƉŝĐ
ǀĞƌƐƵƐŽƉĞŶͿ͕ƚǇƉĞŽĨƐƵƌŐĞƌǇ͕ ĂŶĂƐƚŽŵŽƟĐůĞĂŬĂŐĞ͕;ŶĞŽͿĂĚũƵǀĂŶƚƚƌĞĂƚŵĞŶƚƐ͕ƉƌĞƐĞŶĐĞ
ŽĨ ŵƵůƟƉůĞ ƚƵŵŽƵƌƐ͕ ĂŶĚ  ƌĂĚŝĐĂů ƌĞŵŽǀĂů ŽĨ ƚŚĞ ƚƵŵŽƵƌ͘  ŽŶĐŽƌĚĂŶĐĞ ŝŶĚŝĐĞƐ ĨŽƌ
ƉŽƐƚŽƉĞƌĂƟǀĞ ŵŽƌƚĂůŝƚǇ ǁĞƌĞ Ϭ͘ϴϬ ĂŶĚ Ϭ͘ϳϵ ŝŶ ĐŽůŽŶ ĂŶĚ ƌĞĐƚĂů ĐĂŶĐĞƌ͕  ƌĞƐƉĞĐƟǀĞůǇ͘
ŽƌƌĞƐƉŽŶĚŝŶŐ ŝŶĚŝĐĞƐ ĨŽƌ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ǁĞƌĞ Ϭ͘ϲϵ ĂŶĚ Ϭ͘ϲϳ͕ ƌĞƐƉĞĐƟǀĞůǇ͘ DŽĚĞů




day mortality and overall survival and aid to clinical decision-making for tailored treatment 
ŝŶĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͘
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INTRODUCTION
Colorectal cancer is one of the most frequent cancers in the Netherlands with more than 
ϭϱ͕ϬϬϬŶĞǁůǇĚŝĂŐŶŽƐĞĚĐĂƐĞƐŝŶϮϬϭϱ͘/ƚŝƐĂůƐŽŽŶĞŽĨƚŚĞŵŽƐƚĨƌĞƋƵĞŶƚĐĂƵƐĞƐŽĨĐĂŶĐĞƌ
ĚĞĂƚŚǁŝƚŚĂƉƉƌŽǆŝŵĂƚĞůǇϰ͕ϵϬϬĚĞĂƚŚƐŝŶϮϬϭϰ͘1dŚĞĐŽƌŶĞƌƐƚŽŶĞŽĨĐƵƌĂƟǀĞƚƌĞĂƚŵĞŶƚ
ĨŽƌ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ŝƐ ƐƵƌŐŝĐĂů ƌĞƐĞĐƟŽŶ͘ ^ƵƌŐĞƌǇ ĨŽƌ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŚĂƐ Ă
ŚŝŐŚůǇǀĂƌŝĂďůĞƌŝƐŬŽĨŵŽƌƚĂůŝƚǇǁŝƚŚŝŶƚŚĞĮƌƐƚƚŚƌĞĞŵŽŶƚŚƐƉŽƐƚŽƉĞƌĂƟǀĞůǇĚĞƉĞŶĚŝŶŐ
ŽŶ ƚŚĞƌŝƐŬƉƌŽĮůĞŽĨ ƚŚĞ ŝŶĚŝǀŝĚƵĂůƉĂƟĞŶƚ͘&ĂĐƚŽƌƐ ƚŚĂƚ ŝŶŇƵĞŶĐĞ ůŽŶŐͲƚĞƌŵƉƌŽŐŶŽƐŝƐ












used for the development of a web-based calculator or user-friendly graphical interfaces. 
DĂŶǇƉƌĞǀŝŽƵƐƐƚƵĚŝĞƐůĞĚƚŽĂƐƵĐĐĞƐƐĨƵůĂƉƉůŝĐĂƟŽŶŽĨƉƌĞĚŝĐƟŽŶŵŽĚĞůƐĨŽƌŽŶĐŽůŽŐǇ
ƉƌŽŐŶŽƐƟĐƐ͘11-16
WƌŽŐŶŽƐƟĐ ŵŽĚĞůƐ ƚŽ ƉƌĞĚŝĐƚ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ĂŵŽŶŐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĂƌĞ
scarce.17-20&ƵƌƚŚĞƌŵŽƌĞ͕ĐƵƌƌĞŶƚůǇĂǀĂŝůĂďůĞƉƌĞĚŝĐƟŽŶŵŽĚĞůƐĨŽƌƉŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇ
ŝŶĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐŚĂǀĞƐĞǀĞƌĂů ůŝŵŝƚĂƟŽŶƐ͘DŽƐƚƉƌĞĚŝĐƟŽŶŵŽĚĞůƐƵƐĞĚƚŚĞ
ŽƵƚĐŽŵĞ ƉŽƐƚŽƉĞƌĂƟǀĞ ϯϬͲĚĂǇ ŵŽƌƚĂůŝƚǇ͕  ŝŶƐƚĞĂĚ ŽĨ ƉŽƐƚŽƉĞƌĂƟǀĞ ϵϬͲĚĂǇ ŵŽƌƚĂůŝƚǇ͘
^ƚƵĚŝĞƐŚĂǀĞƐŚŽǁŶƚŚĂƚĂƐƵďƐƚĂŶƟĂůƉƌŽƉŽƌƟŽŶŽĨƐŚŽƌƚͲƚĞƌŵŵŽƌƚĂůŝƚǇŽĐĐƵƌƐďĞƚǁĞĞŶ




dŚĞ Ăŝŵ ŽĨ ƚŚŝƐ ƐƚƵĚǇ ǁĂƐ ƚŽ ĚĞǀĞůŽƉ ĂŶĚ ǀĂůŝĚĂƚĞ ƉƌĞĚŝĐƟŽŶ ŵŽĚĞůƐ ƚŽ ĞƐƟŵĂƚĞ
ƉŽƐƚŽƉĞƌĂƟǀĞϵϬͲĚĂǇŵŽƌƚĂůŝƚǇĂŶĚϱͲǇĞĂƌŽǀĞƌĂůůƐƵƌǀŝǀĂůĨŽƌƐƚĂŐĞ/Ͳ///ĐŽůŽŶĂŶĚƌĞĐƚĂů
ĐĂŶĐĞƌƉĂƟĞŶƚƐ͘dŚĞƉŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇƉƌĞĚŝĐƟŽŶŵŽĚĞůǁĂƐĚĞƐŝŐŶĞĚƚŽƉƌĞĚŝĐƚ








ŵĂŶĂŐĞĚ ďǇ ƚŚĞ EĞƚŚĞƌůĂŶĚƐ ŽŵƉƌĞŚĞŶƐŝǀĞ ĂŶĐĞƌ KƌŐĂŶŝƐĂƟŽŶ ;/<E>Ϳ͘ /ŶĨŽƌŵĂƟŽŶ
ŽŶ ƉĂƟĞŶƚ ĂŶĚ ƚƵŵŽƵƌ ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ͕ ĚŝĂŐŶŽƐŝƐ ĂŶĚ ƚƌĞĂƚŵĞŶƚ ŝƐ ƌŽƵƟŶĞůǇ ĞǆƚƌĂĐƚĞĚ






















set to 20. 
WŽƚĞŶƟĂů ƉƌĞĚŝĐƚŽƌƐ ǁĞƌĞ ƉƌĞƐĞůĞĐƚĞĚ ďĂƐĞĚ ŽŶ ĐůŝŶŝĐĂů ƌĞĂƐŽŶŝŶŐ ĂŶĚ ĞǀŝĚĞŶĐĞ ĨƌŽŵ
ƉƌĞǀŝŽƵƐ ƐƚƵĚŝĞƐ͕ ŝŶƐƚĞĂĚ ŽĨ ŽďƐĞƌǀĞĚ ƐŝŐŶŝĮĐĂŶƚ ƌĞůĂƟŽŶƐ ǁŝƚŚ ŽƵƚĐŽŵĞ ǀĂƌŝĂďůĞƐ ŝŶ
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dŽƌĞĚƵĐĞƚŚĞŶƵŵďĞƌŽĨƉƌĞĚŝĐƚŽƌƐŝŶƚŚĞŵŽĚĞůƐ͕ďĂĐŬǁĂƌĚƐƚĞƉǁŝƐĞĚĞůĞƟŽŶǁĂƐĂƉƉůŝĞĚ
based on the Wald test. A liberal PǀĂůƵĞŽĨϬ͘ϮϬǁĂƐƵƐĞĚĂƐƌĞĐŽŵŵĞŶĚĞĚďǇƉƌĞĚŝĐƟŽŶ
modelling guidelines.31EŽŶͲƐŝŐŶŝĮĐĂŶƚǀĂƌŝĂďůĞƐǁĞƌĞŝŶĐůƵĚĞĚŝĨƚŚĞǇŝŵƉƌŽǀĞĚĂĐĐƵƌĂĐǇ
of the model. 
DƵůƟǀĂƌŝĂďůĞ ůŽŐŝƐƟĐ ƌĞŐƌĞƐƐŝŽŶ ĂŶĂůǇƐĞƐ ǁĞƌĞ ƵƐĞĚ ƚŽ ĚĞǀĞůŽƉ Ă ƉƌĞĚŝĐƟŽŶ ŵŽĚĞů
ĨŽƌ ƉŽƐƚŽƉĞƌĂƟǀĞ ϵϬͲĚĂǇ ŵŽƌƚĂůŝƚǇ͘ Žǆ ƉƌŽƉŽƌƟŽŶĂů ŚĂǌĂƌĚ ŵŽĚĞůƐ ǁĞƌĞ ƵƐĞĚ ƚŽ





Assessment of model performance
DŽĚĞůƉĞƌĨŽƌŵĂŶĐĞǁĂƐƋƵĂŶƟĮĞĚŝŶƚŚĞŵŽĚĞůŝŶŐŐƌŽƵƉƐǁŝƚŚƌĞƐƉĞĐƚƚŽĚŝƐĐƌŝŵŝŶĂƟŽŶ
ĂŶĚĐĂůŝďƌĂƟŽŶ͘dŚĞƌŝĞƌƐĐŽƌĞǁĂƐƵƐĞĚĂƐĂŶŽǀĞƌĂůůƉĞƌĨŽƌŵĂŶĐĞŵĞĂƐƵƌĞƚŽĐĂůĐƵůĂƚĞ
ƚŚĞ ĚŝƐĂŐƌĞĞŵĞŶƚ ďĞƚǁĞĞŶ ĞǆƉĞĐƚĞĚ ƌĂƚĞƐ ĂŶĚ ƚŚĞ ďŝŶĂƌǇ ǀĂƌŝĂďůĞ ƉŽƐƚŽƉĞƌĂƟǀĞ ϵϬͲ
day mortality. A Brier score of 0 indicates a perfect model, while 0.25 indicates a 
ŶŽŶͲŝŶĨŽƌŵĂƟǀĞ ŵŽĚĞů͘ &Žƌ ƚŚĞ ŽƵƚĐŽŵĞ ŵĞĂƐƵƌĞ ƉŽƐƚŽƉĞƌĂƟǀĞ ϵϬͲĚĂǇ ŵŽƌƚĂůŝƚǇ͕ 
ĚŝƐĐƌŝŵŝŶĂƟŽŶǁĂƐĂƐƐĞƐƐĞĚďǇĐĂůĐƵůĂƟŶŐƚŚĞĂƌĞĂƵŶĚĞƌƚŚĞƌĞĐĞŝǀĞƌŽƉĞƌĂƟŶŐĐƵƌǀĞ









/ŶƚĞƌŶĂůǀĂůŝĚŝƚǇŽĨƚŚĞŵŽĚĞůƐǁĂƐĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐďŽŽƚƐƚƌĂƉƚĞĐŚŶŝƋƵĞƐ͘32, 35 Random 
ďŽŽƚƐƚƌĂƉƐĂŵƉůĞƐǁĞƌĞĚƌĂǁŶǁŝƚŚƌĞƉůĂĐĞŵĞŶƚĨƌŽŵƚŚĞŵŽĚĞůŝŶŐƐĞƚ;Ŷсϭ͕ϬϬϬͿ͘ŌĞƌ
ŝŶƚĞƌŶĂů ǀĂůŝĚĂƟŽŶ͕ ƚŚĞ ƌĞŐƌĞƐƐŝŽŶ ĐŽĞĸĐŝĞŶƚƐ ǁĞƌĞ ĐŽƌƌĞĐƚĞĚ ĨŽƌ ŽƉƟŵŝƐŵ ǁŝƚŚ ƚŚĞ
ŚĞƵƌŝƐƟĐƐŚƌŝŶŬĂŐĞĨĂĐƚŽƌɶŽĨǀĂŶ,ŽƵǁĞůŝŶŐĞŶĂŶĚůĞĞƐƐŝĞ͘36 This makes it more likely 
ƚŚĂƚƚŚĞŵŽĚĞůǁŝůůďĞƐƚǁŝƚŚŚŽůĚŝŶĨƵƚƵƌĞƐƚƵĚŝĞƐǁŝƚŚƐŝŵŝůĂƌƐĞƫŶŐƐĂŶĚƉĂƟĞŶƚƐ͘35
ǆƚĞƌŶĂůǀĂůŝĚĂƟŽŶǁĂƐƉĞƌĨŽƌŵĞĚďǇƌĞŐƌĞƐƐŝŽŶĂŶĂůǇƐĞƐŽŶƚŚĞǀĂůŝĚĂƟŽŶĐŽŚŽƌƚƐ͘dŚĞ





TABLE 1 WĂƟĞŶƚ ĂŶĚ ƚƵŵŽƵƌ ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ ŽĨ ƚŚĞ ĞůŝŐŝďůĞ ƉĂƟĞŶƚƐ ďǇ ƚƵŵŽƵƌ ůŽĐĂůŝǌĂƟŽŶ 
 ;ŶсϲϬ͕ϳϰϰͿ͘
Colon Rectum
Variable n йŽĨƚŽƚĂů  n йŽĨƚŽƚĂů
Total 43,551 17,193
Gender
   Male 22,473 52 10,775 63
   Female 21,092 48 6,418 37
ŐĞ;ǇĞĂƌƐ͖ŵĞĂŶц^Ϳ ϳϬ͘ϴцϭϭ͘Ϭ ϲϲ͘ϵцϭϬ͘ϵ
Pathological T stage
   T1 3,685 8 2,820 16
   T2 7,312 17 5,752 34
   T3 26,483 61 7,967 46
   T4 6,071 14 646 4
Pathological N stage
   N0 27,557 64 11,581 68
   N1 10,540 24 3,849 22
   N2 5,240 12 1,703 10
WŽƐƚŽƉĞƌĂƟǀĞϵϬͲĚĂǇŵŽƌƚĂůŝƚǇ 2,368 5 563 3
Vital status
   Alive 29,221 67 12,453 72
   Deceased 14,344 33 4,740 28
&ŽůůŽǁͲƵƉ;ŵŽŶƚŚƐ͖ŵĞĚŝĂŶ;/YZͿͿ ϰϴ͘Ϯ;Ϯϵ͘ϲͲϳϮ͘ϳͿ  ϱϭ͘ϴ;ϯϯ͘ϯͲϳϱ͘ϮͿ
RESULTS
ĞƚǁĞĞŶϮϬϬϴĂŶĚϮϬϭϰ͕ϲϬ͕ϳϱϴƉĂƟĞŶƚƐƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĨŽƌƉƌŝŵĂƌǇŶŽŶͲ
ŵĞƚĂƐƚĂƟĐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͗ ϰϯ͕ϱϲϱ ĐŽůŽŶ ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĂŶĚ ϭϳ͕ϭϵϯ ƌĞĐƚĂů ĐĂŶĐĞƌ
ƉĂƟĞŶƚƐ͘WĂƟĞŶƚĂŶĚƚƵŵŽƵƌĐŚĂƌĂĐƚĞƌŝƐƟĐƐĂƌĞĚŝƐƉůĂǇĞĚŝŶdĂďůĞϭĨŽƌĐŽůŽŶĂŶĚƌĞĐƚĂů
cancer separately. Table 2 shows that random sampling provided well-balanced groups. 
The number of missing values per predictor variable is also presented. 
ƵĞƚŽŚŝŐŚĐŽƌƌĞůĂƟŽŶďĞƚǁĞĞŶ͚dͲƐƚĂŐĞ͛ĂŶĚ͚ĂĚĚŝƟŽŶĂůƌĞƐĞĐƟŽŶ͕͛ ĂŶĚŚŝŐŚĞƌŝŶŇƵĞŶĐĞ
ŽĨ ͚dͲƐƚĂŐĞ͛ ŽŶ ƚŚĞ ƌŝƐŬ ŽĨ ƉŽƐƚŽƉĞƌĂƟǀĞ ŵŽƌƚĂůŝƚǇ͕  ͚ĂĚĚŝƟŽŶĂů ƌĞƐĞĐƟŽŶ͛ ǁĂƐ ŽŵŝƩĞĚ
ĨƌŽŵ ƚŚĞ ŵŽĚĞůƐ͘ DŽƌĞŽǀĞƌ͕  ͚ƚǇƉĞ ŽĨ ƐƵƌŐĞƌǇ͛ ĂŵŽŶŐ ĐŽůŽŶ ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ƐŚŽǁĞĚ
ŚŝŐŚĐŽƌƌĞůĂƟŽŶǁŝƚŚƚŚĞ͚ƉƌĞƐĞŶĐĞŽĨŵƵůƟƉůĞƚƵŵŽƵƌƐ͕͛ ƚŚĞƌĞĨŽƌĞƚŚĞƐĞǀĂƌŝĂďůĞƐǁĞƌĞ
ĐŽŵďŝŶĞĚ͘/ŶĐůƵƐŝŽŶŽĨŝŶƚĞƌĂĐƟŽŶƚĞƌŵƐĚŝĚŶŽƚŝŵƉƌŽǀĞƚŚĞŵŽĚĞů͘
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WÊÝãÊÖÙã®òϵϬͲùÃÊÙã½®ãù
ŌĞƌ ďĂĐŬǁĂƌĚ ĞůŝŵŝŶĂƟŽŶ͕ ƚŚĞ ĨŽůůŽǁŝŶŐ ƉƌĞĚŝĐƚŽƌƐ ǁĞƌĞ ĂĚĚĞĚ ŝŶ ƚŚĞ ŵŽĚĞů ĨŽƌ
ĐŽůŽŶĐĂŶĐĞƌƉĂƟĞŶƚƐ͗ ŐĞŶĚĞƌ͖ĂŐĞ͖ƉĂƚŚŽůŽŐŝĐĂů dͲƐƚĂŐĞ͖ƉĂƚŚŽůŽŐŝĐĂůEͲƐƚĂŐĞ͖ƵƌŐĞŶĐǇ
ŽĨ ƌĞƐĞĐƟŽŶ͖ ƐƵƌŐŝĐĂů ĂƉƉƌŽĂĐŚ ;ůĂƉĂƌŽƐĐŽƉŝĐ ǀĞƌƐƵƐŽƉĞŶͿ͖ ƚǇƉĞŽĨ ƐƵƌŐĞƌǇ ;ƐĞŐŵĞŶƚĂů
ǀĞƌƐƵƐƐƵďƚŽƚĂůͿĐŽŵďŝŶĞĚǁŝƚŚƉƌĞƐĞŶĐĞŽĨŵƵůƟƉůĞƚƵŵŽƵƌƐĂŶĚĂŶĂƐƚŽŵŽƟĐůĞĂŬĂŐĞ
;ĂŵŽŶŐƉĂƟĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶǁŝƚŚƉƌŝŵĂƌǇĂŶĂƐƚŽŵŽƐŝƐͿ͘&ŽƌƌĞĐƚĂů
ĐĂŶĐĞƌ͕  ƉƌĞĚŝĐƚŽƌƐ ĐŽŶƐƟƚƵƟŶŐ ƚŚĞĮŶĂůŵŽĚĞůǁĞƌĞ ŐĞŶĚĞƌ͖ ĂŐĞ͖ ƉĂƚŚŽůŽŐŝĐĂů dͲƐƚĂŐĞ͖
ƉĂƚŚŽůŽŐŝĐĂů EͲƐƚĂŐĞ͖ ƐƵƌŐŝĐĂů ĂƉƉƌŽĂĐŚ͖ ƚǇƉĞ ŽĨ ƐƵƌŐĞƌǇ ĂŶĚ ĂŶĂƐƚŽŵŽƟĐ ůĞĂŬĂŐĞ͘
ŽƌƌĞƐƉŽŶĚŝŶŐŽĚĚƐƌĂƟŽƐ;KZͿĂŶĚƌĞŐƌĞƐƐŝŽŶĐŽĞĸĐŝĞŶƚƐĂƌĞůŝƐƚĞĚŝŶdĂďůĞϯ͘
















ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ͗ ŐĞŶĚĞƌ͖ ĂŐĞ͖ ƚƵŵŽƵƌ ƐƚĂŐĞ͖ ƵƌŐĞŶĐǇ ŽĨ ƌĞƐĞĐƟŽŶ͖ ƚƵŵŽƵƌ ůŽĐĂƟŽŶ͕





Performance was assessed for the modelling groups for colon and rectal cancer. The 
ͲŝŶĚĞǆ ǁĂƐ Ϭ͘ϲϵ ĨŽƌ ĐŽůŽŶ ĐĂŶĐĞƌ ĂŶĚ Ϭ͘ϲϳ ĨŽƌ ƌĞĐƚĂů ĐĂŶĐĞƌ͕  ǁŚŝĐŚ ŝŶĚŝĐĂƚĞƐ ŐŽŽĚ
ĚŝƐĐƌŝŵŝŶĂƟǀĞĂďŝůŝƚǇ͘
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ƚƵŵŽƵƌ͕  ƵƌŐĞŶĐǇ ŽĨ ƌĞƐĞĐƟŽŶ ;ĐŽůŽŶ ĐĂŶĐĞƌͿ͕ ƚƵŵŽƵƌ ůŽĐĂƟŽŶ ;ĐŽůŽŶ ĐĂŶĐĞƌͿ͕ ĂĚũƵǀĂŶƚ
ĐŚĞŵŽƚŚĞƌĂƉǇ ;ƐƚĂŐĞ /// ĐŽůŽŶ ĐĂŶĐĞƌͿ͕ ƉƌĞƐĞŶĐĞ ŽĨ ŵƵůƟƉůĞ ƚƵŵŽƵƌƐ ;ĐŽůŽŶ ĐĂŶĐĞƌͿ͕








are scarce and are focused on advanced colorectal cancer.17, 18, 20 On the contrary, a wide 
ǀĂƌŝĞƚǇ ŽĨ ƌŝƐŬ ƉƌĞĚŝĐƟŽŶ ŵŽĚĞůƐ ƚŽ ƉƌĞĚŝĐƚ ƉŽƐƚŽƉĞƌĂƟǀĞ ŵŽƌƚĂůŝƚǇ ĂŵŽŶŐ ĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌƉĂƟĞŶƚƐŚĂƐďĞĞŶĚĞǀĞůŽƉĞĚŝŶƚŚĞƉĂƐƚĚĞĐĂĚĞƐ͘24, 37-42 One of the largest previous 
ŵŽĚĞůƐƚŽƉƌĞĚŝĐƚƉŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇǁĂƐĚĞǀĞůŽƉĞĚŝŶϮϬϭϮ͕ ŝŶĐůƵĚŝŶŐŵŽƌĞƚŚĂŶ
ϵϬϬ͕ϬϬϬƉĂƟĞŶƚƐƵŶĚĞƌŐŽŝŶŐĐŽůŽŶŽƌƌĞĐƚĂůƌĞƐĞĐƟŽŶ͕ŽĨǁŚŽŵŽŶĞͲƚŚŝƌĚŚĂĚĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌ͘  ^ĞǀĞƌĂů ŽƚŚĞƌ ƌŝƐŬ ƉƌĞĚŝĐƟŽŶ ŵŽĚĞůƐ ĂƌĞ ĂǀĂŝůĂďůĞ ƚŽ ĐĂůĐƵůĂƚĞ ƉŽƐƚŽƉĞƌĂƟǀĞ
ŵŽƌƚĂůŝƚǇ ĂŵŽŶŐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ƵŶĚĞƌŐŽŝŶŐ ƐƵƌŐĞƌǇ͕  ůŝŬĞ ƚŚĞ WK^^hD͕
WͲWK^^hD͕ZͲWK^^hD͕W'/ĂŶĚƚŚĞ&ͲZƐĐŽƌŝŶŐƐǇƐƚĞŵ͘24, 40, 41, 43 These models 
ĞŝƚŚĞƌƵƐĞĚƉŽƐƚŽƉĞƌĂƟǀĞϯϬͲĚĂǇŵŽƌƚĂůŝƚǇŽƌ ŝŶͲŚŽƐƉŝƚĂůŵŽƌƚĂůŝƚǇĂƐĂŶŽƵƚĐŽŵĞĂŶĚ
ǁĞƌĞĚĞǀĞůŽƉĞĚ ƚŽƵƐĞ ŝŶ ĂƉƌĞŽƉĞƌĂƟǀĞ ƐĞƫŶŐ͘tĞĚĞǀĞůŽƉĞĚŵŽĚĞůƐ ƚŽďĞƵƐĞĚ ŝŶ
ĂƉŽƐƚŽƉĞƌĂƟǀĞƐĞƫŶŐĂŶĚƵƐĞĚƉŽƐƚŽƉĞƌĂƟǀĞϵϬͲĚĂǇŵŽƌƚĂůŝƚǇĂƐĂŶĞŶĚƉŽŝŶƚĨŽƌŽƵƌ
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was appropriately large, as a minimum of 100 events and 100 nonevents was suggested 
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the performance parameters calculated with complete case analysis with the imputed 
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Survival stratified by predicted and observed probabilities
Modelling set Validation set
SUPPLEMENTARY FIGURE 2 ĂůŝďƌĂƟŽŶ ŽĨ ƚŚĞ Žǆ ŵŽĚĞůƐ ŝŶ ƚŚĞ ŵŽĚĞůůŝŶŐ ĂŶĚ ǀĂůŝĚĂƟŽŶ
ĚĂƚĂƐĞƚƐĨŽƌĐŽůŽŶ;ĂͿĂŶĚƌĞĐƚĂů;ďͿĐĂŶĐĞƌƚŽƉƌĞĚŝĐƚϱͲǇĞĂƌƐŽǀĞƌĂůů
ƐƵƌǀŝǀĂů͘ ĂƐŚĞĚ ůŝŶĞƐ ƌĞƉƌĞƐĞŶƚ ƉƌĞĚŝĐƚĞĚ ƐƵƌǀŝǀĂů ƉƌŽďĂďŝůŝƟĞƐ͕
ĂŶĚ ǀĞƌƟĐĂů ĐĂƉƉĞĚ ůŝŶĞƐ ĚĞŶŽƚĞ <ĂƉůĂŶͲDĞŝĞƌ ĞƐƟŵĂƚĞƐ ǁŝƚŚ
ϵϱйĐŽŶĮĚĞŶĐĞ ŝŶƚĞƌǀĂůƐ͘dŚƌĞĞƉƌŽŐŶŽƐŝƐŐƌŽƵƉƐĂƌĞƉůŽƩĞĚ͗ ƚŚĞ
͞'ŽŽĚ͟ ŐƌŽƵƉ ;ĚĂƌŬĞƐƚ ůŝŶĞƐͿ͕ ƚŚĞ ͞/ŶƚĞƌŵĞĚŝĂƚĞ͟ŐƌŽƵƉ ;ŵĞĚŝƵŵͲ
ĚĂƌŬůŝŶĞƐͿ͕ĂŶĚƚŚĞ͞WŽŽƌ͟ŐƌŽƵƉ;ƉĂůĞƌůŝŶĞƐͿ͘
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SUPPLEMENTARY FIGURE 3 WƌŝŶƚƐĐƌĞĞŶĨƌŽŵƚŚĞŶŽŵŽŐƌĂŵ͕ƉƌŽǀŝĚŝŶŐƚŚĞƌŝƐŬŽĨƉŽƐƚŽƉĞƌĂƟǀĞ
90-day mortality

Timing of adjuvant chemotherapy 
ĂŶĚŝƚƐƌĞůĂƟŽŶƚŽƐƵƌǀŝǀĂůĂŵŽŶŐ
ƉĂƟĞŶƚƐǁŝƚŚƐƚĂŐĞ///ĐŽůŽŶĐĂŶĐĞƌ
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KƵƌ ĚĂƚĂ ƐƵƉƉŽƌƚ ŝŶŝƟĂƟŶŐ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ŝŶ ƐƚĂŐĞ /// ĐŽůŽŶ ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ
within 8 weeks post-surgery.
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INTRODUCTION





ŚŽǁĞǀĞƌ͕ ƌĞƐƵůƚƐƐŚŽǁĞĚƚŚĂƚ ŝŶĚĂŝůǇĐůŝŶŝĐĂůƉƌĂĐƟĐĞĚĞůĂǇƐ ŝŶĐŽŵŵĞŶĐŝŶŐƚƌĞĂƚŵĞŶƚ
may occur.7-9
dŚĞ ŐƵŝĚĞůŝŶĞƐ ĨƌŽŵ ƚŚĞ ƵƌŽƉĞĂŶ ^ŽĐŝĞƚǇ ĨŽƌ DĞĚŝĐĂů KŶĐŽůŽŐǇ ;^DKͿ ƌĞĐŽŵŵĞŶĚ
ĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇƐŚŽƵůĚƐƚĂƌƚĂƐĞĂƌůǇĂƐƉŽƐƐŝďůĞƐƚĂƌƟŶŐĨƌŽŵƚŚĞĨŽƵƌƚŚǁĞĞŬ
ƵƉƚŽĂŵĂǆŝŵƵŵŽĨϴͲϭϮǁĞĞŬƐƉŽƐƚͲƐƵƌŐĞƌǇ͘ /Ĩ ƚŚĞƐƚĂƌƚŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ ŝƐ
delayed for more than 12 weeks, treatment should be given on the basis of an individual 
ĚĞĐŝƐŝŽŶƚĂŬŝŶŐŝŶƚŽĂĐĐŽƵŶƚƚŚĞƌĞůĂƟǀĞůǇůŝŵŝƚĞĚůŝŬĞůŝŚŽŽĚŽĨďĞŶĞĮƚĂŐĂŝŶƐƚƚŚĞƉŽƚĞŶƟĂů
ƚŽǆŝĐŝƚǇ͘10 The Dutch guideline for the treatment of colorectal cancer 2014 recommends 
ƚŚĂƚĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇƐŚŽƵůĚƐƚĂƌƚďĞƚǁĞĞŶϲĂŶĚϴǁĞĞŬƐĂŌĞƌƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶ͕
ĂŶĚĐĞƌƚĂŝŶůǇǁŝƚŚŝŶϭϮǁĞĞŬƐĨŽůůŽǁŝŶŐƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶ͘11
^ĞǀĞƌĂů ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚŝĞƐ ŚĂǀĞ ƐŚŽǁŶ ƚŚĂƚ Ă ĚĞůĂǇĞĚ ŝŶŝƟĂƟŽŶ ŽĨ ĂĚũƵǀĂŶƚ
chemotherapy is associated with an unfavourable long-term overall survival, cancer-
ƐƉĞĐŝĮĐƐƵƌǀŝǀĂůĂŶĚĚŝƐĞĂƐĞͲĨƌĞĞƐƵƌǀŝǀĂů͘12-17 Results from a meta-analysis has indicated 
ƚŚĂƚƚŚĞƌĞůĂƟǀĞŽǀĞƌĂůůƐƵƌǀŝǀĂůĚĞĐƌĞĂƐĞĚďǇĞǀĞƌǇϰͲǁĞĞŬĚĞůĂǇŝŶƚŚĞĂĚŵŝŶŝƐƚƌĂƟŽŶŽĨ
adjuvant chemotherapy.18 However, in this meta-analysis there was heterogeneity among 
ƚŚĞĚŝīĞƌĞŶƚƐƚƵĚŝĞƐŝŶƚŚĞĐƵƚͲŽīƉŽŝŶƚƐĨŽƌƚŚĞƟŵŝŶŐŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ͕ ƌĂŶŐŝŶŐ
ĨƌŽŵϴǁĞĞŬƐ ƚŽŵŽƌĞƚŚĂŶϭϮǁĞĞŬƐ͕ĂƐǁĞůůĂƐ ŝŶ ƚŚĞƉƌŝŵĂƌǇ ůŽĐĂƟŽŶ ;ĐŽůŽŶǀĞƌƐƵƐ
ƌĞĐƚƵŵͿĂŶĚƐƚĂŐĞŽĨĚŝƐĞĂƐĞ;//ǀĞƌƐƵƐ///Ϳ͘
sĂƌŝŽƵƐƉĂƟĞŶƚĂŶĚ ƚƵŵŽƵƌĐŚĂƌĂĐƚĞƌŝƐƟĐƐŵĂǇĂĐƚĂƐ ŝŶŇƵĞŶĐŝŶŐ ĨĂĐƚŽƌƐ ĨŽƌƟŵŝŶŐŽĨ
adjuvant chemotherapy, including age, comorbidity, tumour grade, tumour size and 





ĞĂƌůǇ ;ŝ͘Ğ͘ ϰͲϲ ǁĞĞŬƐ ƉŽƐƚͲƐƵƌŐĞƌǇͿ ŝƐ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ďĞƩĞƌ ŽƵƚĐŽŵĞƐ ƚŚĂŶ ƐƚĂƌƟŶŐ
ƐŽŵĞǁŚĂƚůĂƚĞƌ͕ ŐŝǀŝŶŐƚŚĞƉĂƟĞŶƚŵŽƌĞƟŵĞƚŽƌĞĐŽǀĞƌĨƌŽŵƐƵƌŐĞƌǇ͘/ƌƌĞƐƉĞĐƟǀĞŽĨƚŚĞƐĞ
ƵŶĐĞƌƚĂŝŶƟĞƐ͕ƚŚĞƟŵŝŶŐŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇŝƐŽŌĞŶƵƐĞĚĂƐĂƋƵĂůŝƚǇŝŶĚŝĐĂƚŽƌ͘ 20 
tĞ ĂŶĂůǇǌĞĚ ĚĂƚĂ ĨƌŽŵ Ă ůĂƌŐĞ͕ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ĐĂŶĐĞƌ ƌĞŐŝƐƚƌǇ ŽĨ ƉĂƟĞŶƚƐǁŚŽ ĂƌĞ







ƌĞŐŝƐƚƌǇ ďĂƐĞĚ ŽŶ ŶŽƟĮĐĂƟŽŶ ŽĨ Ăůů ŶĞǁůǇ ĚŝĂŐŶŽƐĞĚŵĂůŝŐŶĂŶĐŝĞƐ ŝŶ ƚŚĞEĞƚŚĞƌůĂŶĚƐ

















tĞ ƐĞůĞĐƚĞĚ Ăůů ƉĂƟĞŶƚƐ ǁŝƚŚ ĐŽůŽŶ ĐĂŶĐĞƌ ĂŶĚ ůǇŵƉŚ ŶŽĚĞŵĞƚĂƐƚĂƐĞƐ͕ ďƵƚ ǁŝƚŚŽƵƚ
ĚŝƐƚĂŶƚ ŵĞƚĂƐƚĂƐĞƐ Ăƚ ƉƌĞƐĞŶƚĂƟŽŶ ;ƐƚĂŐĞ ///Ϳ͕ ĚŝĂŐŶŽƐĞĚ ŝŶ dŚĞ EĞƚŚĞƌůĂŶĚƐ ŝŶ ϮϬϬϴͲ
ϮϬϭϯǁŚŽƵŶĚĞƌǁĞŶƚƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĂŶĚƌĞĐĞŝǀĞĚĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ;&ŝŐƵƌĞϭͿ͘
WĂƟĞŶƚƐǁĞƌĞĞǆĐůƵĚĞĚ ŝĨ ƚŚĞǇŚĂĚ ƌĞĐĞŝǀĞĚ ůŽĐĂů ĐŚĞŵŽƚŚĞƌĂƉǇ ;ŶсϰͿ Žƌ ŶĞŽĂĚũƵǀĂŶƚ
ĐŚĞŵŽƚŚĞƌĂƉǇ;ŶсϯϭͿ͘ /ŶĂĚĚŝƟŽŶ͕ƉĂƟĞŶƚƐǁĞƌĞĞǆĐůƵĚĞĚŝĨƚŚĞĚĂƚĞŽĨĐŚĞŵŽƚŚĞƌĂƉǇ
ŝŶŝƟĂƟŽŶǁĂƐŵŝƐƐŝŶŐ ;Ŷсϭ͕ϬϱϭͿ Žƌ ŝĨ ĐŚĞŵŽƚŚĞƌĂƉǇǁĂƐ ƐƚĂƌƚĞĚŵŽƌĞ ƚŚĂŶ ϭϲǁĞĞŬƐ





ĐŚĞŵŽƚŚĞƌĂƉǇǁĂƐ ĂǀĂŝůĂďůĞ ĨŽƌ Ă ƐƵďŐƌŽƵƉŽĨ ƉĂƟĞŶƚƐ ;ŶсϳϮϱͿ ĂŶĚǁĞƌĞ ŝŶĐůƵĚĞĚ ĂƐ
ĂƐƵďŐƌŽƵƉĂŶĂůǇƐŝƐ͘WĂƟĞŶƚƐŽĨǁŚŽŵŝŶĨŽƌŵĂƟŽŶŽŶƉƌŽůŽŶŐĞĚƉŽƐƚŽƉĞƌĂƟǀĞŚŽƐƉŝƚĂů
ĂĚŵŝƐƐŝŽŶǁĂƐ ĂǀĂŝůĂďůĞ ;ŶсϮ͕ϱϴϰͿǁĞƌĞ ŝŶĐůƵĚĞĚ ĂƐ Ă ƐƵďŐƌŽƵƉ ĂŶĂůǇƐŝƐ͘ ĚĚŝƟŽŶĂůůǇ͕ 
ƉĂƟĞŶƚƐ ǁŚŽ ƵŶĚĞƌǁĞŶƚ ƐƵƌŐŝĐĂů ƌĞƐĞĐƟŽŶ ǁŝƚŚŽƵƚ ƌĞĐĞŝǀŝŶŐ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ
were included in the crude survival analyses to show overall survival of this group 
;Ŷсϰ͕ϴϵϵ͖ƚŽƚĂůŶсϭϭ͕ϱϭϵͿ͘




















^ƚĂŐĞ ǁĂƐ ďĂƐĞĚ ŽŶ ƚŚĞ ƉĂƚŚŽůŽŐŝĐĂů dED ĐůĂƐƐŝĮĐĂƟŽŶ͘ dƵŵŽƵƌ ůŽĐĂůŝǌĂƟŽŶ ǁĂƐ
ĐĂƚĞŐŽƌŝǌĞĚŝŶƚŽƚŚƌĞĞƐƵďƐŝƚĞƐ͗ƉƌŽǆŝŵĂůĐŽůŽŶ;ϭϴ͘ϬͲϭϴ͘ϱͿ͕ĚŝƐƚĂůĐŽůŽŶ;ϭϴ͘ϲͲϭϴ͘ϳͿ
ĂŶĚ ĐŽůŽŶŽƚŚĞƌͬŶŽƚŽƚŚĞƌǁŝƐĞ ƐƉĞĐŝĮĞĚ ;ϭϴ͘ϴͲϭϴ͘ϵͿ͘ WĂƟĞŶƚƐǁĞƌĞĚŝǀŝĚĞĚ ŝŶƚŽĂŐĞ





ŝīĞƌĞŶĐĞƐ ŝŶ ĐůŝŶŝĐĂů͕ ƉĂƚŚŽůŽŐŝĐĂů ĂŶĚ ƚƌĞĂƚŵĞŶƚͲƌĞůĂƚĞĚ ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ ĂĐƌŽƐƐ ƚŚĞ
ĚŝīĞƌĞŶƚ ƟŵŝŶŐƐ ŽĨ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ǁĞƌĞ ĞǀĂůƵĂƚĞĚ ƵƐŝŶŐ ĐŚŝͲƐƋƵĂƌĞĚ ƚĞƐƚƐ͘
DƵůƟǀĂƌŝĂďůĞ ůŽŐŝƐƟĐ ƌĞŐƌĞƐƐŝŽŶ ĂŶĂůǇƐŝƐ ǁĂƐ ĐŽŶĚƵĐƚĞĚ ƚŽ ĂƐƐĞƐƐ ƚŚĞ ŝŶĚĞƉĞŶĚĞŶƚ
ŝŶŇƵĞŶĐĞ ŽĨ ƐĞǀĞƌĂů ƉĂƟĞŶƚ ĂŶĚ ĐůŝŶŝĐĂů ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ ŽŶ ƚŚĞ ƉƌŽďĂďŝůŝƚǇ ŽĨ ƐƚĂƌƟŶŐ




ϮϬϭϱͿ ĨŽƌƉĂƟĞŶƚƐǁŚŽǁĞƌĞƐƟůůĂůŝǀĞ͘ƌƵĚĞϱͲǇĞĂƌŽǀĞƌĂůů ƐƵƌǀŝǀĂůǁĂƐĞƐƟŵĂƚĞĚ ĨŽƌ
ƚŚĞĚŝīĞƌĞŶƚŐƌŽƵƉƐƵƐŝŶŐ ƚŚĞ<ĂƉůĂŶͲDĞŝĞƌŵĞƚŚŽĚĂŶĚĚŝīĞƌĞŶĐĞƐ ŝŶŽǀĞƌĂůů ƐƵƌǀŝǀĂů
outcomes were assessed with the log-rank test. 
ŵƵůƟǀĂƌŝĂďůĞ Žǆ ƉƌŽƉŽƌƟŽŶĂů ŚĂǌĂƌĚƐ ƌĞŐƌĞƐƐŝŽŶ ŵŽĚĞů ǁĂƐ ƵƐĞĚ ƚŽ ĞǀĂůƵĂƚĞ ƚŚĞ
ƌĞůĂƟŽŶƐŚŝƉ ďĞƚǁĞĞŶ ƟŵŝŶŐ ŽĨ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ĂŶĚ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů͕ ǁŝƚŚ




















'ĞŶĚĞƌ͕  E ƐƚĂŐĞ͕ ĚŝīĞƌĞŶƟĂƟŽŶ ŐƌĂĚĞ ĂŶĚ ŚŝƐƚŽůŽŐǇ ŽĨ ƚŚĞ ƉƌŝŵĂƌǇ ƚƵŵŽƵƌ ǁĞƌĞ ŶŽƚ
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ĂƐƐŽĐŝĂƚĞĚǁŝƚŚƟŵŝŶŐŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ;dĂďůĞϭͿ͘dǇƉĞŽĨĐŚĞŵŽƚŚĞƌĂƉǇǁĂƐ




фϲϱ ǇĞĂƌƐ ϭ͘ϲ ;ϭ͘ϮϱͲϭ͘ϵϰͿͿ͕ ƉĂƟĞŶƚƐ ǁŚŽ ƵŶĚĞƌǁĞŶƚ ĂŶ ĞŵĞƌŐĞŶĐǇ ƌĞƐĞĐƟŽŶ ;KZ ϭ͘ϴ
;ϭ͘ϰϭͲϮ͘ϯϮͿͿ͕ ƉĂƟĞŶƚƐǁŚŽ ƐƵīĞƌĞĚ ĨƌŽŵ ĂŶ ĂŶĂƐƚŽŵŽƟĐ ůĞĂŬĂŐĞ ;KZ ϴ͘ϭ ;ϲ͘ϭϰͲϭϬ͘ϲϮͿͿ
ĂŶĚƉĂƟĞŶƚƐǁŚŽǁĞƌĞƌĞĨĞƌƌĞĚƚŽĂŶŽƚŚĞƌŚŽƐƉŝƚĂůĨŽƌĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ;KZϭ͘ϵ
;ϭ͘ϯϲͲϮ͘ϱϳͿͿ ǁĞƌĞŵŽƌĞ ůŝŬĞůǇ ƚŽ ƐƚĂƌƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ůĂƚĞƌ ƚŚĂŶ ϴ ǁĞĞŬƐ ƉŽƐƚͲƐƵƌŐĞƌǇ͘
&ƵƌƚŚĞƌŵŽƌĞ͕ŝŶƚŚĞƐƵďŐƌŽƵƉŽĨƉĂƟĞŶƚƐ;ĚŝĂŐŶŽƐĞĚŝŶϮϬϭϮͲϮϬϭϯͿǁŝƚŚŝŶĨŽƌŵĂƟŽŶŽŶ
ƉƌŽůŽŶŐĞĚƉŽƐƚŽƉĞƌĂƟǀĞŚŽƐƉŝƚĂůĂĚŵŝƐƐŝŽŶ͕ƚŚĞůĂƩĞƌǁĂƐĂůƐŽĂƐƐŽĐŝĂƚĞĚǁŝƚŚĂƟŵŝŶŐ
ŽĨ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ŽĨ ŵŽƌĞ ƚŚĂŶ ϴ ǁĞĞŬƐ ;KZ ϰ͘ϳ ;ϯ͘ϯϬͲϲ͘ϲϴͿͿ͘ &ƵƌƚŚĞƌŵŽƌĞ͕
ƉĂƟĞŶƚƐƵŶĚĞƌŐŽŝŶŐĂůĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƟŽŶ;KZϬ͘ϱ;Ϭ͘ϰϯͲϬ͘ϲϭͿͿǁĞƌĞŵŽƌĞůŝŬĞůǇƚŽƐƚĂƌƚ






















Timing of adjuvant chemotherapy (weeks)
FIGURE 2 ŝƐƚƌŝďƵƟŽŶ ŽĨ ƚŚĞ ƟŵĞ ;ŝŶ ǁĞĞŬƐͿ ĂŌĞƌ ƐƵƌŐŝĐĂů ƌĞƐĞĐƟŽŶ ƚŽ ƚŚĞ ƐƚĂƌƚ ŽĨ ĂĚũƵǀĂŶƚ 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 ƌƵĚĞ;йͿ OR² ϵϱй/
Gender
   Male 15 reference
   Female 15 1.0 0.87-1.18
Age
   <65 years 14 reference
   65-74 years 16 1.3 1.14-1.58
шϳϱǇĞĂƌƐ 17 1.6 1.25-1.94
Period of diagnosis
   2008-2009 16 reference
   2010-2011 15 0.9 0.78-1.15
   2012-2013 15 0.9 0.71-1.04
T stage 
   T1 10 reference
   T2 14 1.2 0.65-3.52
   T3 14 1.1 0.65-3.23
   T4 16 1.2 0.62-3.23
N stage
   N1 15 reference
   N2 15 0.9 0.78-1.08
dƵŵŽƵƌůŽĐĂƟŽŶ
WƌŽǆŝŵĂůĐŽůŽŶ 15 reference
   Distal colon 15 1.0 0.83-1.14
KƚŚĞƌͬEK^ 20 1.5 0.94-2.44
ŝīĞƌĞŶƟĂƟŽŶŐƌĂĚĞΎ
tĞůůͬŵŽĚĞƌĂƚĞĚ 14 reference
WŽŽƌͬƵŶĚŝīĞƌĞŶƟĂƚĞĚ 17 1.2 0.98-1.44
,ŝƐƚŽůŽŐǇŽĨƉƌŝŵĂƌǇƚƵŵŽƵƌΎ
   Non-mucinous adenocarcinoma 15 reference
   Mucinous adenocarcinoma 17 1.2 0.91-1.62
Surgical procedure 
KƉĞŶƌĞƐĞĐƟŽŶ 18 reference
>ĂƉĂƌŽƐĐŽƉŝĐƌĞƐĞĐƟŽŶ 10 0.5 0.43-0.61
hƌŐĞŶĐǇŽĨƌĞƐĞĐƟŽŶΎ
ůĞĐƟǀĞ 14 reference
ŵĞƌŐĞŶĐǇ 26 1.8 1.41-2.32
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 ƌƵĚĞ;йͿ OR² ϵϱй/
ŶĂƐƚŽŵŽƟĐůĞĂŬΎ
   No 13 reference
zĞƐ 50 8.1 6.14-10.62
,ŽƐƉŝƚĂůĞƋƵĂůƚŽŚŽƐƉŝƚĂůƌĞƐĞĐƟŽŶ
   No 15 reference
zĞƐ 25 1.9 1.36-2.57
WƌŽůŽŶŐĞĚŚŽƐƉŝƚĂůĂĚŵŝƐƐŝŽŶ;хϭϰĚĂǇƐͿΎΎ
   No 11 reference
zĞƐ 47 4.7 3.30-6.68
ĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ͕ /ŽŶĮĚĞŶĐĞŝŶƚĞƌǀĂů͕KZKĚĚƐƌĂƟŽ






ƌĂƚĞƐĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ŝŶŝƟĂƟŽŶŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇǁŝƚŚŝŶϰǁĞĞŬƐ͕ϱͲϲǁĞĞŬƐ͕









ϭ͘ϲϴͿ͖ ,Z ϭϭͲϭϮ ǀĞƌƐƵƐ чϴ ǁĞĞŬƐ ϭ͘ϯ ;ϭ͘ϬϲͲϭ͘ϱϵͿ ĂŶĚ ,Z ϭϯͲϭϲ ǀĞƌƐƵƐ чϴ ǁĞĞŬƐ ϭ͘ϳ
;ϭ͘ϮϯͲϮ͘ϮϯͿͿ͘ /Ŷ ĂĚĚŝƟŽŶ͕ ŝŶŝƟĂƟŽŶ ŽĨ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ďĞƚǁĞĞŶ ϱ ĂŶĚ ϴǁĞĞŬƐ
ƉŽƐƚͲƐƵƌŐĞƌǇ ƐŚŽǁĞĚ ŶŽ ĚĞĐƌĞĂƐĞ ŝŶ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ĐŽŵƉĂƌĞĚ ƚŽ ŝŶŝƟĂƟŽŶ ǁŝƚŚŝŶ ϰ

































FIGURE 3 ƌƵĚĞ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ĂĐĐŽƌĚŝŶŐ ƚŽ ǁŚĞƚŚĞƌ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ǁĂƐ ŝŶŝƟĂƚĞĚ
ǁŝƚŚŝŶϰǁĞĞŬƐ͕ϱͲϲǁĞĞŬƐ͕ϳͲϴǁĞĞŬƐ͕ϵͲϭϬǁĞĞŬƐ͕ϭϭͲϭϮǁĞĞŬƐ͕ϭϯͲϭϲǁĞĞŬƐ;Ŷсϲ͕ϲϮϬͿŽƌƉĂƟĞŶƚƐ
ƵŶĚĞƌŐŽŝŶŐƐƵƌŐĞƌǇŽŶůǇ;Ŷсϰ͕ϴϵϵͿ͘
TABLE 3 ƌƵĚĞ ϱͲǇĞĂƌ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ĂŶĚ ĂĚũƵƐƚĞĚ ŚĂǌĂƌĚ ƌĂƟŽƐϸ ĨŽƌ ĚĞĂƚŚ ĂŵŽŶŐ ƐƚĂŐĞ /// 
 ƌĞƐĞĐƚĞĚĐŽůŽŶĐĂŶĐĞƌƉĂƟĞŶƚƐƌĞĐĞŝǀŝŶŐĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ;Ŷсϲ͕ϲϮϬͿ͘
Variable Crude 5-year survival DƵůƟǀĂƌŝĂďůĞĂŶĂůǇƐŝƐ
 ;йͿ HR² ϵϱй/
Timing of AC
чϰǁĞĞŬƐ 75 1.0 reference
   5-6 weeks 76 0.9 0.79-1.11
   7-8 weeks 72 1.1 0.91-1.30
чϴǁĞĞŬƐ 74 1.0 reference
   9-10 weeks 64 1.4 1.21-1.68
   11-12 weeks 61 1.3 1.06-1.59
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DISCUSSION
Currently available data suggest that a start of adjuvant chemotherapy later than 8 
ǁĞĞŬƐƉŽƐƚͲƐƵƌŐĞƌǇ ŝŶƐƚĂŐĞ///ĐŽůŽŶĐĂŶĐĞƌƉĂƟĞŶƚƐ ŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚƉŽŽƌĞƌƐƵƌǀŝǀĂů͘
tĞŝĚĞŶƟĮĞĚĨĂĐƚŽƌƐƚŚĂƚŝŶŇƵĞŶĐĞĚƚŚĞƉƌŽďĂďŝůŝƚǇŽĨƐƚĂƌƟŶŐĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ





ŝīĞƌĞŶƚ ĐƵƚͲŽīƐ ĨŽƌ ƚŚĞ ŝŶŝƟĂƟŽŶ ŽĨ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ǁĞƌĞ ƵƐĞĚ ŝŶ ƉƌĞǀŝŽƵƐ
ƐƚƵĚŝĞƐůĞĂĚŝŶŐƚŽĚŝīĞƌĞŶƚĚĞĮŶŝƟŽŶƐŽĨĂĚĞůĂǇĞĚƐƚĂƌƚŽĨĐŚĞŵŽƚŚĞƌĂƉǇ͕ ƌĂŶŐŝŶŐĨƌŽŵϴ
to 12 weeks.2, 23KƚŚĞƌƐƚƵĚŝĞƐĂůƐŽŝŶĐůƵĚĞĚƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ18, 24, 25, or high-risk stage 
// ĐŽůŽŶĐĂŶĐĞƌƉĂƟĞŶƚƐ26͘^ŝŶĐĞƚŚĞďĞŶĞĮƚŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ ŝŶƉĂƟĞŶƚƐǁŝƚŚ
ƐƚĂŐĞ//ĐŽůŽŶĐĂŶĐĞƌĂŶĚŝŶƌĞĐƚĂůĐĂŶĐĞƌŝƐůĞƐƐŽďǀŝŽƵƐŽƌĞǀĞŶƋƵĞƐƟŽŶĂďůĞ͕ƚŚĞĞīĞĐƚ
ŽĨƟŵŝŶŐŽĨĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇŽŶŽƵƚĐŽŵĞŵĂǇďĞĚŝůƵƚĞĚŽƌŵĂƐŬĞĚ ŝŶ ƐƚƵĚŝĞƐ
ƚŚĂƚ ŝŶĐůƵĚĞĚ ƚŚĞƐĞ ƉĂƟĞŶƚƐ͘ /Ŷ ŽƵƌ ƐƚƵĚǇ͕  ŽŶůǇ ϭϰй ŽĨ ƚŚĞ ƉĂƟĞŶƚƐ ƐƚĂƌƚĞĚ ĂĚũƵǀĂŶƚ
ĐŚĞŵŽƚŚĞƌĂƉǇďĞǇŽŶĚϴǁĞĞŬƐŽĨƐƵƌŐĞƌǇ͕ ǁŚŝĐŚŝƐůĞƐƐĐŽŵƉĂƌĞĚƚŽƚŚĞϭϵͲϰϮйǁŚŝĐŚ
has been observed in studies performed in other countries.14, 27 
WĂƟĞŶƚ ĂŐĞ͕ ĞŵĞƌŐĞŶĐǇ ƌĞƐĞĐƟŽŶ͕ ƐƵƌŐŝĐĂů ƉƌŽĐĞĚƵƌĞ ;ůĂƉĂƌŽƐĐŽƉŝĐ ǀĞƌƐƵƐ ŽƉĞŶ




other studies.6, 17, 28,ĞŶĚƌĞŶĞƚĂů͘ĨŽƵŶĚƚŚĂƚƚŚĞƉƌĞƐĞŶĐĞŽĨƐƵƌŐŝĐĂůĐŽŵƉůŝĐĂƟŽŶƐǁĂƐ
ƌĞůĂƚĞĚƚŽĂĚĞůĂǇĞĚƐƚĂƌƚĂŶĚŽŵŝƐƐŝŽŶŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇŝŶƐƚĂŐĞ///ĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌƉĂƟĞŶƚƐ͘29/ŶĂƐƚƵĚǇŝŶĐůƵĚŝŶŐƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͕ƚŚĞĚƵƌĂƟŽŶŽĨƉŽƐƚŽƉĞƌĂƟǀĞ
hospital stay was also strongly associated with a delayed start of adjuvant chemotherapy.26 
/ŶůŝŶĞǁŝƚŚƉƌĞǀŝŽƵƐƐƚƵĚŝĞƐŽĨWŽǇůŝŶĞƚĂů͘30ĂŶĚ>ĂĐǇĞƚĂů͘31, we found a lower odds for 
ƐƚĂƌƟŶŐĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇďĞǇŽŶĚϴǁĞĞŬƐǁŚĞŶƉĂƟĞŶƚƐƵŶĚĞƌǁĞŶƚĂůĂƉĂƌŽƐĐŽƉŝĐ
ƌĞƐĞĐƟŽŶŝŶƐƚĞĂĚŽĨĂŶŽƉĞŶƌĞƐĞĐƟŽŶ͘








WƌĞǀŝŽƵƐ ƐƚƵĚŝĞƐŚĂǀĞ ƐŚŽǁŶƐŝŵŝůĂƌ ƌĞƐƵůƚƐƵƐŝŶŐƉŽƉƵůĂƟŽŶͲďĂƐĞĚĚĂƚĂŽŶĂ ƌĞŐŝŽŶĂů




ƉĂƟĞŶƚƐ ƌĞĐĞŝǀŝŶŐ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ĮƌƐƚ͘ ůƚŚŽƵŐŚ ǁĞ ĂĚũƵƐƚĞĚ ĨŽƌ ƐĞǀĞƌĂů
ƉĂƟĞŶƚĂŶĚƚƵŵŽƵƌĐŚĂƌĂĐƚĞƌŝƐƟĐƐ͕ĚĂƚĂĂďŽƵƚĨƵŶĐƟŽŶĂůƐƚĂƚƵƐ͕ƐƉĞĐŝĮĐƉŽƐƚŽƉĞƌĂƟǀĞ
ĐŽŵƉůŝĐĂƟŽŶƐ ŽƚŚĞƌ ƚŚĂŶ ĂŶĂƐƚŽŵŽƟĐ ůĞĂŬĂŐĞ ĂŶĚ ĐŽŵŽƌďŝĚŝƚǇ ǁĞƌĞ ŶŽƚ ĂǀĂŝůĂďůĞ͘
dŚĞƌĞĨŽƌĞ ĂŶ ĂŶĂůǇƐŝƐ ŽĨ ƚŚĞ ĞīĞĐƚ ŽĨ ƟŵŝŶŐ ŽĨ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ŽŶ ůŽŶŐͲƚĞƌŵ
ŽƵƚĐŽŵĞƐŵĂǇďĞƐƵďũĞĐƚƚŽƌĞƐŝĚƵĂůĐŽŶĨŽƵŶĚŝŶŐ͘tĞŚǇƉŽƚŚĞƐŝǌĞƚŚĂƚƉĂƟĞŶƚƐƐƚĂƌƟŶŐ










ŝŶĨŽƌŵĂƟŽŶ ĂďŽƵƚ ƵŶŵĞĂƐƵƌĞĚ ĐŽŶĨŽƵŶĚĞƌƐ ĂŶĚŵŽĚŝĮĐĂƟŽŶŽĨ ƚŚĞ ŝĚĞŶƟĮĞĚ ĨĂĐƚŽƌƐ
ŝƐĂǀĂŝůĂďůĞ͕ǁŽƵůĚďĞǀĂůƵĂďůĞ͘ŶĂƟŽŶĂůƉŽƉƵůĂƟŽŶͲďĂƐĞĚĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƌĞŐŝƐƚƌǇŝƐ
currently in development in The Netherlands.




ĐŚĞŵŽƚŚĞƌĂƉǇ ƚƌĞĂƚŵĞŶƚ ŝƐ ďĂƐĞĚ ŽŶ ƐŚĂƌĞĚ ĚĞĐŝƐŝŽŶͲŵĂŬŝŶŐ ďĞƚǁĞĞŶ ƉĂƟĞŶƚƐ ĂŶĚ
providers whenever possible and appropriate. 
/ŶĐŽŶĐůƵƐŝŽŶ͕ŽƵƌĚĂƚĂƐƵƉƉŽƌƚƚŚĞŝŶŝƟĂƟŽŶŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇŝŶƐƚĂŐĞ///ĐŽůŽŶ
cancer within 8 weeks of surgery. 
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SUMMARY OF THE MAIN FINDINGS
Part I of this thesis starts with an overview of colorectal cancer survival in the Netherlands. 
Chapter 2 provides an overview of the remarkable changes in epidemiology, treatment 
and survival of colorectal cancer in the Netherlands in the period 1989 to 2014. There has 
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^ƵďĂŶĂůǇƐŝƐ ƐŚŽǁĞĚ ƚŚĂƚ ƉĂƟĞŶƚƐ ǁŝƚŚ ƚǁŽ Žƌ ŵŽƌĞ ĐŽŶĐŽŵŝƚĂŶƚ ĚŝƐĞĂƐĞƐ ƉƌĞƐĞŶƚ Ăƚ
ĚŝĂŐŶŽƐŝƐĂůƐŽŚĂĚŚŝŐŚĞǆĐĞƐƐŵŽƌƚĂůŝƚǇ;ϭϭ͘ϯйĨŽƌĐŽůŽŶĐĂŶĐĞƌ͖ϭϭ͘ϭйĨŽƌƌĞĐƚĂůĐĂŶĐĞƌͿ͘
Results of this study suggest that surgery has a greater and prolonged impact on survival 
ƉŽƐƚŽƉĞƌĂƟǀĞůǇ ŝŶ ĞůĚĞƌůǇ͘ ŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŝƚƐĞůĨŵĂǇ ŶŽƚ ďĞ ƚŚĞŵĂŝŶ ĐĂƵƐĞ ŽĨ ĂŐĞͲ
ƌĞůĂƚĞĚĚŝīĞƌĞŶĐĞƐŝŶƐƵƌǀŝǀĂů͕ĂŶĚŝƚĂƉƉĞĂƌƐƚŚĂƚƐƵƌǀŝǀĂůŝŶĞůĚĞƌůǇĂŌĞƌŵĂũŽƌƐƵƌŐĞƌǇ
ŵĂǇďĞŵŽĚŝĮĂďůĞ͘
Part II ŽĨ ƚŚŝƐ ƚŚĞƐŝƐ ĨŽĐƵƐƐĞƐ ŽŶ ĚĞƚĞƌŵŝŶĂŶƚƐ ŽĨ ƐƵƌǀŝǀĂů͘ /Ŷ chapter 4͕ ƚŚĞ ŽďũĞĐƟǀĞ




ƉƌŝŵĂƌǇ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ďĞƚǁĞĞŶ ϮϬϬϴ ĂŶĚ ϮϬϭϯ ǁŚŽ ƵŶĚĞƌǁĞŶƚ ĞůĞĐƟǀĞ ƐƵƌŐĞƌǇ
were selected from the Netherlands Cancer Registry. Synchronous colorectal cancer was 
ĚĞĮŶĞĚĂƐƚǁŽŽƌŵŽƌĞŝŶǀĂƐŝǀĞƚƵŵŽƵƌƐ͕ĚŝĂŐŶŽƐĞĚƐŝŵƵůƚĂŶĞŽƵƐůǇŽƌǁŝƚŚŝŶƐŝǆŵŽŶƚŚƐ͘
KƵƚŽĨϰϭ͕ϬϲϬĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͕ϱйŚĂĚƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͘ WĂƟĞŶƚƐ
ǁŝƚŚ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ǁĞƌĞ ŽůĚĞƌ͕ ŵŽƌĞ ŽŌĞŶŵĂůĞ ĂŶĚ ĚŝĂŐŶŽƐĞĚǁŝƚŚ
ŵŽƌĞĂĚǀĂŶĐĞĚƚƵŵŽƵƌƐƚĂŐĞĐŽŵƉĂƌĞĚƚŽƐŽůŝƚĂƌǇĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͘ ,ĂůĨŽĨƚŚĞƉĂƟĞŶƚƐ
ǁŝƚŚ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƵŶĚĞƌǁĞŶƚ ĂŶ ĞǆƚĞŶĚĞĚ ƐƵƌŐĞƌǇ͘ ^ǇŶĐŚƌŽŶŽƵƐ
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ǁŝƚŚ Ăƚ ůĞĂƐƚ Ă ƐƚĂŐĞ //Ͳ/// ƌĞĐƚĂů ƚƵŵŽƵƌ ǁĞƌĞ ůĞƐƐ ůŝŬĞůǇ ƚŽ
ƌĞĐĞŝǀĞŶĞŽĂĚũƵǀĂŶƚ ;ĐŚĞŵŽͿƌĂĚŝŽƚŚĞƌĂƉǇĂŶĚ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌƐƉĂƟĞŶƚƐ
ǁŝƚŚĂƚůĞĂƐƚŽŶĞƐƚĂŐĞ///ĐŽůŽŶƚƵŵŽƵƌǁĞƌĞůĞƐƐůŝŬĞůǇƚŽƌĞĐĞŝǀĞĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ͘
Synchronous colorectal cancer was independently associated with decreased survival 
;ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů ϳϳй ǀĞƌƐƵƐ ϳϭй ŝŶ ƐŽůŝƚĂƌǇ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͖ ĂĚũƵƐƚĞĚ ZZ ϭ͘ϭ͕ ϵϱй
/ϭ͘ϬϭͲϭ͘ϮϯͿ͘dŚĞƌĞƐƵůƚƐĞŵƉŚĂƐŝǌĞƚŚĂƚŝŶĨŽƌŵĂƟŽŶŽŶĚŝīĞƌĞŶĐĞƐŝŶƐŚŽƌƚͲĂŶĚůŽŶŐͲ
term outcomes between solitary and synchronous colorectal cancer is relevant since 
Ă ƉƌĞŽƉĞƌĂƟǀĞ ĚŝĂŐŶŽƐŝƐ ŽĨ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌƐŵĂǇŵŽĚŝĨǇ Žƌ ĞǆƚĞŶĚ ƚŚĞ
ƚǇƉĞŽĨƐƵƌŐŝĐĂůƉƌŽĐĞĚƵƌĞĂŶĚŝŶŇƵĞŶĐĞĐůŝŶŝĐĂůĚĞĐŝƐŝŽŶŵĂŬŝŶŐŽĨƚŚĞƵƐĞŽĨĂĚĚŝƟŽŶĂů


















/Ŷ ƚŚĞ ƐƚƵĚǇĚĞƐĐƌŝďĞĚ ŝŶ chapter 6ǁĞĚĞǀĞůŽƉĞĚĂŶĚ ǀĂůŝĚĂƚĞĚƉƌĞĚŝĐƟŽŶŵŽĚĞůƐ ƚŽ
ĞƐƟŵĂƚĞƉŽƐƚŽƉĞƌĂƟǀĞϵϬͲĚĂǇŵŽƌƚĂůŝƚǇĂŶĚŽǀĞƌĂůůƐƵƌǀŝǀĂůĨŽƌĐŽůŽŶĂŶĚƌĞĐƚĂůĐĂŶĐĞƌ
ƉĂƟĞŶƚƐ͘ dŚŝƐ ƐƚƵĚǇ ŝŶĐůƵĚĞĚ Ăůů ƉƌŝŵĂƌǇ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĚŝĂŐŶŽƐĞĚ ĂŶĚ
ƌĞƐĞĐƚĞĚďĞƚǁĞĞŶϮϬϬϴĂŶĚϮϬϭϰŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͘sĂƌŝĂďůĞƐƉƌĞĚŝĐƟŶŐƉŽƐƚŽƉĞƌĂƟǀĞ










ďĞ ǀĂůƵĂďůĞ ƚŽ ďŽƚŚ ƉĂƟĞŶƚƐ ĂŶĚ ƐƵƌŐĞŽŶƐ ƚŽ ŚĞůƉ ŝŶ ĐůŝŶŝĐĂů ĚĞĐŝƐŝŽŶŵĂŬŝŶŐ ĂŶĚ ƚŽ
develop individual follow-up schedules. 
dŚĞ ůĂƐƚ ƐƚƵĚǇ ŝŶĐůƵĚĞĚ ŝŶ ƚŚŝƐ ƚŚĞƐŝƐ ŝŶǀĞƐƟŐĂƚĞĚ ĨĂĐƚŽƌƐ ĂīĞĐƟŶŐ ƟŵŝŶŐ ŽĨ ĂĚũƵǀĂŶƚ
ĐŚĞŵŽƚŚĞƌĂƉǇĂŶĚĞǀĂůƵĂƚĞĚƚŚĞŝŶŇƵĞŶĐĞŽŶŽǀĞƌĂůůƐƵƌǀŝǀĂůĂŵŽŶŐƉĂƟĞŶƚƐǁŝƚŚƐƚĂŐĞ
///ĐŽůŽŶĐĂŶĐĞƌǁŚŽƵŶĚĞƌǁĞŶƚƌĞƐĞĐƟŽŶĂŶĚƌĞĐĞŝǀĞĚĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇďĞƚǁĞĞŶ
ϮϬϬϴĂŶĚϮϬϭϯ ŝŶ ƚŚĞEĞƚŚĞƌůĂŶĚƐ ;chapter 7Ϳ͘ dŝŵŝŶŐŽĨ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇǁĂƐ
ƐƵďĚŝǀŝĚĞĚŝŶƚŽ͗чϰ͕ϱͲϲ͕ϳͲϴ͕ϵͲϭϬ͕ϭϭͲϭϮĂŶĚϭϯͲϭϲǁĞĞŬƐƉŽƐƚͲƐƵƌŐĞƌǇ͘dŚĞŵĞĚŝĂŶƟŵŝŶŐ
ŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇǁĂƐϱ͘ϲǁĞĞŬƐƉŽƐƚͲƐƵƌŐĞƌǇ͘&ŽƵƌƚĞĞŶƉĞƌĐĞŶƚŽĨƚŚĞƉĂƟĞŶƚƐ
ƐƚĂƌƚĞĚ ƚƌĞĂƚŵĞŶƚŵŽƌĞ ƚŚĂŶ ϴǁĞĞŬƐ ĂŌĞƌ ƌĞƐĞĐƟŽŶ͘ &ĂĐƚŽƌƐ ĂƐƐŽĐŝĂƚĞĚǁŝƚŚ ƐƚĂƌƟŶŐ
ƚƌĞĂƚŵĞŶƚ ĂŌĞƌ ϴ ǁĞĞŬƐ ǁĞƌĞ ŽůĚĞƌ ĂŐĞ͕ ĞŵĞƌŐĞŶĐǇ ƌĞƐĞĐƟŽŶ͕ ĂŶĂƐƚŽŵŽƟĐ ůĞĂŬĂŐĞ͕
ƌĞĨĞƌƌĂů ƚŽ ĂŶŽƚŚĞƌ ŚŽƐƉŝƚĂů ĨŽƌ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ĂŶĚ ƉƌŽůŽŶŐĞĚ ƉŽƐƚŽƉĞƌĂƟǀĞ
ŚŽƐƉŝƚĂů ĂĚŵŝƐƐŝŽŶ͘ dŚĞ ĐƌƵĚĞ ŽďƐĞƌǀĞĚ ϱͲǇĞĂƌ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ƌĂƚĞƐ ĨŽƌ ƚŚĞ ĚŝīĞƌĞŶƚ
ƟŵŝŶŐƐŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇǁĞƌĞϳϱй͕ϳϲй͕ϳϮй͕ϲϰй͕ϲϭйĂŶĚϱϰй͕ƌĞƐƉĞĐƟǀĞůǇ͘
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Zϴ
ŌĞƌ ĐĂƐĞͲŵŝǆ ĂĚũƵƐƚŵĞŶƚ͕ ƐƚĂƌƟŶŐ ďĞƚǁĞĞŶ ϱ ĂŶĚ ϴ ǁĞĞŬƐ ƉŽƐƚͲƐƵƌŐĞƌǇ ƐŚŽǁĞĚ ŶŽ




dŚĞƐĞƌĞƐƵůƚƐƐƵƉƉŽƌƚ ƚŚĞ ŝŶŝƟĂƟŽŶŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ ŝŶƐƚĂŐĞ ///ĐŽůŽŶĐĂŶĐĞƌ
ƉĂƟĞŶƚƐǁŝƚŚŝŶϴǁĞĞŬƐƉŽƐƚͲƐƵƌŐĞƌǇ͘
Dã«ÊÊ½Ê¦®½ÊÄÝ®Ùã®ÊÄÝ
The studies in this thesis have several strengths and weaknesses related to the data 
sources and study design that were used.
^ãÙÄ¦ã«ÝÄ½®Ã®ãã®ÊÄÝÊ¥ã«ãÝÊçÙÝ
Netherlands Cancer Registry
The studies that are described in this thesis are based on data from the Netherlands 
ĂŶĐĞƌ ZĞŐŝƐƚƌǇ ;EZͿ͘ ^ŝŶĐĞ ϭϵϵϯ͕ ƚŚĞ ƐŽƵƚŚĞĂƐƚ ƉĂƌƚ ŽĨ ƚŚĞ EĞƚŚĞƌůĂŶĚƐ ƌĞŐŝƐƚĞƌƐ
ĐŽŵŽƌďŝĚĐŽŶĚŝƟŽŶƐƉƌĞƐĞŶƚĂƚƟŵĞŽĨĐĂŶĐĞƌĚŝĂŐŶŽƐŝƐ͘1, 2 This is unique compared to 
other cancer registries worldwide.
ZĞŐŝƐƚĞƌͲďĂƐĞĚŽďƐĞƌǀĂƟŽŶĂů ƐƚƵĚŝĞƐŽŌĞŶŚĂǀĞ ůĂƌŐĞƐĂŵƉůĞƐŝǌĞƐĂŶĚŐƌĞĂƚƐƚĂƟƐƟĐĂů
power. Second, the registry covers virtually all cases. However, the data are collected 
ŝŶĚĞƉĞŶĚĞŶƚ ŽĨ ƌĞƐĞĂƌĐŚ ƋƵĞƐƟŽŶƐ͕ ĂŶĚ ĂƐ Ă ƌĞƐƵůƚ ŝŵƉŽƌƚĂŶƚ ŝŶĨŽƌŵĂƟŽŶ ŵŝŐŚƚ ďĞ
lacking.3/ŶƚŚĞĚĂƚĂƵƐĞĚ͕ĨŽƌŝŶƐƚĂŶĐĞ͕ĂĚĚŝƟŽŶĂůŝŶĨŽƌŵĂƟŽŶŽŶƚŚĞĚĞǀĞůŽƉŵĞŶƚĂŶĚ











ƉĂƟĞŶƚ ƉƌĞĨĞƌĞŶĐĞƐ͘ dŚƵƐ͕ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚŝĞƐ ƉƌŽǀŝĚĞ Ă ƵŶŝƋƵĞ ŝŶƐŝŐŚƚ ŝŶƚŽ ƚŚĞ
ĞīĞĐƚƐŽĨƚƌĞĂƚŵĞŶƚƐŝŶĞǀĞƌǇĚĂǇĐůŝŶŝĐĂůƉƌĂĐƟĐĞ͘6-8 





ŽďƐĞƌǀĂƟŽŶĂů ƐƚƵĚŝĞƐ ĂŶĚ ƐŚŽƵůĚ ďĞ ĐŽŶƐŝĚĞƌĞĚ ǁŚĞŶ ŝŶƚĞƌƉƌĞƟŶŐ ƚŚĞ ƌĞƐƵůƚƐ ŽĨ ƚŚĞ
studies included in this thesis.
®ÝÄÊÄ¥ÊçÄ®Ä¦
Here, the most important biases and how these biases were dealt with are discussed.
^ĞůĞĐƟŽŶďŝĂƐ

































ĂĚĞƋƵĂƚĞůǇ ĂƐ ƉŽƐƐŝďůĞ͘ &Žƌ ƐƚƵĚŝĞƐ ŝŶĐůƵĚŝŶŐŽŶůǇ ƉĂƟĞŶƚƐǁŝƚŚ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌǁŚŽ
ƵŶĚĞƌǁĞŶƚƌĞƐĞĐƟŽŶ;chapters 3, 4, 6 & 7Ϳ͕ƚŚĞĚĂƚĞŽĨƌĞƐĞĐƟŽŶŽĨƚŚĞƉƌŝŵĂƌǇƚƵŵŽƵƌ
ǁĂƐ ƵƐĞĚ ƚŽ ĞǀĂůƵĂƚĞ ŽǀĞƌĂůů Žƌ ƌĞůĂƟǀĞ ƐƵƌǀŝǀĂů ďĞƚǁĞĞŶ ŐƌŽƵƉƐ͘DŽƌĞŽǀĞƌ͕  ŝŶ ƐŽŵĞ
ƐƚƵĚŝĞƐǁĞŝŶĐůƵĚĞĚĐŽŶĚŝƟŽŶĂůƐƵƌǀŝǀĂů;ĐŽŶĚŝƟŽŶŽĨƐƵƌǀŝǀŝŶŐĂĐĞƌƚĂŝŶƉĞƌŝŽĚͿ;chapters 
3, 5 & 7Ϳ͘
^ƚĂŐĞŵŝŐƌĂƟŽŶ
KŶĞ ƐŚŽƵůĚ ĐŽŶƐŝĚĞƌ ƉŽƚĞŶƟĂů ƐƚĂŐĞ ŵŝŐƌĂƟŽŶ ĂŶĚ ƌĞůĂƚĞĚ ĨŽƌŵƐ ŽĨ ďŝĂƐ ;ůĞĂĚ ƟŵĞ














ĐŚĂƌĂĐƚĞƌŝƐƟĐƐŵŝŐŚƚ ĂůƐŽ ŚĂǀĞ ŝŶŇƵĞŶĐĞĚ ŽƵƚĐŽŵĞƐ͘8 &Žƌ ŝŶƐƚĂŶĐĞ͕ ŶŽ ŝŶĨŽƌŵĂƟŽŶ ŽŶ
ĨƵŶĐƟŽŶĂůƐƚĂƚƵƐĂŶĚƐƉĞĐŝĮĐƉŽƐƚŽƉĞƌĂƟǀĞĐŽŵƉůŝĐĂƟŽŶƐŽƚŚĞƌƚŚĂŶĂŶĂƐƚŽŵŽƟĐůĞĂŬĂŐĞ
were available.
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GENERAL DISCUSSION
The research underlying this thesis aimed to reveal aspects of colorectal cancer survival 
ŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐďǇƉƌĞƐĞŶƟŶŐƚƌĞŶĚƐŝŶŝŶĐŝĚĞŶĐĞ͕ŵŽƌƚĂůŝƚǇ͕ ƚƌĞĂƚŵĞŶƚĂŶĚƐƵƌǀŝǀĂů͕ĂƐ
ǁĞůůĂƐƚŽŝŶǀĞƐƟŐĂƚĞƚŚĞŝŵƉĂĐƚŽĨĚĞƚĞƌŵŝŶĂŶƚƐŽĨƚŚĞĚŝƐĞĂƐĞŽŶŽƵƚĐŽŵĞŽĨƚƌĞĂƚŵĞŶƚ
and long-term survival, using real-world data from the Netherlands Cancer Registry. 





ĂŌĞƌ ĚŝĂŐŶŽƐŝƐ͘ dŚĞ ĂďƐŽůƵƚĞ ŶƵŵďĞƌ ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ŝŶ ƚŚĞEĞƚŚĞƌůĂŶĚƐ
ŝƐ ƐƟůů ŝŶĐƌĞĂƐŝŶŐ ƌĂƉŝĚůǇ͕  ĂƐ Ă ƌĞƐƵůƚ ŽĨ ƚŚĞ ŝŵƉůĞŵĞŶƚĂƟŽŶ ŽĨ Ă ŶĂƟŽŶǁŝĚĞ ƐĐƌĞĞŶŝŶŐ
ƉƌŽŐƌĂŵŝŶϮϬϭϰĂŶĚĂŐŝŶŐŽĨƚŚĞƉŽƉƵůĂƟŽŶ͘9 Due to the increasing uptake of screening 
ŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͕ŝŶĐŝĚĞŶĐĞƌĂƚĞƐǁŝůůƌŝƐĞĨƵƌƚŚĞƌƚŚĞĨŽƌƚŚĐŽŵŝŶŐǇĞĂƌƐ͕ĂŌĞƌǁŚŝĐŚŝƚŝƐ
ůŝŬĞůǇƚŽĚĞĐƌĞĂƐĞĂŵŽŶŐĞůĚĞƌůǇ͕ ƐŝŵŝůĂƌƚŽǁŚĂƚŝƐƐĞĞŶŝŶƚŚĞh^͘10-12 Mortality rates are 
ĞǆƉĞĐƚĞĚƚŽĚĞĐƌĞĂƐĞĨƵƌƚŚĞƌďĞĐĂƵƐĞŽĨƚŚĞƐĐƌĞĞŶŝŶŐƉƌŽŐƌĂŵ͕ďǇĞĂƌůŝĞƌĚĞƚĞĐƟŽŶĂŶĚ
ƚŚĞƌĞďǇŵŽƌĞĐƵƌĂƟǀĞĂŶĚůĞƐƐŝŶǀĂƐŝǀĞƚƌĞĂƚŵĞŶƚŽƉƟŽŶƐ͘13 However, colorectal cancer 
ŝƐƐƟůůƚŚĞƐĞĐŽŶĚůĞĂĚŝŶŐĐĂƵƐĞŽĨĐĂŶĐĞƌͲƌĞůĂƚĞĚĚĞĂƚŚ͘9
ŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŝƐ ƉƌĞĚŽŵŝŶĂŶƚůǇ Ă ƉƌŽďůĞŵ ŽĨ ƚŚĞ ĞůĚĞƌůǇ͗ ĂůŵŽƐƚ ŚĂůĨ ŽĨ ƚŚĞ ĐĂƐĞƐ
ŽĐĐƵƌ ŝŶƉĂƟĞŶƚƐĂŐĞĚϳϱǇĞĂƌƐŽƌŽůĚĞƌ͘ 9 The incidence increases with advancing age, 
ĚŽƵďůŝŶŐĞǀĞƌǇϳǇĞĂƌƐŝŶƉĂƟĞŶƚƐĂŐĞĚϱϬǇĞĂƌƐŽƌŽůĚĞƌ͘ dŚĞĞůĚĞƌůǇƉŽƉƵůĂƟŽŶŝƐǀĞƌǇ
heterogeneous and tends to have more advanced disease stage.14 >ŝŵŝƚĞĚ ĞǀŝĚĞŶĐĞͲ
based guidelines are available for the age group 70 years or older15͕ ĂƐ ŽůĚĞƌ ƉĂƟĞŶƚƐ
ǁŝƚŚĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌĂƌĞŐĞŶĞƌĂůůǇĞǆĐůƵĚĞĚĨƌŽŵƌĂŶĚŽŵŝǌĞĚĐůŝŶŝĐĂůƚƌŝĂůƐĂŶĚƚŚĞĮƚ
ŽŶĞƐǁŚŽĂƌĞƌĞĐƌƵŝƚĞĚĂƌĞŶŽƚƌĞƉƌĞƐĞŶƚĂƟǀĞŽĨƚŚĞŐĞŶĞƌĂůĞůĚĞƌůǇƉŽƉƵůĂƟŽŶ͘DĂŶǇ




ĐŚĞŵŽƚŚĞƌĂƉǇ ŚĂƐ ďĞĞŶ ƚŚĞ ƐƚĂŶĚĂƌĚ ŽĨ ĐĂƌĞ ĨŽƌ ƐƚĂŐĞ /// ĐŽůŽŶ ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ƐŝŶĐĞ
199016͕ƚŚĞƉƌŽďĂďŝůŝƚǇƚŽƌĞĐĞŝǀĞĐŚĞŵŽƚŚĞƌĂƉǇĨŽůůŽǁŝŶŐƐƵƌŐŝĐĂůƌĞƐĞĐƟŽŶĚĞĐůŝŶĞƐǁŝƚŚ
increasing age17-20 and varies between hospitals20-22. 
tŚĞŶ ĨĞĂƐŝďůĞ͕ ƌĞƐĞĐƟŽŶ ŽĨ ƚŚĞ ƉƌŝŵĂƌǇ ƚƵŵŽƵƌ ŝƐ ƚŚĞ ƉƌĞĨĞƌƌĞĚ ĐƵƌĂƟǀĞ ƚƌĞĂƚŵĞŶƚ











dŚŝƐ ƐƵŐŐĞƐƚƐ ŝŶĐƌĞĂƐĞĚĂǀĂŝůĂďŝůŝƚǇŽĨŽƚŚĞƌ ƚƌĞĂƚŵĞŶƚŽƉƟŽŶƐ͕ĂŶĚďĞƩĞƌ ƐĞůĞĐƟŽŶŽĨ
ƉĂƟĞŶƚƐƚŚƌŽƵŐŚŝŵƉƌŽǀĞĚĚŝĂŐŶŽƐƟĐĂĐĐƵƌĂĐǇĂŶĚƉƌĞŽƉĞƌĂƟǀĞƐƚĂŐŝŶŐ͘25-29 According to 
ĂƌĞƉŽƌƚĨƌŽŵƚŚĞEĂƟŽŶĂůŽǁĞůĂŶĐĞƌƵĚŝƚ͕ƚŚĞƉƌŽƉŽƌƟŽŶŽĨƉĂƟĞŶƚƐǁŝƚŚĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌ ƵŶĚĞƌŐŽŝŶŐŵĂũŽƌ ƌĞƐĞĐƟŽŶ ƐŚŽǁĞĚĂ ƐƚĞĂĚǇĚĞĐƌĞĂƐĞ͘30 This was caused by a 






35͕ ĐŽŵŽƌďŝĚŝƚǇ ĂŶĚ ĨƌĂŝůƚǇ ĐŚĂůůĞŶŐĞ ƐƵƌŐŝĐĂů ŵĂŶĂŐĞŵĞŶƚ ŝŶ ƚŚĞƐĞ ƉĂƟĞŶƚƐ͘36, 37 /Ŷ
ĐŽŵďŝŶĂƟŽŶǁŝƚŚƚŚĞƐƚĂƌƚŽĨƚŚĞƵƚĐŚŽůŽZĞĐƚĂůƵĚŝƚ;ZͿŝŶϮϬϬϵ͕ƚŚŝƐŵĂǇŚĂǀĞ
led to a change in habits and opinions of surgeons, in which they became more careful 
ŝŶŽƉĞƌĂƟŶŐƚŚĞƐĞĨƌĂŐŝůĞŐƌŽƵƉŽĨƉĂƟĞŶƚƐ͘dŚŝƐƚŚĞƐŝƐĚĞŵŽŶƐƚƌĂƚĞƐƚŚĂƚƉŽƐƚŽƉĞƌĂƟǀĞ
mortality was higher with increasing age. The highest mortality rate in the elderly occurs 
ĚƵƌŝŶŐ ƚŚĞĞĂƌůǇƉŽƐƚŽƉĞƌĂƟǀĞƉĞƌŝŽĚ͘23, 38, 39 /ŵƉŽƌƚĂŶƚůǇ͕  ŝŶ ůŝŶĞǁŝƚŚƉƌŝŽƌƉŽƉƵůĂƟŽŶͲ
based studies39-41͕ǁŚĞŶĞůĚĞƌůǇƉĂƟĞŶƚƐƐƵƌǀŝǀĞĚƚŚĞĮƌƐƚǇĞĂƌĂŌĞƌƐƵƌŐĞƌǇ͕ ƐƵƌǀŝǀĂůǁĂƐ
ĐŽŵƉĂƌĂďůĞ ƚŽ ǇŽƵŶŐĞƌƉĂƟĞŶƚƐ͘ dŚŝƐ ĞŵƉŚĂƐŝǌĞƐ ƚŚĂƚ ƐƵƌŐŝĐĂů ƚƌĞĂƚŵĞŶƚŽĨ ĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌ ŝŶ ƚŚĞ ĂŐŝŶŐ ƉŽƉƵůĂƟŽŶ ƌĞŵĂŝŶƐ Ă ĨŽƌŵŝĚĂďůĞ ĐŚĂůůĞŶŐĞ͕ ĂŶĚ ƚŚĞ ĐŚĂŶĐĞƐ ŽĨ Ă
successful outcome with a good quality of life over the remaining life span need to be 
ǁĞŝŐŚĞĚĂŐĂŝŶƐƚƚŚĞƌŝƐŬŽĨƉŽƚĞŶƟĂůĐŽŵƉůŝĐĂƟŽŶƐǁŝƚŚĂĚĞƚƌŝŵĞŶƚĂůŽƵƚĐŽŵĞ͘
½®Ä®½¥ãçÙÝ¥¥ã®Ä¦Ê½ÊÙã½ÄÙãÙãÃÄãÄÝçÙò®ò½
Chronic diseases like diabetes mellitus, mental health problems and cardiovascular 
diseases are an increasing problem in the Western world and generally more common 
among the elderly than younger adults. Many of these diseases are not life threatening 




ƐŽ ĐĂůůĞĚ ďĞŶŝŐŶ ĐŚƌŽŶŝĐ ĐŽŶĚŝƟŽŶƐ͘42 Furthermore, some biological mechanisms that 
ĂƌĞ ĂƐƐŽĐŝĂƚĞĚǁŝƚŚ ĐŽŵŽƌďŝĚŝƚǇŵĂǇ ƉƌĞĚŝƐƉŽƐĞ ƚŽ ĐĂŶĐĞƌ ;Ğ͘Ő͘ ŚĞƉĂƟƟƐ ͕ ĚŝĂďĞƚĞƐ͕
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ƚƵďĞƌĐƵůŽƐŝƐͿ͘43-45tŝƚŚƚŚĞĂŐŝŶŐŽĨƚŚĞƉŽƉƵůĂƟŽŶ͕ĐŽŵŽƌďŝĚŝƚǇĂŵŽŶŐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ
ƉĂƟĞŶƚƐ ŝƐĐŽŵŵŽŶ͘ƐƐŚŽǁŶŝŶƚŚŝƐƚŚĞƐŝƐ͕ƚŚĞƉƌŽƉŽƌƟŽŶŽĨƵƚĐŚĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ




ůŝŬĞůǇ ƚŽ ƌĞĐĞŝǀĞ ĂŶ ĂůƚĞƌĞĚ͕ ůĞƐƐ ŝŶƚĞŶƐŝǀĞ ŽŶĐŽůŽŐŝĐĂů ƚƌĞĂƚŵĞŶƚ ĐŽŵƉĂƌĞĚ ƚŽ ƉĂƟĞŶƚƐ
ǁŝƚŚŽƵƚĐŽŵŽƌďŝĚŝƚǇ͘ &ŽƌŝŶƐƚĂŶĐĞ͕ƉƌĞǀŝŽƵƐƐƚƵĚŝĞƐŚĂǀĞĨŽƵŶĚƚŚĂƚƚŚĞĂĚŵŝŶŝƐƚƌĂƟŽŶŽĨ
ĐŚĞŵŽƚŚĞƌĂƉǇĂŵŽŶŐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐŝƐůŽǁĞƌĂŵŽŶŐƉĂƟĞŶƚƐǁŝƚŚĐŽŵŽƌďŝĚŝƚǇ͕ 
independent of age.46-49ĂŶĐĞƌƉĂƟĞŶƚƐǁŝƚŚĐŽŵŽƌďŝĚŝƚǇŚĂǀĞƉŽŽƌĞƌ ƐƵƌǀŝǀĂů48, 50 and 
quality of life51, 52͘ &ƵƌƚŚĞƌŵŽƌĞ͕ ĚĞůŝǀĞƌǇ ŽĨ ĐĂƌĞ ƚŽ ƉĂƟĞŶƚƐ ǁŝƚŚ ŵƵůƟƉůĞ ƉƌŽďůĞŵƐ
ƌĞƋƵŝƌĞƐĂŐƌĞĂƚĞƌĚŝǀĞƌƐŝƚǇŽĨĞǆƉĞƌƟƐĞƌĞƐƵůƟŶŐŝŶŐƌĞĂƚĞƌĐŽƐƚƐŽĨĐĂƌĞĨŽƌďŽƚŚƉĂƟĞŶƚƐ
as well as the health care system. Between 2003 and 2011 the annual direct costs of cancer 
;ŝŶĐůƵĚŝŶŐďĞŶŝŐŶŶĞŽƉůĂƐŵƐͿĂůƌĞĂĚǇĚŽƵďůĞĚĨƌŽŵϮ͘ϮďŝůůŝŽŶĞƵƌŽƐƚŽϰ͘ϭďŝůůŝŽŶĞƵƌŽƐ͘
dŚĞƐŚĂƌĞŽĨĐŽƐƚƐŝŶƚŽƚĂůĐŽƐƚŽĨƵƚĐŚŚĞĂůƚŚĐĂƌĞǁĂƐϱ͘ϬйŝŶϮϬϬϯĂŶĚϲ͘ϭйŝŶϮϬϭϭ͘53
WƌĞǀŝŽƵƐ ŵĂůŝŐŶĂŶĐǇ ŝƐ Ă ĐŽŵŵŽŶ ĐŽŵŽƌďŝĚ ĚŝƐĞĂƐĞ ŝŶ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ͘ Ɛ
ŵĞŶƟŽŶĞĚ ĂďŽǀĞ͕ ĞĂƌůǇ ĚĞƚĞĐƟŽŶ ŽĨ ĐĂŶĐĞƌ ĂƐ ǁĞůů ĂƐ ĚĞǀĞůŽƉŵĞŶƚƐ ŝŶ ŽŶĐŽůŽŐŝĐĂů
ƚƌĞĂƚŵĞŶƚ ŚĂǀĞ ƌĞƐƵůƚĞĚ ŝŶ Ă ƉƌŽůŽŶŐĞĚ ƐƵƌǀŝǀĂů ƉĞƌŝŽĚ ŽĨ ƟŵĞ ĂŌĞƌ ŵĂŶǇ ƚǇƉĞƐ ŽĨ
ĐĂŶĐĞƌ͘ ĂŶĐĞƌƉĂƟĞŶƚƐǁŚŽƐƵƌǀŝǀĞϱŽƌŵŽƌĞǇĞĂƌƐǁŝƚŚŽƵƚƌĞĐƵƌƌĞŶĐĞƐŽƌŵĞƚĂƐƚĂƐŝƐ
ĂƌĞ ƌĞŐĂƌĚĞĚ ĂƐ ͚ĐůŝŶŝĐĂůůǇ ĐƵƌĞĚ͛͘ ,ŽǁĞǀĞƌ͕  ĐĂŶĐĞƌ ƐƵƌǀŝǀŽƌƐ ĂƌĞ Ăƚ ŝŶĐƌĞĂƐĞĚ ƌŝƐŬ ĨŽƌ Ă
ǀĂƌŝĞƚǇŽĨůĂƚĞĞīĞĐƚƐĂŌĞƌƚƌĞĂƚŵĞŶƚ͕ƐŽŵĞůŝĨĞͲƚŚƌĞĂƚĞŶŝŶŐ͕ƐƵĐŚĂƐƚŚĞĚĞǀĞůŽƉŵĞŶƚŽĨ
secondary tumours. As the number of cancer survivors increases, there is an increase in 
ƉĂƟĞŶƚƐǁŝƚŚŵƵůƟƉůĞŵĂůŝŐŶĂŶĐŝĞƐŽƌƐĞĐŽŶĚƚƵŵŽƵƌƐ͘dŚŝƐĐŽŶĐĞƌŶƐƉĂƌƟĐƵůĂƌůǇŶĂƟŽŶƐ
ǁŝƚŚ Ă ǁĞůůͲĨƵŶĐƟŽŶŝŶŐ ŚĞĂůƚŚ ĐĂƌĞ ƐǇƐƚĞŵ ůŝŬĞ ƚŚĞ EĞƚŚĞƌůĂŶĚƐ͘ dŚĞ ƌĞůĂƟǀĞůǇ ŐŽŽĚ
ƐƵƌǀŝǀĂůƌĂƚĞƐĂŶĚƚŚĞƉƌĞƐĞŶĐĞŽĨĂƉƉƌŽƉƌŝĂƚĞĚŝĂŐŶŽƐƟĐĨĂĐŝůŝƟĞƐŝŶĐƌĞĂƐĞƚŚĞůŝŬĞůŝŚŽŽĚ
ŽĨŵƵůƟƉůĞĐĂŶĐĞƌƐŽĐĐƵƌƌŝŶŐĂŶĚďĞŝŶŐĚĞƚĞĐƚĞĚǁŝƚŚŝŶŽŶĞƉĂƟĞŶƚ͘ŽůŽƌĞĐƚĂůĐĂŶĐĞƌ
is one of the most prevalent second cancers among long-term cancer survivors in the 
Netherlands.54 A second cancer diagnosis may impair survival and undoubtedly result in 
ŵŽƌĞĐŽŵƉůĞǆŽŶĐŽůŽŐŝĐĂůƚƌĞĂƚŵĞŶƚ͘
/Ŷ ƚŚŝƐ ƚŚĞƐŝƐ ǁĞ ĞůĂďŽƌĂƚĞ ŽŶ ƚŚĞ ƚƌĞĂƚŵĞŶƚ ĂŶĚ ŽƵƚĐŽŵĞ ŽĨ ƐǇŶĐŚƌŽŶŽƵƐ ĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌƐ ĂŶĚ ƐŚŽǁ ƚŚĂƚ ϱй ŽĨ ƚŚĞ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ǁĞƌĞ ĚŝĂŐŶŽƐĞĚ ǁŝƚŚ Ă
ƐĞĐŽŶĚĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌǁŝƚŚŝŶϲŵŽŶƚŚƐĂŌĞƌƚŚĞŝŶĚĞǆƚƵŵŽƵƌ͘  /Ŷ ůŝŶĞǁŝƚŚƉƌĞǀŝŽƵƐ
ƐƚƵĚŝĞƐ͕ ƚŚĞƐĞƉĂƟĞŶƚƐǁĞƌĞŵŽƌĞ ůŝŬĞůǇƚŽƵŶĚĞƌŐŽĞǆƚĞŶĚĞĚƐƵƌŐĞƌǇ55, 56 and received 
ůĞƐƐŝŶƚĞŶƐŝǀĞ;ŶĞŽͿĂĚũƵǀĂŶƚƚƌĞĂƚŵĞŶƚĐŽŵƉĂƌĞĚƚŽƉĂƟĞŶƚƐǁŝƚŚŽŶĞĐŽůŽƌĞĐƚĂůƚƵŵŽƵƌ͘ 
ŽŶŇŝĐƟŶŐ ƌĞƐƵůƚƐ ŚĂǀĞ ďĞĞŶ ƌĞƉŽƌƚĞĚ ƌĞŐĂƌĚŝŶŐ ůŽŶŐͲƚĞƌŵ ƉƌŽŐŶŽƐŝƐ ŽĨ ƉĂƟĞŶƚƐǁŝƚŚ
ŵƵůƟƉůĞĐŽůŽƌĞĐƚĂů ƚƵŵŽƵƌƐ͘55, 57, 58 We found that synchronous colorectal cancers were 
ĂƐƐŽĐŝĂƚĞĚǁŝƚŚĂĚĞĐƌĞĂƐĞŝŶƐƵƌǀŝǀĂů͘ƉƌĞǀŝŽƵƐƵƚĐŚƐƚƵĚǇŽĨ>ŝƵĞƚĂů͘ƐŚŽǁĞĚƚŚĂƚ
ĐŽŵƉĂƌĞĚ ƚŽ ƚŚĞ ŐĞŶĞƌĂů ƉŽƉƵůĂƟŽŶ͕ Ă ŚŝŐŚĞƌ ƌŝƐŬ ŽĨ ĚĞǀĞůŽƉŝŶŐ Ă ƐĞĐŽŶĚ ĐŽůŽƌĞĐƚĂů
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ƚƵŵŽƵƌǁĂƐŽďƐĞƌǀĞĚŝŶĂůůƐƵďƐŝƚĞƐŽĨĐŽůŽŶĂŶĚƌĞĐƚƵŵĂŵŽŶŐƉƌĞǀŝŽƵƐƉĂƟĞŶƚƐǁŝƚŚ




ŽĨ ĐůŽƐĞůǇ ŵŽŶŝƚŽƌŝŶŐ ƉĂƟĞŶƚƐ ǁŝƚŚ ƉƌŝŽƌ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŝŶ ŽƌĚĞƌ ƚŽ ĂĐŚŝĞǀĞ ĞĂƌůǇ
ĚĞƚĞĐƟŽŶŽĨĂŶĚƚƌĞĂƚŵĞŶƚĨŽƌĂƉŽƐƐŝďůĞƐĞĐŽŶĚĐŽůŽƌĞĐƚĂůƚƵŵŽƵƌ͘
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YƵĂůŝƚǇ ŽĨ ĐĂŶĐĞƌ ĐĂƌĞ ŝƐ Ă ďƌŽĂĚ ƚĞƌŵ ĂŶĚ ŝƐ ĚŝĸĐƵůƚ ƚŽ ŵĞĂƐƵƌĞ͘ ,ŽǁĞǀĞƌ͕  ŝŶ ƚŚŝƐ
ƚŚĞƐŝƐǁĞŚĂǀĞŵĂĚĞĂ ƐƚĂƌƟŶŐƉŽŝŶƚďǇ ƌĞǀĞĂůŝŶŐ ƚŚĞ ŝŵƉĂĐƚŽĨďŽƚŚĐůŝŶŝĐĂů ;ƉĂƟĞŶƚͲ
ĂŶĚƚƵŵŽƵƌƌĞůĂƚĞĚͿĂŶĚĚĞŵŽŐƌĂƉŚŝĐ ;ŚŽƐƉŝƚĂůͿĚĞƚĞƌŵŝŶĂŶƚƐŽŶƉĂƩĞƌŶƐŽĨĐĂƌĞĂŶĚ
ƐƵƌǀŝǀĂů͕ ƚŚĞƌĞďǇ ĐŽŶƐŝĚĞƌŝŶŐ ŵƵůƟƉůĞ ĐŽŵƉŽŶĞŶƚƐ ƚŚĂƚ ĂƌĞ ŝŶǀŽůǀĞĚ ŝŶ ƚŚĞ ƉƌŽĐĞƐƐ
ŽĨ ƋƵĂůŝƚǇ ŽĨ ĐĂŶĐĞƌ ĐĂƌĞ͘ ǀŝĚĞŶĐĞ ĨƌŽŵ ĐůŝŶŝĐĂů ƚƌŝĂůƐ ŝƐ ƵƐĞĚ ƚŽ ĚĞƚĞƌŵŝŶĞ ƚŚĞ ƌŝŐŚƚ
ƚƌĞĂƚŵĞŶƚ ĨŽƌ ƉĂƟĞŶƚƐǁŝƚŚ ĐĂŶĐĞƌ͘  ǀŝĚĞŶĐĞͲďĂƐĞĚ ŐƵŝĚĞůŝŶĞƐ ĂƌĞ ĚĞǀĞůŽƉĞĚ ƚŽ ŐƵŝĚĞ




of guidelines and evidence-based medicine, the outcome remains dependent on how well 
treatment is delivered.
tŝƚŚ ĐĂŶĐĞƌ ŝŶĐŝĚĞŶĐĞ ŽŶ ƚŚĞ ƌŝƐĞ͕ ƋƵĂůŝƚǇ ŽĨ ĐĂŶĐĞƌ ĐĂƌĞ ƌĂŶŬƐ ŚŝŐŚůǇ ŽŶ ƚŚĞ ƉŽůŝƟĐĂů
ĂŐĞŶĚĂŝŶŵŽƐƚƵƌŽƉĞĂŶĐŽƵŶƚƌŝĞƐ͘dŚĞƌĞŚĂƐďĞĞŶĂŶŝŶĐƌĞĂƐŝŶŐŝŶƚĞƌĞƐƚŝŶŝŵƉƌŽǀŝŶŐ
ƋƵĂůŝƚǇ ŽĨ ĐĂŶĐĞƌ ĐĂƌĞ ĂŶĚ ƚŚĞ ŶĞĞĚ ƚŽ ĨƵƌƚŚĞƌ ŝĚĞŶƟĨǇ ƌĞůŝĂďůĞ ƉĂƌĂŵĞƚĞƌƐ ƚŽ ŐĂŝŶ
ŝŶƐŝŐŚƚŝŶĚŝīĞƌĞŶĐĞƐŝŶƋƵĂůŝƚǇŽĨĐĂƌĞďĞƚǁĞĞŶŝŶƐƟƚƵƟŽŶƐ͘KŶĞĞǆĂŵƉůĞŝƐƚŚĞƉŽƐŝƟǀĞ
ĂƐƐŽĐŝĂƟŽŶďĞƚǁĞĞŶŝŵƉƌŽǀĞĚƐƵƌǀŝǀĂůĂŶĚĐĞŶƚƌĂůŝǌĂƟŽŶŽĨĐŽŵƉůĞǆƐƵƌŐŝĐĂůĐĂŶĐĞƌĐĂƌĞ
ŝŶ ŚŝŐŚ ǀŽůƵŵĞ ŚŽƐƉŝƚĂůƐ ŝŶ ƚƵŵŽƵƌƐǁŝƚŚ ƌĞůĂƟǀĞůǇ ůŽǁ ŝŶĐŝĚĞŶĐĞ ƐƵĐŚ ĂƐ ĞƐŽƉŚĂŐĞĂů
ĂŶĚƉĂŶĐƌĞĂƟĐĐĂŶĐĞƌ͕ ǁŚŝĐŚŚĂƐůĞĚƚŽƚŚĞŝŶƚƌŽĚƵĐƟŽŶŽĨǀŽůƵŵĞƋƵŽƚĂĨŽƌƐƵƌŐĞƌǇŝŶ
several countries.60-62/ŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͕ŝŶĂůůŚŽƐƉŝƚĂůƐƉĂƟĞŶƚƐǁŝƚŚĐŽůŽƌĞĐƚĂůƚƵŵŽƵƌƐ
ĂƌĞ ŽƉĞƌĂƚĞĚ ŽŶ͘ dŚĞ ŶƵŵďĞƌ ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƌĞƐĞĐƟŽŶƐ ƉĞƌ ǇĞĂƌ ƉĞƌ ŚŽƐƉŝƚĂů ŝƐ
ŵƵĐŚŚŝŐŚĞƌ ŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐĐŽŵƉĂƌĞĚƚŽƚŚĞhŶŝƚĞĚ^ƚĂƚĞƐ͕ǁŚĞƌĞŚŝŐŚĞƌŚŽƐƉŝƚĂů
ǀŽůƵŵĞǁĂƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚďĞƩĞƌ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƐƵƌǀŝǀĂů͘ dŚĞŚŽƐƉŝƚĂůƐǁŝƚŚŝŶ ƚŚĞ
lowest volume categories in this thesis would be placed in high volume categories in most 
ƐƚƵĚŝĞƐŽƌŝŐŝŶĂƟŶŐĨƌŽŵƚŚĞhŶŝƚĞĚ^ƚĂƚĞƐ͘63, 64tĞĨŽƵŶĚŶŽĚŝīĞƌĞŶĐĞƐŝŶŽǀĞƌĂůůƐƵƌǀŝǀĂů
ďĞƚǁĞĞŶ ŚŽƐƉŝƚĂů ǀŽůƵŵĞƐ ĨŽƌ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĂŶĚ ŽŶůǇ ŵŝŶŽƌ ĚŝīĞƌĞŶĐĞƐ
ďĞƚǁĞĞŶŚŽƐƉŝƚĂůǀŽůƵŵĞƐŝŶƉŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇ͘/ŶŐĞŶĞƌĂů͕ŽƵƌƚŚĞƐŝƐŝŵƉůŝĞƐƚŚĂƚ
ĨŽƌƚŚĞĐƵƌƌĞŶƚƐŝƚƵĂƟŽŶŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͕ŚŽƐƉŝƚĂůǀŽůƵŵĞŝƐŶŽƚĂĐƌŝƟĐĂůĨĂĐƚŽƌƚŽďĞ
taken into account for future colorectal cancer survival outcome and should not be used 
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ĂƐĂŶŝŶĚŝĐĂƚŽƌƌĞŇĞĐƟŶŐƚŚĞƋƵĂůŝƚǇŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌĐĂƌĞ͘,ŽǁĞǀĞƌ͕ ƚŚĞĐŽŶĐůƵƐŝŽŶƐ
ŽĨƚŚŝƐƐƚƵĚǇĂƌĞŶŽƚĂƉƉůŝĐĂďůĞĨŽƌĂůůĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͘ƐƵďƐƚĂŶƟĂůƉƌŽƉŽƌƟŽŶ
ŽĨ ƉĂƟĞŶƚƐ ǁŝƚŚ ůŽĐĂůůǇ ĂĚǀĂŶĐĞĚ ƌĞĐƚĂů ĐĂŶĐĞƌ ĂƌĞ ƌĞĐŽŵŵĞŶĚĞĚ ƚŽ ďĞ ƌĞĨĞƌƌĞĚ ƚŽ
ƐƉĞĐŝĂůŝǌĞĚĐĞŶƚƌĞƐŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͕ƐŝŶĐĞƚŚĞƐĞƐƵƌŐŝĐĂůƉƌŽĐĞĚƵƌĞƐĂƌĞŵŽƌĞĐŽŵƉůĞǆ͘
ǇƌĞĨĞƌƌŝŶŐƚŚĞƐĞƉĂƟĞŶƚƐ͕ƐƵĸĐŝĞŶƚĞǆƉĞƌƟƐĞŝƐďƵŝůĚŝŶƚŚĞŚŝŐŚǀŽůƵŵĞŚŽƐƉŝƚĂůƐĂŶĚ
bad outcomes are avoided in low volume hospitals.65 A study of Birkmeyer et al. described 
ƚŚĞ ƉŽƚĞŶƟĂů ƉƌŽĐĞƐƐĞƐ ŽĨ ĐĂƌĞ ƚŚĂƚ ŵĂǇ ĞǆƉůĂŝŶ ŝŵƉƌŽǀĞĚ ŽƵƚĐŽŵĞƐ ŝŶ ŚŝŐŚ ǀŽůƵŵĞ
ŚŽƐƉŝƚĂůƐĨŽƌĐŽŵƉůĞǆƐƵƌŐĞƌǇ͘66KŶĞŽĨƚŚĞŵĂŝŶĂƩƌŝďƵƚĞƐĨŽƌŝŵƉƌŽǀĞĚƐƵƌŐŝĐĂůŽƵƚĐŽŵĞ
ǁĂƐĂĚĞƋƵĂƚĞ ƌĞƐŽƵƌĐĞƐ ŝŵďĞĚĚĞĚ ŝŶĂŵƵůƟĚŝƐĐŝƉůŝŶĂƌǇĂƉƉƌŽĂĐŚ͘dŚĞƌĞĨŽƌĞ͕ ŝŶŵĂŶǇ
ŐƵŝĚĞůŝŶĞƐĐŽŶĐĞƌŶŝŶŐĐĂŶĐĞƌĐĂƌĞ͕ĂŵƵůƟĚŝƐĐŝƉůŝŶĂƌǇĂƉƉƌŽĂĐŚŝƐĂĚǀŽĐĂƚĞĚƚŽĂƌƌĂŶŐĞ
ƉƌŽƉĞƌ ĐĂƌĞ ďǇ Ă ƌĂŶŐĞ ŽĨ ƉƌŽĨĞƐƐŝŽŶĂůƐ ǁŝƚŚ ĚŝīĞƌĞŶƚ ďĂĐŬŐƌŽƵŶĚƐ͘67, 68 Other factors 
ĚĞƐĐƌŝďĞĚďǇŝƌŬŵĞǇĞƌĞƚĂů͘ǁĞƌĞĐĂƐĞͲŵŝǆĂŶĚƚŚĞůĞǀĞůŽĨƉĞƌƐŽŶŶĞů Ɛ͛ĞǆƉĞƌƟƐĞĂŶĚƐŬŝůůƐ͘
<ŶŽǁůĞĚŐĞ͕ ĞǆƉĞƌŝĞŶĐĞ ĂŶĚ ƐŬŝůůƐ ŽĨ ŝŶĚŝǀŝĚƵĂů ŵĞĚŝĐĂů ƐƉĞĐŝĂůŝƐƚƐ ƉƌŽǀŝĚŝŶŐ ĐĂƌĞ ĨŽƌ
ĐĂŶĐĞƌƉĂƟĞŶƚƐŵŝŐŚƚǀĂƌǇŝŶƐƵĐŚĂǁĂǇƚŚĂƚŝƚůĞĂĚƐƚŽǀĂƌŝĂƟŽŶďĞƚǁĞĞŶŚŽƐƉŝƚĂůƐĂŶĚ
in outcome. Although evidence-based guidelines were developed to transfer the best 
ĂǀĂŝůĂďůĞ ŬŶŽǁůĞĚŐĞ ŽŶ ĐĂŶĐĞƌ ĐĂƌĞ ƚŽ Ăůů ŵĞĚŝĐĂů ƐƉĞĐŝĂůŝƐƚƐ ƚƌĞĂƟŶŐ ƚŚĞƐĞ ƉĂƟĞŶƚƐ͕
ƌĞĐŽŵŵĞŶĚĂƟŽŶƐŝŶŐƵŝĚĞůŝŶĞƐĂƌĞŶŽƚĂůǁĂǇƐĨŽůůŽǁĞĚůĞĂĚŝŶŐƚŽŝŶƚĞƌͲŚŽƐƉŝƚĂůǀĂƌŝĂƟŽŶ͕
which is observed in previous Dutch studies.20, 69-72dŚĞĐĞŶƚƌĂůƋƵĞƐƟŽŶƌĞŵĂŝŶƐǁŚĞƚŚĞƌ
ŝŶƚĞƌͲŚŽƐƉŝƚĂů ǀĂƌŝĂƟŽŶ ŝƐ ŝŶĂƉƉƌŽƉƌŝĂƚĞ Žƌ ƌĞŇĞĐƚƐ ŐŽŽĚ ƋƵĂůŝƚǇ ŽĨ ĐĂƌĞ͘ /ŶĚŝǀŝĚƵĂůŝǌĞĚ
ƚƌĞĂƚŵĞŶƚ͕ ĞƐƉĞĐŝĂůůǇ ĂŵŽŶŐ ĞůĚĞƌůǇ Žƌ ĨƌĂŐŝůĞ ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ͕ ŝƐ ŽŌĞŶ ĐŽŶƐŝĚĞƌĞĚ ƚŽ
ďĞďĞŶĞĮĐŝĂů͘ /ŶŵĂŶǇŝŶƐƚĂŶĐĞƐƚŚŝƐŵŝŐŚƚůĞĂĚƚŽĂůƚĞƌŶĂƟǀĞŽŶĐŽůŽŐŝĐĂůƚƌĞĂƚŵĞŶƚŽƌ
ĞǀĞŶǁŝƚŚŚŽůĚŝŶŐ ƚƌĞĂƚŵĞŶƚ͘ /Ĩ ƚŚŝƐ ƉƌĞǀĞŶƚƐ ƚƌĞĂƚŵĞŶƚ ƌĞůĂƚĞĚ ĐŽŵƉůŝĐĂƟŽŶƐ ǁŝƚŚŽƵƚ
ĞǆƉŽƐŝŶŐƚŚĞƉĂƟĞŶƚƚŽĂĚŝƐƉƌŽƉŽƌƟŽŶĂƚĞƌŝƐŬŽĨƚƵŵŽƵƌƌĞĐƵƌƌĞŶĐĞŽƌĚĞĂƚŚ͕ƚŚŝƐŵŝŐŚƚ
ďĞĐŽŶƐŝĚĞƌĞĚŐŽŽĚƋƵĂůŝƚǇŽĨĐĂƌĞ͘&ŽƌĞǆĂŵƉůĞ͕ĨŽƌƐƚĂŐĞ///ĐŽůŽŶĐĂŶĐĞƌƉĂƟĞŶƚƐ͕ƚŚĞ
ƟŵĞ ŝŶƚĞƌǀĂů ĨƌŽŵƐƵƌŐĞƌǇ ƚŽ ƚŚĞ ŝŶŝƟĂƟŽŶŽĨ ĐŚĞŵŽƚŚĞƌĂƉǇŚĂƐďĞĞŶƉƌŽƉŽƐĞĚĂƐĂŶ
ŝŵƉŽƌƚĂŶƚ ĨĂĐƚŽƌ ƚŚĂƚ ĐŽƵůĚ ĂīĞĐƚ ƚŚĞ ŽǀĞƌĂůů ŽƵƚĐŽŵĞ͘ /Ŷ ƚŚŝƐ ƚŚĞƐŝƐǁĞ ƐŚŽǁĞĚ ƚŚĂƚ
ŝŶŝƟĂƟŶŐ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ďĞǇŽŶĚ ϴ ǁĞĞŬƐ ǁĂƐ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ Ă ĚĞĐƌĞĂƐĞ ŝŶ

















ŝŶƐŝŐŚƚĂŶĚ ƚŽ ĐĂůĐƵůĂƚĞ ƚŚĞŽǀĞƌĂůů ƉƌŽďĂďŝůŝƚǇŽĨ Ă ƐƉĞĐŝĮĐŽƵƚĐŽŵĞ͘ /Ŷ ƚŚŝƐ ƚŚĞƐŝƐǁĞ
ĚĞǀĞůŽƉĞĚ ĂŶĚ ǀĂůŝĚĂƚĞĚ ƉƌŽŐŶŽƐƟĐŵŽĚĞůƐ ƚŽ ƉƌĞĚŝĐƚ ƉŽƐƚŽƉĞƌĂƟǀĞ ϵϬͲĚĂǇŵŽƌƚĂůŝƚǇ
ĂŶĚŽǀĞƌĂůůƐƵƌǀŝǀĂůĂŵŽŶŐƐƚĂŐĞ/Ͳ///ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐǁŚŽƵŶĚĞƌǁĞŶƚƌĞƐĞĐƟŽŶ͘
Results can be used to develop web-based calculators which are simple to use in everyday 
ƉƌĂĐƟĐĞĂŶĚŵĂǇƉƌŽǀŝĚĞďŽƚŚƉĂƟĞŶƚƐĂŶĚƐƵƌŐĞŽŶƐǁŝƚŚƌĞůĞǀĂŶƚŝŶĨŽƌŵĂƟŽŶƚŽŵĂŬĞ
a shared treatment plan.
FUTURE PERSPECTIVE
ŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ǁĂƐ ŽŶĐĞ ƐĞĞŶ ĂƐ Ă ƐŝŶŐůĞ ĞŶƟƚǇ͕  ŚŽǁĞǀĞƌ͕  ŶŽǁĂĚĂǇƐ ŝƚ ƐŚŽƵůĚ ďĞ
ĚŝǀŝĚĞĚŝŶŵƵůƟƉůĞƐƵďŐƌŽƵƉƐ͘ůĚĞƌůǇƌĞƉƌĞƐĞŶƚĂůĂƌŐĞƉĂƌƚŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͘
ŽŵŽƌďŝĚŝƟĞƐ͕ ǁŚŝĐŚ ĂƌĞ ƉĂƌƟĐƵůĂƌůǇ ĨƌĞƋƵĞŶƚ ŝŶ ĞůĚĞƌůǇ͕  ŝŶĐƌĞĂƐĞ ƚŚĞ ĐŽŵƉůĞǆŝƚǇ ŽĨ
ĐĂŶĐĞƌƚƌĞĂƚŵĞŶƚĂŶĚƐƵƌǀŝǀĂů͘ƐŵĞŶƟŽŶĞĚĂďŽǀĞ͕ƚŚĞĂŐŝŶŐƉŽƉƵůĂƟŽŶĂŶĚƚŚĞƌĞďǇƚŚĞ
ŝŶĐƌĞĂƐŝŶŐŶƵŵďĞƌŽĨĐŽŵŽƌďŝĚŝƟĞƐŝŶĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐƐŚŽƵůĚďĞĐŽŵĞŽŶĞŽĨƚŚĞ




/ŶƚĞƌͲŚŽƐƉŝƚĂů ǀĂƌŝĂƟŽŶ ŝƐƉƌĞƐĞŶƚ ŝŶ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ĐĂƌĞĂŶĚ ƐƵŐŐĞƐƚƐ ƚŚĞƌĞ ŝƐ ƌŽŽŵ
for improvement in outcome. However, to improve quality of cancer care, the whole 
ĐĂƌĞƉƌŽĐĞƐƐƐŚŽƵůĚďĞĂŶĂůǇǌĞĚ͘&ŽĐƵƐŝŶŐŽŶŽŶůǇŽŶĞĨĂĐƚŽƌ;Ğ͘Ő͘ƐƵƌŐĞƌǇͿŝƐŝŶƐƵĸĐŝĞŶƚ








ŐĞƐŚŽƵůĚŶŽƚďĞĂ ůŝŵŝƟŶŐ ĨĂĐƚŽƌ ŝŶ ƚŚĞ ƚƌĞĂƚŵĞŶƚŽĨĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͘dŚĞ
ŵĂŶĂŐĞŵĞŶƚŽĨƚŚĞŚĞƚĞƌŽŐĞŶĞŽƵƐŽůĚĞƌƉĂƟĞŶƚƉŽƉƵůĂƟŽŶƌĞƋƵŝƌĞƐĂƐƚĞƉǁŝƐĞĂƉƉƌŽĂĐŚ
ĂƚĚŝīĞƌĞŶƚƐƚĂŐĞƐŝŶǁŚŝĐŚĂŐĞƌŝĂƚƌŝĐŝĂŶƐŚŽƵůĚďĞŝŶǀŽůǀĞĚ͘/ŶĂƉƌĞǀŝŽƵƐƐƚƵĚǇƚŚĞŶĞĞĚ
for geriatric screening and assessment and the feasibility of including geriatrics in the 
process of oncological care has been shown.75 The inclusion of geriatrics and geriatric 
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ĂƐƐĞƐƐŵĞŶƚƐ ƉƌŽǀŝĚĞƐ ĨƵƌƚŚĞƌ ƌĞĮŶĞŵĞŶƚ ŽĨ ƚŚĞ ƐĞůĞĐƟŽŶ ŽĨ ƚŚĞ ĞůĚĞƌůǇ ǁŚŽ ĐŽƵůĚ
ďĞŶĞĮƚĨƌŽŵƐƚĂŶĚĂƌĚŽŶĐŽůŽŐŝĐĂůƚƌĞĂƚŵĞŶƚƐďĂƐĞĚŽŶŵŽƌďŝĚŝƚǇƉƌŽĮůĞƐŽƌĚĞĮŶĞƚŚĞ






/Ŷ ŽƌĚĞƌ ƚŽ ƌĞĂůŝǌĞ ƉĞƌƐŽŶĂůŝǌĞĚ ĐĂŶĐĞƌ ƚƌĞĂƚŵĞŶƚ͕ ĞīŽƌƚƐ ƐŚŽƵůĚ ďĞ ŵĂĚĞ ƚŽ ĚĞƐŝŐŶ
ƉƌŽƐƉĞĐƟǀĞ ŽďƐĞƌǀĂƟŽŶĂů ƐƚƵĚŝĞƐ ĂŶĚ ĐůŝŶŝĐĂů ƚƌŝĂůƐ ĨŽƌ ƚŚĞ ŚĞƚĞƌŽŐĞŶĞŽƵƐ ĐŽůŽƌĞĐƚĂů
ĐĂŶĐĞƌ ƉĂƟĞŶƚ ƉŽƉƵůĂƟŽŶ͕ ŝŶ ǁŚŝĐŚ ƉĂƟĞŶƚ ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ ĂŶĚ ŽƵƚĐŽŵĞƐ ƐŚŽƵůĚ ďĞ
ĞǀĂůƵĂƚĞĚ͕ ŝŶĐůƵĚŝŶŐ ƋƵĂůŝƚǇ ŽĨ ůŝĨĞ͘ ƵƌƌĞŶƚůǇ͕  Ă ŶĂƟŽŶĂů ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƉƌŽƐƉĞĐƟǀĞ
ĐŽŚŽƌƚƐƚƵĚǇ;W>ZͿ ŝƐƌƵŶŶŝŶŐŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐ͕ ŝŶǁŚŝĐŚĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ
ĂƌĞ ĨŽůůŽǁĞĚ ŽǀĞƌ ƟŵĞ͕ ĂŶĚ ĨƌŽŵ ǁŚŝĐŚ ŝŶĨŽƌŵĂƟŽŶ ĂďŽƵƚ ůŽŶŐͲƚĞƌŵ ĐůŝŶŝĐĂů ĚĂƚĂ͕
ƟƐƐƵĞ ĂŶĚ ďůŽŽĚ ƐĂŵƉůĞƐ͕ ĂŶĚ ƉĂƟĞŶƚͲƌĞƉŽƌƚĞĚ ŽƵƚĐŽŵĞ ŵĞĂƐƵƌĞƐ ǁŝůů ďĞ ĂǀĂŝůĂďůĞ͘
DŽƌĞŽǀĞƌ͕ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚƐƚƵĚŝĞƐƵƐŝŶŐĚĂƚĂůŝŬĞƚŚĞEĞƚŚĞƌůĂŶĚƐĂŶĐĞƌZĞŐŝƐƚƌǇ͕ ǁŝůů
ƌĞŵĂŝŶŶĞĐĞƐƐĂƌǇ ƚŽŽīĞƌ ŝŶƐŝŐŚƚ ŝŶĞǀĞƌǇĚĂǇĐůŝŶŝĐĂůƉƌĂĐƟĐĞ͘dŚĞEĞƚŚĞƌůĂŶĚƐĂŶĐĞƌ
ZĞŐŝƐƚƌǇ ůĂƌŐĞůǇ ĞǆƚĞŶĚĞĚ ŝƚƐ ĚĂƚĂƐĞƚ ĨŽƌ Ăůů ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĚŝĂŐŶŽƐĞĚ ĨƌŽŵ
ϮϬϭϱŽŶǁĂƌĚƐ͘/ƚŶŽǁŝŶĐůƵĚĞƐŵŽƌĞĚĞƚĂŝůĞĚŝŶĨŽƌŵĂƟŽŶƌĞŐĂƌĚŝŶŐĚŝĂŐŶŽƐƟĐƉƌŽĐĞƐƐĞƐ͕
treatment and long-term follow-up regarding tumour progression and recurrence. This 
ŽīĞƌƐƚŚĞƵŶŝƋƵĞƉŽƐƐŝďŝůŝƚǇƚŽĨƵƌƚŚĞƌĞǀĂůƵĂƚĞƚŚĞĞīĞĐƚŽĨƉĂƟĞŶƚ͕ĐůŝŶŝĐĂůĂŶĚŚŽƐƉŝƚĂů
features on treatment choice and long-term survival. Despite a growing body of data, it 
ŝƐŽĨƵƚŵŽƐƚ ŝŵƉŽƌƚĂŶĐĞƚŽĞǀĂůƵĂƚĞǁŚĞƚŚĞƌĐŽŶƟŶƵŽƵƐƌĞŐŝƐƚƌĂƟŽŶŽĨĂůůŽĨ ƚŚŝƐĚĂƚĂ
ŝƐŶĞĞĚĞĚĨŽƌƌĞƐĞĂƌĐŚƉƵƌƉŽƐĞƐ͘dŚĞǀĂůŝĚŝƚǇĂŶĚƉƌŽŐŶŽƐƟĐƐŝŐŶŝĮĐĂŶĐĞŽĨĐĞƌƚĂŝŶĚĂƚĂ
ŝƚĞŵƐŵĂǇďĞ ůĂĐŬŝŶŐ͘ dŚĞƌĞĨŽƌĞ ŝƚ ŝƐ ƚƌŝǀŝĂů ƚŚĂƚĚĂƚĂƐĞƚƐ ĂƌĞĞǀĂůƵĂƚĞĚĂŶĚ ƌĞĮŶĞĚ ƚŽ
ensure their clinical relevance. 
CONCLUDING REMARKS
This thesis reports numerous real-world aspects of colorectal cancer survival in the 




Ă ĚĞĐƌĞĂƐĞ ŝŶ ƐƵƌǀŝǀĂů͘ tĞ ĂůƐŽ ĚĞŵŽŶƐƚƌĂƚĞ ƚŚĞ ĞīĞĐƚ ŽĨ ǀĂƌŝĂƟŽŶ ŝŶ ĚĞŵŽŐƌĂƉŚŝĐ
ĚĞƚĞƌŵŝŶĂŶƚƐ;ŚŽƐƉŝƚĂůǀŽůƵŵĞĂŶĚƟŵŝŶŐƚŽĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇͿŽŶĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ





ϭ͘ ŝŶĚŚŽǀĞŶĂŶĐĞƌZĞŐŝƐƚƌǇ͘ ͞ZĞƐƵůƚƐ ŽĨ ϱϬ
years cancer registry in the south of the 
EĞƚŚĞƌůĂŶĚƐϭϵϱϱͲϮϬϬϰ;ŝŶƵƚĐŚͿ͘͟ ϮϬϬϱ͘
Ϯ͘ ǀĂŶ >ĞĞƌƐƵŵ E:͕ :ĂŶƐƐĞŶͲ,ĞŝũŶĞŶ D>͕
tŽƵƚĞƌƐ Dt͕ ZƵƩĞŶ ,:͕ ŽĞďĞƌŐŚ :t͕
dŽůůĞŶĂĂƌ Z͕ Ğƚ Ăů͘ /ŶĐƌĞĂƐŝŶŐ ƉƌĞǀĂůĞŶĐĞ
ŽĨ ĐŽŵŽƌďŝĚŝƚǇ ŝŶ ƉĂƟĞŶƚƐǁŝƚŚ ĐŽůŽƌĞĐƚĂů
cancer in the South of the Netherlands 
ϭϵϵϱͲϮϬϭϬ͘/Ŷƚ:ĂŶĐĞƌ͘ ϮϬϭϯ͖ϭϯϮ;ϵͿ͗ϮϭϱϳͲ
63.
ϯ͘ dŚǇŐĞƐĞŶ >͕ ƌƐďŽůů <͘tŚĞŶ ƚŚĞ ĞŶƟƌĞ
ƉŽƉƵůĂƟŽŶ ŝƐ ƚŚĞ ƐĂŵƉůĞ͗ ƐƚƌĞŶŐƚŚƐ ĂŶĚ
ůŝŵŝƚĂƟŽŶƐ ŝŶƌĞŐŝƐƚĞƌͲďĂƐĞĚĞƉŝĚĞŵŝŽůŽŐǇ͘
Ƶƌ:ƉŝĚĞŵŝŽů͘ϮϬϭϰ͖Ϯϵ;ϴͿ͗ϱϱϭͲϴ͘
ϰ͘ ,ĞƌƐŚŵĂŶ >͕ tƌŝŐŚƚ :͘ ŽŵƉĂƌĂƟǀĞ
ĞīĞĐƟǀĞŶĞƐƐ ƌĞƐĞĂƌĐŚ ŝŶ ŽŶĐŽůŽŐǇ




ƚƌĞĂƚĞĚ ǁŝƚŚŝŶ ĂŶĚ ŽƵƚƐŝĚĞ ĐůŝŶŝĐĂů ƚƌŝĂůƐ͗
conceptual framework and structured 
ƌĞǀŝĞǁ͘>ĂŶĐĞƚ͘ϮϬϬϰ͖ϯϲϯ;ϵϰϬϱͿ͗ϮϲϯͲϳϬ͘




ϳ͘ ŽŽƚŚ D͕ dĂŶŶŽĐŬ /&͘  ǀĂůƵĂƟŽŶ ŽĨ
ƚƌĞĂƚŵĞŶƚ ďĞŶĞĮƚ͗ ƌĂŶĚŽŵŝǌĞĚ ĐŽŶƚƌŽůůĞĚ
ƚƌŝĂůƐ ĂŶĚ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ŽďƐĞƌǀĂƟŽŶĂů
ƌĞƐĞĂƌĐŚ͘:ůŝŶKŶĐŽů͘ϮϬϭϯ͖ϯϭ;ϮϲͿ͗ϯϮϵϴͲϵ͘
ϴ͘  ͛ŐŽƐƟŶŽ Z͕ :ƌ͘ ͕  ͛ŐŽƐƟŶŽ Z͕ ^ƌ͘ 
ƐƟŵĂƟŶŐ ƚƌĞĂƚŵĞŶƚ ĞīĞĐƚƐ ƵƐŝŶŐ
ŽďƐĞƌǀĂƟŽŶĂůĚĂƚĂ͘:D͘ϮϬϬϳ͖Ϯϵϳ;ϯͿ͗ϯϭϰͲ
6.
9. Netherlands Cancer Registry. Cijfers over 
ŬĂŶŬĞƌ͘  ΀ϯͲϴͲϮϬϭϳ΁͘ ǀĂŝůĂďůĞ ĨƌŽŵ͗ ŚƩƉ͗ͬͬ
ǁǁǁ͘ĐŝũĨĞƌƐŽǀĞƌŬĂŶŬĞƌ͘ Ŷůͬ͘
ϭϬ͘ ƵƐƟŶ,͕,ĞŶůĞǇ^:͕<ŝŶŐ:͕ZŝĐŚĂƌĚƐŽŶ>͕
ŚĞŵĂŶ ͘ ŚĂŶŐĞƐ ŝŶ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ
incidence rates in young and older adults 
ŝŶ ƚŚĞ hŶŝƚĞĚ ^ƚĂƚĞƐ͗ ǁŚĂƚ ĚŽĞƐ ŝƚ ƚĞůů ƵƐ
about screening. Cancer Causes Control. 
ϮϬϭϰ͖Ϯϱ;ϮͿ͗ϭϵϭͲϮϬϭ͘
ϭϭ͘ DĂŶĚĞů :^͕ ŚƵƌĐŚ dZ͕ ŽŶĚ :,͕ ĚĞƌĞƌ &͕ 
'ĞŝƐƐĞƌ D^͕ DŽŶŐŝŶ ^:͕ Ğƚ Ăů͘ dŚĞ ĞīĞĐƚ
of fecal occult-blood screening on the 
ŝŶĐŝĚĞŶĐĞ ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͘  E ŶŐů :
DĞĚ͘ϮϬϬϬ͖ϯϰϯ;ϮϮͿ͗ϭϲϬϯͲϳ͘
ϭϮ͘ ĂƵďĞƌ '͘ dŚĞ ŝŵƉĂĐƚ ŽĨ ƐĐƌĞĞŶŝŶŐ ŽŶ




CS, Fraser CG, Carey FA, Steele RJ, et 
Ăů͘ /ŵƉĂĐƚ ŽĨ ƚŚĞ h< ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ
screening pilot studies on incidence, stage 
ĚŝƐƚƌŝďƵƟŽŶ ĂŶĚ ŵŽƌƚĂůŝƚǇ ƚƌĞŶĚƐ͘ ĂŶĐĞƌ
ƉŝĚĞŵŝŽů͘ϮϬϭϮ͖ϯϲ;ϰͿ͗ĞϮϯϮͲϰϮ͘
14. Papamichael D, Audisio RA, Glimelius B, 
de Gramont A, Glynne-Jones R, Haller 
D, et al. Treatment of colorectal cancer 
ŝŶ ŽůĚĞƌ ƉĂƟĞŶƚƐ͗ /ŶƚĞƌŶĂƟŽŶĂů ^ŽĐŝĞƚǇ
ŽĨ 'ĞƌŝĂƚƌŝĐ KŶĐŽůŽŐǇ ;^/K'Ϳ ĐŽŶƐĞŶƐƵƐ
ƌĞĐŽŵŵĞŶĚĂƟŽŶƐ ϮϬϭϯ͘ ŶŶ KŶĐŽů͘
ϮϬϭϱ͖Ϯϲ;ϯͿ͗ϰϲϯͲϳϲ͘
15. Netherlands Comprehensive Cancer 
KƌŐĂŶŝƐĂƟŽŶ͘ EĂƟŽŶĂů ǀŝĚĞŶĐĞ ĂƐĞĚ
Guideline for Colon and Rectal Cancer 2014 
΀ϯͲϴͲϮϬϭϳ΁͘ ǀĂŝůĂďůĞ ĨƌŽŵ͗ ŚƩƉ͗ͬͬǁǁǁ͘
ŽŶĐŽůŝŶĞ͘ŶůͬĐŽůŽŶĐĂƌĐŝŶŽŽŵ͘
ϭϲ͘ ǀĂŶ^ƚĞĞŶďĞƌŐĞŶ>E͕>ĞŵŵĞŶƐs͕ZƵƩĞŶ
,:͕ tǇŵĞŶŐĂ E͕ EŽƌƟĞƌ :t͕ :ĂŶƐƐĞŶͲ
,ĞŝũŶĞŶD>͘/ŶĐƌĞĂƐĞĚĂĚũƵǀĂŶƚƚƌĞĂƚŵĞŶƚ
ĂŶĚ ŝŵƉƌŽǀĞĚ ƐƵƌǀŝǀĂů ŝŶ ĞůĚĞƌůǇ ƐƚĂŐĞ ///
ĐŽůŽŶ ĐĂŶĐĞƌƉĂƟĞŶƚƐ ŝŶ dŚĞEĞƚŚĞƌůĂŶĚƐ͘
ŶŶKŶĐŽů͘ϮϬϭϮ͖Ϯϯ;ϭϭͿ͗ϮϴϬϱͲϭϭ͘
ϭϳ͘ <ĂŚŶ<>͕ĚĂŵƐ :>͕tĞĞŬƐ :͕ ŚƌŝƐĐŚŝůůĞƐ
͕ ^ĐŚƌĂŐ ͕ ǇĂŶŝĂŶ :͕ Ğƚ Ăů͘ ĚũƵǀĂŶƚ
chemotherapy use and adverse events 
ĂŵŽŶŐ ŽůĚĞƌ ƉĂƟĞŶƚƐ ǁŝƚŚ ƐƚĂŐĞ /// ĐŽůŽŶ
ĐĂŶĐĞƌ͘ :D͘ϮϬϭϬ͖ϯϬϯ;ϭϭͿ͗ϭϬϯϳͲϰϱ͘
ϭϴ͘ ^ĂŶŽī ,<͕ ĂƌƉĞŶƚĞƌ tZ͕ ^ƚƵƌŵĞƌ d͕ 
'ŽůĚďĞƌŐ ZD͕ DĂƌƟŶ &͕  &ŝŶĞ :W͕  Ğƚ Ăů͘
īĞĐƚ ŽĨ ĂĚũƵǀĂŶƚ ĐŚĞŵŽƚŚĞƌĂƉǇ ŽŶ
ƐƵƌǀŝǀĂů ŽĨ ƉĂƟĞŶƚƐ ǁŝƚŚ ƐƚĂŐĞ /// ĐŽůŽŶ
ĐĂŶĐĞƌĚŝĂŐŶŽƐĞĚĂŌĞƌĂŐĞϳϱǇĞĂƌƐ͘:ůŝŶ
KŶĐŽů͘ϮϬϭϮ͖ϯϬ;ϮϭͿ͗ϮϲϮϰͲϯϰ͘
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ϭϵ͘ ^ĐŚƌĂŐ ͕ ƌĂŵĞƌ >͕ ĂĐŚ W͕ ĞŐŐ ͘
ŐĞĂŶĚĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇƵƐĞĂŌĞƌ
ƐƵƌŐĞƌǇ ĨŽƌ ƐƚĂŐĞ /// ĐŽůŽŶ ĐĂŶĐĞƌ͘  : EĂƚů
ĂŶĐĞƌ/ŶƐƚ͘ϮϬϬϭ͖ϵϯ;ϭϭͿ͗ϴϱϬͲϳ͘
ϮϬ͘ ǀĂŶ ƌŶŝŶŐ &E͕ ĞƌŶĂƌĚƐ E͕ ƌĞĞŵĞƌƐ ':͕
sƌĞƵŐĚĞŶŚŝů ͕ >ĞŶƐĞŶ :͕ >ĞŵŵĞŶƐ s͘
ĚŵŝŶŝƐƚƌĂƟŽŶ ŽĨ ĂĚũƵǀĂŶƚ ŽǆĂůŝƉůĂƟŶ
ƚŽ ƉĂƟĞŶƚƐ ǁŝƚŚ ƐƚĂŐĞ /// ĐŽůŽŶ ĐĂŶĐĞƌ ŝƐ
ĂīĞĐƚĞĚ ďǇ ĂŐĞ ĂŶĚ ŚŽƐƉŝƚĂů͘ ĐƚĂ KŶĐŽů͘
ϮϬϭϰ͖ϱϯ;ϳͿ͗ϵϳϱͲϴϬ͘





surgeons and medical oncologists. J Geriatr 
KŶĐŽů͘ϮϬϭϱ͖ϲ;ϯͿ͗ϮϭϵͲϮϰ͘
ϮϮ͘ ǀĂŶ ^ƚĞĞŶďĞƌŐĞŶ >E͕ZƵƩĞŶ,:͕ ƌĞĞŵĞƌƐ
':͕ WƌƵŝũƚ :&͕  ŽĞďĞƌŐŚ :t͕ >ĞŵŵĞŶƐ
s͘ >ĂƌŐĞ ĂŐĞ ĂŶĚ ŚŽƐƉŝƚĂůͲĚĞƉĞŶĚĞŶƚ
ǀĂƌŝĂƟŽŶ ŝŶ ĂĚŵŝŶŝƐƚƌĂƟŽŶ ŽĨ ĂĚũƵǀĂŶƚ
ĐŚĞŵŽƚŚĞƌĂƉǇ ĨŽƌ ƐƚĂŐĞ /// ĐŽůŽŶ ĐĂŶĐĞƌ
in southern Netherlands. Ann Oncol. 
ϮϬϭϬ͖Ϯϭ;ϲͿ͗ϭϮϳϯͲϴ͘
23. Surgery for colorectal cancer in elderly 
ƉĂƟĞŶƚƐ͗ Ă ƐǇƐƚĞŵĂƟĐ ƌĞǀŝĞǁ͘ ŽůŽƌĞĐƚĂů
ĂŶĐĞƌ ŽůůĂďŽƌĂƟǀĞ 'ƌŽƵƉ͘ >ĂŶĐĞƚ͘
ϮϬϬϬ͖ϯϱϲ;ϵϮϯϰͿ͗ϵϲϴͲϳϰ͘
Ϯϰ͘ ^ƉĞĞůŵĂŶ ͕ ǀĂŶ 'ĞƐƚĞů zZ͕ ZƵƩĞŶ ,:͕
ĚĞ ,ŝŶŐŚ /,͕ >ĞŵŵĞŶƐ s͘ ŚĂŶŐĞƐ ŝŶ
ŐĂƐƚƌŽŝŶƚĞƐƟŶĂůĐĂŶĐĞƌƌĞƐĞĐƟŽŶƌĂƚĞƐ͘ƌ:
^ƵƌŐ͘ϮϬϭϱ͖ϭϬϮ;ϵͿ͗ϭϭϭϰͲϮϮ͘
Ϯϱ͘ ƉĂƌŝĐŝŽ d͕  EĂǀĂǌĞƐŚ ͕ ŽƵƚƌŽŶ /͕
Bouarioua N, Chosidow D, Mion M, et al. 
,ĂůĨŽĨĞůĚĞƌůǇƉĂƟĞŶƚƐƌŽƵƟŶĞůǇƚƌĞĂƚĞĚĨŽƌ
colorectal cancer receive a sub-standard 
treatment. Crit Rev Oncol Hematol. 
ϮϬϬϵ͖ϳϭ;ϯͿ͗ϮϰϵͲϱϳ͘
26. Audisio RA, Papamichael D. Treatment of 
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌŝŶŽůĚĞƌƉĂƟĞŶƚƐ͘EĂƚZĞǀ
'ĂƐƚƌŽĞŶƚĞƌŽů,ĞƉĂƚŽů͘ϮϬϭϮ͖ϵ;ϭϮͿ͗ϳϭϲͲϮϱ͘
Ϯϳ͘ ŶŐĞůĞŶ ^D͕ ĞĞƚƐͲdĂŶ Z'͕ >ĂŚĂǇĞ D:͕
>ĂŵŵĞƌŝŶŐ'͕:ĂŶƐĞŶZ>͕ǀĂŶĂŵZD͕Ğƚ
Ăů͘DZ/ ĂŌĞƌ ĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉǇ ŽĨ ƌĞĐƚĂů
ĐĂŶĐĞƌ͗ Ă ƵƐĞĨƵů ƚŽŽů ƚŽ ƐĞůĞĐƚ ƉĂƟĞŶƚƐ
ĨŽƌ ůŽĐĂů ĞǆĐŝƐŝŽŶ͘ ŝƐ ŽůŽŶ ZĞĐƚƵŵ͘
ϮϬϭϬ͖ϱϯ;ϳͿ͗ϵϳϵͲϴϲ͘
Ϯϴ͘ >ĞƵŅĞŶƐ D͕ ǀĂŶ ĚĞŶ ŽƐĐŚ D͕ ǀĂŶ
>ĞĞƵǁĞŶ D^͕ ^ŝĞƌƐĞŵĂ W͘ ŝĂŐŶŽƐƟĐ
accuracy of computed tomography for 
ĐŽůŽŶ ĐĂŶĐĞƌ ƐƚĂŐŝŶŐ͗ Ă ƐǇƐƚĞŵĂƟĐ ƌĞǀŝĞǁ͘
^ĐĂŶĚ : 'ĂƐƚƌŽĞŶƚĞƌŽů͘ ϮϬϭϭ͖ϰϲ;ϳͲϴͿ͗ϴϴϳͲ
94.
Ϯϵ͘ ZŽůůǀĞŶ ͕ ,Žůŵ d͕  'ůŝŵĞůŝƵƐ ͕ >ŽƌŝŶĐ ͕
ůŽŵƋǀŝƐƚ >͘ WŽƚĞŶƟĂůƐ ŽĨ ŚŝŐŚ ƌĞƐŽůƵƟŽŶ
ŵĂŐŶĞƟĐ ƌĞƐŽŶĂŶĐĞ ŝŵĂŐŝŶŐ ǀĞƌƐƵƐ
ĐŽŵƉƵƚĞĚ ƚŽŵŽŐƌĂƉŚǇ ĨŽƌ ƉƌĞŽƉĞƌĂƟǀĞ
local staging of colon cancer. Acta Radiol. 
ϮϬϭϯ͖ϱϰ;ϳͿ͗ϳϮϮͲϯϬ͘
ϯϬ͘ ^ĐŽƩE͕,ŝůů:͕^ŵŝƚŚ:͕tĂůŬĞƌ<͕<ƵƌǇďĂ͕
ǀĂŶ ĚĞƌDĞƵůĞŶ :͘ EĂƟŽŶĂů ŽǁĞů ĂŶĐĞƌ
Audit Annual Report 2013. Health and 
^ŽĐŝĂů ĂƌĞ /ŶĨŽƌŵĂƟŽŶ ĞŶƚƌĞ͗ >ĞĞĚƐ͗
2013.
ϯϭ͘ ZƵƩĞŶ,:͕ĚĞŶƵůŬD͕ >ĞŵŵĞŶƐs͕ ǀĂŶ
de Velde CJ, Marijnen CA. Controversies 
ŽĨ ƚŽƚĂů ŵĞƐŽƌĞĐƚĂů ĞǆĐŝƐŝŽŶ ĨŽƌ ƌĞĐƚĂů
ĐĂŶĐĞƌ ŝŶ ĞůĚĞƌůǇ ƉĂƟĞŶƚƐ͘ >ĂŶĐĞƚ KŶĐŽů͘
ϮϬϬϴ͖ϵ;ϱͿ͗ϰϵϰͲϱϬϭ͘
ϯϮ͘ ^ĞƌƌĂͲƌĂĐŝů y͕ DŽƌĂͲ>ŽƉĞǌ >͕ ůĐĂŶƚĂƌĂͲ
Moral M, Corredera-Cantarin C, Gomez-
ŝĂǌ͕EĂǀĂƌƌŽͲ^ŽƚŽ^͘ƚǇƉŝĐĂůŝŶĚŝĐĂƟŽŶƐ
for transanal endoscopic microsurgery 
to avoid major surgery. Tech Coloproctol. 
ϮϬϭϰ͖ϭϴ;ϮͿ͗ϭϱϳͲϲϰ͘
33. Habr-Gama A, Perez RO, Nadalin W, 
^ĂďďĂŐĂ:͕ZŝďĞŝƌŽh͕:ƌ͘ ͕^ŝůǀĂĞ^ŽƵƐĂ,͕
:ƌ͘ ͕ Ğƚ Ăů͘ KƉĞƌĂƟǀĞ ǀĞƌƐƵƐ ŶŽŶŽƉĞƌĂƟǀĞ
treatment for stage 0 distal rectal cancer 
ĨŽůůŽǁŝŶŐ ĐŚĞŵŽƌĂĚŝĂƟŽŶ ƚŚĞƌĂƉǇ͗ ůŽŶŐͲ
ƚĞƌŵƌĞƐƵůƚƐ͘ŶŶ^ƵƌŐ͘ϮϬϬϰ͖ϮϰϬ;ϰͿ͗ϳϭϭͲϳ͖
discussion 7-8.
ϯϰ͘ KŶŐ ^͕ ůĂƐƐĂƐ D͕ ƵŶŶ <͕ ZĂũƉƵƚ ͘
ŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƐƵƌŐĞƌǇ ŝŶ ƚŚĞ ĞůĚĞƌůǇ͗
ĂĐĐĞƉƚĂďůĞ ŵŽƌďŝĚŝƚǇ͍ ŵ : ^ƵƌŐ͘
ϮϬϬϴ͖ϭϵϱ;ϯͿ͗ϯϰϰͲϴ͖ĚŝƐĐƵƐƐŝŽŶϴ͘
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ϯϱ͘ dĂŶ <z͕  <ĂǁĂŵƵƌĂ z͕  DŝǌŽŬĂŵŝ <͕ ^ĂƐĂŬŝ
J, Tsujinaka S, Maeda T, et al. Colorectal 




^͕ >ĞŵŵĞŶƐ s͕ ZƵƩĞŶ ,:͕ ŽĞďĞƌŐŚ
JW. Comorbidity in older surgical cancer 
ƉĂƟĞŶƚƐ͗ ŝŶŇƵĞŶĐĞ ŽŶ ƉĂƟĞŶƚ ĐĂƌĞ ĂŶĚ
ŽƵƚĐŽŵĞ͘ Ƶƌ : ĂŶĐĞƌ͘  ϮϬϬϳ͖ϰϯ;ϭϱͿ͗ϮϭϳϵͲ
93.
ϯϳ͘ >ĞŵŵĞŶƐ s͕ :ĂŶƐƐĞŶͲ,ĞŝũŶĞŶ D>͕
,ŽƵƚĞƌŵĂŶ ^͕ sĞƌŚĞŝũ <͕ DĂƌƟũŶ ,͕ ǀĂŶ
ĚĞ WŽůůͲ&ƌĂŶƐĞ >͕ Ğƚ Ăů͘ tŚŝĐŚ ĐŽŵŽƌďŝĚ





ƌĞƐĞĐƟŽŶƐ ŝŶ ƉĂƟĞŶƚƐ ĂŐĞĚ ϴϬ ǇĞĂƌƐ ĂŶĚ
ŽůĚĞƌ͗ ĐůŝŶŝĐĂů ĐŚĂƌĂĐƚĞƌŝƐƟĐƐ͕ ŵŽƌďŝĚŝƚǇ͕ 









Kwaan M, Spencer MP, Henderson WG, 
Ğƚ Ăů͘ KƉĞƌĂƟǀĞ ŽƵƚĐŽŵĞƐ ďĞǇŽŶĚ ϯϬͲĚĂǇ
ŵŽƌƚĂůŝƚǇ͗ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƐƵƌŐĞƌǇ ŝŶ
ŽůĚĞƐƚŽůĚ͘ŶŶ^ƵƌŐ͘ϮϬϭϭ͖Ϯϱϯ;ϱͿ͗ϵϰϳͲϱϮ͘
ϰϭ͘ DŽƌƌŝƐ:͕^ ĂŶĚŝŶ&͕ >ĂŵďĞƌƚW͕ƌĂǇ&͕ <ůŝŶƚ
͕ >ŝŶŬůĂƚĞƌ <͕ Ğƚ Ăů͘  ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ
ĐŽŵƉĂƌŝƐŽŶ ŽĨ ƚŚĞ ƐƵƌǀŝǀĂů ŽĨ ƉĂƟĞŶƚƐ
ǁŝƚŚĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ ŝŶŶŐůĂŶĚ͕EŽƌǁĂǇ
and Sweden between 1996 and 2004. Gut. 
ϮϬϭϭ͖ϲϬ;ϴͿ͗ϭϬϴϳͲϵϯ͘
ϰϮ͘ ǆƚĞƌŵĂŶŶ D͘ /ŶƚĞƌĂĐƟŽŶ ďĞƚǁĞĞŶ
comorbidity and cancer. Cancer Control. 
ϮϬϬϳ͖ϭϰ;ϭͿ͗ϭϯͲϮϮ͘
ϰϯ͘ 'ŝŽǀĂŶŶƵĐĐŝ ͕ ,ĂƌůĂŶ D͕ ƌĐŚĞƌ D͕
ĞƌŐĞŶƐƚĂůZD͕'ĂƉƐƚƵƌ^ D͕,ĂďĞů>͕ĞƚĂů͘
ŝĂďĞƚĞƐ ĂŶĚ ĐĂŶĐĞƌ͗ Ă ĐŽŶƐĞŶƐƵƐ ƌĞƉŽƌƚ͘
ŝĂďĞƚĞƐĂƌĞ͘ϮϬϭϬ͖ϯϯ;ϳͿ͗ϭϲϳϰͲϴϱ͘
ϰϰ͘ ^ĐŚƵƩĞ <͕ ŽƌŶƐĐŚĞŝŶ :͕ DĂůĨĞƌƚŚĞŝŶĞƌ W͘ 
Hepatocellular carcinoma--epidemiological 
trends and risk factors. Dig Dis. 
ϮϬϬϵ͖Ϯϳ;ϮͿ͗ϴϬͲϵϮ͘
ϰϱ͘ tƵz͕ ,Ƶ,z͕ WƵz͕ ,ƵĂŶŐE͕^ŚĞŶ,͕>ŝ




impact of chronic illnesses on the use and 
ĞīĞĐƟǀĞŶĞƐƐŽĨĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇĨŽƌ
ĐŽůŽŶĐĂŶĐĞƌ͘ ĂŶĐĞƌ͘ ϮϬϬϳ͖ϭϬϵ;ϭϮͿ͗ϮϰϭϬͲϵ͘
ϰϳ͘ :ĂŶƐƐĞŶͲ,ĞŝũŶĞŶ D>͕ ,ŽƵƚĞƌŵĂŶ ^͕
>ĞŵŵĞŶƐ s͕ >ŽƵǁŵĂŶ Dt͕ DĂĂƐ
,͕ ŽĞďĞƌŐŚ :t͘ WƌŽŐŶŽƐƟĐ ŝŵƉĂĐƚ ŽĨ




CD, Houterman S, Repelaer van Driel OJ, 
Coebergh JW. Co-morbidity leads to altered 
treatment and worse survival of elderly 




on the use of adjuvant chemotherapy and 
ƐƵƌǀŝǀĂůĨƌŽŵĐŽůŽŶĐĂŶĐĞƌ͗ĂƌĞƚƌŽƐƉĞĐƟǀĞ
ĐŽŚŽƌƚƐƚƵĚǇ͘DĂŶĐĞƌ͘ ϮϬϬϵ͖ϵ͗ϭϭϲ͘
ϱϬ͘ /ǀĞƌƐĞŶ >,͕ EŽƌŐĂĂƌĚ D͕ :ĂĐŽďƐĞŶ :͕
>ĂƵƌďĞƌŐ ^͕ ^ŽƌĞŶƐĞŶ ,d͘  dŚĞ ŝŵƉĂĐƚ
of comorbidity on survival of Danish 
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƉĂƟĞŶƚƐ ĨƌŽŵ ϭϵϵϱ ƚŽ
ϮϬϬϲͲͲĂƉŽƉƵůĂƟŽŶͲďĂƐĞĚĐŽŚŽƌƚƐƚƵĚǇ͘ŝƐ
ŽůŽŶZĞĐƚƵŵ͘ϮϬϬϵ͖ϱϮ;ϭͿ͗ϳϭͲϴ͘
ϱϭ͘ &ŽƌƟŶ D͕ ƌĂǀŽ '͕ ,ƵĚŽŶ ͕ >ĂƉŽŝŶƚĞ >͕
ůŵŝƌĂůů :͕ ƵďŽŝƐ D&͕  Ğƚ Ăů͘ ZĞůĂƟŽŶƐŚŝƉ
ďĞƚǁĞĞŶ ŵƵůƟŵŽƌďŝĚŝƚǇ ĂŶĚ ŚĞĂůƚŚͲ
ƌĞůĂƚĞĚƋƵĂůŝƚǇŽĨůŝĨĞŽĨƉĂƟĞŶƚƐŝŶƉƌŝŵĂƌǇ
ĐĂƌĞ͘YƵĂů>ŝĨĞZĞƐ͘ϮϬϬϲ͖ϭϱ;ϭͿ͗ϴϯͲϵϭ͘
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ϱϮ͘ DƵŬŚĞƌũĞĞ͕KƵ,d͕ tĂŶŐ&͕ ƌŝĐŬƐŽŶ^Z͘
ŶĞǁĐŽŵŽƌďŝĚŝƚǇŝŶĚĞǆ͗ƚŚĞŚĞĂůƚŚͲƌĞůĂƚĞĚ
ƋƵĂůŝƚǇ ŽĨ ůŝĨĞ ĐŽŵŽƌďŝĚŝƚǇ ŝŶĚĞǆ͘ : ůŝŶ
ƉŝĚĞŵŝŽů͘ϮϬϭϭ͖ϲϰ;ϯͿ͗ϯϬϵͲϭϵ͘




ϱϰ͘ >ŝƵ >͕ ĚĞ sƌŝĞƐ ͕ >ŽƵǁŵĂŶ D͕ ďĞŶ
K, Janssen-Heijnen M, Brink M, et al. 
WƌĞǀĂůĞŶĐĞ ŽĨ ŵƵůƟƉůĞ ŵĂůŝŐŶĂŶĐŝĞƐ ŝŶ
ƚŚĞ EĞƚŚĞƌůĂŶĚƐ ŝŶ ϮϬϬϳ͘ /Ŷƚ : ĂŶĐĞƌ͘ 
ϮϬϭϭ͖ϭϮϴ;ϳͿ͗ϭϲϱϵͲϲϳ͘
55. Mulder SA, Kranse R, Damhuis RA, de 
tŝůƚ :,͕ KƵǁĞŶĚŝũŬ Z:͕ <ƵŝƉĞƌƐ :͕ Ğƚ Ăů͘
Prevalence and prognosis of synchronous 
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͗ĂƵƚĐŚƉŽƉƵůĂƟŽŶͲďĂƐĞĚ
ƐƚƵĚǇ͘ĂŶĐĞƌƉŝĚĞŵŝŽů͘ϮϬϭϭ͖ϯϱ;ϱͿ͗ϰϰϮͲϳ͘
ϱϲ͘ ǀĂŶ >ĞĞƌƐƵŵ E:͕ ĂůďĞƌƐ '͕ ^ŶŝũĚĞƌƐ ,^͕
Henneman D, Wouters MW, Tollenaar RA, 
ĞƚĂů͘^ǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂƌĐŝŶŽŵĂ͗Ă
risk factor in colorectal cancer surgery. Dis 
ŽůŽŶZĞĐƚƵŵ͘ϮϬϭϰ͖ϱϳ;ϰͿ͗ϰϲϬͲϲ͘
ϱϳ͘ >ĂƚŽƵƌŶĞƌŝĞD͕ :ŽŽƐƚĞ s͕ ŽƩĞƚ s͕ >ĞƉĂŐĞ
͕ &ĂŝǀƌĞ :͕ ŽƵǀŝĞƌ D͘ ƉŝĚĞŵŝŽůŽŐǇ
and prognosis of synchronous colorectal 
ĐĂŶĐĞƌƐ͘ƌ:^ƵƌŐ͘ϮϬϬϴ͖ϵϱ;ϭϮͿ͗ϭϱϮϴͲϯϯ͘
58. Oya M, Takahashi S, Okuyama T, 
zĂŵĂŐƵĐŚŝ D͕ hĞĚĂ z͘  ^ǇŶĐŚƌŽŶŽƵƐ
ĐŽůŽƌĞĐƚĂů ĐĂƌĐŝŶŽŵĂ͗ ĐůŝŶŝĐŽͲƉĂƚŚŽůŽŐŝĐĂů








ϲϬ͘ 'ŽŽŝŬĞƌ '͕ ǀĂŶ ĚĞƌ 'ĞĞƐƚ >'͕ tŽƵƚĞƌƐ
MW, Vonk M, Karsten TM, Tollenaar RA, 
Ğƚ Ăů͘ YƵĂůŝƚǇ ŝŵƉƌŽǀĞŵĞŶƚ ŽĨ ƉĂŶĐƌĞĂƟĐ
ƐƵƌŐĞƌǇ ďǇ ĐĞŶƚƌĂůŝǌĂƟŽŶ ŝŶ ƚŚĞ ǁĞƐƚĞƌŶ




Ğƚ Ăů͘ ĞŶƚƌĂůŝǌĂƟŽŶ ŽĨ ĞƐŽƉŚĂŐĞĐƚŽŵǇ͗
ŚŽǁ ĨĂƌ ƐŚŽƵůĚ ǁĞ ŐŽ͍ ŶŶ ^ƵƌŐ KŶĐŽů͘
ϮϬϭϰ͖Ϯϭ;ϭϯͿ͗ϰϬϲϴͲϳϰ͘
ϲϮ͘ >ĞŵŵĞŶƐs͕ŽƐƐĐŚĂ<͕ǀĂŶĚĞƌ^ĐŚĞůůŝŶŐ
G, Brenninkmeijer S, Coebergh JW, de Hingh 
/,͘ /ŵƉƌŽǀŝŶŐ ŽƵƚĐŽŵĞ ĨŽƌ ƉĂƟĞŶƚƐ ǁŝƚŚ
ƉĂŶĐƌĞĂƟĐ ĐĂŶĐĞƌ ƚŚƌŽƵŐŚ ĐĞŶƚƌĂůŝǌĂƟŽŶ͘
ƌ:^ƵƌŐ͘ϮϬϭϭ͖ϵϴ;ϭϬͿ͗ϭϰϱϱͲϲϮ͘
ϲϯ͘ ŝƌŬŵĞǇĞƌ :͕ ^ƚƵŬĞů d͕ ^ŝĞǁĞƌƐ ͕
'ŽŽĚŶĞǇ WW͕  tĞŶŶďĞƌŐ ͕ >ƵĐĂƐ &>͘
^ƵƌŐĞŽŶ ǀŽůƵŵĞ ĂŶĚ ŽƉĞƌĂƟǀĞ ŵŽƌƚĂůŝƚǇ
ŝŶ ƚŚĞ hŶŝƚĞĚ ^ƚĂƚĞƐ͘ E ŶŐů : DĞĚ͘
ϮϬϬϯ͖ϯϰϵ;ϮϮͿ͗ϮϭϭϳͲϮϳ͘
ϲϰ͘ ƌŽůĞƚ^͕DĂĐ>ĞĂŶZ͕DǇĞƌƐZW͕ ^ŚĂŚĞĞŶ
͕ ŝǆŽŶ ͕ ƵŝĞ t͘ ůĞĐƟǀĞ ƌĞƐĞĐƟŽŶ
of colon cancer by high-volume surgeons 
is associated with decreased morbidity 
and mortality. J Gastrointest Surg. 
ϮϬϭϭ͖ϭϱ;ϰͿ͗ϱϰϭͲϱϬ͘
ϲϱ͘ ǀĂŶ ƌŶŝŶŐ &E͕ ǀĂŶ ^ƚĞĞŶďĞƌŐĞŶ >E͕
ǀĂŶ ĚĞŶ ƌŽĞŬ td͕  ZƵƩĞŶ ,:͕ >ĞŵŵĞŶƐ
s͘ EŽ ĚŝīĞƌĞŶĐĞ ďĞƚǁĞĞŶ ůŽǁĞƐƚ ĂŶĚ
highest volume hospitals in outcome 
ĂŌĞƌ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ƐƵƌŐĞƌǇ ŝŶ ƚŚĞ
ƐŽƵƚŚĞƌŶ EĞƚŚĞƌůĂŶĚƐ͘ Ƶƌ : ^ƵƌŐ KŶĐŽů͘
ϮϬϭϯ͖ϯϵ;ϭϭͿ͗ϭϭϵϵͲϮϬϲ͘





management for esophageal and gastric 
ĐĂŶĐĞƌ͘ ĂŶĐĞƌDĂŶĂŐZĞƐ͘ϮϬϭϲ͖ϴ͗ϯϵͲϰϰ͘
68. Taylor C, Munro AJ, Glynne-Jones R, 
'ƌŝĸƚŚ ͕ dƌĞǀĂƩ W͕  ZŝĐŚĂƌĚƐ D͕ Ğƚ Ăů͘
DƵůƟĚŝƐĐŝƉůŝŶĂƌǇ ƚĞĂŵ ǁŽƌŬŝŶŐ ŝŶ ĐĂŶĐĞƌ͗
ǁŚĂƚŝƐƚŚĞĞǀŝĚĞŶĐĞ͍D:͘ϮϬϭϬ͖ϯϰϬ͗Đϵϱϭ͘




region, hospital type and volume in the 




ǀĂŶ <ƌŝĞŬĞŶ :,͕ dŽůůĞŶĂĂƌ Z͕ Ğƚ Ăů͘ >ĂƌŐĞ
ǀĂƌŝĂƟŽŶďĞƚǁĞĞŶŚŽƐƉŝƚĂůƐĂŶĚƉĂƚŚŽůŽŐǇ
ůĂďŽƌĂƚŽƌŝĞƐ ŝŶ ůǇŵƉŚ ŶŽĚĞ ĞǀĂůƵĂƟŽŶ ŝŶ
colon cancer and its impact on survival, a 
ŶĂƟŽŶǁŝĚĞƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ƐƚƵĚǇ ŝŶ ƚŚĞ
EĞƚŚĞƌůĂŶĚƐ͘ŶŶKŶĐŽů͘ϮϬϭϭ͖ϮϮ;ϭͿ͗ϭϭϬͲϳ͘
ϳϭ͘ ůĨĞƌŝŶŬ D͕ tŽƵƚĞƌƐ Dt͕ <ƌŝũŶĞŶ W͕ 
>ĞŵŵĞŶƐ s͕ :ĂŶƐĞŶͲ>ĂŶĚŚĞĞƌ D>͕ ǀĂŶ
ĚĞsĞůĚĞ:͕ĞƚĂů͘ŝƐƉĂƌŝƟĞƐ ŝŶƋƵĂůŝƚǇŽĨ
care for colon cancer between hospitals in 
ƚŚĞEĞƚŚĞƌůĂŶĚƐ͘Ƶƌ:^ƵƌŐKŶĐŽů͘ϮϬϭϬ͖ϯϲ
^ƵƉƉůϭ͗^ϲϰͲϳϯ͘
ϳϮ͘ <ƌĞƵůĞŶ͘KƵĚĞƌĞŵĞƚŬĂŶŬĞƌ ůŽŽƉƚ ũƵŝƐƚĞ
zorg mis. Trouw2016.
ϳϯ͘ ,ĞŶĚƌĞŶ ^͕ ŝƌŬŵĞǇĞƌ :͕ zŝŶ,͕ ĂŶĞƌũĞĞ
M, Sonnenday C, Morris AM. Surgical 
ĐŽŵƉůŝĐĂƟŽŶƐ ĂƌĞ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ
ŽŵŝƐƐŝŽŶ ŽĨ ĐŚĞŵŽƚŚĞƌĂƉǇ ĨŽƌ ƐƚĂŐĞ ///
colorectal cancer. Dis Colon Rectum. 
ϮϬϭϬ͖ϱϯ;ϭϮͿ͗ϭϱϴϳͲϵϯ͘
ϳϰ͘ ^ƟŐŐĞůďŽƵƚD͕sĂŶĚĞƌtĞŝũĚĞŶd͕ Ğtŝƚ
DW͕  &ƌŽƐĐŚ ͕ >ĞŐĂƌĞ &͕  DŽŶƚŽƌŝ sD͕ Ğƚ
Ăů͘ ^ŚĂƌĞĚ ĚĞĐŝƐŝŽŶŵĂŬŝŶŐ͗ ƌĞĂůůǇ ƉƵƫŶŐ
ƉĂƟĞŶƚƐĂƚ ƚŚĞĐĞŶƚƌĞŽĨŚĞĂůƚŚĐĂƌĞ͘D:͘
ϮϬϭϮ͖ϯϰϰ͗ĞϮϱϲ͘
ϳϱ͘ <ĞŶŝƐ ͕ ƌŽŶ ͕ >ŝďĞƌƚ z͕  ĞĐŽƐƚĞƌ >͕ sĂŶ
Puyvelde K, Scalliet P, et al. Relevance 
ŽĨ Ă ƐǇƐƚĞŵĂƟĐ ŐĞƌŝĂƚƌŝĐ ƐĐƌĞĞŶŝŶŐ ĂŶĚ
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ƉĂƟģŶƚĞŶ ƉĞƌ ƟũĚƐĞĞŶŚĞŝĚ ĞŶ ƉĞƌ ĂĂŶƚĂů ǀĂŶ ĚĞ ďĞǀŽůŬŝŶŐ ;ǌŽŐĞŚĞƚĞŶ ΖΖŝŶĐŝĚĞŶƟĞΖΖͿ
ǀĞƌĚĞƌƐƟũŐĞŶĂůƐŐĞǀŽůŐǀĂŶƚŽĞŶĞŵĞŶĚĞǀĞƌŐƌŝũǌŝŶŐǀĂŶĚĞďĞǀŽůŬŝŶŐĞŶŚĞƚůĂŶĚĞůŝũŬĞ
bevolkingsonderzoek naar darmkanker dat in 2014 is geïntroduceerd.
ĂƌŵŬĂŶŬĞƌ ǁŽƌĚƚ ŽŶĚĞƌǀĞƌĚĞĞůĚ ŝŶ ƚƵŵŽƌĞŶ ŝŶ ĚĞ ĚŝŬŬĞ ĚĂƌŵ ;ĐŽůŽŶƚƵŵŽƌĞŶͿ ĞŶ
ƚƵŵŽƌĞŶŝŶĚĞĞŶĚĞůĚĂƌŵ;ƌĞĐƚƵŵƚƵŵŽƌĞŶͿ͘ƌǌŝũŶǀĞƌƐĐŚŝůůĞŶĚĞƐŽŽƌƚĞŶďĞŚĂŶĚĞůŝŶŐĞŶ
ŵŽŐĞůŝũŬďŝũĚĂƌŵŬĂŶŬĞƌ͘ ĞůŽĐĂƟĞŝŶŚĞƚĚĂƌŵŬĂŶĂĂůĞŶŚĞƚƐƚĂĚŝƵŵǀĂŶĚĞƚƵŵŽƌǌŝũŶ
belangrijke factoren die een rol spelen bij het maken van een behandelkeuze. Bij vrijwel 
ĂůůĞƉĂƟģŶƚĞŶŵĞƚĚĂƌŵŬĂŶŬĞƌǁŽƌĚƚĚĞ ƚƵŵŽƌĐŚŝƌƵƌŐŝƐĐŚǀĞƌǁŝũĚĞƌĚ͘,ŝĞƌďŝũ ŬƵŶŶĞŶ
ǀŽŽƌĂĨŐĂĂŶĚ ĂĂŶ ĚĞ ŽƉĞƌĂƟĞ ;ŶĞŽͲĂĚũƵǀĂŶƚͿ ŽĨ ŶĂ ĚĞ ŽƉĞƌĂƟĞ ;ĂĚũƵǀĂŶƚͿ ĂĂŶǀƵůůĞŶĚĞ
ďĞŚĂŶĚĞůŝŶŐĞŶŶŽĚŝŐ ǌŝũŶ ;ĐŚĞŵŽƚŚĞƌĂƉŝĞ͕ ƌĂĚŝŽƚŚĞƌĂƉŝĞŽĨ ĞĞŶ ĐŽŵďŝŶĂƟĞ ǀĂŶďĞŝĚĞ͕
ǌŽŐĞŚĞƚĞŶĐŚĞŵŽƌĂĚŝŽƚŚĞƌĂƉŝĞͿ͘
ŽŽƌǀĞƌďĞƚĞƌŝŶŐĞŶŝŶĚŝĂŐŶŽƐƟĞŬĞŶďĞŚĂŶĚĞůŝŶŐǌŝũŶĚĞŽǀĞƌůĞǀŝŶŐƐŬĂŶƐĞŶǀĂŶƉĂƟģŶƚĞŶ







ǀĂŶ ǀŽŽƌŬŽŵĞŶ ;ǌŽŐĞŚĞƚĞŶ ΖΖŵŽƌďŝĚŝƚĞŝƚΖΖͿ ĞŶ ŚĞƚ ĂĂŶƚĂů ƐƚĞƌŌĞŐĞǀĂůůĞŶ ;ǌŽŐĞŚĞƚĞŶ
ΖΖŵŽƌƚĂůŝƚĞŝƚΖΖͿ ǀĂŶĚĞǌĞ ƚƵŵŽƌŚŽŽŐ ŝŶEĞĚĞƌůĂŶĚ͘KŵĚĞƉƌŽŐŶŽƐĞǀĂŶƉĂƟģŶƚĞŶŵĞƚ
darmkanker te verbeteren, is het belangrijk beter inzicht te krijgen welke factoren van 
ŝŶǀůŽĞĚǌŝũŶŽƉĚĞĚĂŐĞůŝũŬƐĞǌŽƌŐĞŶĚĞŽǀĞƌůĞǀŝŶŐǀĂŶƉĂƟģŶƚĞŶŵĞƚĚĂƌŵŬĂŶŬĞƌ͘ ,ŝĞƌďŝũ
ŬƵŶŶĞŶǌŽǁĞůƉĂƟģŶƚͲĂůƐŬůŝŶŝƐĐŚŐĞƌĞůĂƚĞĞƌĚĞĨĂĐƚŽƌĞŶ͕ĂůƐŵĞĚĞǌŝĞŬĞŶŚƵŝƐĨĂĐƚŽƌĞŶǀĂŶ
ŝŶǀůŽĞĚ ǌŝũŶ ŽƉĚĞŽǀĞƌůĞǀŝŶŐ͘,Ğƚ ĞǀĂůƵĞƌĞŶ ǀĂŶŚĞƚ ĞīĞĐƚ ǀĂŶ ǀĞƌƐĐŚŝůůĞŶĚĞ ŬůŝŶŝƐĐŚĞ
ĨĂĐƚŽƌĞŶ ĞŶ ǌŝĞŬĞŶŚƵŝƐĨĂĐƚŽƌĞŶ ŐĞĞŌ ŶŝĞƵǁĞ ŝŶǌŝĐŚƚĞŶ ĂĂŶ ŵĞĚŝƐĐŚĞ ƐƉĞĐŝĂůŝƐƚĞŶ ĞŶ
ziekenhuizen om de kwaliteit van de darmkankerzorg en overlevingskansen van deze 
ƉĂƟģŶƚĞŶǀĞƌĚĞƌƚĞŽƉƟŵĂůŝƐĞƌĞŶ͘
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,Ğƚ ĚŽĞů ǀĂŶ Ěŝƚ ƉƌŽĞĨƐĐŚƌŝŌ ŝƐ ŝͿ ŝŶǌŝĐŚƚ ŐĞǀĞŶ ŝŶ ĚĞ ŽǀĞƌůĞǀŝŶŐƐĐŝũĨĞƌƐ ĞŶ ŝŝͿ ĨĂĐƚŽƌĞŶ
ŝĚĞŶƟĮĐĞƌĞŶĚŝĞŝŶǀůŽĞĚŬƵŶŶĞŶƵŝƚŽĞĨĞŶĞŶŽƉĚĞŬǁĂůŝƚĞŝƚǀĂŶĚĂŐĞůŝũŬƐĞŬĂŶŬĞƌǌŽƌŐĞŶ
ƉƌŽŐŶŽƐĞ ǀĂŶƉĂƟģŶƚĞŶŵĞƚĚĂƌŵŬĂŶŬĞƌ ŝŶEĞĚĞƌůĂŶĚ͘KŵĚĞǌĞŽŶĚĞƌǌŽĞŬƐǀƌĂŐĞŶ ƚĞ
ďĞĂŶƚǁŽŽƌĚĞŶ͕ŚĞďďĞŶǁŝũŐĞďƌƵŝŬŐĞŵĂĂŬƚǀĂŶĚĂƚĂƵŝƚĚĞEĞĚĞƌůĂŶĚƐĞ<ĂŶŬĞƌƌĞŐŝƐƚƌĂƟĞ
;E<ZͿ ǀĂŶ ŚĞƚ /ŶƚĞŐƌĂĂů <ĂŶŬĞƌĐĞŶƚƌƵŵEĞĚĞƌůĂŶĚ ;/<E>Ϳ͘tĞ ďĞƐƚƵĚĞĞƌĚĞŶ ƚƌĞŶĚƐ ŝŶ
ŝŶĐŝĚĞŶƟĞ͕ŵŽƌƚĂůŝƚĞŝƚ͕ďĞŚĂŶĚĞůŝŶŐĞŶŽǀĞƌůĞǀŝŶŐ;deel IͿ͘ĂĂƌŶĂĂƐƚŝƐĚĞŝŵƉĂĐƚǀĂŶĞĞŶ






ĞŶ ĚĞ ĐŽŶĚŝƟŽŶĞůĞ ŽǀĞƌůĞǀŝŶŐ ;ŽǀĞƌůĞǀŝŶŐ ŽƉ ǀŽŽƌǁĂĂƌĚĞ ĚĂƚ ĞĞŶ ƉĂƟģŶƚ ƌĞĞĚƐ ĞĞŶ
ďĞƉĂĂůĚĞƉĞƌŝŽĚĞŚĞĞŌŽǀĞƌůĞĞĨĚͿ͘
BELANGRIJKSTE BEVINDINGEN VAN DIT PROEFSCHRIFT
/Ŷdeel I ǀĂŶ Ěŝƚ ƉƌŽĞĨƐĐŚƌŝŌǁŽƌĚƚ ĞĞŶ ŽǀĞƌǌŝĐŚƚ ŐĞŐĞǀĞŶ ǀĂŶ ĚĂƌŵŬĂŶŬĞƌ ŽǀĞƌůĞǀŝŶŐ
in Nederland. De studie beschreven in hoofdstuk 2 ŐĞĞŌ ŝŶǌŝĐŚƚ ŝŶ ĚĞ ŽŶƚǁŝŬŬĞůŝŶŐĞŶ
ŽƉ ŚĞƚ ŐĞďŝĞĚ ǀĂŶ ŝŶĐŝĚĞŶƟĞ͕ ŵŽƌƚĂůŝƚĞŝƚ͕ ďĞŚĂŶĚĞůŝŶŐ ĞŶ ŽǀĞƌůĞǀŝŶŐ ǀĂŶ ƉĂƟģŶƚĞŶ
ŵĞƚ ĚĂƌŵŬĂŶŬĞƌ ŝŶEĞĚĞƌůĂŶĚŽǀĞƌ ĚĞ ĂĨŐĞůŽƉĞŶϮϱ ũĂĂƌ͘ hŝƚ ĚĞǌĞ ƐƚƵĚŝĞ ďůŝũŬƚ ĚĂƚ ĚĞ
ŝŶĐŝĚĞŶƟĞǀĂŶĐŽůŽŶͲĞŶƌĞĐƚƵŵƚƵŵŽƌĞŶŝƐŐĞƐƚĞŐĞŶĞŶĚĞŵŽƌƚĂůŝƚĞŝƚĂĂŶďĞŝĚĞƚƵŵŽƌĞŶ
ŝƐ ŐĞĚĂĂůĚ͘ ŝũŵĞĞƌ ĚĂŶ ϵϬй ǀĂŶĚĞƉĂƟģŶƚĞŶŵĞƚ ƐƚĂĚŝƵŵ /Ͳ/// ĚĂƌŵŬĂŶŬĞƌǁĞƌĚĚĞ
ƚƵŵŽƌĐŚŝƌƵƌŐŝƐĐŚǀĞƌǁŝũĚĞƌĚ͘ĂĂƌŶĂĂƐƚŬƌĞŐĞŶƉĂƟģŶƚĞŶŝŶƌĞĐĞŶƚĞƌĞƉĞƌŝŽĚĞƐƐƚĞĞĚƐ
ǀĂŬĞƌ ĞĞŶ ĂĂŶǀƵůůĞŶĚĞ ďĞŚĂŶĚĞůŝŶŐ͕ ǌŽĂůƐ ĂĚũƵǀĂŶƚĞ ĐŚĞŵŽƚŚĞƌĂƉŝĞ ďŝũ ƉĂƟģŶƚĞŶ
ŵĞƚ ĞĞŶ ƐƚĂĚŝƵŵ /// ĐŽůŽŶƚƵŵŽƌ ĞŶ ŶĞŽͲĂĚũƵǀĂŶƚĞ ƌĂĚŝŽƚŚĞƌĂƉŝĞ ĞŶ ĐŚĞŵŽƌĂĚŝĂƟĞ ďŝũ
ƉĂƟģŶƚĞŶŵĞƚĞĞŶƐƚĂĚŝƵŵ//Ͳ///ƌĞĐƚƵŵƚƵŵŽƌ͘ KŽŬƉĂƟģŶƚĞŶŵĞƚƐƚĂĚŝƵŵ/sĚĂƌŵŬĂŶŬĞƌ






/Ŷhoofdstuk 3 evalueren we welke verschillen in overleving er zijn tussen de verschillende 
ůĞĞŌŝũĚƐŐƌŽĞƉĞŶ͘/ŶĚĞǌĞƐƚƵĚŝĞǁĞƌĚĞŶĂůůĞƉĂƟģŶƚĞŶŽƉŐĞŶŽŵĞŶĚŝĞŐĞĚŝĂŐŶŽƐƟĐĞĞƌĚ
zijn met niet-gemetastaseerde darmkanker tussen 2008 en 2013 en die hiervoor een 
ŽƉĞƌĂƟĞ ŬƌĞŐĞŶ͘ WĂƟģŶƚĞŶ ǁĞƌĚĞŶ ŝŶŐĞĚĞĞůĚ ŝŶ ǀŝĞƌ ůĞĞŌŝũĚƐĐĂƚĞŐŽƌŝĞģŶ͗ фϲϱ͕ ϲϱͲ
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ϳϰ͕ ϳϱͲϴϰ ĞŶ шϴϱ ũĂĂƌ͘  tĞ ǀŽŶĚĞŶ ĞĞŶ ůĂŐĞƌĞ ƌƵǁĞ ϱͲũĂĂƌƐŽǀĞƌůĞǀŝŶŐ ďŝũ ĚĞ ŽƵĚĞƌĞ




/Ŷ deel II ǀĂŶ Ěŝƚ ƉƌŽĞĨƐĐŚƌŝŌ ďĞƐĐŚƌŝũǀĞŶ ǁĞ ŽŶĚĞƌǌŽĞŬ ŶĂĂƌ ĚĞƚĞƌŵŝŶĂŶƚĞŶ ĚŝĞ
ŝŵƉĂĐƚŚĞďďĞŶŽƉĚĞŬĞƵǌĞǀĂŶĞĞŶďĞŚĂŶĚĞůŝŶŐĞŶĚĞŽǀĞƌůĞǀŝŶŐ ǀĂŶƉĂƟģŶƚĞŶŵĞƚ




ĞĞŶ ŽƉĞƌĂƟĞ ŬƌĞŐĞŶ͘ /Ŷ ƚŽƚĂĂů ǁĞƌĚ ďŝũ ϱй ǀĂŶ ĚĞǌĞ ƉĂƟģŶƚĞŶ ;ŶсϭϵϲϵͿ ƐǇŶĐŚƌŽŶĞ
ĚĂƌŵƚƵŵŽƌĞŶ ŐĞǀŽŶĚĞŶ͘ Ğ ŚĞůŌ ǀĂŶ ĚĞ ƉĂƟģŶƚĞŶ ŵĞƚ ĞĞŶ ƐǇŶĐŚƌŽŶĞ ĚĂƌŵƚƵŵŽƌ
ŬƌĞĞŐĞĞŶƵŝƚŐĞďƌĞŝĚĞƌĞŽƉĞƌĂƟĞŝŶǀĞƌŐĞůŝũŬŝŶŐƚŽƚƉĂƟģŶƚĞŶŵĞƚĞĞŶĠĠŶĚĂƌŵƚƵŵŽƌ͘ 
ĂĂƌŶĂĂƐƚďůĞĞŬĚĂƚƉĂƟģŶƚĞŶŵĞƚƐǇŶĐŚƌŽŶĞĚĂƌŵƚƵŵŽƌĞŶŵŝŶĚĞƌǀĂĂŬŶĞŽͲĂĚũƵǀĂŶƚĞ
;ĐŚĞŵŽͿƌĂĚŝŽƚŚĞƌĂƉŝĞ ŽĨ ĂĚũƵǀĂŶƚĞ ĐŚĞŵŽƚŚĞƌĂƉŝĞ ŬƌŝũŐĞŶ͘ Ğ ƐƚƵĚŝĞ ƚŽŽŶĚĞ ŽŽŬ ĂĂŶ





/Ŷ hoofdstuk 5 hebben we onderzocht of het ziekenhuisvolume samenhangt met de 
ŬŽƌƚĞƚĞƌŵŝũŶ ƵŝƚŬŽŵƐƚĞŶ ĞŶ ŽǀĞƌůĞǀŝŶŐ ǀĂŶ ƉĂƟģŶƚĞŶ ŵĞƚ ĚĂƌŵŬĂŶŬĞƌ͘  ŝĞŬĞŶŚƵŝǌĞŶ
ǁĞƌĚĞŶŐĞŐƌŽĞƉĞĞƌĚŽƉďĂƐŝƐǀĂŶŚĞƚĂĂŶƚĂůŽƉĞƌĂƟĞƐďŝũƉĂƟģŶƚĞŶŵĞƚĐŽůŽŶƚƵŵŽƌĞŶ
;фϱϬ͕ϱϬͲϳϰ͕ϳϱͲϵϵ͕ĞŶшϭϬϬŽƉĞƌĂƟĞƐƉĞƌ ũĂĂƌͿĞŶ ƌĞĐƚƵŵƚƵŵŽƌĞŶ ;фϮϬ͕ϮϬͲϯϵĞŶшϰϬ




van deze factoren kan meer inzicht geven in het debat over de kwaliteit van zorg en de 
ǀƌĂĂŐŽĨĞĞŶŽƉĞƌĂƟĞŝŶĞĞŶǌŽŐĞŚĞƚĞŶΖůĂĂŐͲǀŽůƵŵĞǌŝĞŬĞŶŚƵŝƐΖĞĞŶƌŝƐŝĐŽĨĂĐƚŽƌǀŽƌŵƚ
ǀŽŽƌŽŶŐƵŶƐƟŐĞƵŝƚŬŽŵƐƚĞŶǀŽŽƌĚĞƉĂƟģŶƚ͘
/Ŷ hoofdstuk 6 ŽŶƚǁŝŬŬĞůĚĞŶ ĞŶ ǀĂůŝĚĞĞƌĚĞŶ ǁŝũ ĞĞŶ ƉƌĞĚŝĐƟĞŵŽĚĞů ;ǀŽŽƌƐƉĞůůĞŶĚ
ŵŽĚĞůͿ Žŵ ĚĞ ƉŽƐƚŽƉĞƌĂƟĞǀĞ ϵϬͲĚĂŐĞŶ ŵŽƌƚĂůŝƚĞŝƚ ĞŶ ĚĞ ƌƵǁĞ ϱͲũĂĂƌƐŽǀĞƌůĞǀŝŶŐ ǀĂŶ
ƉĂƟģŶƚĞŶŵĞƚ ŶŝĞƚͲŐĞŵĞƚĂƐƚĂƐĞĞƌĚĞ ĚĂƌŵŬĂŶŬĞƌ ƚĞ ŬƵŶŶĞŶ ǀŽŽƌƐƉĞůůĞŶ͘ &ĂĐƚŽƌĞŶ ĚŝĞ
ĚĞƉŽƐƚŽƉĞƌĂƟĞǀĞϵϬͲĚĂŐĞŶŵŽƌƚĂůŝƚĞŝƚŬƵŶŶĞŶǀŽŽƌƐƉĞůůĞŶǌŝũŶŐĞƐůĂĐŚƚĞŶůĞĞŌŝũĚǀĂŶ
ĚĞƉĂƟģŶƚ͕ ƚƵŵŽƌŐƌŽŽƩĞĞŶƵŝƚǌĂĂŝŝŶŐĞŶ ŝŶĚĞ ůǇŵĨĞŬůŝĞƌĞŶ͕ ƵƌŐĞŶƟĞ ǀĂŶĚĞŽƉĞƌĂƟĞ͕
168 | WWE/y
ŽƉĞƌĂƟĞŵĞƚŚŽĚĞ ;ůĂƉĂƌŽƐĐŽƉŝƐĐŚ ŽĨ ŽƉĞŶͿ͕ ƚǇƉĞ ŽƉĞƌĂƟĞ ;ƐĞŐŵĞŶƚ ǀĂŶ ĚĞ ĚĂƌŵ
ǀĞƌǁŝũĚĞƌĞŶŽĨƚŽƚĂůĞĚĂƌŵǀĞƌǁŝũĚĞƌĞŶͿĞŶŚĞƚŽƉƚƌĞĚĞŶǀĂŶĞĞŶĐŽŵƉůŝĐĂƟĞ;ůĞŬŬĂŐĞ
ǀĂŶĚĞĚĂƌŵŝŶŚŽƵĚŽƉĚĞůŽĐĂƟĞǁĂĂƌĞĞŶŶŝĞƵǁĞǀĞƌďŝŶĚŝŶŐǀĂŶĚĞĚĂƌŵŝƐĂĂŶŐĞůĞŐĚ͕
ǌŽŐĞŚĞƚĞŶ ΖΖŶĂĂĚůĞŬŬĂŐĞΖΖͿ͘ sŽŽƌƐƉĞůůĞŶĚĞ ĨĂĐƚŽƌĞŶ ǀŽŽƌ ĚĞ ϱͲũĂĂƌƐŽǀĞƌůĞǀŝŶŐ ǁĂƌĞŶ





ondersteunen bij de individuele besluitvorming omtrent het behandel- en vervolgtraject 
ǀĂŶƉĂƟģŶƚĞŶŵĞƚĚĂƌŵŬĂŶŬĞƌ͘
/Ŷ hoofdstuk 7 ǀĂŶ Ěŝƚ ƉƌŽĞĨƐĐŚƌŝŌ ŝƐ ŽŶĚĞƌǌŽĐŚƚ ǁĞůŬĞ ĚĞŵŽŐƌĂĮƐĐŚĞ ĞŶ ŬůŝŶŝƐĐŚĞ
ǀĂƌŝĂďĞůĞŶ ǀĂŶ ŝŶǀůŽĞĚ ǌŝũŶ ŽƉ ĚĞ ƟũĚ ĚŝĞ ǀĞƌƐƚƌĞŬĞŶ ŝƐ ƚŽƚ ŚĞƚ ŬƌŝũŐĞŶ ǀĂŶ ĂĚũƵǀĂŶƚĞ





ůĂƚĞƌŵĞƚĚĞǌĞďĞŚĂŶĚĞůŝŶŐďĞŐŝŶŶĞŶ͘sĂŶĂĨ ϱ ƚŽƚ ϴǁĞŬĞŶŶĂĚĞŽƉĞƌĂƟĞǁĞƌĚ ŐĞĞŶ
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ǌŝĞŶǀĂŶǀĂƌŝĂƟĞŝŶďŝũǀŽŽƌďĞĞůĚǌŝĞŬĞŶŚƵŝƐǀŽůƵŵĞĞŶĚĞƟũĚƚŽƚŚĞƚƐƚĂƌƚĞŶǀĂŶĂĚũƵǀĂŶƚĞ














aantal personen wil ik in het bijzonder benoemen.
Allereerst wil ik mijn promotoren en mijn copromoter hartelijk bedanken voor hun 
ďĞŐĞůĞŝĚŝŶŐƟũĚĞŶƐŵŝũŶƉƌŽŵŽƟĞƚƌĂũĞĐƚ͘
WƌŽĨ͘ ƌ͘  >ĞŵŵĞŶƐ͕ďĞƐƚĞsĂůĞƌǇ͕ ǁĂƚ ŝƐĚĞƟũĚ ƐŶĞůŐĞŐĂĂŶ͊ĞĂĨŐĞůŽƉĞŶƉĞƌŝŽĚĞǁĂƐ
ǀŽŽƌŵŝũŶŝĞƚĂůƟũĚĞǀĞŶŵĂŬŬĞůŝũŬ͘KŶĚĂŶŬƐũĞǀŽůůĞĂŐĞŶĚĂƐƚŽŶĚũĞĂůƟũĚǀŽŽƌŵŝũŬůĂĂƌ
ĞŶǁŝƐƚ ũĞŵŝũŚĞƌŶŝĞƵǁĚĞĞŶĞƌŐŝĞƚĞŐĞǀĞŶĂůƐ ŝŬŚĞƚĞǀĞŶŶŝĞƚŵĞĞƌǌĂŐǌŝƩĞŶ͘,Ğƚ ŝƐ
ĞĞŶǀŽŽƌƌĞĐŚƚŵĞƚũŽƵƚĞŵŽŐĞŶƐĂŵĞŶǁĞƌŬĞŶ͊:ŽƵǁŵĞŶƐĞůŝũŬŚĞŝĚ͕ŐĞĚƵůĚĞŶƉŽƐŝƟĞǀĞ
benadering bewonder ik enorm. Bedankt voor alles wat ik tot nu toe van je mocht leren, 
ŚĞƚǀĞƌƚƌŽƵǁĞŶĚĂƚũĞŝŶŵŝũƐƚĞůƚĞŶďŽǀĞŶĂů͕ĚĞƌƵŝŵƚĞĚŝĞũĞŵŝũĞůŬĞŬĞĞƌǁĞĞƌŐĞĞŌ
verder te groeien. Samen met Peter bedenk je steeds weer een manier mij in het diepe 
ƚĞŐŽŽŝĞŶ͕ǁĂĂƌŶĂŚĞƚŵĞŶŽŐĂůƟũĚůƵŬƚŽŵďŽǀĞŶƚĞŬŽŵĞŶ͘/ŬŬŝũŬǀŽůĞŶƚŚŽƵƐŝĂƐŵĞƵŝƚ
opnieuw kopje onder te gaan en nog meer van je te mogen leren!












De leden van de leescommissie, Prof. Dr. C. Verhoef, Prof. Dr. J.H.W. de Wilt en Prof. Dr. 
D͘<ŽŽƉŵĂŶ͕ǁŝů ŝŬďĞĚĂŶŬĞŶǀŽŽƌĚĞďĞƌĞŝĚŚĞŝĚŽŵŵŝũŶƉƌŽĞĨƐĐŚƌŝŌ ƚĞďĞŽŽƌĚĞůĞŶ͘
Daarnaast wil ik Prof. Dr. A.H.J. Mathijssen, Dr. H.A.A.M. Maas en Dr. M.G.H. van Oijen 
ďĞĚĂŶŬĞŶǀŽŽƌŚĞƚǌŝƫŶŐŶĞŵĞŶŝŶĚĞĐŽŵŵŝƐƐŝĞ͘
ŽͲĂƵƚĞƵƌƐŚƌŝƐƟĂŶĞƵƐŬĞŶƐ͕EĞůůĞŬĞƌŽƵǁĞƌ͕ 'ĞĞƌƚͲ:ĂŶƌĞĞŵĞƌƐ͕:ĂŶtŝůůĞŵĞŬŬĞƌ͕ 
DĂƌůŽĞƐ ůĨĞƌŝŶŬ͕ zǀĞƩĞ ǀĂŶ'ĞƐƚĞů͕ sŝŶĐĞŶƚ,Ž͕EŝĞŬ,ƵŐĞŶ͕ĂŶŝƋƵĞ<ŽƌƚďĞĞŬ͕,ƵƵď










ǀŝŶĂƐŚ͕'ŝŶĂ͕:ĂŶDĂĂƌƚĞŶ͕<ĂǇ͕ /ƌŵĂ͕<ĞůůǇ͕ >ŝŶĚǇ͕ DĂƌŝĂŶŶĞ͕DĂƌŝůǇŶ͕DĂƌŝƐƐĂ͕sŝŶĐĞŶƚ






ũƵůůŝĞ ŶĂƵǁŬĞƵƌŝŐĞ ĞŶ ĐŽŶƐĞƋƵĞŶƚĞ ƌĞŐŝƐƚƌĂƟĞ ďĞƐĐŚŝŬŬĞŶǁŝũ ŽǀĞƌ ĞĞŶ ŽŶƵŝƚƉƵƩĞůŝũŬĞ͕
betrouwbare dataset waarmee wij als onderzoekers waardevol onderzoek kunnen doen. 




ŽƉ ŬĂŶƚŽŽƌǁŽƌĚƚ ĚĞǁĞƌŬĚĂŐ ĞĞŶ ƐƚƵŬ ǌŽŶŶŝŐĞƌ͊ /Ŭ ǌĂů ŽŶǌĞ ŬŽĸĞůĞƵƚͲŵŽŵĞŶƚũĞƐ ĞŶ
ůĂŶŐĞͲůƵŶĐŚĞƐŽŶǁŝũƐŐĂĂŶŵŝƐƐĞŶ͘>ŝĞǀĞDŝƌŝĂŶ͕ŽŶǌĞ;ǀŽŽƌŵĂůŝŐͿŬůĞŝŶͲǁŝƚƐĞƌůĂŶĚ͕ŵĂĂƌ








het een beetje goed dat ik ben gestopt met mijn rechten studie. Bedankt voor al je liefde, 
steun en goede zorgen de afgelopen 32 jaar.
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>ŝĞǀĞ ƉĂƉĂ͕ ŚĞƚ ǌĂů ǀĂŶĚĂĂŐ ŚĞĞů ǌǁĂĂƌ ǌŝũŶ ŽŵĚĂƚ ũĞ Ğƌ ŚĞůĂĂƐ ŶŝĞƚ ďŝũ ŬƵŶƚ ǌŝũŶ͘ /Ŭ
hoop dat je boven een mooi wolkje hebt uitgekozen om toch een eersterangs plekje te 
ďĞŵĂĐŚƟŐĞŶ͘ĂŶŬũĞǁĞůǀŽŽƌĞĞŶůƵŝƐƚĞƌĞŶĚŽŽƌ͕ ũĞŵĞĞůĞǀĞŶĚŚĞŝĚ͕ũĞƐƚĞƵŶ͕ũĞůŝĞĨĚĞĞŶ
ũĞǀĞƌƚƌŽƵǁĞŶŝŶŵŝũ͕ŽŽŬĂůďĞŐƌĞĞƉũĞŶŝĞƚĂůƟũĚǁĂƚŝŬŶŽƵĞŝŐĞŶůŝũŬĂĂŶŚĞƚĚŽĞŶǁĂƐ͘
DŝũŶ ĚŽŽƌǌĞƫŶŐƐǀĞƌŵŽŐĞŶ ĞŶŚĂƌĚĞǁĞƌŬĞŶŚĞď ŝŬ ŽŶŐĞƚǁŝũĨĞůĚ ǀĂŶ ũŽƵ ŐĞŬƌĞŐĞŶ͘ /Ŭ
hoop dat je apetrots op mij bent!
>ŝĞǀĞ:ŝůů͕ũŝũďĞŶƚŵŝũŶŐƌŽŽƚƐƚĞŐĞƐĐŚĞŶŬ;ũĞͿ͊KŽŬĂůďĞŶũĞƉĂƐϴŵĂĂŶĚĞŶŝŶŽŶƐůĞǀĞŶ͕ũĞ
hebt ons zoveel vreugde en liefde gebracht. Dank je wel voor alle keren dat je lief naast 
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cancer survival in the Netherlands using real-world data. During her PhD training she 





L I S T  O F  P U B L I C AT I O N S | 183
PUBLICATIONS INCLUDED IN THIS THESIS
1. Bos ACRK͕<ŽƌƚďĞĞŬ͕ǀĂŶƌŶŝŶŐ&E͕ŝŵŵĞƌŵĂŶ͕>ĞŵŵĞŶƐsWW͕ ĞŬŬĞƌ:td
ΘDĂĂƐ,D͘WŽƐƚŽƉĞƌĂƟǀĞŵŽƌƚĂůŝƚǇŝŶĞůĚĞƌůǇƉĂƟĞŶƚƐǁŝƚŚĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͗ƚŚĞ
ŝŵƉĂĐƚŽĨĂŐĞ͕ƟŵĞͲƚƌĞŶĚƐĂŶĚĐŽŵƉĞƟŶŐƌŝƐŬƐŽĨĚǇŝŶŐ͘^ƵďŵŝƩĞĚ.
2. Bos ACRK͕,Žs<z͕ ǀĂŶƌŶŝŶŐ&E͕ƵƐŬĞŶƐ:͕dĂŶŝƐW:͕ǀĂŶKŝũĞŶD',Θ>ĞŵŵĞŶƐ
sWW͘  ĞǀĞůŽƉŵĞŶƚ ĂŶĚ ǀĂůŝĚĂƟŽŶ ŽĨ ƉƌĞĚŝĐƟŽŶ ŵŽĚĞůƐ ĨŽƌ ƉŽƐƚŽƉĞƌĂƟǀĞ ϵϬͲĚĂǇ
ŵŽƌƚĂůŝƚǇĂŶĚŽǀĞƌĂůůƐƵƌǀŝǀĂůŝŶĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͘^ƵďŵŝƩĞĚ. 
3. Brouwer NPM, Bos ACRK͕ >ĞŵŵĞŶƐsWW͕ dĂŶŝƐW:͕,ƵŐĞŶE͕EĂŐƚĞŐĂĂů /͕ĚĞtŝůƚ
:,tΘsĞƌŚŽĞǀĞŶZ,͘ ^ƵƌǀŝǀĂů ĐŽŶƟŶƵŽƵƐůǇ ŝŵƉƌŽǀĞƐĚƵƌŝŶŐϮϱǇĞĂƌƐŽĨ ƚƌĞĂƟŶŐ
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƉĂƟĞŶƚƐ͘ZĞƐƵůƚƐĨƌŽŵƚŚĞƵƚĐŚĂŶĐĞƌZĞŐŝƐƚƌǇ͘^ƵďŵŝƩĞĚ.
4. Bos ACRK͕DĂƩŚŝũƐĞŶZ͕ǀĂŶƌŶŝŶŐ&E͕ǀĂŶKŝũĞŶD',͕ZƵƩĞŶ,:Θ>ĞŵŵĞŶƐsWW͘ 
dƌĞĂƚŵĞŶƚĂŶĚŽƵƚĐŽŵĞŽĨƐǇŶĐŚƌŽŶŽƵƐĐŽůŽƌĞĐƚĂůĐĂƌĐŝŶŽŵĂƐ͗ĂŶĂƟŽŶǁŝĚĞƐƚƵĚǇ͘
ŶŶĂůƐŽĨ^ƵƌŐŝĐĂůKŶĐŽůŽŐǇ͕ ϮϬϭϳ͖Ϯϱ;ϮͿ͗ϰϭϰͲϰϮϭ͘
5. Bos ACRK͕ ǀĂŶ ƌŶŝŶŐ &E͕ ůĨĞƌŝŶŬD͕ ZƵƩĞŶ,:͕ ǀĂŶKŝũĞŶD',͕ ĚĞtŝůƚ :,tΘ
>ĞŵŵĞŶƐ sWW͘  EŽ ĚŝīĞƌĞŶĐĞ ŝŶ ŽǀĞƌĂůů ƐƵƌǀŝǀĂů ďĞƚǁĞĞŶ ŚŽƐƉŝƚĂů ǀŽůƵŵĞƐ ĨŽƌ
ƉĂƟĞŶƚƐǁŝƚŚ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ŝŶ ƚŚĞEĞƚŚĞƌůĂŶĚƐ͘ŝƐĞĂƐĞƐ ŽĨ ŽůŽŶ ĂŶĚZĞĐƚƵŵ͕
ϮϬϭϲ͖ϱϵ;ϭϬͿ͗ϵϰϯͲϱϮ͘







ƉƌŽŐƌĂŵ͘ůŝŶŝĐĂů'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇĂŶĚ,ĞƉĂƚŽůŽŐǇ͕ ϮϬϭϴ͖Epub ahead of print.
Ϯ͘ ĂďĞŝD͕:ĂŶƐĞŶ>͕ĂůĂǀĂƌĐĂz͕ ^ ũƂǀĂůů͕Bos ACRK͕ǀĂŶĚĞsĞůĚĞd͕ DŽƌĞĂƵD͕>ŝďĞƌĂůĞ
'͕'ŽŶĐĂůǀĞƐ&͕ ĞŶƚŽD:͕hůůƌŝĐŚD͕^ĐŚƌŽƚǌͲ<ŝŶŐW͕ >ĞŵŵĞŶƐsWW͕ 'ůŝŵĞůŝƵƐΘ




3. Fles R, Bos ACRK͕^ƵƉƌŝǇĂƟ͕ZĂĐŚŵĂǁĂƟ͕tĂůŝǇĂŶƟ͕dĂŶ/͕,ĂƌǇĂŶĂ^D͕^ĐŚŵŝĚƚ
D<Θ Ğǁŝ &^d͘  dŚĞ ƌŽůĞ ŽĨ /ŶĚŽŶĞƐŝĂŶ ƉĂƟĞŶƚƐ͛ ŚĞĂůƚŚ ďĞŚĂǀŝŽƌƐ ŝŶ ĚĞůĂǇŝŶŐ ƚŚĞ
ĚŝĂŐŶŽƐŝƐŽĨŶĂƐŽƉŚĂƌǇŶŐĞĂůĐĂƌĐŝŶŽŵĂ͘DWƵďůŝĐ,ĞĂůƚŚ͕ϮϬϭϳ͖ϭϳ;ϭͿ͗ϱϭϬ͘
ϰ͘ ǀĂŶĚĞƌsůƵŐƚD͕'ƌŽďďĞĞ:͕ŽƐƐƵǇƚWDD͕Bos ACRK͕ŽŶŐĞƌƐ͕^ƉŝũŬĞƌt͕<ƵŝƉĞƌƐ
:͕ >ĂŶƐĚŽƌƉͲsŽŐĞůĂĂƌ /͕ ^ƉĂĂŶĚĞƌ Dt Θ ĞŬŬĞƌ ͘ /ŶƚĞƌǀĂů ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ
ŝŶĐŝĚĞŶĐĞ ĂŵŽŶŐ ƐƵďũĞĐƚƐ ƵŶĚĞƌŐŽŝŶŐ ŵƵůƟƉůĞ ƌŽƵŶĚƐ ŽĨ ĨĞĐĂů ŝŵŵƵŶŽĐŚĞŵŝĐĂů
ƚĞƐƟŶŐ͘'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇ͕ ϮϬϭϳ͖ϭϱϯ;ϮͿ͗ϰϯϵͲϰϰϳ͘
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WƌŽŵŽƚŽƌƐ͗ WƌŽĨ͘ ƌ͘ s͘ ͘W͘ W͘ >ĞŵŵĞŶƐΘWƌŽĨ͘ ƌ͘ W͘͘,ƵŝũŐĞŶƐ






























Dutch seminars and conferences
/<E>ƐǇŵƉŽƐŝƵŵ͚E<ZŝŶďĞǁĞŐŝŶŐ͛ 2015 ϴ;Ϭ͘ϯͿ
ƌĂƐŵƵƐDͲ/<E>ƐǇŵƉŽƐŝƵŵWƌŽĨ͘ Ěƌ͘ s͘ ͘W͘ W͘ >ĞŵŵĞŶƐ 2015 ϲ;Ϭ͘ϮͿ












Making regional reports about colorectal cancer for hospitals 2015-2017 ϮϴϬ;ϭϬͿ
'ŝǀŝŶŐŝŶƉƵƚĨŽƌǁĞďͲďĂƐĞĚƚŽŽů͚E<ZŽŶůŝŶĞ͛ƐƉĞĐŝĮĐĂůůǇĨŽƌ
colorectal cancer 2016-2017 ϮϰϬ;ϴ͘ϲͿ
Total ϭϰϱϲ;ϱϭ͘ϲͿ


